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Summary 
Human cytomegalovirus (HCMV) is a β-herpesvirus that causes complications in immuno-
compromised individuals and is the leading infectious cause of birth defects. The HCMV 
genome contains 15 gene families, which contain between 2 to 14 members. One of these, 
the US12 gene family, consists of a sequential cluster of 10 genes (US12 to US21) that are 
highly conserved in clinical isolates. This family has roles in tropism and immune evasion 
and was recently found to regulate the cell surface expression of a wide array of immune 
ligands. This included the regulation of ligands for the natural killer (NK) cell activating 
receptors NKG2D and NKp30 (MICA and B7-H6 respectively), which were targeted by US18 
and US20. To complement these mechanistic studies, a C-terminal V5 epitope tag was 
added to each US12 family gene within the HCMV Merlin genome. A large proportion of 
the US12 family were shown to be degraded within the cell, possibly within lysosomes, 
which suggests that they may interact with their targets proteins in order to redirect them 
for degradation. Expression of US12 family members was detectable by immunoblotting 
during an infection time-course, with many US12 family members expressed during the Tp3 
temporal class of HCMV gene expression. Three members of the family were also 
demonstrated to be N-glycosylated during HCMV infection. The US12 family appear to have 
associations with the virion assembly compartment, and correspondingly, 7 US12 family 
members are found within the virion. Furthermore, the majority of the US12 family also 
show co-localisation with endoplasmic reticulum-derived membranes. These data build on 
our previous functional characterisation to give insights into the workings of this important 
HCMV gene family. 
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1.1 Herpesviruses 
Herpesviruses (or Herpesviridae) are a large group of DNA viruses that infect a wide range 
of species including primates, birds, amphibians, reptiles and invertebrates. Over 200 have 
been identified to date, each of which is usually restricted to one species alone although 
hosts can be infected with more than 1 herpesviruses at a time (Fields et al., 2013). Due to 
the size of the group, they have recently been classified into 3 further groups by the 
International Committee on the Taxonomy of Viruses (ICTV, 2011) into Herpesviridae 
(herpesviruses of mammals, birds and reptiles), Alloherpesviridae (herpesviruses of fish and 
amphibians) and Malacoherpesviridae (herpesviruses of bivalves). Herpesviruses are also 
split into three mammalian subfamilies- alpha (α), beta (β) and gamma (γ) – that arose 
around 180-220 million years ago. The emergence of divergence of species within sub-
lineages has expanded rapidly over the last 80 million years, most likely prior to or 
alongside speciation of the host lineages (McGeoch et al., 1995). Each sub-family contain 
multiple genera of viruses (Table 1.1). α-herpesviruses generally have short replication 
cycles and have the most variable host range of these 3 groups, infecting bird and reptile 
classes as well as mammals (Whitley, 1996, Pellett and Roizman, 2013). Members of the α-
herpesvirus sub-family can spread rapidly in cell culture, set up latent infections primarily in 
sensory ganglia, but have a wide host range. Herpes simplex virus (HSV)-1 and HSV-2 for 
example can infect neuronal cells, leukocytes, epithelial cells and fibroblasts (Spear and 
Longnecker, 2003) and rapidly destroy the cells they infect. β-herpesviruses are mid-range 
in that their host range is restricted, but generally less so than the γ-herpesviruses, and 
tend to have long reproductive cycles, which can be over 7 days. Their infection in cultured 
cells is relatively slow and infected cells frequently become enlarged as demonstrated by 
cytomegaloviruses (Whitley, 1996). γ-herpesviruses on the other hand tend to have a more 
restricted host range within the family or order of the natural host (Pellett and Roizman, 
2013). This sub-family are usually specific for lymphoid cells but can also infect other cells 
types, e.g. Epstein Barr virus (EBV) persistence is associated with B lymphocytes yet the 
virus also replicates in epithelial cells (Grinde, 2013).  
Herpesviruses have evolved alongside (and are generally well adapted to) their hosts, 
causing life-long infection, with all known members to date having the ability to both 
remain latent (or in a low replicative state) in their natural host, and with the ability to re-
activate (Pellett and Roizman, 2013, Grinde, 2013). They all have a characteristic spherical 
virion morphology consisting of an envelope, tegument, capsid and a core. All  
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Table 1.1: Current mammalian sub-groups of herpesviruses and their genera, 
adapted from Davison (2007b) and updated using data from the ICTV*  
Sub-group Genera◊ Examples (non-exclusive) 
Alpha Simplexvirus Herpes Simplex virus types 1 and 2 (HSV-1 
and HSV-2), Spider monkey herpesvirus 
(Herpesvirus ateles 1, HVA-1) 
Varicellovirus Varicella-Zoster virus (VZV), Equine 
herpesvirus (EHV) 
Mardivirus Avian (Gallid) herpesvirus 2 (GaHV-2) 
Iltovirus  Avian (Gallid) herpesvirus 1 (GaHV-1) 
Scutavirus Chelonid herpesvirus 5 (ChHV-5) 
Beta Cytomegalovirus (CMV) Human CMV (HHV-5/HCMV) 
Muromegalovirus Murid herpesviruses/Mouse 
cytomegaloviruses 1, 2 and 8 (MuHV-
/MCMV- 1,2 and 8) 
Roseolovirus Human herpesviruses (HHV-) 6A, 6B and 7 
Proboscivirus Elephantid herpesvirus 1 (EIHV-1) 
Gamma Lymphocryptovirus  Human herpesvirus 4/Epstein-Barr virus 
(HHV-4/EBV) 
Rhadinovirus Bovine herpesvirus 4 (BoHV-4), Kaposi's 
Sarcoma-associated herpesvirus (KSVH) 
Macavirus† Bovine herpesvirus 6 (BoHV-6) 
Percavirus† Equid herpesvirus 2 and 5 (EHV-2,5) 
Undefined Ictalurivirus ꙳ Ictalurid herpesvirus 1/Channel catfish 
virus (CCV) 
 
† More recently defined genera                                                                                                                             
◊ Unassigned genera within each group (1 unassigned genera in alpha and beta, 
and two in the gamma sub-family) have not been included 
꙳ Ictalurivirus is an additional genus which has not yet been assigned to a sub-
family 
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herpesviruses have large linear, double-stranded DNA genomes (125-240 kbp) with viral 
DNA replication and capsids assembly completed in the nucleus (Whitley, 1996, Davison, 
2007b). Their DNA is contained in the core, which is encapsulated by the icosahedral 
capsid. The nucleocapsid is then surrounded by tegument (which has a poorly defined 
structure) and enclosed by a lipid envelope that generally contains ten or more viral 
membrane glycoproteins, some of which are relatively conserved across different family 
members and some of which vary widely (Davison, 2007b). A common feature of 
herpesviruses is that they encode their own enzymes for viral nucleic acid biosynthesis and 
that productive replication and virion release tends to be linked to cell death (Whitley, 
1996). Their structural similarity suggests a common ancestor and, although their 
classification was originally based solely upon this virion structure (Fields et al., 2013), 
newer members tend to be classified primarily on the basis of their genomic sequence. 
Herpesviruses are designated by the species they infect, their family or sub-family, and 
then by sequential numbering, such as ‘Human herpesvirus 7’ (HHV-7). These viruses often 
have a common name as well, such as ‘human herpesvirus 3’ which is known as ‘varicella-
zoster virus’ (or VZV). 
One commonality of herpesvirus genomes is the conservation of their sequence 
organisation, and they can therefore be grouped into classes based on the copy number, 
location, and orientation of repeat elements. (Roizman and Pellett, 2001, Barry and Chang, 
2007). These 6 structure classes (named A-F) correspond to different genome layouts 
(Figure 1.1). Class A genomes contain a unique sequence flanked by a direct repeat, and is 
represented by viruses such as HHV-6 and HHV-7 (Davison, 2007a). Class B defines 
genomes that have direct repeated sequences at the termini that consist of variable copy 
numbers of a tandemly repeated sequences, and contains mostly γ-herpesviruses, such as 
HHV-8. The class C structure is a derivative of class B, where the internal direct repeats are 
unrelated to the terminal set, and this structure is found in viruses such as EBV (Davison, 
2007a). Class D genomes are characteristic of alpha-herpesviruses in the Varicellovirus 
genus, such as VZV, and contain two unique regions each flanked by inverted repeats 
(Davison, 2007a). Class E genomes are the most complex structure type and are generally 
characteristic of Simplexviruses (α-herpesviruses) but have also evolved independently in 
the β-herpesvirus lineage in the cytomegaloviruses (CMVs) of higher primates such as 
humans and chimpanzees (HCMV and CCMV respectively) (Weststrate et al., 1980, Davison 
et al., 2003b). Class E genomes are similar to class D, as they also contain internal unique 
sequences whereby both termini are repeated  
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Figure 1.1: The 6 classes of herpesvirus genome structure. Genome structure classes A-F 
figure taken from A. J. Davison (2007a) as initially described by (Roizman & Pellett, 2001). 
Horizontal lines depict the unique regions and rectangles depict the repeat regions of the 
genome, with orientations shown with arrows. Regions are detailed for class E only; with 
regions named as follows, US= Unique short, UL= Unique long, TR/IR= Terminal/internal 
repeat (L, Long or S, Short). a denotes terminal redundancy and a’ the internal inverted copy. 
Genomes are not to scale. 
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in an inverted orientation, except that the repeat regions are much larger and segment 
inversion gives rise to four equimolar genome isomers (Davison, 2007a, Whitley, 1996). 
These unique regions are termed unique long (UL) and unique short (US). Class F genomes 
lack the inverted and direct repeats across other herpesvirus genomes, and is represented 
by a beta-herpesvirus Tupaiid herpesvirus (THV), but not by any human viruses (Davison, 
2007a). 
The core genes conserved down through herpesvirus evolution are found in seven blocks 
near the centre of the genome, encoding proteins involved in nucleic acid metabolism, DNA 
replication, virion structure and maturation (Barry and Chang, 2007, Roizman and Pellett, 
2001). This includes the conservation of three gene families (UL25, UL82, and US22) (Barry 
and Chang, 2007). Across β-herpesvirus genomes, there are also three blocks of conserved 
genes, and a G-protein coupled receptor. This has now also been expanded to include 
blocks UL23-43, UL82-84, and US22-26, along with two loci whose location, structures and 
splicing patterns are highly preserved (Barry and Chang, 2007, Davison et al., 2003b). The β-
herpesvirus sub-family cluster into 4 distinct groups as previously mentioned, as seen by 
phylogenetic tree analysis of core genes (Figure 1.2 A). All 4 groups however share a 
common appearance, prolonged replication cycles, species specificity, and their tropism for 
the salivary gland (Mocarski et al., 2013).  
Across the range of sub-families, there are 9 herpesviruses in total that can infect humans 
as their primary hosts (Table 1.2). Herpes simplex viruses 1 and 2 along with varicella-
zoster virus are α-herpesviruses; human cytomegalovirus (HCMV), human herpesviruses 
6A, 6B and 7 (HHV-6A, 6B and 7) are β-herpesviruses; and Kaposi's sarcoma-associated 
herpesvirus (HHV-8/KSVH) and Epstein-Barr virus (EBV) are γ-herpesviruses (Pellett and 
Roizman, 2013). These human viruses and their relationships are demonstrated in Figure 
1.2B, with their grouping into α, β and γ sub-groups made apparent. 
 
1.2 Human Cytomegalovirus (HCMV) 
The cytomegalovirus genus is one of the four β-herpesvirus genera that can infect a range 
of primate species including humans (HCMV), chimpanzees (CCMV), African green monkeys 
(SCMV), New World monkeys (Aotine herpesviruses 1 and 3) and Rhesus monkeys 
(RhCMV). CMVs are known as salivary gland viruses and have common growth 
characteristics with nuclear and cytoplasmic inclusions contributing to their characteristic  
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Abbreviations 
HCMV= human cytomegalovirus 
(CMV)  
CCMC= chimpanzee CMV              
GMCMV= green monkey CMV             
RhCMV= rhesus CMV                   
OMCMV= owl monkey CMV                  
SMCMV= squirrel monkey CMV  
GPCMV= guinea pig CMV 
MSHV= miniopterus schreibersii 
herpesvirus 
TuHV= tupaiid herpesvirus 1;  
MCMV= murine CMV 
RCMV= rat CMV 
RCMVE= rat CMV England 
HHV6A= human herpesvirus 6A 
HHV6B= human herpesvirus 6B 
HHV7= human herpesvirus 7 
PCMV= porcine cytomegalovirus 
Abbreviations 
KSHV= Kaposi’s sarcoma-
associated herpesvirus 
EBV= Epstein Barr virus 
 
HHV7= human herpesvirus 7 
HHV6= human herpesvirus 6 
(variants A and B) 
HCMV= human CMV  
 
VZV= Varicella-zoster virus              
HSV-1= Herpes simplex virus 1             
HSV-2= Herpes simplex virus 2                    
A 
 
 
 
 
 
 
 
 
 
B 
Figure 1.2: Phylogenetic analysis of herpesviruses.  A) Phylogenetic tree of the 4 β-herpesvirus 
genera using amino acid sequences of core genes (U38, U39, U40, U41, U57, U60, U77, and U81) as 
created by Wilkie et al. (2014). The scale bar shows nucleotide differences/nucleotide. B) 
Phylogenetic tree of the human herpesviruses into their sub-families, edited from Moore et al. 
(1996), based on aligned amino acid sequences between for the Major capsid protein (MCP). Branch 
lengths are based on evolutionary distance. 
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Table 1.2: The 9 Herpesviruses that infect humans as their primary host, as 
modified from Pellett and Roizman (2013)◊ 
 
◊ collated from the data provided by the Herpesvirales Study Group of the International 
Committee on Taxonomy of Viruses (ICTV, 2011).  
* Values obtained in different labs  
† 2 well-known strains of HCMV given as examples 
 
 
 
 
 
 
Virus designation Common virus name Sub-family (genus) Genome size 
Human Herpesvirus 
1 (HHV-1) 
Herpes simplex virus 1 
(HSV-1) 
α-herpesvirus 
(Simplexvirus) 
152 Kbp 
Human Herpesvirus 
2 (HHV-2) 
Herpes simplex virus 2 
(HSV-2) 
α-herpesvirus 
(Simplexvirus) 
152 Kbp 
Human Herpesvirus 
3 (HHV-3) 
Varicella-zoster virus 
(VZV) 
α-herpesvirus  
(Varicellovirus) 
125 Kbp 
Human Herpesvirus 
4 (HHV-4) 
Epstein Barr virus (EBV) γ-herpesvirus  
(Lymphocryptovirus) 
172 Kbp 
Human Herpesvirus 
5 (HHV-5) 
Human 
Cytomegalovirus 
(HCMV) 
β-herpesvirus  
(Cytomegalovirus) 
Merlin 236 Kbp,                           
AD169 230 
Kbp† 
Human Herpesvirus 
6 (HHV-6) 
HHV-6 A  
 
β-herpesvirus  
(Roseolovirus) 
159/170* Kbp  
HHV-6 B 
 
β-herpesvirus  
(Roseolovirus) 
162/168* Kbp  
Human Herpesvirus 
7 (HHV-7) 
HHV-7 β-herpesvirus  
(Roseolovirus) 
145 Kbp 
Human Herpesvirus 
8 (HHV-8) 
Kaposi’s sarcoma-
associated herpesvirus 
(KSVH) 
γ-herpesvirus 
(Rhadinovirus) 
170/210* Kbp 
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cytopathology which were first noted in 1881 but was originally thought to be caused by 
protozoa (Ribbert, 1904). They were named due to this common enlargement of the 
infected cells, as ‘cytomegalovirus’ (cytomegalia meaning large cell) and they were 
subsequently linked to ‘generalized cytomegalic inclusion disease’ seen in children (Wyatt 
et al., 1950, Rowe et al., 1953). Viruses were historically hard to culture, and it wasn’t until 
after 1949 when the successful cultivation and isolation of poliomyelitis virus was carried 
out using human embryonic cells, that HCMV was isolated in a cell culture system (Enders 
et al., 1949, Rowe et al., 1953).HCMV, also designated human herpesvirus 5 (HHV-5), can 
now be cultured in a range of human cells (Section 1.4.1.1). HCMV has long been perceived 
as a slowly replicating virus based on the time it takes to see the cytopathic effect and 
virion release in in vitro experiments. HCMV however seems to have a moderately quicker 
replication rate in vivo with a doubling time of approximately one day, indicating that it 
may not be the replicative cycle itself which is slow, but possibly other factors also (Emery 
et al., 1999, Emery, 2001).  
 
1.3 HCMV Genome  
The class E structure (Figure 1.1) of HCMV’s genome is organized into 2 unique regions- 
unique long (UL) and unique short (US) sequences that are each flanked by inverted 
repeats, referred to as TRL/IRL and IRS/TRS (terminal repeat long/short and internal repeat 
long/short). This results in an overall genome configuration of TRL–UL–IRL–IRS– US–TRS 
(Chee et al., 1990, Mocarski and Courcelle, 2001). The biological reason for this class E type 
structure remains unknown. HCMV’s genes are named according to their position in the 
genome and are generally sequential, for example US1 to designate the 1st gene in the US 
region of the genome, however this can be disturbed due to the historical designation of 
genes prior to this agreement (Spaete et al., 1994, Chee et al., 1990). 
HCMV has the largest genome of all the characterized herpesviruses and has evolved to 
produce a larger capsid than other herpesviruses, with a diameter of 130 nm (rather than 
the 125 nm of the HSV-1 capsid), however its DNA is still tightly packed within it (Butcher et 
al., 1998, Bhella et al., 2000). The genome size of HCMV varies with strain but ranges from 
230 to 235 kDa (Mocarski et al., 2013). The genome of HCMV contains over 200 open-
reading frames (ORFs) to date and encodes at least 170 protein-coding genes, many of 
these with unknown functions (Davison et al., 2003a, Dolan et al., 2004, Zhang et al., 2007, 
Gatherer et al., 2011). Core genes are found across all three subfamilies of human 
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herpesviruses (α, β and γ) and often encode genes that are essential for viral growth, such 
as proteins of the DNA polymerase complex and the major capsid protein (MCP)(Davison, 
2007a). Only 45 of HCMV’s genes are required for replication in fibroblasts, leaving the vast 
majority of genes having the potential to promote virulence and/or avoid the host’s 
defences (Wilkinson et al., 2015, Dunn et al., 2003b, Yu et al., 2003).  
Also present in the genome are cellular homologues that indicate that HCMV originally 
acquired many of its genes by ‘gene capture’, where recombination occurred from the host 
in a lateral transmission. Cellular homologues are common in herpesviruses and gene 
capture has resulted in the addition of functions in cell signalling, apoptosis and immune 
regulation (Davison, 2011). This has even occurred independently in various lineages during 
herpesvirus evolution, including with human interleukin-10 (IL-10) that occurred on 3 
occasions across 2 sub-families in the genera Cytomegalovirus, Lymphocryptovirus and 
Percavirus (Davison, 2011). Capturing host anti-inflammatory cytokines could be 
advantageous to the virus as they can reduce the immune response to viral infections. 
HCMV has a broader selection of captured genes than other herpesvirus members, and 
also uses gene duplication as a way to produce gene families that can diverge in function 
(Section 1.8). HCMV is also unusual as it has a number of hypervariable genes that exist as 
different variants and can be highly divergent, thought to have been caused by ancestral 
immune selection in different human populations (Davison, 2011). Due to the possibility of 
co-infection with multiple strains, recombination is also evident between current HCMV 
strains which will similarly affect their evolution. As well as regions encoding proteins, 
HCMV also encodes three non-coding RNAs and 14 miRNAs (Davison, 2011). Multiple anti-
sense RNAs are also known to be transcribed but their function is not yet clear (Gatherer et 
al., 2011).   
 
1.3.1 HCMV strains  
The main HCMV strains used in laboratories across the world are AD169, Merlin, TB40/E, 
Toledo, TR and Towne (Table 1.3). The phylogenetic relationships of some of these strains 
is shown in Figure 1.3. Different strains of HCMV can have varying genome length and vary 
in the copy number of terminal and internal repeats sequences, as well as containing 
mutations and deletions (Table 1.3). AD169 has been widely used in research since its 
original isolation in ~1955 from the adenoids of an infected child and was the first strain of 
HCMV to be fully sequenced (Chee et al., 1990, Rowe et al., 1953). Towne has also been 
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extensively used since its isolation back in 1970 (Plotkin et al., 1975). Both these strains are 
termed ‘laboratory strains’ or ‘high passage strains’ as they have been passaged extensively 
in vitro which has caused them to acquire mutations and they may no longer represent the 
clinical strain they originated from (Wilkinson et al., 2015, Cha et al., 1996). Numerous 
point mutations and deletions that have accumulated have changed not just the genetic 
content but also the biological properties of the viruses, resulting in AD169 and Towne 
becoming easier and quicker to cultivate than clinical isolates. It has however also resulted 
in them being unable to replicate in several cell types, including epithelial and endothelial 
cells (Ryckman et al., 2006) and they have been altered so much that they now cause little 
or no virulence when introduced to seronegative individuals (Just et al., 1975; Plotkin et al., 
1976; Neff et al., 1979 as cited by Sijmons et al. (2014)).  
Other isolates are termed ‘low-passage strains’, and these are much closer to HCMV 
isolates in the population but are not readily propagated in cell culture. This includes 
Toledo which has been passaged much less than the AD169 and Towne and still retains its 
virulence, producing the normal primary symptoms of a mononucleosis-type illness in the 
exposed individuals (Quinnan et al., 1984 as cited by Sijmons et al. (2014)). Merlin is a low 
passage strain originally isolated from a congenitally infected child (Davison et al., 2003a) 
and is often referred to as a ‘clinical strain’ as the cloned viral genome was restored to 
match the sequence found in the original clinical sample, prior to being passaged in 
cultured cells (Stanton et al., 2010). Merlin is the first strain to accurately represent a fully 
‘wildtype’ clinical strain, and was achieved using a bacterial artificial chromosome (BAC) in 
which mutations gained in vitro were repaired. The BAC is an invaluable tool that allows for 
a reliable genetically stable source of ‘wildtype’ or ‘clinical’-type virus and is used to avoid 
over-passaging the virus and to prevent mutations that would alter its genome (Stanton et 
al., 2010). The only difference to the clinical form of this strain is two genes (RL13 and 
UL128) that are interrupted by point mutations that were rapidly selected in cell culture 
(Davison et al., 2003a, Dolan et al., 2004, Stanton et al., 2010, Dargan et al., 2010). This is 
not uncommon, with both RL13, and the UL128 locus (UL128L, consisting of genes UL128, 
UL130 and UL131A) consistently and rapidly affected by mutations (Murrell et al., 2013). 
Generally the first mutation to be selected for in cell culture impacts RL13, with the UL128L 
mutating shortly afterwards. Mutations in the unique long/b' (UL/b′) 
12 
 
Table 1.3: A summary of the main research strains of HCMV, how they were 
originally isolated and the main mutations or alterations in their genomes.  
Strain ◊ Type Main differences† Isolated from References 
 
Merlin Low 
passage 
strain 
The BAC derived 
virus has a fully 
wildtype genome, 
except for point 
mutations in RL13 
and UL128. Almost 
100% identity to 
original clinical 
sample  
 
 
Isolated from 
fibroblasts by 3 
passages from a 
congenitally 
infected child’s 
urine sample 
(Cardiff Diagnostic 
Virology laboratory) 
(Wilkinson et al., 
2008, Dolan et al., 
2004, Wilkinson et 
al., 2015) 
AD169 High 
passage 
lab-
adapted 
strain 
Deletion of 15 kbp 
(~19 genes) from the 
UL/b’ region (UL133-
UL151), acquired 
duplications of RL1-
14, and mutations in 
RL13 and UL128L. 
Altered tropism and 
virulence. 
 
Isolated from the 
adenoids of a 7-
year-old, and 
passaged 14 times 
in human fibroblast 
cells (National 
Institutes of Health, 
Bethesda, MD, USA)  
(Rowe et al., 1953, 
Bradley et al., 
2009, Cha et al., 
1996, Sijmons et 
al., 2014).  
Toledo* Low 
passage 
strain 
Some UL/b’ region 
genes are inverted. 
BAC strain is missing 
US2-US11. Not 
representative of 
wild-type. Some 
variants don’t 
replicate in 
endothelial cells. 
 
Isolated from the 
urine of a 
congenitally 
infected child 
(Stanford 
University). BAC 
clone was a plaque-
purified derivative  
(Cha et al., 1996, 
Quinnan et al., 
1984, Baldanti et 
al., 2003, 
Wilkinson et al., 
2015)  
 
Towne* High 
passage 
lab-
adapted 
strain 
Deletion of ~13 kbp 
from UL/b’ region 
including the region 
UL144-UL151, plus 
duplication of 
sequences within UL1 
as well as a and b 
repeats. 
 
Isolated in 1970 
from the urine of a 
2-month old 
congenitally 
infected infant, and 
passaged in human 
fibroblasts  
(Cha et al., 1996, 
Murphy and 
Shenk, 2008, 
Plotkin et al., 
1975). 
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Strain Type Main differences Isolated from References 
 
TR Low 
passage 
strain 
BAC clone is missing 
US2-US5.  
Isolated from an 
AIDS patient with 
retinitis (“patient 
2”). 
(Smith et al., 1998, 
Murphy et al., 
2003)  
 
TB40/E Low 
passage 
strain 
Mutations in UL/b’ 
region including a 
frameshift in UL141. 
One derivative 
additionally lacks 
UL145 and UL144. 
Highly 
endotheliotropic 
strain with release of 
high titres  
 
Originally derived 
from a mixed 
population of 
mutant variants 
from a throat wash 
of a bone marrow 
transplant recipient 
by propagation in 
fibroblasts  
(Sinzger et al., 
2008, Wilkinson et 
al., 2015, Dolan et 
al., 2004, Tomasec 
et al., 2005)  
 
◊ There are however multiple variants of most HCMV strains which can have varying 
properties and mutations  
† Non-exhaustive list 
* In Towne and Toledo BAC strains vector cassette sequences replaced the US1-US11 and 
US2-US11 genes respectively  
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Figure 1.3: Phylogenetic analysis of several HCMV strains. A) Phylogenetic analysis by 
Deckers et al. (2009) of the UL33 proteins of multiple HCMV strains, using chimpanzee 
cytomegalovirus (CCMV) as outlier. The branch length is proportional to evolutionary distance. 
B) Phylogenetic analysis by Dolan et al. (2004) of the UL146 proteins of different HCMV 
strains. Grey circles indicate regions of unresolved branching order, and black circles indicate 
sets of closely grouped strains. The scale bar indicates divergence as substitutions per amino 
acid site. 
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region also occur but take longer and generally take place between the UL140 and the 
UL145 region (Murrell et al., 2013, Stanton et al., 2010, Dargan et al., 2010). Other genome 
alterations during cell culture are more strain specific and include a variety of mutations, 
deletions, duplications, differences in repeat regions and re-arrangement (Murphy and 
Shenk, 2008, Cha et al., 1996). AD169 and Towne for example both have extensive 
deletions in the UL/b’ region due to their extensive passaging. The Towne strain is missing a 
~13 kbp DNA segment from this region, including genes UL144-UL151, and the AD169 
strain is missing a 15 kbp segment (~19 genes) including UL133-UL151 (Cha et al., 1996) 
(Table 1.3).  
Aside from the commonly affected UL/b’ region, analysis of AD169 variants from 3 
laboratories revealed that numerous other genetic changes had accumulated over time 
during passage of this virus. This also caused differences between the variants, and the 
situation is similar with the Towne strain (Wilkinson et al., 2015, Bradley et al., 2009). Both 
AD169 and Towne strains have acquired a multigene repeated sequence, with AD169 
containing duplications of RL1-14 (termed TRL1-14 and IRL1-14 to differentiate) and Towne 
underwent duplication of sequences within UL1 as well as a and b repeats (Murphy and 
Shenk, 2008). A portion of the UL region of AD169, are present in the Toledo strain, but in 
an inverted orientation, with a shortened b’ repeat sequence (Cha et al., 1996). Sporadic 
mutations can also occur across other regions over time and a few of the genes found to 
have been previously affected include RL5A, UL36, UL131A, RL1, UL42, UL43 (Wilkinson et 
al., 2015, Sijmons et al., 2015). 
Alongside Merlin there is now also a BAC-derived low passage TR strain, originally isolated 
from an AIDS patient with retinitis (Smith et al., 1998), as well as a TB40-E variant (TB40/E) 
strain, originally derived from a bone marrow transplant recipient as a mixed population of 
mutant variants (Wilkinson et al., 2015, Sinzger et al., 2008). The virus derived from BAC 
TB40/E can be grown to exceptionally high titres and is able to infect a wide range of cell 
types for a culture strain (Sinzger et al., 2008), however it still contains mutations in some 
key genes (Wilkinson et al., 2015, Dolan et al., 2004). Most BAC derived constructs also 
contain an incorporated cassette that replaces genes in the US2 and US6 gene families, 
with Towne and Toledo BAC-derived strains missing US1-US11 and US2-US11 genes 
respectively (Wilkinson et al., 2015)(Table 1.3). 
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1.4 HCMV Life Cycle 
The HCMV life cycle in vivo is classically divided into productive lytic infection (Section 
1.4.1) and non-productive infection termed ‘latency’ (Section 1.4.2), although the reality 
may be much more complex. As herpesvirus infections are lifelong, initial exposure to the 
virus establishes systemic acute infection, but the virus must also establish sites of long-
term persistence. All stages of the HCMV lifecycle can greatly alter the proteome of the cell 
surface, with changes in abundance occurring in 24% of the host proteins at 72 hours post 
infection (hpi) (Jean Beltran and Cristea, 2014). 
1.4.1 HCMV Productive Lytic Infection 
During the productive HCMV infection life cycle (Figure 1.4), virions enter the host cell and 
initiate a multi-step process that involves delivery of virion components to the nucleus, 
initiation of transcription followed by a cascade through early to late phase gene 
expression, ultimately leading to the production of new virions and their egress from the 
cell. HCMV can replicate in a vast array of cell types in vivo and in vitro, and this broad 
tropism is important for viral spread within and between hosts. 
1.4.1.1 Tropism 
HCMV can target a broad range of cell types during infection including fibroblasts, epithelial 
cells, endothelial cells (ECs) and smooth muscle cells (Sinzger et al., 1995). Epithelial cells 
and ECs are found across a multitude of organs and tissues, with bone marrow, lung and 
gastrointestinal ECs frequently infected (Sinzger et al., 1995, Myerson et al., 1984). They 
can facilitate viral spread to and from the environment and other hosts, as well as 
facilitating the spread of HCMV to other organs within the same host (Söderberg-Nauclér 
and Nelson, 1999, Waldman et al., 1995, Hahn et al., 2004). Vascular ECs for example may 
allow HCMV to spread through the bloodstream, aiding spread and dissemination 
(Waldman et al., 1995, Grefte et al., 1993). EC subtypes can have differing gene expression 
and differ in their susceptibilities to HCMV (reviewed in Jarvis and Nelson (2007)), with 
some EC subtypes even being suggested as sources of latency (Fish et al., 1998). Other 
commonly infected cells are macrophages and fibroblasts, with HCMV occasionally found in 
neuronal cells, smooth muscle cells and hepatocytes (Söderberg-Nauclér and Nelson, 
1999). For in vitro HCMV growth and experimentation, fibroblasts, endothelial cells and 
epithelial cells are most commonly used.  
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HCMV transcription differs between cell types, with the transcriptome of the Merlin strain 
shown to be different in fibroblasts, epithelial cells and astrocytoma cells over time (Towler 
et al., 2012). Genes that are down-regulated include those that are involved in  genome 
replication, virion assembly, and virion maturation and release stages (Towler et al., 2012) 
which may account for the differing growth kinetics in the different cell types. 
 
1.4.1.2 HCMV Entry 
The first stage of the life cycle process is that the virus must enter the host cell by 
membrane fusion, mediated by the binding of HCMV’s envelope glycoproteins to host cell 
receptor(s). Glycoprotein B (gB) mediates HCMV entry by acting as a fusion protein, which 
is required for virus entry and cell-to-cell spread, although not absolutely required for virus 
attachment (Isaacson and Compton, 2009, Wille et al., 2013). There is some evidence for 
the direct binding of gB to the platelet-derived growth factor receptor (PDGFR) and the 
epidermal growth factor receptor (EGFR), although PDGFR does not appear to be required 
for standard HCMV entry and EGFR is not required for cellular expression of HCMV-
essential genes (Soroceanu et al., 2008, Vanarsdall et al., 2012, Wang et al., 2003). There is 
also the possibility that gB binds integrins and activates integrin-specific signal transduction 
pathways (Feire et al., 2004). 
Glycoproteins gH and gL are also needed for both cell entry and for cell-cell fusion; and 
alongside gB they form the minimal HCMV fusion machinery, where they possibly trigger gB 
for fusion (Wille et al., 2013, Vanarsdall and Johnson, 2012, Isaacson and Compton, 2009). 
These entry proteins can be seen as tropism determinants, and gH and gL form the core 
components of 2 distinct complexes that are required for viral entry in different cell types. 
The ‘pentameric complex’ consists of gH, gL, pUL128, pUL130A and pUL131 (gH/gL/UL128-
131) and it is required for viral infection of endothelial, epithelial and myeloid cell types, 
whereas the ‘trimer complex’ consisting of gH, gL and gO (gH/gL/gO) is required for entry 
into fibroblasts (Wang and Shenk, 2005b, Wang and Shenk, 2005a, Hahn et al., 2004). 
Recent updates suggest however that it may in fact only be gH/gL that is required in the 
virion for fibroblast entry in the TR strain at least, with gO just required as a chaperone 
(Wille et al., 2010). Other complexes or additional proteins may also be involved (Caló et 
al., 2016). A viral regulator of these complexes has also been found to affect cell tropism, 
with UL148 suggested to favour the gH/gL/gO complex by competing with pUL128 for the 
partially assembled gH/gL complexes, regulating the relative amounts of the two gH/gL 
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complexes (Li et al., 2015). Some strains have selected for mutations in these entry 
complex genes due to passaging in certain cell types and therefore can no longer propagate 
in other cell types. Mutations in UL128, UL130 or UL131 are capable of abolishing 
endothelial cell tropism (Hahn et al., 2004, Akter et al., 2003), and repairing the mutated 
UL131 gene in AD169 restores its ability to infect both epithelial and endothelial cells 
(Wang and Shenk, 2005a).  
Glycoproteins gM and gN are found in high abundance in the virion envelope, are both 
essential for HCMV replication, and form a complex (gM/gN) (Mach et al., 2000, Krzyzaniak 
et al., 2007, Varnum et al., 2004). It is not clear whether the gM/gN complex promotes 
virus entry, but it has been suggested that they can promote virus assembly and 
envelopment of capsids (Krzyzaniak et al., 2007, Mach et al., 2007). 
Once the glycoproteins have bound, entry of the virus occurs either by fusion or 
endocytosis, depending on the cell type and the conditions. In epithelial and endothelial 
cells, endocytosis occurs and as the virus enters it becomes enclosed in the plasma 
membrane in an endosome. Escape from the endosome requires acidification, with the low 
pH triggering the viral membrane proteins to fuse with the endosomal membrane (Wang 
and Shenk, 2005b, Bodaghi et al., 1999). In fibroblasts however, entry is by direct fusion 
with the plasma membrane and virions do not become enclosed in endosomes, so direct 
entry is pH-independent (Compton et al., 1992). 
Tegument proteins from the input virus can regulate some of the cellular pathways which 
are predicted to be involved in the final steps of entry, and the stages of transporting the 
uncoated capsid to the nucleus (reviewed by Kalejta (2008)). The interaction of gB (pUL55) 
and gH (pUL75) with host cell surface receptors upon viral entry also activates cellular 
transcription factors, including nuclear factor kappa B (NF-κB) and specificity protein 1 
(Sp1), as well the interferon (IFN) response by strongly inducing many IFN-stimulated genes 
(Huang and Johnson, 2000, Yurochko et al., 1997, Boehme et al., 2004, Simmen et al., 
2001). HCMV encodes proteins to downregulate these antiviral immune responses, 
including the input protein pp65 (ppUL83) which can dampen and the induction of pro-
inflammatory cytokines and IFN-responsive genes (Browne and Shenk, 2003). The NF-κB 
pathway however is still required for the transactivation of the major immediate early 
promoter (MIEP) so its modulation must be balanced (DeMeritt et al., 2004, Browne and 
Shenk, 2003). NF-κB activation can start as early as 15 mins after HCMV entry, with the 
pathway subsequently activated within ~24 hpi (Yurochko et al., 1997).  
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1.4.1.3 Nuclear Transport  
After membrane fusion, some tegument proteins are released while pUL47 and pUL48 
remain tightly bound to the capsid where they are thought to interact with the host 
dynein-microtubule system in order to transport the viral capsids to the nuclear pore (Liu 
and Zhou, 2007, Ogawa-Goto et al., 2003). Viral DNA enters the nucleus through the 
nuclear pore complex (NPC) where pUL47, pUL48, pUL69 and the major capsid protein 
(MCP; pUL86) together facilitate the release of the viral DNA from the capsid into the 
nucleus (Bechtel and Shenk, 2002, Kobiler et al., 2012). Some tegument proteins inhibit the 
initial immune response or regulate viral gene expression, such as pp65 (reviewed by 
Kalejta (2008)). Others can migrate to the nucleus independently of the nucleocapsid, 
including pp71 (ppUL82) which subsequently targets the human death-domain associated 
protein hDaxx (Woodhall et al., 2006). Other tegument proteins traffic to different sub-
cellular locations, such as pp28 which localises to the vAC (Section 1.4.1.6) (Sanchez et al., 
2000b). 
Once inside the nucleus, the genome requires interactions with cellular histones which can 
be modified by various enzymes that can remodel the chromatin, such as histone 
deacetylase 1 (HDAC1). This enzyme is a member of the nucleosome remodelling and 
deacetylase (NuRD) protein complex, and it can regulate immediate-early (IE) gene 
expression (Terhune et al., 2010, Groves et al., 2009, Reeves et al., 2006). Once in the 
nucleus, viral genome transcription and replication can be initiated. 
1.4.1.4 Viral Gene Expression 
A large number of viral genes are expressed across lytic replication, which are not all 
expressed simultaneously, but in a cascade of expression. Traditionally there has been 3 
main cascades, immediate early (IE/α), early (E/β) and late (L/γ) cascades. 
Immediate early gene expression 
Immediate early (IE, α) genes are the first to be transcribed and these are triggered after 
cell entry, usually appearing within 1 hour post infection (hpi) and peaking around 4-8 hpi. 
Initiation of IE gene expression depends upon pre-existing machinery so is not reliant on de 
novo viral protein synthesis and is also sensitive to the cell cycle phase (Stinski et al., 1983, 
Salvant et al., 1998, Stenberg et al., 1984). IE transcripts therefore accumulate in the 
presence of cycloheximide or other protein synthesis inhibitors (Chambers et al., 1999). IE 
gene expression is mapped to 4 regions of the genome, with the majority of expression 
occurring at the IE1/IE2 locus, giving rise to the major IE1 and IE2 products, with their 
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expression controlled by the major immediate early promoter (MIEP) (Wilkinson et al., 
1984, Akrigg et al., 1985, Stenberg et al., 1984). These 2 gene products share an 85 amino 
acid domain which splices to UL123 or UL122 respectively (Stenberg et al., 1984, Stinski et 
al., 1983, Akrigg et al., 1985). IE genes can function as transcription factors and by 
definition can instigate the onward transcriptional cascade (White and Spector, 2007, 
Guetta et al., 2001, Stinski et al., 1983). IE2 is vital for activating the subsequent stages and 
is essential for viral replication and has many functions (Sarisky and Hayward, 1996, 
Iskenderian et al., 1996). IE2 is also implicated in auto-regulation of the MIEP, with IE1 
functioning as an accessory protein, having an indirect enhancement on transcription 
(Wilkinson et al., 1998, Reeves et al., 2006). Aside from IE1 and IE2, the other 3 regions of 
IE/α genes are UL36-UL38, TRS1-IRS1 and US3 (Colberg-Poley, 1996).  
Activating the viral cascade is important, but detailed studies reveal that IE genes are 
primarily required to counter intrinsic, innate and adaptive immune defences. pIE1 for 
example disrupts PML-bodies; pIE1, pIRS1 and pTRS1 counter the interferon response, 
pUL36 and pUL37 have anti-apoptotic functions, and pUS3 sequesters MHC-1 (Colberg-
Poley, 1996, Noriega et al., 2012b, Skaletskaya et al., 2001, Goldmacher, 2005, Child et al., 
2004, Wilkinson et al., 1998). Although not an IE protein itself, pp71 (UL82) is a virion 
protein that acts as a transactivator and is required for IE gene expression, and functions 
through binding with and degrading hDaxx to relieve hDaxx and HDAC-mediated silencing 
of MIEP (Cantrell and Bresnahan, 2006, Woodhall et al., 2006). 
Early gene expression 
Early (E/β) genes are next to be transcribed, with their gene expression triggered by 
functional IE genes, especially IE2, and are therefore triggered ~8-12 hpi. Early genes are 
transcribed even in the presence of a viral DNA synthesis inhibitor and are required for 
initiating viral genome replication (Chambers et al., 1999). Genes in this cascade include 
genes that play a role in viral DNA synthesis and processing, as well as immune modulators, 
anti-apoptosis genes and cell cycle regulators (Huang and Johnson, 2000, White and 
Spector, 2007). Most early genes accumulate gradually over the course of infection, and 
generally continue through the late phase. Classically these genes were split into 2 subsets, 
β1 (early) and β2 (early-late) genes as defined by a difference in their expression patterns, 
with β2 genes commonly partially inhibited by viral DNA synthesis inhibitors such as 
Phosphonoformate (PFA) (Chambers et al., 1999). 
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Late gene expression 
Late (L/γ) genes are the last to be produced and their expression is highest after viral DNA 
replication has begun (~24 hpi), their expression is dependent upon the expression of E 
genes, and they are partially or completely inhibited by the use of viral DNA synthesis 
inhibitors (Chambers et al., 1999). This cascade subset includes mostly structural virion 
proteins, capsid maturation proteins or proteins that play roles in virion maturation and 
egress (Brinkworth and Thorn, 2013, Mocarski et al., 2013). Classically, late (γ) genes were 
divided into the 2 sub-categories of leaky-late (γ1) and true-late (γ2) proteins depending on 
their pattern of expression and their dependence on viral DNA synthesis, with true-late 
genes expressed exclusively after DNA replication. Their pattern and timing can differ with 
cell type however. 
Temporal kinetics classification 
Another gene classification system has also been created by studying the temporal protein 
analysis of 139 canonical HCMV proteins and 14 non-canonical ORFs, clustering them based 
on their time of expression and expression patterns (Weekes et al., 2014). This 
demonstrated that all detected HCMV proteins clustered into 5 distinct cascades, classified 
as temporal classes Tp1-5 the average expression patterns of which are depicted in Figure 
1.5. This temporal class classification system is believed to be more definitive and accurate 
than the previous system which had studied proteins in a range of different viral strains and 
cell types. It does however have a good correlation with the classical classes with the 
known late proteins UL99, UL94, UL75, UL115, and UL32 all correspondingly classified as 
Tp5 for example (Weekes et al., 2014). The use of PFA also demonstrated a good 
correlation between the 2 systems, generally having little effect on Tp1 or Tp2 proteins, 
partially inhibiting Tp3 and Tp4 proteins, and completely or almost completely inhibiting 
the majority of Tp5-class protein s (Weekes et al., 2014). This temporal classification system 
also has a good correlation with other classification systems, with ten of the thirteen Tp1 
proteins being categorised into the equivalent temporal class (Tr1) by their mRNA (Weekes 
et al., 2014, Stern-Ginossar et al., 2012). Proteomics did however reveal that eight proteins 
(UL27, UL29, UL135, UL138, US2, US11, US23 and US24) were expressed earlier in infection 
than previously understood (Weekes et al., 2014). 
Tp1 proteins are expressed with a similar pattern to IE proteins, demonstrating relatively 
high levels of expression from ~6 hpi (Figure 1.5). Both Tp2 and Tp3 proteins show a similar 
pattern to early and early-late proteins (Weekes et al., 2014), with Tp2 proteins tending to 
accumulate rapidly through early time points, staying high and constant throughout  
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Figure 1.5: The 5 Temporal Classes of HCMV Gene Expression. HCMV gene expression 
profiles were classified into 5 distinct classes depending on their gene expression 
patterns and timings. Figure from Weekes et al. (2014). They used k-means clustering 
to assign all quantified HCMV proteins to temporal classes. Shown are the average 
temporal profiles of each class.
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infection. An example of a Tp2 protein is the DNA polymerase pUL54 which is produced 
early and peaks ~24 hpi, levelling off over the infection time course (Weekes et al., 2014). 
Tp3 proteins tend to accumulate slower but steadily, peaking at late time points, such as 
with pUL71 (Weekes et al., 2014). Tp4 proteins have a distinct profile, with maximum 
expression at ~48 hpi and low/lower expression at other time points (Weekes et al., 2014). 
These proteins seem to cluster in the genome and includes the gpRL11 and gpRL12 proteins 
(Weekes et al., 2014). Tp5 proteins have minimal protein expression at 24 and 48 hpi and 
peak between 72 and 96 hpi, with PFA inhibiting 87% of Tp5 proteins (Weekes et al., 2014). 
pp28 (ppUL99) is a Tp5 protein (also categorised as γ2) and has low expression levels at 48 
hpi, and peak expression at 96 hpi. All of HCMV’s capsid proteins are also Tp5 proteins, 
including the major capsid protein (MCP, pUL86) (Weekes et al., 2014). The majority of late 
proteins were originally classified as γ1 proteins, but due to the redefining of the late 
protein subsets, most late proteins (85%) were re-classified as Tp5 proteins (Weekes et al., 
2014), with this new classifications having a high level of correlation with the mRNA 
category defined as Tr5 (Stern-Ginossar et al., 2012). 
1.4.1.5 Viral DNA Replication 
Viral DNA (vDNA) synthesis does not occur until around 24 hpi in cell culture and is initiated 
by β2 (Tp3) gene expression. Once the viral DNA is released from the capsid into the 
nucleus, it circularises and likely forms into a chain of multiple copies of the DNA sequence 
linked together in a ‘concatemer’ (Pari, 2008). Replication takes place from the origin of 
lytic replication, OriLyt, which is the only functional replicator in the genome of HCMV. 
OriLyt is found in the UL region of the genome between UL57 and UL69 and is ~1500bp 
long and structurally complex (Anders et al., 1992, Pari, 2008). The majority of the proteins 
required for synthesis and processing of the viral DNA are expressed with early kinetics 
(Pari and Anders, 1993). pUL44 is responsible for bringing together the other components 
of the replisome complex which includes 11 loci in total, including genes encoding a DNA 
polymerase and DNA binding proteins. These loci include IE1/2, UL36-UL38, UL54, UL57, 
UL70, UL84, UL101-2, UL105 and IRS1/TRS1 (Pari and Anders, 1993). UL112-113 may also 
play a role in the recruitment of the core replication machinery proteins (Ahn et al., 1999). 
The pUL84 gene product is essential for viral DNA synthesis and productive infection and is 
suggested to act in concert with IE2-p86 to trigger viral DNA synthesis (Anders et al., 2007, 
Sarisky and Hayward, 1996).  
Tens of thousands of viral genome copies can be produced per cell by 72-96 hpi during lytic 
replication in fibroblasts, however under 1000 genome copies per cell are produced in 
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epithelial (RPE-1s) and astrocytoma (U373MGs) cells, with total viral yields 1,000- and 
10,000-fold lower respectively (Towler et al., 2012). 
1.4.1.6 Virus Assembly and Structure 
HCMV virions share the common herpesvirus structure of an envelope, tegument, capsid 
and a core (Figure 1.6). Assembly of the virus involves forming the capsid in the nucleus 
and inserting the DNA into the core of the capsid. The tegument is then formed around the 
capsid scaffold, and the particle is enveloped before egressing from the host cell.  
Capsid assembly 
HCMV capsids have the common herpesviruses shell structure of 100nm that consists of 
162 capsomeres. Of these, 150 are hexameric and 12 are pentametric, with both pentons 
and hexons having a cylindrical shape (Chen et al., 1999). These are connected in groups of 
three by asymmetric structures on the capsid floor which form into the icosahedral capsid 
that has 20 triangular faces (Liu and Zhou, 2007). The capsid is formed of 4 main proteins- 
the major capsid protein (MCP/pUL86), the small capsid protein (SCP/pUL48A), the minor 
capsid protein (mCP/pUL46) and mCP binding protein (mCP-BP/pUL85) (Colberg-Poley and 
Williamson, 2013). The penton consists of five copies of the MCP (pUL86) and the hexon 
has six copies of MCP along with six copies of the SCP (pUL48.5) (Chen et al., 1999, Gibson, 
1996). Proteins also required for capsid development include the proteinase precursor 
(pNP1, pUL80A) and related assembly protein precursor (pAP, pUL80.5) which help to 
transport the MCP to the nucleus (Wood et al., 1997, Plafker and Gibson, 1998). mCP-BP on 
the other hand contains its own nuclear localisation signal so appears to transport itself 
and its partners mCP and SCP to the nucleus separately (Plafker and Gibson, 1998). Once 
the capsid is fully formed, the cleavage of pAP and pNP1 by the viral protease (Pr) disrupts 
their interactions with the MCP and allows the internal scaffolding to be removed (Welch 
et al., 1991, Yu et al., 2005). This makes space in the capsid for the viral genome, with 
pUL56 and pUL89 playing a role in the cleaving and packaging of the viral DNA through the 
portal protein (PORT/pUL104) formed on a single vertex of the capsid (Colberg-Poley and 
Williamson, 2013, Bogner et al., 1998). The timing of the protease is essential for DNA 
encapsidation and fully infectious virions (Yu et al., 2005) and to avoid incomplete capsids 
being formed. ‘A’ capsids are empty capsid shells, ‘B’ capsids contain scaffold but no DNA, 
and ‘C’ capsids are fully-formed and contain viral DNA and will subsequently become 
infectious virions (Tandon et al., 2015). 
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Figure 1.6: HCMV virion structure. A) Simplified version of the virion structure of 
HCMV including the 4 main components, the envelope, the tegument, the capsid and 
the core (area inside the capsid where the viral DNA is held). B) STEM tomography of 
the HCMV particle within a vesicle after secondary envelopment has taken place, 
taken from Schauflinger et al. (2013). 
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Addition of Tegument 
Once the DNA is packaged, the addition of tegument can start. The tegument is a unique 
feature of herpesviruses and is found between the capsid and the envelope, with HCMV’s 
tegument containing at least 38 viral proteins (Guo et al., 2010, Varnum et al., 2004). Some 
tegument proteins are conserved in all herpesviruses, with UL71, UL47, UL48, UL87, UL94, 
UL95, UL97, UL99, and UL103 all having homologs in HSV-1, EBV and KSVH (Guo et al., 
2010). Despite this conservation, the tegument has no distinctive features (Guo et al., 2010, 
Varnum et al., 2004). The capsid acts as the scaffold to which the tegument is added (Chen 
et al., 1999). After previous debate as to the location of the tegument addition, it is now 
established that it first occurs in the nucleus and then continues in the virion assembly 
compartment (vAC) described below (Britt and Boppana, 2004). The localisation of protein 
expression can indicate at which site they are added to the maturing virion. pp65 (pUL83) 
for example translocates over time, migrating to the nucleus independently of the capsid 
and vDNA (Britt and Boppana, 2004) so it is likely that pp65 is added to the virion in the 
nucleus (Ahlqvist and Mocarski, 2011). The same is suggested for pp71 which is an 
important protein for the initiation of tegument assembly (Liu and Zhou, 2007, Ahlqvist and 
Mocarski, 2011). pp71 is suggested to provide structure by having a tight association with 
the nucleocapsid, along with proteins pp150 (ppUL32), pp28 (ppUL99) and pUL48 (Chen et 
al., 1999, Liu and Zhou, 2007). The location of where pp150 is added to the capsid is 
debated, but it is the most capsid-proximal tegument protein and is essential for tegument 
formation, and it is possible that it helps with the stability and transport of the capsid to 
the vAC (Hensel et al., 1995, Salsman et al., 2008, Meyer et al., 1997, Sanchez et al., 2000a, 
Homman-Loudiyi et al., 2003). 
Additional tegument proteins are added in the vAC after nuclear egress has occurred. Many 
tegument proteins co-localise to the vAC during virion assembly, but it is unclear whether 
they are added to the virion at this location or whether they accumulate here due to their 
attachment to the capsid/initial tegument. Viral tegument proteins are generally 
phosphorylated and the tegument also contains cellular proteins as well as RNAs (Kalejta, 
2008). These all accumulate during virion assembly and are likely to reside in the tegument. 
The tegument is also known to have DNA polymerase, protein kinase, and cellular 
topoisomerase for DNA replication (Huang and Johnson, 2000). By studying homologs in 
other herpesviruses, it has suggested that some of these outer tegument proteins bind to 
the membrane envelope (Guo et al., 2010). 
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Nuclear egress 
With the initial tegument added in the nucleus, the nucleocapsids can egress through the 
nuclear membrane. This occurs in the part of the nuclear membrane that faces the vAC and 
a nuclear egress complex (NEC) is formed at the inner nuclear membrane (INM) (Alwine, 
2012, Colberg-Poley and Williamson, 2013). It is composed of a type II membrane spanning 
component (NEC1, pUL50) and nuclear lamina-interacting component (NEC2, pUL53) which 
facilitate the capsids exit from the nucleus (Milbradt et al., 2007, Sharma et al., 2014). This 
occurs by disruption and re-modelling of the nuclear lamina by cellular and viral kinases 
and chaperones such as pUL97 (Marschall et al., 2005, Milbradt et al., 2007, Sharma et al., 
2014). The NEC also appears to act as a quality control checkpoint, preferentially allowing 
DNA-containing capsids to egress over incorrectly formed ones (Tandon and Mocarski, 
2012). It is suggested that the capsids are likely to be enveloped through the inner nuclear 
membrane (INM) and de-enveloped through the outer nuclear membrane (ONM), with 
capsids being released into the cytoplasm, and possibly transported via the microtubule-
organizing center (MTOC) system to the vAC (Alwine, 2012, Das et al., 2007).  
VAC Formation 
During HCMV infection, the virus ‘hijacks’ the host cell’s secretory machinery and arranges 
them in concentric cylinders known as the virion assembly compartment (vAC). This 
involves a multitude of host cell organelles, with Golgi and trans-Golgi apparatus circling 
the endosomal machinery, or at least vesicles that share properties with recycling 
endosomes (Figure 1.7) (Das et al., 2014, Das et al., 2007). There is also a network of 
microtubules (cytoskeletal filaments) radiating outward from the centre of the cVAC where 
the microtubule- organizing centre (MTOC) is located (Das and Pellett, 2011, Das and 
Pellett, 2007, Das et al., 2007, Sanchez et al., 2000a). This structure arises adjacent to the 
nucleus which causes the common ‘kidney-shaped’ nucleus frequently seen in HCMV 
infected cells. This is due to dynein pulling the nuclear membrane toward the MTOC, likely 
promoting a tight association with the vAC, with nuclear enlargement alleviating the 
nuclear breakdown that would occur otherwise (Alwine, 2012). 
As well as host organelles, the vAC also contains tegument proteins including pp28 
(ppUL99), pp65 (ppUL83), pp71 (ppUL82), and pp150 (ppUL32), and envelope glycoproteins 
such as gB (gpUL55), gH (gpUL75) and gL (gpUL115)(Sanchez et al., 2000b, Sanchez et al., 
2000a, Homman-Loudiyi et al., 2003). 
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Figure 1.7: The virion assembly compartment (vAC). HCMV re-arranges the cellular 
secretory machinery and arranges them in concentric cylinders, including Golgi and 
trans-Golgi apparatus circling vesicles that share properties with endosomes. This forms 
around the microtubule-organizing centre (MTOC) from which a network of microtubules 
(cytoskeletal filaments) radiating outward from the centre of the cVAC. This structure 
arises adjacent to the nucleus and causes the common ‘kidney-shaped’ nucleus 
frequently seen in HCMV infected cells. 
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The vAC is a unique feature of β-herpesvirus-infected cells and is essential for HCMV virion 
assembly and egress (Das et al., 2007). This structure requires viral DNA synthesis to form, 
with pUL48, pUL94, and pUL103 vital for vAC development (Das et al., 2014). Little 
infectious virus is produced before the vAC is fully developed, which can take 3 to 4 days of 
re-modelling in fibroblasts by HCMV AD169, but can be quicker in other strains (Alwine, 
2012, Das et al., 2007). Secondary envelopment is also believed to occur in the vAC, 
possibly in the early endosome-derived region (Das et al., 2014, Liu and Zhou, 2007, 
Hollinshead et al., 2012, Tooze et al., 1993). The reorganisation of host organelles also 
involves the rearrangement of the endoplasmic reticulum (ER), which becomes more 
condensed as cytoplasmic structures, compared to its typical diffuse staining pattern in 
uninfected cells (Buchkovich et al., 2009, Cavaletto et al., 2015). 
1.4.1.7 Final Envelopment  
The envelope is the outermost layer of the virus and contains most or all of the virion 
glycoproteins (Gibson, 1996). It is a triple layered structure and is acquired from altered cell 
membranes with the presence of lipids and numerous projections of glycoproteins 
(Homman-Loudiyi et al., 2003, Sanchez et al., 2000a). Previous studies suggested that these 
membranes could originate from the Trans-Golgi network (TGN), the ER-Golgi intermediate 
compartment (ERGIC), recycling endosomal compartments or vesicles derived from the 
above (Homman-Loudiyi et al., 2003, Cepeda et al., 2010). However, it is now generally 
accepted that the envelope proteins are first processed through Golgi/TGN, then exported 
to the plasma membrane and are retrieved by the endocytic system before being used to 
envelope the capsids (Hollinshead et al., 2012).  
HCMV virions contain over 70 viral proteins as well as over 70 host cellular proteins 
(Varnum et al., 2004, Murrell, 2014), and the envelope of AD169 contains ~ 23 viral 
glycoproteins including gB, gH, gL, gM (gpUL100), gO (gpUL74), gp48 (gpUL4), gpTRL10, and 
gpUL33 (Varnum et al., 2004). Some proteins however are typically found in much higher 
concentrations than others, including gB which has around 800 molecules per AD169 virion 
(Varnum et al., 2004). Although there is a high degree of conservation between the virions 
and dense bodies of different HCMV strains, their compositions are flexible, and can differ 
across different strains and when grown in different cell types (Scrivano et al., 2011, 
Büscher et al., 2015, Murrell et al., 2013). The Merlin virion proteome shows many 
similarities to the virion of AD169, but the sensitivity of detection or strain differences 
revealed novel virion components of high confidence, some of which have homologs in 
RhCMV or MCMV virions (Murrell, 2014). The composition of the gH/gL entry complexes 
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can also be regulated, which can subsequently affect tropism as well as cell-cell 
transmission (Section 1.4.1.1 and 1.4.1.2) (Li et al., 2015, Luganini et al., 2017, Murrell et 
al., 2017, Wille et al., 2010). The membranes of dense bodies and enveloped virus appear 
to have the same composition, although dense bodies contain less cellular proteins 
(Büscher et al., 2015, Homman-Loudiyi et al., 2003).  
1.4.1.8 Virion Egress 
Mature enveloped infectious virions are released from the cells alongside non-infectious 
enveloped particles (NIEPs) and dense bodies (Tandon et al., 2015). Fully-formed virions 
contain C capsids with complete viral DNA and are therefore infectious. NIEPs on the other 
hand are enveloped particles which contain B capsids with either no or incomplete DNA 
which makes them non-infectious (Irmiere and Gibson, 1983). Dense bodies contain 
enveloped tegument proteins but lack capsids and viral DNA and are composed mainly of 
pp65 (Baldick and Shenk, 1996, Irmiere and Gibson, 1983, Büscher et al., 2015). Different 
amounts and percentages of each type of viral particles can be released by different strains 
and in different cell types, with AD169 overproducing NIEPs by ~10-fold in fibroblasts 
compared to other strains (Irmiere and Gibson, 1983).  
After acquisition of the envelope, the particles exit the cell via the common cellular 
exocytosis pathway. This is facilitated by pUL103 (VEP), which controls the cell-free release 
of progeny as well as cell-to-cell spread, and this tegument protein is conserved across 
herpesvirus subgroups (Ahlqvist and Mocarski, 2011). Virions are generally released 3-4 
days after infection of the cell but can vary between strains and cell types. Production of 
cell-released Merlin virions for example, can first be detected at 72 hpi in fibroblasts, but 
not until 120 hpi in RPE-1s and U373MGs (Towler et al., 2012). 
 
1.4.2 HCMV Latent Infection and Reactivation 
All studied herpesviruses are capable of latency and re-activation, although core genes do 
not appear to be involved, so it is likely that this trait has been acquired in different 
lineages rather than through a common herpesvirus ancestor (Davison, 2011). The majority 
of HCMV’s life cycle is spent in this ‘latent’-type phase of non-productive infection, where 
only a small number of genes are detectable and virions are not produced (Goodrum et al., 
2002, Keyes et al., 2012). HCMV genomes are also maintained in fewer cells and cell types 
and it is estimated that only one in every 105 mononuclear cells isolated from the 
peripheral blood are carrying HCMV latent genomes at a time (Slobedman and Mocarski, 
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1999). This makes latency hard to study and therefore the mechanisms of this phase in 
HCMV’s life cycle are not currently well understood. It is also likely that HCMV does not 
enter ‘true latency’ but could instead be in a constant state of reactivation that is 
continually controlled by host’s immune system. This has been previously described as 
‘smouldering persistence’ (Bughio et al., 2013). HCMV infection is generally well-controlled 
and suppressed by the host (Sinclair and Sissons, 2006), however if the host is 
immunocompromised, reactivation can become a problem as viral replication can become 
uncontrolled. This can allow HCMV to become an opportunistic pathogen and can lead to 
greater morbidity and mortality (Section 1.5). 
‘Latency’ or non-productive infection is important as it allows the virus to persist in the cell 
(and host) indefinitely. Unlike other cell types, latent HCMV-containing cells have the ability 
to prevent apoptosis upon viral infection which may an important factor for enabling long-
term infection whilst maintaining normal functions (Wang et al., 2008). Less HCMV genes 
are expressed during this non-productive infection phase than in lytic infection (Goodrum 
et al., 2002), and these include UL133-UL138, UL144, UL82AS, US28, UL111A, IE1-x4 (a 
small form of IE1/UL123), a UL126a transcript, and 2 long non-coding (lnc) RNAs of 2.7 and 
4.9 kb (reviewed by Goodrum (2016)). Many of these have unknown function and it is 
unclear what role they play in the establishment or maintenance of latency, with many 
dispensable for replication in fibroblasts (Dunn et al., 2003b). Most of these ‘latency’ genes 
are not solely produced during latency but are also produced during lytic infection (Dutta et 
al., 2015, Keyes et al., 2012). UL111A for example, encodes the viral homologue of 
Interleukin-10 (cmvIL-10) but alternative splicing also produces a latency-associated cmvIL-
10 (LAcmvIL-10). This has been detected both in vitro and in vivo and contributes to 
latency-associated effects in the cell and may also function to avoid the host immune 
system (Sinclair, 2008, Poole et al., 2014).  
HCMV ‘latency’ mainly occurs in undifferentiated (CD14+) myeloid cells and can be detected 
as far back as CD34+ hematopoietic cells, the precursor to both myeloid and lymphoid 
progenitor cells (Goodrum et al., 2002, Maciejewski et al., 1992, Jarvis and Nelson, 2002). 
Other latency reservoirs are also possible, including some subsets of endothelial cells (Fish 
et al., 1998, Jarvis and Nelson, 2002). Although the CD34+ precursor is a carrier of latent 
CMV, not all cells that have differentiated from this precursor maintain the latent virus, so 
primary human hematopoietic cells are often used for in vitro latency studies (Goodrum et 
al., 2002). Differentiation can play a huge role in the permissiveness of cells for infection, 
and once the progenitor cell has differentiated into dendritic cells (DCs) for example, HCMV 
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no longer remains latent in this cell type and can reactivate (Reeves et al., 2005b). It has 
been suggested that differentiation can cause a change in transcription factors around the 
MIEP region that then interact with cellular factors and subsequently modify chromatin 
structure to allow for transcriptional activation of IE gene expression (Reeves et al., 2005a, 
Sinclair and Sissons, 2006, Sinclair, 2008, Reeves et al., 2005b). This upregulation of viral 
immediate early genes then switches the virus into lytic phase, with IE1 or IE2 expression 
often used as a marker of reactivation. 
 
1.5 HCMV Clinical disease  
HCMV is ubiquitous in human populations worldwide. In the United States for example, an 
average of ∼60% of all adults are infected, however the incidence increases to ~90% in 
those over 80 years old (Kenneson and Cannon, 2007, Staras et al., 2006). Seroprevalance 
rates around the world vary due to a range of socio-economic factors, and in some 
countries in the developing world, nearly 100% of individuals have acquired the virus by 
age 11 (Staras et al., 2006, Kenneson and Cannon, 2007). HCMV can be transmitted 
sexually or through a wide range of body fluids, including saliva, urine, blood and breast 
milk (Cannon et al., 2011). Infected young children can secrete the virus for long periods 
and are thus a common source of infection (Noyola et al., 2000, Cannon et al., 2011). 
HCMV causes a life-long infection with prolonged periods of dormancy. HCMV infection is 
generally asymptomatic in healthy individuals, causing only non-specific symptoms such as 
fever or fatigue in ~10% of individuals, which can develop 9-60 days after the primary 
infection (Whitley, 1996). HCMV can cause serious complications in immuno-compromised 
individuals, where it acts as an opportunistic pathogen. In these cases, the virus is capable 
of infecting the majority of organs where fever, pneumonia, retinitis, myelitis, hepatitis and 
other neurological and gastrointestinal issues can be associated with high levels or 
morbidity and mortality (Emery, 2001, Grattan et al., 1989, Lee et al., 2017, Deayton et al., 
2004, Azevedo et al., 2015). Individuals undergoing organ transplantation (Section 1.5.1), 
unborn babies (Section 1.5.2) and HIV/AIDS patients (Section 1.5.3) are all particularly 
vulnerable to HCMV disease.  
Alongside the reduction in quality and length of life for the individuals affected, HCMV also 
costs the health care system a vast amount of money, both for the treatment of the long 
term consequences of the birth defects caused by congenital HCMV and the disease 
outcomes of immunocompromised patients (Grosse et al., 2013). It has been estimated 
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that in the 1990s symptomatic congenital infection alone costs the US around $1.86 billion 
annually, with an average cost per child of over $300,000 (Demmler, 2006, Modlin et al., 
2004). Antivirals help to reduce the incidence of disease outcomes in some patient groups 
(Section 1.6.1). 
1.5.1 Transplant patients 
Transplant patients are given immuno-suppressive drugs to prevent organ rejection, but 
this weakens the immune response which also results in HCMV infection becoming a 
common complication (Azevedo et al., 2015, Grattan et al., 1989). With seronegative 
patients, infection from a donor HCMV strain occurs in a HCMV-naïve immune system. This 
scenario generally holds the greatest risk for HCMV infection and disease for solid organ 
transplant patients (Azevedo et al., 2015, La Rosa et al., 2007, Seo and Boeckh, 2013, Emery 
et al., 2013). With seropositive transplant recipients, HCMV infection can instead occur 
either due to re-activation of an existing strain or from re-infection with a new strain from 
the donor. HCMV infection after transplantation increases the risk of complications, 
reduces the lifetime of the graft and increases the risk of organ rejection (Boppana and 
Britt, 2013, Azevedo et al., 2015). HCMV can also cause different complications depending 
on the type of transplant. For example, HCMV infection significantly increases the risk in 
heart transplant patients of more frequent and severe graft atherosclerosis and increased 
graft loss (Grattan et al., 1989). In allogenic haemopoietic (stem) cell transplant (HCT) 
recipients, HCMV pneumonia is a significant disease manifestation, causing over 60% of 
HCT deaths. It often occurs within 2 months of transplantation and comes with a poor 
outcome, with the median lifespan after the onset being just 25 days (Erard et al., 2015). 
Graft-versus-host disease (GvHD) is a situation that can occur post-transplantation and is 
associated with impaired graft survival and increased mortality. HCMV seropositivity is an 
important risk factor for acquiring GvHD, and acute GvHD has been linked to increased 
HCMV reactivation rates and viral loads (Broers et al., 2000). 
The use of antivirals (Section 1.6.1) during transplantation reduces the risk of HCMV 
morbidity and mortality, but does not remove the risk completely, thus HCMV disease and 
other symptoms still occur at an unacceptable rate (La Rosa et al., 2007, Hodson et al., 
2008, Erard et al., 2015, Broers et al., 2000). HCMV can also reactivate to cause disease 
once antivirals have been terminated.  
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1.5.2 HIV/AIDs patients 
Individuals with HIV/AIDs are at a great risk of infections due to their compromised 
immune systems, and in this situation HCMV can become an opportunistic pathogen. 
HCMV infection can result in end-organ damage such as hepatitis, the most common being 
retinitis which can lead to loss of sight (Aramă et al., 2014, Casado et al., 1999, Emery, 
2001). The likelihood of HCMV retinitis increases from 2% to 38% if the patient is HCMV 
seropositive (Casado et al., 1999). Co-infection with HCMV and detectable viremia also 
significantly increases the patient’s progression towards AIDS and death by 2-3 times, with 
increased morbidity observed, even when anti-retroviral therapy was given (Aramă et al., 
2014, Deayton et al., 2004, Spector et al., 1998, Adland et al., 2015). Babies who are 
infected with HIV also have a 3 times higher risk for acquiring a symptomatic congenital 
HCMV infection (Section 1.5.3) (Manicklal et al., 2013).  
1.5.3 Congenital infection  
Compared to adults, the foetal immune system is much more immature, with reduced 
immune responsiveness, making them more susceptible to HCMV infection (Hassan et al., 
2007). The average birth prevalence of congenital HCMV is 0.64% of live births, although 
this can reach ~1% in some populations (Kenneson and Cannon, 2007). A large proportion 
of babies with HCMV infection will be asymptomatic at birth, with ~11% of them having 
symptomatic disease, however this varies by population and definition of ‘symptomatic’ 
(Kenneson and Cannon, 2007, Friedman and Ford-Jones, 1999). Common complications 
caused by congenital HCMV include damaged hearing or eyesight, hepatosplenomegaly, 
jaundice, neurological damage and even death (Fowler  et al., 1992, Friedman and Ford-
Jones, 1999, Boppana et al., 2005, Pass et al., 2006). The high frequency of these serious 
complications causes HCMV to be the leading infectious cause of birth defects (Luo et al., 
2010). HCMV is also the leading cause of non-hereditary sensorineural hearing loss (SNHL) 
in children, with symptomatic children at a much higher risk (Friedman and Ford-Jones, 
1999, Ogawa et al., 2007, Boppana et al., 2005). The majority of symptomatic children 
develop SNHL, brain disorders or behavioural problems, along with up to 15% of those who 
were asymptomatic at birth (Luo et al., 2010, Pass et al., 1980, Fowler et al., 1993, Cheeran 
et al., 2009).  
The rate of transmission to the foetus increases during the course of gestation, however 
neurological outcomes are more severe when infection occurs during the first trimester 
(Pass et al., 2006, Enders et al., 2011). Seronegative women who undergo a primary HCMV 
infection are more likely to have a child with more serious congenital HCMV infection 
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(Fowler et al., 2003, Fowler  et al., 1992). Although likely due to the increased likelihood of 
primary infection, maternal age can also be a risk factor for congenital HCMV, with foetuses 
of younger women (under the age of 25), more likely to have more severe infection and 
symptoms, (Fowler et al., 2003, Fowler et al., 1993, Kenneson and Cannon, 2007, Lanzieri 
et al., 2014). Despite this, recurrent infections are more common in general due to the 
large number of seropositive women, so recurrent infections are believed to account for 
the majority of the overall disease burden, especially in low-income populations (Cheeran 
et al., 2009, Stagno et al., 1986, Ross et al., 2006, Wang et al., 2011). Many other risk 
factors are involved which often overlap or impact on each other, so it can be hard to 
pinpoint which are significant or identify which women are most at risk during their 
pregnancy (Kenneson and Cannon, 2007, Staras et al., 2006, Fowler et al., 1993).  
1.5.4 Other at-risk groups 
In conjunction with the common patient groups above, and those with autoimmune 
diseases (Lee et al., 2017), HCMV has also been proposed to play a role in chronic 
inflammatory diseases, vascular disease, atherosclerosis, and accelerated immune 
senescence in the elderly (reviewed by Boppana and Britt (2013)). It is likely that the host 
inflammatory responses plays a big part in these outcomes, but overall, HCMV 
seropositivity is a major risk factor, and high viral loads have a huge impact on the severity 
of infections and disease outcomes (Boppana et al., 2005, Aramă et al., 2014, Lee et al., 
2017, Broers et al., 2000, Spector et al., 1998). HCMV DNA load can therefore be a useful 
predictor of at-risk patients (Spector et al., 1998, Boppana et al., 2005, Deayton et al., 2004, 
Lee et al., 2017). 
 
1.6 HCMV Antiviral Treatments and Vaccines 
1.6.1 Antiviral treatments 
Those who are immunosuppressed can be given antivirals to help reduce the risk and 
severity of primary HCMV infection. Some of the antivirals currently given include 
Ganciclovir, Valganciclovir, Foscarnet and Cidofovir (Cheeran et al., 2009). All work by 
targeting DNA replication but have different side effects and are preferentially given in 
different cases of HCMV infection. Ganciclovir is an example of a nucleotide analogue, 
which can competitively inhibit the cellular nucleotides to stop replication, and can cause 
DNA chain termination (Chen et al., 2014). Once Ganciclovir is phosphorylated by HCMV’s 
pUL97 and then by cellular kinases, it mimics the cellular guanine nucleoside dGTP and 
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competitively inhibits its incorporation into DNA. This can preferentially inhibit the viral 
DNA polymerase over cellular DNA polymerases in order to preferentially disrupt viral DNA 
synthesis (Chen et al., 2014). Ganciclovir was the first compound licensed specifically for 
the treatment of severe HCMV infections and it is usually given to bone marrow, solid 
organ transplant recipients or HIV patients (Cheeran et al., 2009, Hodson et al., 2008). 
Ganciclovir can reduce the risk of infection and disease, as well as increasing survival rates 
in some patient groups, although this was not always by a significant amount (Hodson et 
al., 2008, Lee et al., 2017, Nakamae et al., 2011). It does also have some side effects, and is 
prone to causing a reduction of mature blood cells (cytopenia) which occurs in nearly 40% 
of HCT patients, although this is generally reversible (Nakamae et al., 2011). Neurological 
dysfunction can also occur, which was more common with Ganciclovir than Valganciclovir 
in transplant patients (Hodson et al., 2008). Valganciclovir is an ester of Ganciclovir and is 
rapidly metabolized into Ganciclovir following oral administration. It has similar side effects 
and efficacy as IV Ganciclovir but is better absorbed than oral Ganciclovir, even in patients 
with GvHD (Einsele et al., 2006, Hodson et al., 2008). It is generally used for treatment of 
HIV patients with HCMV retinitis, as well as for prevention of HCMV infection in transplant 
patients, especially those at high risk (Einsele et al., 2006).  
 
Both Foscarnet and Cidofovir have similar mechanisms in which they inhibit the HCMV DNA 
polymerase; with Cidofovir requiring phosphorylation by cellular kinases to be selectively 
incorporated into the viral DNA chain, whereas Forscarnet does not require 
phosphorylation to competitively inhibit the polymerase (Cheeran et al., 2009, Seo and 
Boeckh, 2013). Treatment times with Cidofovir can be more flexible, due to its long 
intracellular half-life but both are second-line treatments due to their toxicity effects. 
Nephrotoxicity is the most significant of these side effects, and necessitates pre-hydration, 
requiring intravenous (IV) administration and added cost (Bregante et al., 2000, Einsele et 
al., 2006, Ljungman et al., 2001). Side effects such as electrolyte abnormalities, 
neutropenia, diarrhoea, liver toxicity and metabolic acidosis can also occur, however with 
Foscarnet there are no risks of haematological toxicity and is therefore recommended for 
patients with bone marrow failure (Bregante et al., 2000).  
 
Maribavir is one of the newer antivirals, which works by inhibiting the UL97 kinase and 
preventing viral encapsidation and nuclear egress. It has only mild toxicity effects such as 
taste disturbance and resulted in the clearance of HCMV DNA in patients who had 
38 
 
resistance to other treatments (Avery et al., 2010). Other potential new drugs include 
Leflunomide (a rheumatoid arthritis drug), Artesunate (an anti-malaria drug), and 
Letermovir (a new CMV-specific drug). HCMV immunoglobulin (Ig) has also been used, 
often in combination with one of the main current antivirals (Avery et al., 2010, Seo and 
Boeckh, 2013, Cheeran et al., 2009, Ljungman et al., 1992, Nigro et al., 2005, Marty et al., 
2017). HIV/AIDS patients are currently given highly active antiretroviral therapy (HAART) 
which reduces the risk of HCMV related death, as well as retinitis, although unexpectedly 
can instead result in inflammatory vitritis which could also lead to loss of sight (Deayton et 
al., 2004, Karavellas et al., 1999).  
 
Due to a relatively small selection of antivirals, problems with resistance can occur, 
including Ganciclovir resistance which is primarily caused by mutations in the UL97 kinase 
gene. This has especially become a problem for HIV patients, pancreas, or kidney and 
pancreas transplant patients, with many Ganciclovir-resistant isolates also resistant to 
Cidofovir (Limaye et al., 2000). In one study, Ganciclovir-resistant HCMV disease made up 
2.1% of the overall HCMV occurrence, with antiviral-resistance a cause of morbidity and 
mortality, especially in HCT recipients and organ transplant recipients with seropositive 
donors (Avery et al., 2010, Limaye et al., 2000).  Mutations in the viral DNA polymerase 
gene (UL54) can confer resistance to Foscarnet (Limaye et al., 2000, Cheeran et al., 2009), 
and this is becoming more common due to the increased use of antivirals (Chen et al., 
2014, Emery, 2001). It is especially problematic if a patient has mutations in both UL54 and 
UL97 genes as it severely limits treatment options.  
Antivirals and HAART therapy have reduced the incidence of disease outcomes in some 
patient groups, but the levels of morbidity and mortality are still high across a wide range 
of people due to HCMV infection (Deayton et al., 2004, Emery, 2001, Erard et al., 2015, 
Broers et al., 2000). HCMV is therefore still considered a high priority vaccine target by the 
National Vaccine Advisory Board (Modlin et al., 2004). 
 
1.6.2 Vaccines 
While HCMV antivirals are clearly extremely important, there remains an urgent need to 
generate an effective preventative vaccine, particularly to prevent congenital infections. To 
date, vaccines against HCMV have been unsuccessful or have limited efficacy. Main 
strategies adopted include attenuated or modified versions of HCMV, individual antigen 
vaccines, or virus-like particles (Table 1.4). 
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Table 1.4: A summary of different HCMV vaccine strategies that have been developed 
and trialled, with examples of each type. 
 
Type of vaccine Examples 
Live virus (attenuated 
HCMV) 
 
Attenuated AD169 (Elek and Stern, 1974) 
Attenuated Towne (Plotkin et al., 1994, Plotkin et al., 1984, 
Plotkin et al., 1991) 
Towne–Toledo recombinant chimeras (Adler et al., 2016) 
Viral vectors Canarypox vector expressing gB (Adler et al., 1999, Bernstein et 
al., 2002) 
Alphavirus replicon expressing HCMV gB, pp65 and IE1 
(Bernstein et al., 2009)  
Modified vaccinia ankara (MVA) virus expressing all five 
proteins of the  gH/gL pentameric complex (Wussow et al., 
2014)* 
Defined antigens/ 
peptides/ recombinant 
proteins 
Glycoprotein B (gB) with MF59 adjuvant (Pass et al., 2009, Pass 
et al., 1999, Griffiths et al., 2011)  
Peptide of pp65 and tetanus epitopes, with TLR9 agonist as an 
adjuvant (Nakamura et al., 2016). 
Pentameric complex (Genini et al., 2011, Gerna et al., 2017, 
Lilleri et al., 2013) 
DNA 
 
DNA vaccine of gB and pp65 with adjuvant CRL1005 and 
benzalkonium chloride (Kharfan-Dabaja et al., Smith et al., 
2013a) 
Virus like particles Non-infectious dense bodies (from AD169 and Towne) (Cayatte 
et al., 2013) 
 
*Not yet in human studies 
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1.6.2.1 Attenuated HCMV vaccines 
HCMV vaccine development in the 1970s used live attenuated viruses such as the AD169 
strain (Elek and Stern, 1974) or the Towne strain that had been extensively passaged in 
fibroblasts to diminish its pathogenicity (Plotkin et al., 1975). The attenuated Towne strain 
was deemed safe in healthy volunteers, but mothers of infected children were not 
protected from acquiring HCMV (Adler et al., 1995). It also did not significantly affect the 
rate of infection in kidney transplant patients who had HCMV seropositive donors, 
although it did protect against more severe HCMV disease outcomes (Plotkin et al., 1984, 
Plotkin et al., 1994, Plotkin et al., 1991). It was considered that the Towne virus may be too 
attenuated, so chimera viruses of Towne and Toledo were made and were tested in a 
phase 1 study. These chimera viruses did not cause disease, were not shed by vaccinated 
individuals, and the majority of patients produced neutralising activity and CD8+ T-cell 
responses, both of which could be detected a year after vaccination occurred (Adler et al., 
2016). Attenuated live viruses are valuable due to their similarity to wildtype strains, but 
proving their safety can be challenging and there is a small chance that they could 
potentially be modified and reactivate in the patient (Anderholm et al., 2016). 
1.6.2.2 Subunit antigen vaccines 
A simpler strategy is to generate a subunit vaccine based on key HCMV antigens. Such 
vaccines have been designed with or without adjuvants and generally focus on the 
envelope glycoprotein B (gB) (Frey et al., 1999, Griffiths et al., 2011, Pass et al., 1999, Pass 
et al., 2009). In a phase 2 trial, a gB vaccine with an MF59 adjuvant was found to reduce the 
duration of viraemia and thus reduce the number of days on pre- emptive antiviral therapy, 
with gB antibody titres remaining high as the patients progressed to transplantation 
(Griffiths et al., 2011). Moreover, women of childbearing age who received the vaccine 
were twice as likely to remain uninfected from HCMV, although conclusions about 
incidence of congenital infection could not be formed (Pass et al., 2009). Other subunit 
vaccine approaches have involved immunogenic targets such as the tegument protein pp65 
(UL83) or proteins in pentameric complex gH/gL/UL128-131 (Genini et al., 2011, Gerna et 
al., 2017, Lilleri et al., 2013, Nakamura et al., 2016). 
1.6.2.3 Virus like particles 
Another strategy is vaccines that express some of these immunogenic proteins from viral 
vectors such as a canarypox vector (Adler et al., 1999, Bernstein et al., 2002), a modified 
vaccinia ankara (MVA) virus (Wussow et al., 2014), or an alphavirus replicon particles 
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vaccine based on Venezuelan equine encephalitis virus (VEEV) (Bernstein et al., 2009, 
Loomis et al., 2013). These viral vectors are non-replicating but can provide high expression 
of proteins and can boost both the cellular and humoral immune responses to the 
presented peptides (Bernstein et al., 2009). Any strategy that can improve or increase the 
involvement of the host’s immune system are potentially beneficial to a vaccine. One 
vaccine named CMVPepVax has been trialled that uses a chimeric peptide that consists of a 
cytotoxic CD8 T-cell epitope from pp65 and a tetanus T-helper cell epitope, alongside a 
Toll-like receptor 9 (TLR9) agonist as an adjuvant to drive cellular immunity (Nakamura et 
al., 2016). In HCT patients the vaccine caused a significant increase in pp65 specific T cells 
and provided an increased protection from HCMV viraemia and reactivation as well as the 
reduction of adverse events, and a reduction of the usage of antivirals. The only downside 
to this vaccine is that it can only be given to 40% of the population who are HLA A*0201, 
but it shows a promising step in the right direction (Nakamura et al., 2016). 
Other vaccine strategies have used viral DNA (Kharfan-Dabaja et al., 2012, Smith et al., 
2013a), or dense bodies (Cayatte et al., 2013). Overall, several vaccines that have been 
trialled have had an impact in lessening the severity of HCMV symptoms but often do not 
affect the rate of infection, and do not completely eliminate the problem of HCMV disease 
or mortality as much as hoped. Other treatments trialled have included the use of 
antibodies and immunoglobulin/hyperimmune globulin (Ishida et al., 2017, Nigro et al., 
2005, Genini et al., 2011, Lilleri et al., 2013). 
 
1.7 Immune Responses to HCMV 
The human immune system is highly complex and consists of 2 main branches- innate 
immunity (Section 1.7.1) and adaptive immunity (Section 1.7.2). There is also a third type 
of immunity which is mechanistically distinct from innate and adaptive immunity. It is 
similar to adaptive immunity in that it targets specific viruses, however it does not respond 
differently upon subsequent infection with the same pathogen. Intrinsic immune proteins 
are constitutively expressed and can therefore act against the virus immediately after 
infection (Rossini et al., 2012, Saffert and Kalejta, 2006). One example is the human death-
domain associated protein (hDaxx) which silences viral promoters (Saffert and Kalejta, 
2006), however this type of immunity will not be covered in this thesis. 
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1.7.1 Innate immunity 
The innate branch of the immune system is a constant detection system that is non-specific 
to the pathogen or environment that has triggered it. This includes physical barriers such as 
the skin, non-specific antimicrobial peptides, and includes the processes of inflammation 
and phagocytosis to non-specifically kill pathogens (Pfeffer, 2003, Boehme et al., 2006, 
Boehme et al., 2004, Thompson et al., 2011). Host cells have many pathways that can be 
triggered in response to pathogens such as HCMV, with HCMV triggering a similar response 
to the one generated by interferon (IFN) (Hertel and Mocarski, 2004, Simmen et al., 2001). 
The principle cell types and processes involved are detailed below.  
1.7.1.1 Pattern recognition receptors 
Cells can detect microbe-, pathogen- or damage-associated molecular patterns 
(MAMPS/PAMPS/DAMPs), which can be cellular proteins that come from damage or 
abnormalities, cellular DNA or extracellular matrix proteins, or the presence of microbial or 
viral proteins and nucleic acids including viral DNA (Thompson et al., 2011, DeFilippis et al., 
2010, Boehme et al., 2006, E and Kowalik, 2014). These molecular patterns are recognised 
through pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and 
nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), that can respond 
quickly and non-specifically to infections such as HCMV (Muralidharan and Mandrekar, 
2013, Thompson et al., 2011, Rossini et al., 2012). Different cell types contain different 
receptors which can have different signalling outputs, as well as different responsiveness to 
different ligands (Barr et al., 2007, Kaisho and Akira, 2006).  
Activation of PRRs can lead to downstream inflammatory signalling which triggers the 
activation of transcription factors including the nuclear factor kappa-B (NF-κB), mitogen-
activated protein kinase (MAPK) and interferon regulatory factors (IRFs) 1, 3, 5 and 7 
(Arango Duque and Descoteaux, 2014, Deng et al., 2004, Thompson et al., 2011, 
Muralidharan and Mandrekar, 2013). For example, the binding of HCMV gB and gH to TLR-2 
upon viral entry triggers multiple signalling pathways (Section 1.4.1.2), and the detection of 
HCMV double-stranded DNA by the PRR Z-DNA binding protein 1 (ZBP1) is essential for IRF3 
activation and IFN-β expression (DeFilippis et al., 2010).  
1.7.1.2 Apoptosis 
Apoptosis is highly regulated programmed cell death, and it can be triggered in multiple 
ways, both intrinsically or extrinsically. Intrinsic triggering of apoptosis can occur when DNA 
damage is detected but cannot be repaired (E and Kowalik, 2014), or when 
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unfolded/denatured proteins cannot be re-folded (Isler et al., 2005), and these stresses can 
be mediated by viruses such as HCMV. Intracellular stresses can often lead to the release of 
cytochrome c from mitochondria which results in the formation of a protein complex called 
the apoptosome, which subsequently activates the caspase cascade, leading to apoptosis 
(Kominami et al., 2012, Peter and Krammer, 2003).  
Apoptosis can also be triggered extrinsically where the process is initiated by signals from 
cytotoxic effector cells such as cytotoxic T lymphocytes (CTLs) or NK cells. They can trigger 
apoptosis extrinsically through the release of perforin which forms pores in the infected 
cell’s membrane, allowing granzymes (proteolytic enzymes) to enter. This activates the 
downstream cellular pathways that lead to apoptosis (Smyth et al., 2001, Lieberman, 2010, 
Pegram et al., 2011, Barber, 2001). Another method is through the activation of ‘death 
receptors’ such as CD95/Fas which leads to caspase activation (Seirafian et al., 2014, Peter 
and Krammer, 2003, Kominami et al., 2012, Goldmacher, 2005). Once the process of 
apoptosis has been triggered it cannot be stopped, with effector caspases cleaving host 
proteins, causing the cell to be broken down into cell fragments called apoptotic bodies. 
These are then phagocytosed by neighbouring cells such as by macrophages, destroying 
both the cell and the internal pathogen, limiting viral spread (Peter and Krammer, 2003, 
Holcik and Sonenberg, 2005, García-García and Rosales, 2000-2013).  
1.7.1.3 Cytokine and chemokine responses 
When immune cells are triggered they can activate the production of type I and 2 
interferons (IFN), pro-inflammatory cytokines (such as IL-1, IL-12 and TNF-α) and 
chemokines (Muralidharan and Mandrekar, 2013, Khairallah et al., 2017, Varani et al., 
2007). Inflammatory chemokines can attract cells from the bloodstream towards the site of 
infection (Megjugorac et al., 2004, Khairallah et al., 2017, Thompson et al., 2011, Arango 
Duque and Descoteaux, 2014). For example, upon contact with HCMV, plasmacytoid 
dendritic cells (pDCs) produce CCL3 (a β-chemokine) which attracts NK cells, Th1 cells, B 
cells and immature myeloid DCs to sites of viral infection (Megjugorac et al., 2004, Varani 
et al., 2007). Neutrophils, NK cells and CTLs are recruited rapidly, with cytokines such as IL-
12 and IL-18 able to enhance their cytolytic activity (Watford et al., 2003, Biron et al., 
1999). Cytokines can prevent the replication of a variety of viruses and also increase the 
sensitivity of neighbouring cells, sensitizing them to apoptosis which may inhibit the spread 
of infection (Barber, 2001, Muralidharan and Mandrekar, 2013). Cytokines also lead to the 
activation and differentiation of immune cells (Griffin et al., 2012, Watford et al., 2003, 
Arango Duque and Descoteaux, 2014, Pfeffer, 2003, Katze et al., 2002), including dendritic 
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cells (DCs) (Megjugorac et al., 2004) and NK cells (Biron et al., 1999, Nguyen et al., 2002). 
This is also true for cells of the adaptive response such as T and B lymphocytes  (Ben-Sasson 
et al., 2009). 
1.7.1.4 Antigen presenting cells (APCs) 
Professional antigen-presenting cells (APCs) such as macrophages and DCs play a huge role 
in the crossover between the innate and adaptive branches of the immune system. APCs 
can intracellularly degrade pathogenic proteins such as by phagocytosis where the 
pathogen is subject to lysosomal digestion by enzymes and the production of reactive 
oxygen and nitrogen species (ROS, NOS) (Nathan and Shiloh, 2000, Muralidharan and 
Mandrekar, 2013). HCMV antigens can then be presented on cell surface major 
histocompatibility complexes (MHC) to T cells. With HCMV infection it is often peptides 
from abundant proteins such as pp65 and IE1 that are presented to CTLs on MHC-I, and 
MHC upregulation by the host is one way to attempt to increase the recognition by T cells 
(Besold et al., 2007, McLaughlin-Taylor et al., 1994, Biron et al., 1999). Most APCs will also 
be stimulated to produce T-helper1 (Th1)-inducing cytokines, such as IL-12 and IL-18; with 
pDCs producing unusually high amounts of type I IFNs (Megjugorac et al., 2004, Varani et 
al., 2007, Thompson et al., 2011, Kaisho and Akira, 2006, Smith et al., 2008).  
1.7.1.5 Natural killer (NK) cells 
Classical NK cells play a role in clearing virus-infected cells and receive activating and 
inhibitory signals (ligands) from a broad range of cell surface receptors, and it is the balance 
of these signals that determines whether or not the NK cell is activated to kill the target 
cell. The main families of NK receptors are the killer immunoglobulin-like receptors (KIR) 
family, leukocyte immunoglobulin-like receptors (LIRS), the natural cytotoxicity receptor 
(NCR) family and the NKG2 (CD94) family. The KIRs, LIRs and NCRs belong to the 
immunoglobulin (Ig) superfamily, and the NKG2 family are C-lectin type receptors (Pegram 
et al., 2011). Each family tends to contain both activating and inhibitory receptors, for 
example in the NKG2 family, NKG2A and B are inhibitory receptors and NKG2C, D and E are 
activating receptors (La Rosa and Diamond, 2012, Prod’homme et al., 2007). The main 
inhibitory ligands on target cells are endogenous major histocompatibility complex class I 
(MHC-I) molecules. NK cells are also unique in that they can detect reduced or atypical 
MHC-I molecules, termed “missing self” (Pegram et al., 2011, Gasser and Raulet, 2006, 
Ljunggren and Karre, 1986).  
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The NKG2D activating receptor is unusual in recognizing multiple ligands that have been 
shown to be upregulated when cells are stressed (e.g. by virus infection) (Eagle and 
Trowsdale, 2007, Rolle et al., 2003, Eagle et al., 2009). These ligands include the MHC class 
I-polypeptide related sequences (MIC) A and B, and the human UL16-binding protein 
(ULBP) proteins 1-6; and their increase can potentially tip the balance and activate the NK 
cell (Prod’homme et al., 2007, Rolle et al., 2003, Eagle et al., 2009, Slavuljica et al., 2011). 
NKG2D is expressed not only on NK cells, but also on CD8+ T cells, some γδ T cells, some NK-
T cells, and activated macrophages (Slavuljica et al., 2011, Wilkinson et al., 2008).  
Activating receptors can signal through immuno-receptor tyrosine-based activating motifs 
(ITAMs) using DAP-12, or through phosphatidylinositol-3 kinase (PI3K) and other pathways 
via DAP-10; whereas inhibitory receptors signal through intracellular immuno-receptor 
tyrosine-based inhibitory motifs (ITIMs) instead (Wu et al., 1999, Lanier et al., 1998, 
Pegram et al., 2011). NKG2D associates with DAP10 in order to produce a strong activating 
signal (Lanier, 2008, Wu et al., 1999). 
As mentioned, it is the balance of inhibitory and activating signals that determines NK 
activation. If activated, the NK cell stimulates cytotoxicity of the infected target cell, 
mediated by the release of perforin and granzymes that lead to apoptosis (Section 1.7.1.2). 
This can also be brought about by Fc receptor (CD16) ligation with Ig molecules bound to 
cell surface antigens on the target cell, mediating killing by antibody dependent cell-
mediated cytotoxicity (ADCC) (reviewed by Aicheler et al. (2013) and Biron et al. (1999)). 
NK cells can also kill target cells via the ligation of death receptors such as Fas with their 
ligands, their activation also leading to apoptosis (Section 1.7.1.2) (Seirafian et al., 2014, 
Peter and Krammer, 2003). NK activation can also lead to the production of cytokines and 
chemokines (Section 1.7.1.3) which can attract and activate cells of the adaptive response 
(Wu et al., 1999, Lanier, 2008, La Rosa and Diamond, 2012, Biron et al., 1999). Cytokines 
such as IFN, IL-12 and IL-15 can stimulate NK cells and can regulate NK cell responses, 
inducing NK cytotoxicity, NK IFN-gamma expression, NK cell accumulation and proliferation, 
and protective NK cell responses (Nguyen et al., 2002, Biron et al., 1999).  
Due to all of these early detection systems of the innate immunity, host cells can activate 
anti-viral immune responses before the outset of viral replication (Boehme, Singh, Perry, & 
Compton, 2004). 
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1.7.2 Adaptive response 
The adaptive arm of the immune response takes longer to take effect due to the 
complicated activation process that can take up to 7 days. It can however provide a 
pathogen-specific response and can lead to lasting memory that provides a quicker 
response to a future attack (La Rosa and Diamond, 2012). Cells of the adaptive immune 
system recognising pathogen-specific antigens and distinct epitopes instead of PAMPs or 
DAMPs. This process involves both B and T lymphocytes which can recognise antigen 
epitopes directly, or through antigen peptide presentation from MHCs on APCs (Section 
1.7.1.4) respectively. The receptors on T and B lymphocytes (TCRs and BCRs/ 
immunoglobulins respectively) are generated through gene rearrangements, providing 
them with a highly varied array of receptor combinations allowing an unlimited range of 
detection for potential pathogen epitopes, with a system in place that selects away from 
the detection of self-antigens (Janeway et al., 2001, Spits et al., 1995). Once activated by an 
antigen, both T and B lymphocytes can clonally replicate within ~96 hours (Brinkworth and 
Thorn, 2013). 
1.7.2.1 B lymphocytes 
B cells express receptor immunoglobulins (Igs) or antibodies that are made of heavy and 
light chains, that are found membrane-bound as well as in secreted forms. These are often 
directed against abundant HCMV proteins such as pp65, pp150, gB, gH, and gH/gL 
multimeric complexes as well as non-structural proteins such as IE1 (La Rosa and Diamond, 
2012, Dauby et al., 2014). B cells are activated and differentiated into Ig-secreting plasma 
cells with cytokines (Section 1.7.1.3), often need the presence of T cells or T cell-secreted 
IL-2 for antibody production (Varani et al., 2007). It is around day 7 that plasma cells are 
detected, but longer for antibody secretion to be observed (Varani et al., 2007). Antibodies 
can sometimes neutralise the pathogen directly e.g. by blocking a binding receptor as 
exemplified by gB antibodies preventing HCMV entry into cells (Gerna et al., 2008). 
Antibodies can also mark the infected cell for attack by other immune cells (such as NK 
cells) through their Ig receptors, with an outcome of antibody dependent cell-mediated 
cytotoxicity (ADCC) (Aicheler et al., 2013).  
Upon activation, B cells can also make cytokines such as IL-10 and IFN-γ so have the 
potential to affect T cell differentiation (Barr et al., 2007). Primary HCMV infection also 
mobilizes a large pool of memory B cells (MBCs) that includes activated and atypical MBCs 
(Dauby et al., 2014). 
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1.7.2.2 T lymphocytes  
T cell receptors (TCRs) are made up of either an α and β chain, or a γ and δ chain, making 
the 2 distinct lineages αβ and γδ T cells, with T cell recognition occurring via the MHC class I 
and II antigen presentation pathways displayed from APCs (Section 1.7.1.4) (Janeway et al., 
2001). Over the course of infection, T cells populations change and differentiate between 
naïve, effector and memory T cells, and it is the αβ T cells that develop into CD4+ and CD8+ 
T effector cells, with helper T cells (Th) expressing CD4, and cytolytic T lymphocytes (CTLs) 
expressing CD8 (Ben-Sasson et al., 2009, Whitmire, 2011, Sylwester et al., 2005, Janeway et 
al., 2001). HCMV-specific CD4+ T cells will start to circulate ~7 days after viral replication 
starts, with HCMV-specific CD8+ T cells appearing in the peripheral blood later on (La Rosa 
and Diamond, 2012). Subtype differentiation is triggered by cytokine responses such as IL-
12 (Watford et al., 2003, Varani et al., 2007, Barr et al., 2007, Ben-Sasson et al., 2009). 
Subsets themselves also produce different cytokines and have different effects, including 
upregulation of MHC presentation and aiding B cell differentiation (Biron et al., 1999, La 
Rosa and Diamond, 2012, Whitmire, 2011). CD8+ CTLs are able to lyse HCMV-infected cells 
using perforin and granzyme B as described above (Section 1.7.1.2) (La Rosa and Diamond, 
2012, Lieberman, 2010).  
Memory CD8+ cells form later on, upon recovery from HCMV infection, and provide 
important long-term protection against the antigen and recurrent infections, with 
protective immunity shown to be transferred through adoptive therapy of HCMV-specific T 
cells (La Rosa and Diamond, 2012, Besold et al., 2007). Memory T cells retain their cytolytic 
potential and can be induced to expand vigorously and rapidly (La Rosa and Diamond, 
2012, Dauby et al., 2014, Khairallah et al., 2017). The CD4+ and CD8+ T cell responses are 
mainly directed against pp65 and IE1 proteins, although can also be against other tegument 
proteins such as pp28, capsid proteins, or envelope proteins such as gB (Besold et al., 2007, 
McLaughlin-Taylor et al., 1994, Sylwester et al., 2005). 
 
The T cell response raised against HCMV is larger than that to any other virus, with HCMV-
specific memory T cells on average making up ~10% of both the CD4+ and CD8+ memory 
compartments in peripheral blood (Sylwester et al., 2005). The activation of both memory 
CD4+ T cells and CD8+ T cells are required for a more protective CTL response to recurrent 
infection (Whitmire, 2011). 
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1.7.3 Summary 
The immune system is extremely complex, and all parts of the system overlap, with 
different cells signalling to each other and affecting each other’s activation and 
differentiation. These cell types are all important and they work together to achieve the 
desired outcome of preventing viral replication. Individuals who are missing parts of this 
defence system have a compromised immune system and can be more susceptible to 
diseases or have increased disease severity such as in the clinical disease situations covered 
above (Section 1.6). This is particularly true for individuals with HCMV who have a defect in 
their NK responses (reviewed by Orange (2013).  
 
1.7.4 Immune Modulation by HCMV 
HCMV has evolved along with its host to encode a remarkable variety of ways to avoid or 
modulate the immune system. Firstly, HCMV can cause transcriptional changes within the 
host cell, and regulate host cell proteins. Transcriptional changes can be seen throughout 
the course of infection, starting from ~15 mins post infection, with viral protein synthesis 
overtaking cellular protein synthesis by 48 hpi (Hertel and Mocarski, 2004, Simmen et al., 
2001, Stinski, 1977). HCMV targets host genes that are involved in regulation of the cell 
cycle, DNA replication, cell surface receptors, energy production and inflammation, 
including a high degree of modulation of interferon stimulated genes (Hertel and Mocarski, 
2004, Simmen et al., 2001). A main player in this role is the abundant tegument protein 
pp65 (ppUL83), which blocks the induction of some of the IFN-responsive genes, restricting 
the activation of NF-κB and IRF1 and blocking IFN-α signalling, making the cells less 
responsive to endogenous cytokines (Browne and Shenk, 2003). pUL144 (a member of the 
TNF receptor family) that can activate the NF-κB pathway, enhancing the expression of the 
chemokine CCL22, which can attract Th2 and regulatory T cells and may help with immune 
evasion (Poole et al., 2006). 
1.7.4.1 T cell evasion 
Another important immune evasion strategy is to reduce the detection of infected cells, 
principally through the down-regulation of antigen presentation by MHC-I and II to reduce 
T cell (Section 1.7.2.2) activation, as well as reducing the presentation of some of the NK 
activating ligands (Section 1.7.3.2), reducing the infected cell’s susceptibility for cytotoxic 
killing. Mechanisms involved in this process include MHC retention in the ER, increased 
degradation, and prevention of the transport of peptides via the TAP transporter (Besold et 
al., 2007; Hsu et al., 2015; Noriega et al., 2012).  
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US2 and US6 family proteins, along with pp71 (ppUL82) are all involved in modulating 
MHC-I molecules (Section 1.8.7, 1.8.11 and 1.8.12) (Hsu et al., 2015, Huber et al., 2002, 
Noriega et al., 2012b, Pande et al., 2005, Besold et al., 2007, Furman et al., 2002, Tirabassi 
and Ploegh, 2002, Trgovcich et al., 2006). pUS2 and pUS3 also play a role in MHC-II 
reduction and pUS2 also degrades an additional array of binding ligands, reducing integrin 
signalling, cell adhesion and cell migration (Section 1.8.11) (Hsu et al., 2015, Tomazin et al., 
1999).  
1.7.4.2 NK cell evasion 
Reductions in MHC presentation will impact NK cells which detect MHC ligands through 
activating and inhibitory receptors (Section 1.7.1.5). HCMV encodes an array of genes that 
are capable of suppressing NK cell recognition- UL16, UL18, UL40, UL83, UL135, UL141, 
UL142, US18 and US20, along with microRNA (miR-UL112) (Wilkinson et al., 2008, 
Wilkinson et al., 2015). The overall consequence is to effectively alter the balance of the NK 
activating and inhibiting receptors signals to tip the balance towards non-activation of the 
NK cell towards the infected cell, to allow the infected cell to persist undetected. Multiple 
HCMV genes function by downregulating stress-induced ligands for NK activating receptors, 
including UL16, miRUL112, UL141, US18 and US20. gpUL16 for example reduces the cell 
surface of three NKG2D ligands, MICB, ULBP1 and ULBP2, by retaining them intracellularly 
(Welte et al., 2003, Cosman et al., 2001, Sutherland et al., 2002). HCMV miRUL112 also 
downregulates MICB by preventing translation of the MICB mRNA (Stern-Ginossar et al., 
2007). pUS18 and pUS20 target both the NKG2D ligand MICA, and NKp30 ligand B7-H6 for 
degradation (Section 1.8.15) (Fielding et al., 2014, Fielding et al., 2017). HCMV gpUL141 
and gpUL142 also provide resistance to NK attack (Section 1.8.3 and 1.8.4. These 2 genes 
are located within the UL/b’ region and helps explain why some laboratory strains of HCMV 
that are missing this region are less pathogenic and more easily targeted for cytolysis 
(Wilkinson et al., 2015, Wilkinson et al., 2008, Cha et al., 1996). 
HCMV signal peptide (sp)UL40 doesn’t reduce an NK activating ligand, but instead 
upregulates the non-classical MHC molecule HLA-E, which binds to the NK inhibitory 
receptor CD94/NKG2A (Prod’homme et al., 2012, Tomasec et al., 2000, Wang et al., 2002). 
Interestingly, The HLA-E binding peptide derived from spUL40 upregulates cell surface 
expression of gpUL18 (Prod’homme et al., 2012). HCMV gpUL18 encodes an MHC class I 
homolog binds the inhibitory leukocyte Ig-like receptor 1 (LIR1) which is found on NK cells 
as well as B lymphocytes, monocytes, dendritic cells, and subsets of T cells (Prod’homme et 
al., 2007). gpUL18 strongly inhibits NK cells by binding to LIR1 (Section 1.8.4) (Prod’homme 
50 
 
et al., 2007), although its role is a complicated and controversial one, as although cells 
containing the LIR1 receptor were inhibited, another NK subset which were LIR1 negative 
were activated (Prod’homme et al., 2007). 
The viral tegument protein pp65 (ppUL83) has a different mechanism for NK evasion which 
involves targeting the activating receptor NKp30 itself, causing dissociation of the linked 
CD3ζ chain and leading to general inhibition of cytotoxicity against the infected cells (Arnon 
et al., 2005). Overall, HCMV manages to balance the down-regulation of MHC-I molecules 
without alerting the host to ‘missing self’ by modulating ligands for both activating and 
inhibitory receptors. 
1.7.4.3 Other immune modulation functions 
Other than HCMV’s multiple mechanisms for the evasion of NK cell and T cell recognition 
and killing, it also encodes other functions for mechanisms to avoid apoptosis through the 
inhibition of death receptors, through Fc binding proteins and homologues of cellular 
cytokines or receptors. For example, HCMV encodes 3 proteins that can target death 
receptors to protect the infected cell against both soluble TRAIL and TRAIL-dependent 
killing. gpUL141, aside from blocking CD155, can also bind directly to TRAIL receptor 2 (TR2) 
and sequester this death receptor in the endoplasmic reticulum (Smith et al., 2013b). 
HCMV pUL35 and pUL37 are instead involved in the downregulation of Fas (CD95) to 
prevent Fas-mediated apoptosis of the cell (Seirafian et al., 2014). pUL36 achieves this by 
being a viral inhibitor of caspase-8 activation (vICA) (Section 1.8.13), whilst pUL37 is a viral 
mitochondrion-localised inhibitor of apoptosis (vMIA) that inhibits apoptosis by 
suppressing cytochrome c release (Section 1.7.1.2) (Skaletskaya et al., 2001, Goldmacher, 
2005, Seirafian et al., 2014). pIE1, pIE2 and pUL38 have also been suggested to function as 
inhibitors of apoptosis (Zhu et al., 1995, Terhune et al., 2007). 
Human cytomegalovirus (HCMV) is unique among viruses in that it encodes an array of 
proteins that recognize the constant Fc domain of IgG, called Fcγ-binding receptors (FcγRs), 
that are found on the cell surface and function as rivals of host FcγRs (Corrales-Aguilar et 
al., 2014a). These viral FcγRs (RL11, RL12, RL13, and UL119-118) mostly belong to the RL11 
multigene family (Section 1.8.2) (Corrales-Aguilar et al., 2014a, Cortese et al., 2012). Both 
gpRL11 (gp34) and gpUL119-118 (gp68) have shown to have a broad inhibition effect 
towards 3 host Fc receptors (FcγRIIIA, FcγRIIA and FcγRI) which can reduce or prevent the 
antibody-mediated triggering of antiviral immunity (Corrales-Aguilar et al., 2014b). 
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Other HCMV mimics of host receptors includes chemokine receptor homologues pUS28, 
pUL33 and pUL78 (Section 1.8.14) (Rosenkilde et al., 2001, Tadagaki et al., 2012, Bodaghi et 
al., 1998), and UL22A which is a viral chemokine receptor decoy that binds to the 
chemokine RANTES to block its interaction with cellular receptors (Wang et al., 2004). 
pUL146 and pUL147 on the other hand, are chemokine homologues (Section 1.8.9) 
(Scarborough et al., 2017, Penfold et al., 1999, Lüttichau, 2010). HCMV also encodes a 
homologue of human IL-10, pUL111A, termed viral IL-10 (vIL-10,) (Kotenko et al., 2000, 
Chang et al., 2004). This has low sequence similarity to human IL-10 but is biologically 
active and still has immunosuppressive properties (Spencer et al., 2002, Kotenko et al., 
2000).  
Additional HCMV modulation proteins include the antiviral protein kinase R (PKR) 
antagonists pTRS1 and pIRS1 (Section 1.8.13) (Ziehr et al., 2016, Colberg-Poley, 1996, Child 
et al., 2004), and pUL135 which inhibits synapse formation by remodelling the actin 
cytoskeleton to impair immune recognition of infected cells (Stanton et al., 2014).  
This vast array of genes and mechanisms are summarised in Table 1.5 and allows HCMV to 
counteract the host detection and killing mechanisms, allowing it to remain in the host as a 
lifelong infection, and it is likely that more of these functions will come to light in the 
future. 
 
1.8 HCMV Gene Families 
HCMV, like many DNA viruses, uses many mechanisms in order to generate genetic 
diversity including host gene capture, gene duplication, substitution, deletion or insertion 
of nucleotides and large scale genome rearrangements (Prince and Pickett, 2002, Davison 
et al., 2002). Multiple gene duplications can expand rapidly and have been termed 
‘accordion expansions’, which have been demonstrated in poxviruses under selection 
pressure (Elde et al., 2012). This process may have resulted in the emergence of a number 
of distinct multi-gene families in HCMV (Davison et al., 2003a, Chee et al., 1990). The extra 
gene copies formed by duplications can undergo a divergence in function over time, and 
some can be subsequently lost. With most families, duplication has resulted in a set of 
tandem genes, but in others, these duplicate genes have been translocated to other parts 
of the genome, sometimes with more duplications occurring afterwards, explaining the 
spread of some gene family members across the genome (Davison, 2011) (Fig. 1.8).  
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Table 1.5: Summary of HCMV immune evasion functions†.  
 
 Function 
category 
Genes References 
Modulation of 
NK ligands 
UL16, 
miR-UL112,  
UL141*, 
UL142, US18,  
US20 
(Welte et al., 2003, Cosman et al., 2001, 
Sutherland et al., 2002, Stern-Ginossar et al., 
2007, Tomasec et al., 2005, Tomasec et al., 
2000, Fielding et al., 2014, Fielding et al., 2017, 
Prod’homme et al., 2012, Dunn et al., 2003a) 
Other NK 
evasion 
strategies 
UL83*, 
UL135, UL18, 
UL40 
(Arnon et al., 2005, Stanton et al., 2014, 
Prod’homme et al., 2007, Prod’homme et al., 
2012, Wang et al., 2002) 
Down-
regulation of 
MHC 
US2, US3, 
US6, US11, 
US8, US10,  
UL82 
(Hsu et al., 2015, Tomazin et al., 1999, Besold 
et al., 2007, Pande et al., 2005, Noriega et al., 
2012b, Lehner et al., 1997, Huber et al., 2002, 
Tirabassi and Ploegh, 2002, Furman et al., 
2002, Trgovcich et al., 2006). 
Fc binding 
proteins 
RL11, RL12, 
RL13, UL119-
118 
(Cortese et al., 2012, Corrales-Aguilar et al., 
2014a, Corrales-Aguilar et al., 2014b) 
Cellular 
homologues 
UL111A, 
US28, UL18, 
UL33, UL78, 
UL146,  
UL22A, 
UL144 
(Kotenko et al., 2000, Chang et al., 2004, 
Bodaghi et al., 1998, Rosenkilde et al., 2001, 
Tadagaki et al., 2012, Lüttichau, 2010, Penfold 
et al., 1999, Scarborough et al., 2017, Wang et 
al., 2004, Poole et al., 2006, Griffin et al., 
2005). 
Inhibitors of 
apoptosis 
IE1, IE2, 
UL36, UL37, 
UL38, 
UL141* 
(Terhune et al., 2007, Zhu et al., 1995, 
Goldmacher, 2005, Goldmacher et al., 1999, 
Seirafian et al., 2014, Skaletskaya et al., 2001, 
Smith et al., 2013b) 
Other antiviral 
mechanisms 
IRS1, TRS1, 
UL82, UL83*, 
UL55 
(Child et al., 2004, Colberg-Poley, 1996, Ziehr 
et al., 2016, Browne and Shenk, 2003, Li et al., 
2013, Saffert and Kalejta, 2006, Boehme et al., 
2004) 
 
† Non-exhaustive list 
* Protein has more than 1 role 
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Figure 1.8: The genome of HCMV Merlin with its 15 gene families indicated. Annotation of 
the Merlin genome including the locations of each gene family. Taken from Steven Sijmons 
et al. (2014). The single line denotes the dsDNA genome, with nucleotide positions given in 
basepairs. Genes are represented by block arrows, as well as the 4 non-coding RNAs and the 
origin of lytic replication. The terminal and internal repeat regions (TRL, IRL/IRS and TRS) are 
indicated by white boxes. Different gene families are designated with different colour codes, 
as shown by the key at the bottom of the figure. The UL18, UL82 and UL146 families are also 
referred to as the MHC, DURP and CXCL families as explained below. 
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HCMV contains 15 gene families, which is an unusually high number, even compared to 
other herpesviruses (Davison and Bhella, 2007). The 15 distinct gene families within the 
HCMV genome include the RL1, RL11, UL14, UL18, UL25, UL30, UL82, UL120, UL146, US1, 
US2, US6, US12, US22 and G-protein couple receptor (GPCR) families (Fig. 1.8) (Sijmons et 
al., 2014, Gatherer et al., 2011, Chee et al., 1990, Adair et al., 2002, Davison et al., 2003b) . 
These gene families contain a total of 70 genes, which is over 40% of all canonical genes, 
and over 55% of non-core genes (Davison, 2011). Nine multigene families were first 
identified in AD169 (Chee et al., 1990), with additional families being designated later, 
along with further family members. These additions were added due to advances in 
sequencing and analytical methods, and the sequencing of additional strains, including low 
passage clinical strains which retained some genes that heavily passaged strains had lost 
(Davison et al., 2003b, Dolan et al., 2004, Davison et al., 2003a).  
HCMV’s gene families range from as few as 2 members (such as the UL14 and UL18 
families) to as many as 14 members (the RL11 family). Most of these duplicated and 
diverged genes have functions that are non-essential for replication in vitro, except for 
UL84 which is essential to the Towne strain for growth in fibroblasts (Dunn et al., 2003b). 
Some other gene family members do cause growth defects however when deleted in 
Towne or AD169 (Dunn et al., 2003b, Yu et al., 2003). Some HCMV gene family members 
are highly variable across different isolates, with the majority of the most variable HCMV 
genes existing within the RL11 family (Sijmons et al., 2015). As well as gene variability, 
around 75% of strains tested contained disruptive mutations in 26 genes, including within 
half of the RL11 family members, with members of the RL1, US6 and US12 families also 
affected, albeit to a lesser extent (Sijmons et al., 2015). Many gene family members 
however, are highly conserved in clinical samples, including US1, US12, US22, UL25 and 
UL82 family members (Sijmons et al., 2015). The UL25, UL82, and US22 gene families are 
even found within the blocks of core genes that are conserved across beta-herpesviruses 
(Barry and Chang, 2007). The conservation of gene families and members means they are 
likely to have important functions, and some members play important roles in vivo, and are 
often involved in immune modulation, including members of the UL14, UL18, US2, US3 and 
US12 gene families (below). Other gene family members instead have relatively unknown 
functions. A summary of each gene family can be found below, and in Table 1.6. 
1.8.1 The RL1 family  
The RL1 family is one of the smaller families, consisting of just RL1 and UL145. This is one of 
the few HCMV gene families in which the genes are not found adjacent in the genome, with  
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Table 1.6: A summary of HCMV’s 15 gene families, including the current members for each 
family and a brief outline of their functions 
Gene 
family 
Family 
members 
Summary of functions* References 
RL1 RL1, UL145 Functions remain uncharacterised  
RL11 RL5A, RL6, 
RL11, RL12, 
RL13, UL1, 
UL4, UL5, 
UL6, UL7, 
UL8, UL9, 
UL10, UL11 
Immunomodulatory roles including 
disruption of T cell activation (UL10, 
UL11), reduction of downstream 
signalling pathways, and affecting 
pro-inflammatory cytokine 
production (UL7). RL11, RL12 and 
RL13 are viral Fcγ receptors. 
(Bruno et al., 2016, Gabaev et al., 
2011, Engel et al., 2011, Corrales-
Aguilar et al., 2014b, Lilley et al., 
2001, Zischke et al., 2017) 
UL14 UL14, 
UL141 
UL141 targets NK activating receptor 
ligands and TRAIL death receptors to 
protect against NK cell killing. UL14 
has been suggested to impair cell 
adhesion. 
(Tomasec et al., 2005, 
Prod'homme et al., 2010, 
Wilkinson et al., 2008, Hsu et al., 
2015, Smith et al., 2013b, 
Cochrane, 2009) 
UL18 
(or 
MHC) 
UL18, 
UL142 
MHC-I homologues that provide 
protection from NK cell killing. UL18 
achieves this by binding to LIR1 
inhibitory receptor, and UL142 
possibly down-modulates the 
NKG2D ligand MICA. 
(Chapman et al., 1999, 
Prod’homme et al., 2007, Wills et 
al., 2005, Chalupny et al., 2006) 
UL25 UL25 
(pp85), 
UL35 
UL25 is a tegument protein.  
UL35 and UL35a appear to interact 
with pp71 and USP7. UUL35 
remodels PML bodies and degrades 
BclAF1 
(Battista et al., 1999, Salsman et 
al., 2012, Salsman et al., 2011, 
Lee et al., 2012) 
UL30 UL30, 
UL30A 
Functions remain uncharacterised (Salsman et al., 2008) 
UL82 
(or 
DURP) 
UL82 
(pp71), 
UL83(pp65)
, UL84, 
UL31, UL72  
UL82 and UL83 are tegument 
proteins that affect the cell cycle, 
modulate gene expression and 
inhibit antiviral signalling pathways. 
UL84 is involved in transcriptional 
activation, DNA replication and viral 
growth.  
(Cantrell and Bresnahan, 2006, 
Trgovcich et al., 2006, Bresnahan 
and Shenk, 2000, Arnon et al., 
2005, Browne and Shenk, 2003, 
Fu et al., 2017, Li et al., 2013, Gao 
et al., 2008, Spector and Yetming, 
2010) 
UL120 UL120, 
UL121 
Functions remain uncharacterised.  
UL146 
( or 
CXCL) 
UL146, 
UL147 
Predicted CXC-chemokines, with 
UL146 a functional viral homologue 
of CXCL1 (vCXCL1) that targets 
CXCR1 and CXCR2. UL147 remains 
uncharacterised. 
(Lüttichau, 2010, Penfold et al., 
1999, Scarborough et al., 2017) 
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* See section of each individual gene family for more details of their functions and other 
characterisation 
Gene 
family 
Family 
members 
Summary of functions* References 
US1 US1, US31, 
US32 
Functions remain uncharacterised  
US2 US2, US3 Both retain or degrade MHC class I 
and class II proteins to down-
regulate their expression on the cell 
surface. US2 can also reduce 
integrin signalling, cell adhesion and 
cell migration through an array of 
ligands 
(Noriega et al., 2012b, Pande et 
al., 2005, Hsu et al., 2015, 
Tomazin et al., 1999, Besold et 
al., 2007, Halenius et al., 2011, 
Jones and Sun, 1997). 
US6 US6, US7, 
US8, US9, 
US10, US11 
All members regulate MHC 
molecules in some way, by retaining 
or degrading them (US9, US11), 
delaying their exit (US10) or binding 
them on the surface (US8). US6 
inhibits the movement of MHC 
peptides by binding to the 
transporter associated with antigen 
processing (TAP) complex. US7 
remains uncharacterised.  
(Lehner et al., 1997, Halenius et 
al., 2011, Besold et al., 2007, Hsu 
et al., 2015, Furman et al., 2002, 
Park et al., 2010, Seidel et al., 
2015) 
US12 US12,US13, 
US14,US15, 
US16, 
US17, 
US18, 
US19, 
US20, US21 
The whole family regulate cellular 
immune ligands, often by targeting 
them for degradation, and US12, 
US14, US18 and US20 are NK 
evasion functions. US16, US18 and 
US20 are also involved in tropism 
and US17 can regulate the immune 
response by altering the content of 
the virion. 
(Cavaletto et al., 2015, Fielding et 
al., 2017, Luganini et al., 2017, 
Bronzini et al., 2012, Fielding et 
al., 2014, Gurczynski et al., 2014, 
Hai et al., 2006) 
US22 US22,US23, 
US24,US26, 
UL23, UL24, 
UL28, UL29, 
UL36, UL43, 
TRS1 and 
IRS1 
The majority are tegument proteins, 
and some have roles in immune 
evasion; UL36 is a viral inhibitor of 
caspase-8-induced apoptosis, and 
TRS1 and IRS1 are antagonists to the 
antiviral protein kinase R (PKR).  
(Adair et al., 2002, Colberg-Poley, 
1996, Skaletskaya et al., 2001, 
Child et al., 2004, Ziehr et al., 
2016) 
GPCR UL33, UL78, 
US27 and 
US28 
All members are chemokine 
receptor homologues, with US28 
able to bind to and sequester a 
broad range of chemokines. The 
functions of the remaining family 
members remain uncharacterised. 
(Scarborough et al., 2017, 
Tadagaki et al., 2012, Bodaghi et 
al., 1998, Kledal et al., 1998) 
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RL1 found in the terminal repeat long region, and UL145 found in the unique long region of 
the genome. Little is known about this gene family and neither of these members have yet 
to be assigned a function. Only one strain of HCMV (0.8% of strains) studied contained a 
mutation in RL1 (Sijmons et al., 2015). RL1 is also subjected to higher levels of positive 
selection than would be expected (Sijmons et al., 2015), so there is a chance that RL1 may 
interact with host antiviral mechanisms.  
1.8.2 The RL11 family 
The RL11 family on the other hand is one of the larger families, with 14 members; RL5A, 
RL6, RL11, RL12, RL13, UL1, UL4, UL5, UL6, UL7, UL8, UL9, UL10 and UL11. They are found 
near the left terminus of the genome, and members RL11-UL11 are arranged in tandem 
except for presence of 2 unrelated genes on the opposing strand (UL2 and UL3) (Fig. 1.8) 
(Davison et al., 2003a). Most members of the RL11 family are predicted to be surface 
glycoproteins, and all contain a conserved RL11D domain that has homology with human 
adenovirus E3 membrane glycoproteins CR1 domain (Davison et al., 2003a). Members also 
generally have a signal peptide, and a transmembrane domain, however not all RL11 
proteins contain all 3 of these characteristics; with RL5A and RL6 (found only in HCMV) for 
example, containing the potential N-linked glycosylation sites but lacking both signal 
peptides and transmembrane domains (Davison et al., 2003a, Shikhagaie et al., 2012). 
Hypervariability is a common trait for the family, with RL12, RL13, UL1, UL6, UL9, UL11 and 
RL6 all shown to have great variability (Dolan et al., 2004, Davison et al., 2003a, Sijmons et 
al., 2015). As mentioned, there are also an unusually high incidence rate of disrupting 
mutations found within this family, both in vivo and in adaptation to cell culture (Sijmons et 
al., 2015, Stanton et al., 2010, Dargan et al., 2010, Yu et al., 2002).  
Currently 3 members of this gene family are known to function as Fcγ receptors 
homologues, with gpRL11, gpRL12 and gpRL13 binding to the Fc portion of human IgG 
which may contribute to HCMV immune evasion (Cortese et al., 2012, Corrales-Aguilar et 
al., 2014a, Lilley et al., 2001). gpUL7 mediates adhesion to leukocytes and attenuates their 
production of pro-inflammatory cytokines (Engel et al., 2011). gpUL7 also results in the 
production of IL-6 by acting as a ligand for the Fms-like tyrosine kinase 3 receptor (Flt-3R) 
and appears to mediate cellular differentiation of myeloid cells (Crawford et al., 2018). 
gpUL10 and gpUL11 also have immune modulatory roles, disrupting T cell activation and 
function, reducing downstream signaling pathways, and affecting pro-inflammatory 
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cytokine production (Bruno et al., 2016, Gabaev et al., 2011, Zischke et al., 2017). Other 
proteins, such as gpUL6, currently have no known functions (Sekulin et al., 2007).  
1.8.3 The UL14 family 
The UL14 family consists of UL14 and UL141, which were defined as a new gene family due 
to their amino acid homology (Davison et al., 2003b). gpUL141 targets the NK activating 
receptor ligands CD155 and CD112, providing significant protection against NK cell killing 
(Tomasec et al., 2005, Prod'homme et al., 2010, Wilkinson et al., 2008). It was found to 
cooperate with US2 in order to achieve more efficient degradation of specific target cell 
surface proteins e.g. CD112, and was also shown to target the TRAIL death receptors to 
protect from TRAIL-dependent NK cell killing (Smith et al., 2013b, Hsu et al., 2015). pUL14 is 
an uncharacterised homologue but has been suggested to impair cell adhesion (Cochrane, 
2009). 
1.8.4 The UL18 family 
The UL18 family consists of UL18 and UL142, and is known as the MHC family, as each 
member contains an MHC-I domain, with both members shown to provide protection from 
NK cell-mediated cytolysis. gpUL18 functions as an MHC class I homolog, binding to the LIR-
1 NK inhibitory receptor with >1000 times greater affinity than the endogenous MHC class I 
ligands (HLA-A, -B, -C, -E, -F and -G), blocking NK-mediated killing (Chapman et al., 1999, 
Prod’homme et al., 2007). gpUL142 on the other hand, down-modulates the NKG2D ligand 
MICA (except for the truncated MICA*008 allele) by retaining it in the cis-golgi, also 
providing a role in NK evasion (Ashiru et al., 2009, Chalupny et al., 2006, Wills et al., 2005). 
However, in the context of a productive HCMV infection, while gpUL142 provides 
resistance to NK attack, it does not modulate cell surface expression of MICA (H. Elasifer, 
personal communication and Fielding et al. (2014)) so the mechanism by which gpUL142 
promotes NK evasion is thus uncertain. 
1.8.5 The UL25 family  
The UL25 family contains just 2 members, UL25 and UL35, with ppUL25 (pp85) encoding a 
structural tegument protein located in the virion assembly compartment (vAC) (Battista et 
al., 1999). UL35 encodes 2 proteins, a full-length 75 kDa protein located in the vAC, and a 
22 kDa protein (pUL35A) located in the nucleus (Liu and Biegalke, 2002). Both ppUL25 and 
the full-length pUL35 protein are packaged into virions and are also found in dense bodies, 
of which ppUL25 makes up 13% of the total protein amount (Varnum et al., 2004, Liu and 
Biegalke, 2002, Baldick and Shenk, 1996). UL25 is dispensable for growth in fibroblasts, 
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however the UL35 deletion mutant has a moderate growth defect (Dunn et al., 2003b). 
Both pUL35 and pUL35a interact with pp71 and it has been suggested that the pUL35A 
protein may modulate expression of the major IE gene expression by inhibiting activation 
of the promoter by pp71 (ppUL82) (Liu and Biegalke, 2002). Both pUL35 and pUL35a 
appear to also interact with each other and the ubiquitin-specific protease USP7 (Salsman 
et al., 2012, Salsman et al., 2011). pUL35 is able to remodel promyelocytic leukemia (PML) 
nuclear bodies and is implicated in contributing to viral replication through the 
manipulation of host responses, including the DNA damage response (Salsman et al., 2012) 
and degrading the viral restriction factor Bcl-2 associated factor 1 (BclAF1)(Lee et al., 2012). 
1.8.6 The UL30 family 
The 2 members of this family, UL30 and UL30A, are adjacent in the UL region of the 
genome, and are conserved among primate cytomegaloviruses (Davison, 2010). The UL30-
UL32 region has multiple overlapping transcripts throughout it, including at least eight 
mRNAs, and it is predicted that the UL30 gene is transcribed from the complementary 
strand (Ma et al., 2013). UL30A is related to UL30, and is located on the 0.55 kb transcript, 
with its potential coding region located between the transcriptional initiation site and the 
translational initiation codon of UL30. This UL30A region is conserved in Old World primate 
CMV members but likely uses a non-ATG codon (Davison, 2010, Gatherer et al., 2011). 
pUL30 was found in sub-organelles of the nucleus, causing the loss or disruption of cajal 
bodies, which are the main sites for the assembly of small nuclear ribonucleoproteins 
(RNPs). This may mean that pUL30 plays a role in inhibiting transcription or RNP maturation 
(Salsman et al., 2008). pUL30 also causes a significant decrease in the number of 
promyelocytic leukemia (PML) bodies (also known as nuclear domain 10s; ND10s) which 
are involved in host cell processes such as apoptosis and the DNA damage response, 
(reviewed by Rabellino and Scaglioni (2013)), disrupting them in a similar fashion to IE1 
(Wilkinson et al., 1998). Moreover, PML bodies are known to suppress lytic viral infections 
(Saffert and Kalejta, 2006, Tavalai et al., 2006) so pUL30 therefore likely reduces the host’s 
suppression on viral infection. Correspondingly, the Towne UL30 deletion virus has a severe 
growth defect in fibroblasts (Dunn et al., 2003b) 
1.8.7 The UL82 family 
The UL82 family consists of UL31, UL72, UL82, UL83, and UL84. They are known as the 
DURP family as they are deoxyuridine triphosphatase (dUTPase)-related proteins (DURPs), 
although it is unlikely that they retain this enzymatic activity (Davison, 2013, Davison and 
Stow, 2005). It is probable that UL82, UL83, and UL84 arose from the same ancestral gene 
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that evolved from host capture of a dUTPase gene, followed by a duplication and 
subsequent loss of function (Davison and Stow, 2005). ppUL82 (pp71) and ppUL83 (pp65) 
are both tegument proteins found in high quantities, with pp65 being the most abundant 
protein in virions (Fu et al., 2017, Varnum et al., 2004). Both proteins are conserved across 
β-herpesviruses, although pp65 is dispensable for growth in vitro, whereas the UL82 
deletion mutant has severe growth defects (Dunn et al., 2003b, Fu et al., 2017). Both 
function as immune evasion proteins, playing a variety of roles from affecting the cell cycle 
(Cantrell and Bresnahan, 2006, Trgovcich et al., 2006), modulating gene expression 
(Bresnahan and Shenk, 2000) and inhibiting antiviral signalling pathways (Noriega et al., 
2012b, Halenius et al., 2011, Fu et al., 2017, Arnon et al., 2005, Browne and Shenk, 2003, Li 
et al., 2013). pUL84 has been shown to interact with ppUL83 and is also present in virions, 
but not in large quantities (Varnum et al., 2004, Gao et al., 2008). pUL84 shuttles from the 
nucleus to the cytoplasm, is involved in transcriptional activation, DNA replication and viral 
growth, and is essential for growth of both Towne and AD169 strains, although not TB40/E 
(Dunn et al., 2003b, Gao et al., 2008, Spector and Yetming, 2010, Davison and Stow, 2005).  
 
UL31 and UL72 members belong in a separate group, with little known about either 
member except that pUL31 localizes to the nucleolus in uninfected cells (Salsman et al., 
2008). Both members cause moderate growth defects in fibroblasts when deleted, despite 
not being essential for growth (Dunn et al., 2003b). UL72 comprises a core HCMV gene and 
has been revealed not to be an activate dUTPase despite being an ortholog of functional 
dUTPases (Davison and Stow, 2005, Caposio et al., 2004). 
 
1.8.8 The UL120 family 
The UL120 family consists of just UL120 and UL121, found adjacent in the major IE (MIE) 
region of the genome, alongside UL123 (IE1) (Grey et al., 2007). They are both putative 
membrane glycoproteins that are distantly related to each other, and comprise one of the 
newer gene families (Dolan et al., 2004). It is possible that they arose via duplication of the 
UL119 ancestor gene as there is marginal conservation between them in a portion of the 
immunoglobulin domain, making UL119 another possible family member (Davison and 
Bhella, 2007). UL120 and UL121 constitute 2 of the target sequences for the viral microRNA 
miR-UL112-1. Their function is currently unknown, but miR-UL112-1 regulates the 
expression of genes involved in viral replication, and their location in the MIE has suggested 
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that UL120 and UL121 may encode exons within the MIE family of transcripts (Grey et al., 
2007). 
1.8.9 The UL146 family 
The UL146 family consists of UL146 and UL147 and are known as the CXCL family as the 
proteins are either known or predicted CXC-chemokines (Penfold et al., 1999, Dolan et al., 
2004). CXC receptors 1 (CXCR1 and CXCR2) are the main host chemokines receptors 
expressed on neutrophils and they play a major role in the inflammatory response. UL146 
is a viral homologue of the endogenous CXC ligand CXCL1 (vCXCL1), which targets CXCR1 as 
a selective agonist, and also CXCR2 with lower affinity and potency (Lüttichau, 2010, 
Penfold et al., 1999). gpUL146 has known chemokine function and HCMV may use gpUL146 
to attract neutrophils to infected cells after which they could act as carriers of the virus to 
uninfected locations (Lüttichau, 2010, Penfold et al., 1999). UL146 is one of the most 
hypervariable HCMV genes and is highly divergent throughout its length, and exists as 14 
variants or alleles, which may be driven by differing gene function (Davison, 2011, Stanton 
et al., 2005). pUL147 (designated vCXCL2) has yet to be fully characterised but has less 
homology to CXC chemokines and is less likely to have chemotactic ability (Scarborough et 
al., 2017, Penfold et al., 1999). 
1.8.10 The US1 family 
The US1 family includes the members US1, US31, US32 (Rigoutsos et al., 2003). Little is 
known about their function but all 3 members are dispensable for growth in vitro (Dunn et 
al., 2003b). This gene family are found in HCMV, RhCMV and CCMV amongst others, and 
each members contains two copies of a motif in their N-terminal regions which may 
coordinate a metal ion (Davison and Bhella, 2007). pUS32 is a late protein that co-localises 
with PML or ND10s and its expression results in altered size and shapes of nuclear bodies, 
although the mechanism and reason are unknown (Salsman et al., 2008, Strang, 2015).  
1.8.11 The US2 family 
The US2 family members, US2 and US3, are 50% similar at the amino acid level and both 
glycoproteins are expressed early in infection (Jones and Sun, 1997). As mentioned in 
Section 1.7.4.1, gpUS2 and gpUS3 both down-regulate both MHC class I and class II 
expression on the cell surface (Noriega et al., 2012b, Pande et al., 2005, Hsu et al., 2015, 
Tomazin et al., 1999, Besold et al., 2007). gpUS3 functions by retaining MHC class I heavy 
chains within the ER and can also interfere with the chaperone tapasin that controls 
peptide loading (Halenius et al., 2011, Noriega et al., 2012b). gpUS2 on the other hand 
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causes the rapid destabilization and degradation of the retained MHC proteins but can also 
reduce integrin signalling, cell adhesion and cell migration through an array of ligands (Hsu 
et al., 2015, Tomazin et al., 1999, Jones and Sun, 1997).  
1.8.12 The US6 family 
The US6 family currently consists of 6 predicted glycoproteins US6 to US11, which cluster 
separately as a family but have partial amino acid homology with the US2 family (Huber et 
al., 2002, Pande et al., 2005). Multiple transcripts are produced across the family region 
with members sometimes present on more than 1 transcript (Jones and Muzithras, 1991). 
The deletion of both US2 and US6 families (US2-11) was able to completely prevent the 
presentation of IE1 antigens (Besold et al., 2007). Most US6 family members work to down-
regulate MHC I expression to avoid immune detection or are involved in antigen 
presentation in some way (Huber et al., 2002, Noriega et al., 2012a). gpUS6 inhibits the 
movement of peptides across the lumen of the ER membrane by binding to the 
transporter-associated with antigen processing (TAP) complex, and US11 retains and 
degrades MHC molecules (Huber et al., 2002, Lehner et al., 1997, Halenius et al., 2011, 
Besold et al., 2007, Hsu et al., 2015). pUS8 is able to bind to MHC I on the surface and 
pUS10 can delay the exit of MHC I and down-regulating the cell surface expression of HLA-
G (Furman et al., 2002, Huber et al., 2002, Park et al., 2010). pUS9 downregulates the 
glycosylphosphatidylinositol (GPI)-anchored MICA*008 allele by targeting it for 
proteasomal degradation, although it does not appear to affect the overall MICA*008 
levels during HCMV infection (Seidel et al., 2015). pUS7 is also predicted to have an 
immune evasion function but remains largely uncharacterised. The US6 family are not 
required for growth of HCMV in fibroblasts in vitro, and mutations that naturally occur in 
US6, US7, and US9 point to functional redundancy of the family (Sijmons et al., 2015, Dunn 
et al., 2003b).  
1.8.13 The US22 family 
The US22 family is the second largest HCMV gene family, as well as the most highly 
conserved, also being encoded by other β-herpesviruses (Lesniewski et al., 2006). It 
contains the members US22, US23, US24, US26, UL23, UL24, UL28, UL29, UL36, UL43, TRS1 
and IRS1, with at least 7 members documented as tegument proteins, indicating that the 
rest may play a similar role (Adair et al., 2002). Accordingly, most members are found in 
HCMV virions and some can also be found in aggregates resembling dense bodies (Adair et 
al., 2002). 
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Their conserved US22 sequence motifs may be tegument signals that have evolved to allow 
for more diverse functions, and as such, they play a role in a variety of processes, including 
immune evasion (Lesniewski et al., 2006). pUL36 encodes a cell death suppressor and is a 
viral inhibitor of caspase-8-induced apoptosis (vICA) by binding to caspase-8 and preventing 
its activation and thereby Fas-mediated apoptosis (Skaletskaya et al., 2001). pTRS1 and 
pIRS1 are highly homologous proteins that are also involved in the evasion of the hosts 
antiviral responses (Ziehr et al., 2016, Colberg-Poley, 1996, Child et al., 2004), both proteins 
designated as antagonists to the antiviral protein kinase R (PKR) which normally limits viral 
protein translation and synthesis upon binding to viral dsRNA. Both are likely to be 
transcriptional transactivators and may cooperate with other IE proteins, and expression of 
either is sufficient to bind and inactivate PKR, thereby allowing for efficient synthesis and 
replication to take place (Ziehr et al., 2016, Child et al., 2004). The deletion of either is most 
likely not detrimental due to their common functions or targets, however the deletion of 
both results in a replication-deficient virus (Ziehr et al., 2016, Jones and Muzithras, 1991, 
Strang, 2015). Many US22 family members still have unknown function, and although all 
are non-essential for growth in AD169 or Towne strains in vitro, deletion of US24 does 
cause a growth defect, with a delay and a decrease in the expression of IE, E and L proteins 
(Feng et al., 2006, Dunn et al., 2003b).  
1.8.14 The GPCR family 
The G-protein coupled receptor (GPCR) family includes the members UL33, UL78, US27 and 
US28, 2 of which are found in the UL region and 2 in the US region of the genome. These 4 
proteins are predicted to encode 7-transmembrane proteins which contain the key 
hallmark features of chemokine receptor homologues (Scarborough et al., 2017). US27 and 
US28 exhibit homology to, and likely arose from, a common ancestor with human 
chemokine receptor CX3CR1 (Kledal et al., 1998, Scarborough et al., 2017). pUS28 binds to, 
and can sequester, a broad range of chemokines including RANTES, MIP-1α, and MCP-1, 
although it is much more specific for the CX3CR1 ligand fractalkine (Kledal et al., 1998, 
Bodaghi et al., 1998). It can subsequently activate the major MAP-kinase pathways, as well 
as activating the transcription of NF-κB (Rosenkilde et al., 2001) and is one of the few genes 
expressed during “latency” (Scarborough et al., 2017). pUS27 is a putative chemokine 
receptor, and although it has no known ligands to date, it appears to directly enhance the 
calcium signalling activity of a human chemokine receptor, CXCR4 (Arnolds et al., 2013). 
pUL33 and pUL78 can also regulate cellular chemokine receptors CXCR4 and CCR5 through 
receptor heteromerization and are suggested to be important for virulence, however their 
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functions and mechanisms are also unknown (Rosenkilde et al., 2001, Tadagaki et al., 
2012). The importance of US27 and US28 is indicated through their high conservation of 
across different HCMV strains, with a minimum of 94.74% and 97.46% identity respectively 
(Scarborough et al., 2017). As homologues of chemokine receptors, the GPCR family could 
have a range of functions including protecting the receptor from recognition by the host 
immune system, a way to eliminate chemoattractants from the surrounding area, and 
potential involvement with HCMV cell entry, tissue targeting or attracting specific immune 
cells for dissemination purposes (Kledal et al., 1998, Bodaghi et al., 1998, Rosenkilde et al., 
2001).  
1.8.15 The US12 family 
The US12 family is comprised of 10 tandemly aligned members US12 to US21, arranged 
across 9 kb in HCMV’s unique short (US) region (Dolan et al., 2004, Chee et al., 1990). The 
US12 family is one of the larger multi-gene families, and its members are produced across 3 
transcriptional cassettes, US21, US20-US18 and US17-US12 (Guo, 1993, Lu et al., 2016). The 
US12 family are highly conserved across HCMV strains and in the CMVs of higher primates, 
with the ancestral virus likely to have encoded at least 8 of the US12 family members prior 
to the divergence of the rhesus and hominoid lineages (Lesniewski et al., 2006). Some 
primate CMVs are missing some of the US12 family members and others have extra 
members, with eleven members found in the rhesus macaque CMV (RhCMV) genome, 
which lacks US15 and US16, but has 4 homologues of US14 (Hansen et al., 2003). The 
peripheral members of the group (US12, US13 and US17-US21) are the highest conserved 
members, with US21 having the most similarity across higher primate CMV strains. US21 
also shows significant overall sequence similarity to three human proteins (lifeguard, CGI-
119, and PP1201), so proto-US21 is suggested to represent the origin of the family 
(Lesniewski et al., 2006, Holzerlandt et al., 2002). It is thought that the duplication and 
divergence of proto-US21 lead to the creation of US20 which was then important for the 
development of the rest of the family (Lesniewski et al., 2006). 
The US12 family have some homology to G-protein coupled receptor (GPCR) proteins, with 
most members predicted to have 7 transmembrane (7TM) domains, 6 members having 
DRY motif related sequences and 5 members containing a motif closely related to a 
sequence found in the conserved GPCR Frizzled (Lesniewski et al., 2006). Overall, US12 and 
US14 are the most GPCR-like as they contain the greatest number of similar motifs, 
whereas US19 is the least similar, containing just 1 GPCR motif (Rigoutsos et al., 2003, 
Lesniewski et al., 2006). There is no evidence however of the US12 family having any GPCR-
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like signalling, and they represent a distinct branch of the GPCR group so have the potential 
to encode vastly different functions (Lesniewski et al., 2006). There is also shared similarity 
in a motif between the US12 family and the transmembrane BAX Inhibitor-1 Motif-
containing (TMBIM) protein family that includes Bax inhibitor-1 (BI-1) and related 7TM 
proteins (Lesniewski et al., 2006, Rojas-Rivera and Hetz, 2015). BI-1 inhibits Bax-mediated 
apoptosis, but to date no apoptosis-related functions have been discovered within the 
US12 family.   
All US12 family members are non-essential for growth in fibroblasts in vitro, however US13 
does cause a slight growth defect when deleted in fibroblasts (Dunn et al., 2003b), and 
other members have growth defects when grown in different cell types (Section 1.8.15.2). 
Despite being non-essential, the US12 family are still highly conserved in clinical isolates, 
with US13 and US18 in the top 25 most conserved genes within HCMV (Sijmons et al., 2015, 
Dunn et al., 2003b, Yu et al., 2003). Most US12 family members also showed no ORF-
disrupting mutations within 124 clinical isolates tested, with just 1 strain presenting with a 
2 nucleotide (nt) insertion in US12 and 3 strains demonstrating a 24 nt deletion within 
US13 (Sijmons et al., 2015). Their conservation implies that they play important roles in 
vivo, and so far the family have been shown to have a variety of roles in immune evasion, 
replication, and tropism in vitro (Section 1.8.15.2 and 1.8.15.4).  
1.8.15.1 The localisation of the US12 family 
Many US12 family members are expressed early during infection, including pUS19 and 
gpUS20 (Chambers et al., 1999, Guo, 1993, Cavaletto et al., 2015), with some members 
accumulating later during infection such as pUS16, pUS17 and pUS18 (Bronzini et al., 2012, 
Das et al., 2006). Proteins pUS14, pUS16, pUS17 and pUS18 from the TR or AD169 strains 
displayed localisation with the virion assembly compartment (vAC) at some point during 
infection, mostly accumulating there at later time-points (Das and Pellett, 2007, Das et al., 
2006, Bronzini et al., 2012). AD169 pUS14 and pUS18 also had cytoplasmic distributions, 
with pUS14 presenting in a granular manner, and pUS17 also having nuclear localisation of 
its C-terminal segment (Das et al., 2006, Das and Pellett, 2007, Bronzini et al., 2012). TR 
pUS20 however, was shown to localise to ER-derived membranes (Cavaletto et al., 2015). 
Although it is obvious that all US12 family members do not share the same localisation, 
there does appear to be a trend towards an association with the vAC, although these 
locations may differ in other strains and in other cell types (Das and Pellett, 2007, Das et al., 
2006, Bronzini et al., 2012).  
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1.8.15.2 The role of the US12 family in replication and tropism 
Currently, three members have been shown to play roles in HCMV replication and are 
involved with the ability of HCMV to grow in different cell types, with some deletion 
mutants failing to express immediate-early (IE) genes upon infection, abrogating growth of 
the virus (Bronzini et al., 2012, Hai et al., 2006, Dunn et al., 2003b). Deletion of the AD169 
US16 gene for example, was found to cause a major growth defect in both endothelial cells 
and epithelial cells, whilst replication was normal in fibroblasts (Bronzini et al., 2012). US16 
appears to function during the final stages of virus maturation, reducing the virion content 
of the pentamer complex that is required for efficient entry into endothelial and epithelial 
cells, thereby reducing viral growth in those cells types only (Luganini et al., 2017, Bronzini 
et al., 2012). Another major growth defect was observed with the deletion of US18 from 
the Towne strain, this time observed in cultured human gingival tissues derived from 
human keratinocytes (Hai et al., 2006). There was reduced viral growth in this cell type 
compared to fibroblasts, with the mutant appearing to be deficient in infecting the tissue 
as well as replicating within them, blocked at a stage prior to (or at) IE gene expression (Hai 
et al., 2006). US20 was instead required for efficient growth in endothelial cells at a stage 
after attachment and entry, but the US20 deletion mutant replicated normally in 
fibroblasts and epithelial cells (Cavaletto et al., 2015). Other differential effects have yet to 
be discovered, but the US12 family themselves are also differentially regulated in different 
cell types, with at least 5 members (US12, US14, US18, US19 and US20) having differential 
genes expression between astrocytoma cells, fibroblasts and retinal pigmented epithelial 
cells (Towler et al., 2012).  
1.8.15.3 The role of the US12 family in regulating the cellular and virion proteome 
HCMV modifies the host’s cellular gene expression in order to evade the host’s defences, 
with the US12 family targeting multiple host plasma membrane proteins (Weekes et al., 
2014, Fielding et al., 2017). The US12 family caused major changes in the expression levels 
of over 80 proteins, some of them targeted for lysosomal degradation by the family 
(Fielding et al., 2017). Pathways significantly affected by the US12 family, included cell 
adhesion molecules, cytokine-cytokine receptor interactions and natural killer (NK) cell-
mediated cytotoxicity pathways (Fielding et al., 2017). Multiple US12 family members have 
the ability to target more than 1 protein each, with gpUS20 able to regulate 54 cellular 
targets. Different family members can also target the same proteins; with 29% of plasma 
membrane proteins regulated >3 fold by 2 or more family members, and 6% by 3 or more 
family members (Fielding et al., 2017). gpUS20 for example, shares at least 14 of its targets 
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with pUS18, and the 2 have demonstrated to act in concert (Section 1.8.15.4) (Fielding et 
al., 2017, Fielding et al., 2014). 
As well as regulating their target proteins, the US12 family can also affect the expression 
levels of each other, for example, the deletion of US13 or US15 increases the expression of 
pUS14, and deletion of US21 increases pUS20 levels (Fielding et al., 2017). This may suggest 
a compensation mechanism for members that regulate the same targets, or may imply that 
these proteins form complexes with each other in order to accomplish their roles (Fielding 
et al., 2014). 
The US12 family can also exert effects on the virion proteome. pUS17 not only plays a role 
in the final stages of virion assembly and egress, but also alters the levels of virion proteins, 
such as the envelope glycoprotein H (gH) (Gurczynski et al., 2014). pUS17 additionally alters 
the ratio of infectious to non-infectious particles, with ΔUS17 producing more genome-
containing non-infectious particles than its parental virus, whilst producing the same 
number of infectious virions (Gurczynski et al., 2014). The US16 deletion mutant instead 
reduces the levels of the pentamer complex on the virion, abrogating entry into epithelial 
and endothelial cells (Bronzini et al., 2012, Luganini et al., 2017). Other links between US12 
family members are virion composition have yet to be established. 
1.8.15.4 The role of the US12 family in immune evasion 
The modulation of the cellular proteome by HCMV includes the targeting of many cellular 
immune ligands for degradation, and this may allow HCMV to favourably alter the host 
immune response. The US12 family’s regulation of the NK cell-mediated cytotoxicity 
pathway for example, includes the ability to downregulate NK activating receptor ligands 
such as MICA, MICB, ULBP2 and B7-H6 (Fielding et al., 2017, Fielding et al., 2014). Further 
to this, US12, US14, US18, US20 and US21 have all been identified as NK evasins (Fielding et 
al., 2017, Fielding et al., 2014). The family either retain their targets intracellularly, or they 
target them for degradation. pUS18 and gpUS20 for example, both work in concert to 
target the NKG2D ligand MICA for lysosomal degradation and to target the NKp30 ligand 
B7-H6 for proteolysis, reducing activation of NK cells in response to the infected cell 
(Fielding et al., 2017, Fielding et al., 2014). 
The US12 family can also influence immune evasion indirectly, with the deletion of US17 
causing an alteration in virion composition. The deletion of US17 leads to decreased levels 
of gH and increased amounts of pp65 being delivered to newly infected cells, causing 
significantly differential expression of innate and intrinsic immune response-related gene 
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transcripts. This alters the immune response to HCMV in newly infected cells and 
differentially regulates the endoplasmic reticulum stress response at 96 hpi (Gurczynski et 
al., 2014). The fact that some members, especially US14 and US18, seem to be subjected to 
higher levels of positive selection than would be expected from their diversity supports the 
idea that they may interact with host antiviral mechanisms (Sijmons et al., 2015).  
1.8.15.5 Summary 
In summary the US12 family have a variety of roles including tropism (US16, US18 and 
US20), immune evasion (US12, US14, US18, US20 and US21) and virion composition and 
maturation (US16, US17) as summarised in Table 1.7 (Bronzini et al., 2012, Hai et al., 2006, 
Cavaletto et al., 2015, Luganini et al., 2017, Gurczynski et al., 2014). The US12 family affect 
the levels of a wide range of host proteins and immune ligands, as well as each other 
(Fielding et al., 2014, Fielding et al., 2017). Although the localisation and expression levels 
of certain US12 family members have been determined, these have generally yet to be 
tested in a clinically relevant virus such as Merlin, with US12, US13, US15, US19 and US21 
having little or no functional or characterisation data available. 
 
1.8.16 Aims and hypothesis 
The US12 family is one of the largest of the 15 multigene families in HCMV’s genome and 
some US12 family members have been shown to have important roles in HCMV infection in 
different strains and different cell types (Bronzini et al., 2012, Hai et al., 2006, Cavaletto et 
al., 2015, Fielding et al., 2014). It is likely that other family members are likely to have 
similar roles and be similarly important for HCMV. Despite some recent functional studies 
on the target proteins of the US12 family (Fielding et al., 2017), little is known about the 
fundamental aspects of the proteins themselves. The aim of this project is therefore to 
further characterise the US12 family in the clinically relevant strain Merlin, and to give a 
greater understanding of the basic fundamental aspects of the entire gene family in 
productive HCMV infection. The intention of the project is also to assess whether these 
findings give insights into their mechanism of action, including their role in immune 
evasion, and how the US12 family link into the overall HCMV infection. 
The US12 family members appear to play a role in immune modulation by targeting cellular 
immune receptors for lysosomal degradation (Fielding et al., 2017), and we hypothesise 
that they may achieve this by trafficking the proteins to the lysosomes themselves. If this is 
the case, the US12 family members may also be degraded themselves, and this can be  
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Table 1.7: Summary of the current published knowledge of the US12 gene family 
members, pertaining to their localisation, tropism and immune evasion functions.  
Protein Localisation Tropism Immune evasion 
US12   NK evasion function. Regulates 
cellular immune ligands, 
including ULBP2 [a]  
US13   Regulates cellular immune 
ligands, including MICB [a]  
US14 vAC and dispersive 
cytoplasmic (AD169) 
[b, c]  
 NK evasion function. Regulates 
cellular immune ligands, 
including JAM3 [a] 
US15   Regulates cellular immune 
ligands, including IL6ST [a] 
US16 vAC (TR strain) [d]  Required for 
efficient infection 
of endothelial and 
epithelial cells [d,e]  
 
US17 N-terminus to the 
periphery of the vAC 
and C-terminus to the 
nucleus and cytoplasm 
(AD169) [b, c]  
 Affects immune responses 
through altered virion 
composition e.g. of pp65 [f].  
US18 Cytoplasmic, moving to 
the vAC later on 
(AD169) [b, c]  
Required for 
efficient growth in 
human gingival 
tissue [g]  
NK evasion function. Regulates 
cellular immune ligands including 
B7-H6 and MICA in concert with 
US20 [a, h] 
US19    
US20 Sub-cytoplasmic ER 
localisation (TR strain) 
[i]  
Required for 
efficient growth in 
endothelial cells [i] 
NK evasion function. Regulates 
cellular immune ligands, 
including MICA and B7-H6 [a, h] 
US21   Possible NK evasion function [a].  
 
[a]= Fielding et al. (2017); [b]= Das and Pellett (2007); [c]= Das et al. (2006); [d]= Bronzini et 
al. (2012); [e]= Luganini et al. (2017); [f]= Gurczynski et al. (2014); [g]= Hai et al. (2006); [h]= 
Fielding et al. (2014); and [i]= Cavaletto et al. (2015). 
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tested by observing the effects of adding a lysosomal inhibitor. We hypothesize that some 
US12 family members may work together in a complex, supported by the fact that multiple 
proteins can target the same cellular proteins, and identifying their localisations could 
postulate whether multiple members are found in the same locations. We additionally 
theorize that any US12 family members that are found in the vAC are also likely to be 
incorporated into the virion. 
In order to achieve these goals, HCMV bacterial artificial chromosomes (BACs) were 
constructed with a V5 tag added to each US12-US21 gene individually. These viruses were 
then used to characterise the US12 family members for their expression levels, their 
intracellular trafficking and their post-translational modifications. This investigation of the 
US12 family could advance our understanding of HCMV pathogenesis and immune 
modulation and may potentially allow for the family to be targeted in therapy in the future.  
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2 Materials and 
Methods 
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2.1 Molecular Biology 
2.1.1 Growth of E. coli SW102 cultures  
The HCMV Merlin bacterial artificial chromosome (BAC) was propagated using Escherichia 
coli SW102 bacteria for fast growth and easy BAC manipulation. E. coli SW102 were utilised 
as they contain lambda phage Red recombination genes under temperature sensitive 
expression. These genes could be induced by incubating the bacteria at 42⁰C allowing 
homologous recombination of DNA to take place, and the bacteria otherwise grown at 
32⁰C to avoid inappropriate recombination.   
2.1.2 Selection media and plates  
E. coli SW102 containing the Merlin BAC were grown overnight in 5ml Luria-Bertani (LB) 
broth at 32⁰C overnight in a shaking incubator (Stuart orbital incubator) as standard. All 
media was autoclaved for sterility and allowed to cool to below 50⁰C before antibiotics 
were added. Chloramphenicol was used as standard to select for SW102 bacteria that 
contained the HCMV BAC. Transformed bacteria were grown on LB agar plates when 
selecting for single colonies or correctly recombineered BACs. Different selection cassettes 
(Section 2.1.4.1) required different antibiotics and chemicals which were prepared as 
described in Table 2.1. The LB agar was then poured into sterile petri dishes (20 ml each, 
Fisher, PDS-140-050F) under the sterility of a Bunsen burner and allowed to solidify before 
being stored upside down at 4⁰C.  
GalK recombineering methods required M63 minimal media plates, and 2-deoxy-galactose 
(DOG) was utilised as the carbon source as only the second round of recombineering was 
undertaken (Section 2.1.4.1). 
 
LB broth media: 10g of LB powder (Melford Biolaboratories Ltd, L1703) dissolved in 500ml 
dH20 
LB agar: add 7.5g agar (Sigma-Aldrich) to 500ml LB broth 
Sucrose LB agar plates: 5g tryptone (Thermo Fisher), 2.5g yeast extract (Sigma-Aldrich), 
7.5g agar and 25g sucrose (Fisher, BP2201) dissolved in 500 ml dH20.  
M63 minimal media plates: 15 g agar dissolved in 800 ml dH2O and autoclaved. Once 
cooled a little, add 200 ml 5X M63 medium and 1 ml 1 M Magnesium sulfate heptahydrate 
(MgSO4·7H2O). Top up to 1l with dH20 if required. Once cooled to 50°C, add 10 ml 2-  
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Table 2.1: Supplementary antibiotics and chemicals added to LB broth and agar plates 
Antibiotic/chemical Main stock: Working stock: Use at: 
Chloramphenicol Powder 
(Doehringer) 
Made to 12.5 mg/ml by 
dissolving 625 mg in 50 ml 
ethanol 
1:1000 (12.5 
μg/ml final 
concentration) 
Ampicillin sodium Powder 
(Duchefa 
Biochemie) 
Made to 100mg/ml by 
dissolving 1g ampicillin 
sodium sulphate in 10 ml 
dH20, then filter sterilized* 
1:2000 
(50μg/ml final 
concentration) 
Kanamycin 
monosulphate 
Powder 
(Melford) 
Made to 15 mg/ml by 
dissolving 150 mg in 10 ml 
dH20, then filter sterilized* 
1:1000 
(15μg/ml final 
concentration) 
Streptomycin 
sulphate 
Powder 
(Melford 
Made to 200mg/ml by 
dissolving 2g of Streptomycin 
sulphate in 10 ml dH20, then 
filter sterilized* 
1:500 
(400μg/ml final 
concentration) 
5-bromo-4-chloro-
indolyl-β-D-
galactopyranoside (X-
gal)† 
Powder 
(Melford) 
Made to 40mg/ml by 
dissolving 400mg of X-gal in 
10ml 100% DMSO, and 
stored in foil 
1:500 (80 ug/ml 
final 
concentration) 
Isopropyl β-D-1-
thiogalactopyranoside 
(IPTG)† 
Powder 
(Melford) 
Made to 100mM by 
dissolving 0.238g IPTG in 
10ml dH20, then filter 
sterilized* 
1:500 (200 nM 
final 
concentration) 
*Once dissolved, the solution must be filter sterilised by passing through a 0.22μm filter 
† Chemicals used to aid the blue/white screening of recombinants (Section 3.1, Figure 3.3). 
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deoxy-galactose (DOG) (0.2%), 5 ml biotin (1 mg), 4.5 ml leucine (45 mg), and 500 ml 
chloramphenicol (12.5 mg/ml).  
5X M63: 10 g of ammonium sulfate ((NH4)2SO4), 68 g potassium dihydrogen phosphate 
(KH2PO4) and 2.5 mg ferrous sulfate heptahydrate (FeSO4·7H2O) in 1l of dH20. Adjust to 
pH7 with potassium hydroxide (KOH).  
 
2.1.3 Generation of glycerol stocks 
Long term storage stocks of each clone were made from overnight cultures of SW102 
containing the required HCMV Merlin BAC, with 500 ml of LB culture added to 75 μl 
glycerol (15%) in 1 ml screw cap tubes with seals (VWR, 16466-054). Once mixed, the stocks 
could be frozen at -70⁰C for future use, providing a reproducible source of BAC. To 
propagate from these, an inoculation loop was used to take a scrape of the frozen glycerol 
stock which was added to 5 ml of LB with appropriate selection antibiotics and grown 
overnight at 32⁰C in a shaking incubator. 
 
2.1.4 Recombineering 
Recombination-mediated genetic engineering or ‘recombineering’ is a method of altering 
the virus BAC genome utilising the lambda red genes of E. coli SW102. To construct US12 
family V5-tagged virus BACs, 2 rounds of homologous recombination were required 
(Section 3.1, Figure 3.2). Briefly, the first round of recombineering involved inserting a 
selection cassette after the gene of interest (US12 family member), by adding in a PCR 
product of the cassette that contains homology arms adjacent to the gene. In the second 
round of recombineering, the cassette was then swapped for oligos of the V5 tag that is 
flanked by homology arms of the gene of interest and downstream homology. 
2.1.4.1 Selection cassettes  
A variety of selection cassettes were used for recombineering, the SacB, Rpsl and GalK 
cassettes. Each selection cassette contains an antibiotic resistance gene which allows for 
positive selection of clones that have successfully inserted the cassette during the first 
round of recombineering, along with a gene used for negative selection of clones that have 
subsequently swapped out the cassette for the V5 tag during the second round of 
recombineering (Table 2.2). The Rpsl cassette (KanR/SmS/LacZ/Rpsl) encoded for 
kanamycin resistance for positive selection and streptomycin sensitivity for negative 
selection, which inhibited growth for clones that had failed to remove the cassette. The  
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Table 2.2: Selection cassettes utilised for the production of V5-tagged genes in the HCMV 
merlin BAC by recombineering 
Cassette Resistance/ 
positive selection 
genes 
Sensitivity/ 
negative selection 
genes 
Other 
genes 
Reference 
Rpsl 
(KanR/SmS/ 
LacZ/Rpsl) 
 
 
Kanamycin 
resistance marker 
(neoR/KanR) 
Streptomycin 
sensitivity (Rpsl+) 
LacZα for 
white/blue 
screening 
(lacZ) 
(Sung et al., 
2001) 
SacB 
(AmpR/LacZ/ 
SacB) 
 
 
Ampicillin 
resistance gene and 
lacZ  (ampR) 
SacB for sucrose 
sensitivity (SacB) 
LacZα for 
blue/white 
screening 
(lacZ) 
(Stanton et al., 
2008)  
GalK 
 
 
Ability to use 
galactose as the 
only carbon source 
(galE, galT, galK 
and galM) 
2-deoxy-galactose 
(DOG) 
sensitivity/toxic 
build up (galK)  
- (Warming et 
al., 2005) 
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SacB cassette (AmpR/LacZ/SacB) encoded for ampicillin resistance for positive selection 
and levansucrase for negative selection, inhibiting growth for cassette-containing clones in 
the presence of sucrose. Both Rpsl and SacB cassettes also contained the LacZ gene which 
encoded for β-galactosidase (Table 2.2). Isopropyl β-D-1-thiogalactopyranoside (IPTG) in 
the selection media stimulated lacZ transcription, and the induced β-galactosidase cleaved 
its chromogenic substrate 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside (X-gal). X-gal 
is a colourless analog of lactose, and it’s cleavage resulted in the formation of a blue 
insoluble pigment (5,5'-dibromo-4,4'-dichloro-indigo), and allowed for the identification of 
successfully transformed colonies by colour, termed ‘blue/white screening’ (Section 3.1, 
Figure 3.3). 
The GalK cassette encoded for galactokinase (galK) which phosphorylates galactose and its 
derivatives and was used for both positive and negative selection. The GalK cassette 
allowed SW102 bacteria (which contain a deletion of galK) to grow on minimal media with 
galatose as the only carbon source, allowing for positive selection. By exchanging the 
galactose in the media for its analog 2-deoxy-galactose (DOG), the presence of galK would 
lead to a toxic build-up of the product 2-deoxy-galactose-1-phosphate, allowing for 
negative selection (Table 2.1). Appropriate antibiotics for each cassette were made up and 
added to selection media or agar plates (Section 2.1.2). 
 
2.1.4.2 Preparation of competent bacteria for recombineering  
The first round of recombineering required SW102 that contained the HCMV Merlin 
pAL1111 BAC, to be grown overnight at 32⁰C in LB with chloramphenicol. The 2nd round 
required SW102 that contained the BAC in which the cassette had been inserted at the end 
of the US12 family gene (e.g. Merlin BAC with US12-Rpsl) which was grown overnight in LB 
with chloramphenicol and the appropriate selection cassette antibiotic (e.g. kanamycin for 
Rpsl). 0.5 ml of this overnight culture was added to 25 ml LB with appropriate antibiotics in 
a falcon tube and was left in a shaking incubator at 32⁰C until it reached an optical density 
(OD) of 0.6 at 600nm. A UV spectrophotomer (Pharmacia Ultraspec 3000) was used to 
measure the OD, and OD 0.6 signalled the exponential phase of bacterial growth. Once this 
OD was achieved, the falcon tube was heated to 42⁰C in a waterbath for 15 min, whilst 
inverting often, to induce the lambda phage genes. The bacteria were then cooled by 
rocking on ice for 15 min, and kept at ~0°C for all future steps to keep the cells competent 
in preparation for recombination. The samples were centrifuged at 4000 rpm for 5 min at 
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0°C, the supernatants discarded, and the pellets re-suspended in 1ml sterile ice-cold water 
by gentle shaking. These were topped up to 25 ml with cold water and re-centrifuged at 
4000 rpm for 5 min. This wash step was repeated once more and after the final 
centrifugation, the supernatant was discarded and the pellet re-suspended in the small 
volume of water left in the falcon tube. 
 
2.1.4.3 Transformation of competent bacteria 
A 25 µl aliquot of the competent SW102 resuspension was added into a pre-cooled 0.2 cm 
electroporation cuvette (GeneFlow, E6-0060) with the addition of the DNA of interest- 
either 4 µl of purified cassette PCR product or 1 µl of the V5 tag oligonucleotides and left 
on ice for 5 min. The sample was then electroporated at 2.5 kV on program EC2 on a 
Micropulser (Bio-Rad). For recovery, 1ml LB was added and samples kept at 32°C for 1 hour 
in the shaking incubator, with a 4 hour recovery in 5ml LB for the SacB negative selection 
step.  
Multiple dilutions of recovered transformed SW102 (generally 20 and 100 μl) were added 
onto the required LB selection plates (Section 2.1.4.4) and spread using a disposable 
spreader. The GalK cassette protocol required an extra 3 washing steps with M9 salts by 
pelleting and re-suspending before plating out. Selection plates were inverted once dry and 
incubated for 3 days at 32°C and were stored at 4⁰C after this time. Single colonies were 
chosen by colour (blue for positive selection and white for negative selection) for Rpsl and 
SacB methods of recombineering and colonies were grown overnight for further use. 
Generally 10 colonies were selected to be analysed by polymerase chain reaction (PCR), 
restriction digest and sequencing.  
M9 salts: 6 g sodium phosphate dibasic (Na2HPO4), 3 g potassium dihydrogen phosphate 
(KH2PO4), 1 g ammonium chloride (NH4Cl), and 0.5 g sodium chloride (NaCl) in 1l of dH20. 
 
2.1.5 Polymerase Chain Reaction 
Polymerase Chain Reaction (or PCR) was used to amplify specific segments of DNA such as 
selection cassettes for use in recombineering, or to send sections of the genome for 
sequencing. Reagents were used from the Expand high fidelity (HiFi) PCR system kit 
(Roche), unless otherwise stated. The HiFi enzyme consisted of a blend of Taq DNA 
polymerase and a thermostable DNA polymerase with proof-reading, and was used as 
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standard for the PCR of miniprep DNA, including that of selection cassettes and for the PCR 
of sequencing regions, with the PCR mix indicated in Table 2.3. The Phusion enzyme PCR kit 
(Thermo Fischer scientific, K0191) was used for TOPO cloning steps when recombineering 
US16-V5 and US17-V5 (Section 2.1.6), with the PCR mix seen in Table 2.4. Primers were 
designed and purchased from Sigma-Aldrich at desalted purity and were diluted to 100pM, 
and all primers are listed in Appendix Table 7.1. Primers were diluted 1/10 in dH20 before 
being added to the PCR mixture. The enzymes were added last to the mix for stability.  
The standard PCR program (Table 2.5) was run using a PCR machine (T3000 Thermocycler, 
Biometra). PCR programs could be adjusted according to the primers and DNA used. 
Annealing times could be altered dependent on the melting temperatures of the primers, 
and extension times could be altered depending on fragment length. Longer extension 
times were required for the production of longer products, with a longer PCR program 
required for the PCR of the larger SacB cassette as described in Table 2.6. A slightly altered 
program was also required for Phusion PCRs (Table 2.7). 
 
2.1.6 TOPO cloning 
TOPO cloning steps were utilised in adding the V5 tag to the C-terminus of US16 and US17 
using the TOPO cloning kit (Thermo Fisher scientific) as depicted in Section 3.1, Fig. 3.2D. 
Briefly, the US16/US17 sequencing forward primer and the V5 reverse primer were used to 
add the V5 tag to the C-terminus of the US16/US17 gene and this was added to the TOPO 
vector. Once the V5 tagged US16/US17 PCR product was produced, the TOPO cloning 
reaction could be set up, with 0.5-4 µl fresh PCR product added to 1 µl TOPO vector, 1 µl 
salt solution, with water added to a total volume of 5 µl. These should be mixed gently and 
incubated for 5 min at room temperature (or longer for PCR products over 1 kb). A further 
18 µl is added to the reaction mixture, and 2 µl of this is added to DH5α competent cells, in 
a cuvette and electroporated at 2.5 kV as previously described (Section 2.1.4.3). 
Immediately 250 µl of room temperature super optimal broth (SOC) medium (provided) 
was added and the mixture incubated in a shaking incubator at 37⁰C for 1 hour. 10-50 µl 
from each transformation was spread onto a pre-warmed selective plate and incubated 
overnight at 37°C. As before, 10 colonies were selected and analysed for the insert. Plasmid 
DNA was isolated (Section 2.1.10) and analyse by restriction digest (Section 2.1.12) and/or 
sequencing (Section 2.1.13) as normal. For clones that looked correct, the US16/US17 
sequencing forward primer and the V5 forward primers could then be used to  
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Table 2.3: PCR mixture for HiFi polymerase PCR reaction 
Ingredients Amount 
10x HiFi PCR buffer 5 μl 
Dimethyl sulfoxide (DMSO) (Sigma-Aldrich, 41647) 1.5 μl 
1/10 primer mix (Forward and Reverse)* 2.5 μl 
Deoxynucleotide (dNTP) mix (New England Biolabs, N0447L) 1 μl 
DNA  1 μl 
HiFi polymerase enzyme 0.5 μl 
dH20 Make up to 50 μl 
 
 
Table 2.4: PCR mixture for Phusion polymerase PCR reaction 
Ingredients Amount 
10x Phusion PCR buffer 5 µL   
1/10 primer mix (Forward and Reverse) 2.5 µl 
Deoxynucleotide (dNTP) mix  0.5 µL   
DNA  10–100 ng   
Phusion enzyme 1 µL             
dH20 (sterile, distilled) Make up to 50 µL   
 
 
Table 2.5: Standard PCR program  
PCR step Temperature and time Number of cycles 
Initial denaturing 95ᵒC for 2 min 1 
Denaturing 95ᵒC for 30 sec  
35 cycles Annealing 58ᵒC for 30 sec 
Extension 72ᵒC for 2 min 
Final extension 72ᵒC for 15 min 1 
Pause Held at 4ᵒC 1 
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Table 2.6: Long PCR program for amplifying the larger SacB cassette 
PCR step Temperature and time Number of cycles 
Initial denaturing 95⁰C for 2 min 1 
Denaturing 95⁰C for 30 sec  
34 Annealing 55⁰C for 30 sec 
Extension 68⁰C for 4 min 
Final extension 72⁰C for 15 min 1 
Pause Held at 4⁰C  1 
 
 
Table 2.7: PCR program for Phusion 
PCR step Temperature and time Number of cycles 
Initial denaturing 94⁰C for 2 min 1 
Denaturing 94⁰C for 1 min  
25 Annealing 55⁰C for 1 min 
Extension 72⁰C for 1 min 
Final extension 72⁰C for 7 min 1 
Pause Held at 4⁰C  1 
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amplify the V5-tagged US16/US17 gene from the TOPO vector, whilst providing the 
addition of the intergenic region of homology after the V5 tag (Figure 3.2D). This PCR could 
then be used for the second step of recombineering (Section 2.1.4) where the US16/US17 
gene disrupted by the GalK cassette could be swapped for the V5-tagged US16/US17 gene. 
 
2.1.7 Agarose gel electrophoresis 
The size of the PCR product amplified was determined by agarose gel electrophoresis. 
Agarose gel was made by adding 1.5% (0.75 g) HiRes standard agarose powder (AGTC 
Bioproducts/GeneFlow, A4-0700) to 50 ml 1x Tris-acetate-EDTA (TAE) buffer (50x, National 
diagnostics, EC-872) and microwaved to dissolve. Once cooled to 50-60⁰C (~15-20 min), 2.5 
μl Ethidium bromide (Sigma) was added for DNA visualization and the solution poured into 
a gel mould that was taped at either end, and had a comb added to produce wells. Once 
solidified, the comb and tape were removed, and the gel transferred into a gel tank 
containing 1x TAE buffer that covers the gel. 6x DNA loading buffer was added at X1 
concentration to the PCR product mixture and the samples loaded alongside 10 μl of a DNA 
ladder (HighRanger Plus 100kb DNA ladder, Norgen). This gel was run at a voltage of 100V 
for ~45 min or until the lower dye front reached the bottom of the gel to allow for 
separation of the product by size. The bands were visualized under UV light using a GelDoc 
system (Syngene) and the gel band excised if required for further processing or sequencing. 
6x DNA loading buffer: 0.25% bromophenol blue (Sigma-Aldrich), 0.25% xylene cyanol FF 
(Sigma-Aldrich), 30% glycerol (Fisher Scientific) in dH20. 
 
2.1.8 Purification of DNA gel fragments from agarose gel slices 
UV light from a Spectroline transilluminator (model TVC-312A) was used to visualise the 
ethidium bromide-stained DNA bands whilst using a UV visor. DNA bands of the expected 
size were excised from the gel using a scalpel (Swann-Morton) and transferred into 1.5 ml 
eppendorfs. The gel band was then purified using the Q spin gel extraction/PCR purification 
kit and buffers (GeneFlow, K10040) following manufacturer’s instructions. For every mg of 
gel that was excised, 1μl of binding buffer was added, and the gel sample heated to 50-
60⁰C. Once the gel slice had dissolved, the solution was added to a GeneFlow column in a 
collection tube and left for 1 min. All spins were carried out at 13,000 rpm in a benchtop 
centrifuge (Biofuge fresco, Heraeus). The tubes containing the columns were centrifuged 
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and the flow-through discarded. 500 µl of the wash buffer was added to the column and 
the samples centrifuged again for 30 sec. This spin and wash step was repeated, and after 
the flow-through discarded, the column and tube were spun once more and the column 
transferred to a clean collection tube. 30μl of elution buffer was added to the column 
membrane for 1 min, and the DNA eluted during a final 1 min spin. 
 
2.1.9 Measurement of DNA concentration using the Nanodrop 
spectrophotometer 
The concentration of eluted DNA was measured using a NanoDrop ND-1000 
Spectrophotometer (Thermo Scientific). 1μl of water was used to calibrate the nanodrop 
machine, then 1μl of the elution buffer used as a blank. 1μl of sample DNA was then loaded 
and the DNA concentration was given in ng/μl.  
 
2.1.10 Small scale purification of BAC DNA  
Minipreparation or ‘miniprep’ allowed for the extraction and purification of BAC DNA from 
a small scale SW102 culture. The SW102 culture containing the appropriate BAC was grown 
in 5ml LB with selection antibiotics (Section 2.1.2) overnight at 32⁰C in a shaking incubator. 
The samples were kept and spun at room temperature unless otherwise stated. The 
overnight culture was pelleted at 4000 rpm for 5 min using a benchtop centrifuge (Biofuge 
fresco, Heraeus), the supernatant discarded and the pellet re-suspended in 250μl P1 buffer 
(Qiagen, 19051) and transferred to an eppendorf tube. 250μl of P2 buffer (Qiagen, 19052) 
was added and mixed then incubated at room temperature for 5 min. 250μl P3 buffer 
(Qiagen, 19053) was added and inverted to mix. This was centrifuged at 13,000 rpm for 10 
min and the supernatant transferred to a new tube. The DNA was precipitated with 750 μl 
isopropanol and centrifuged at 13,000 rpm for 10 min at 4ᵒC. The supernatant was 
removed and 500 μl 70% ethanol was added before centrifuging at 13,000 rpm for 10 min. 
The supernatant was removed and allowed to air-dry before being re-dissolved in 40 μl Tris 
EDTA.  
Tris EDTA: 10mM Tris-Cl (Fisher scientific) and 1mM Ethylenediaminetetraacetic acid 
(EDTA) in dH20, adjusted to pH8. 
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2.1.11 Large scale purification of BAC DNA  
Maxipreparation or ‘maxiprep’ allowed for the extraction and purification of BAC DNA from 
a large scale SW102 culture in order to get transfection-quality DNA. The SW102 culture 
containing the appropriate V5-tagged BAC was grown in 250 or 500 ml LB with selection 
antibiotic overnight at 32⁰C in a sterile conical flask in a large shaking incubator 
(Gallenkamp). The DNA from the culture was purified using the Nucleobond BAC100 kit 
(Macherey-Nagel) following the instructions of their ‘Low-copy plasmid purification’ section 
under ‘Maxi/BAC’. Firstly the culture was transferred to 250 ml polycarbonate centrifuge 
bottles (Thermo Fisher scientific, CFS-300 520C), and centrifuged at 6000 rpm for 10 min at 
4⁰C (Beckman Coulter centrifuge, rotor JLA 16.250). The supernatants were discarded and 
the pellets re-suspended in 24 ml of buffer S1. 24 ml buffer S2 was then added to lyse the 
cells and the mixture inverted 4-6 times and incubated for 5 min at room temperature. 24 
ml buffer S3 was then added and the bottle incubated for 5 min on ice. The supernatants 
were passed through a funnel lined with filter paper in to a column, which was previously 
equilibrated with 6 ml N2 buffer. The column was allowed to empty by gravity flow and the 
flow through discarded. The column was then washed twice in 18 ml N3 wash buffer by 
gravity flow. The DNA was then eluted in to 30 ml polypropylene tubes (Thermo Fisher 
Scientific, 03719) using 15 ml N5 buffer which was pre-heated to 50°C for higher recovery 
of DNA. 11 ml room temperature isopropanol was added and the tubes centrifuged at 
>15000 rpm and 4°C for 30 min (Beckman Coulter centrifuge, JLA25.50 rotor). The 
supernatant was discarded and the pellet washed in 5 ml 70% ethanol, and centrifuged at 
>15000 rpm for 15 min at room temperature. The supernatant was removed and the 
ethanol allowed to evaporate from the pellet (~20 min). The DNA was re-suspended in 250 
µl elution buffer (Tris EDTA) and left in a shaking incubator for 30-60 min to aid recovery. 
The eluate was then transferred to a fresh tube, and DNA concentration was measured 
using a Nanodrop ND1000 spectrophotometer (Section 2.1.9).  
 
2.1.12 Restriction endonuclease digestion 
Restriction endonuclease digests were performed by adding 8 μl of the purified miniprep 
DNA mixture to 1 μl of the restriction endonuclease enzyme and 1μl of corresponding 
buffer (Table 2.8). BamHI was used as standard. The samples were then incubated at 37ᵒC 
for 4 hours or overnight and separated by agarose gel electrophoresis. Restriction 
endonucleases digest the HCMV BAC at their specific enzyme binding sites in the genome, 
digesting it into a predictable pattern of bands of particular molecular weights as predicted 
84 
 
by CLC workbench software (CLC bio, Qiagen). Figure 2.1 depicts the predicted patterns of 
the HCMV BAC (pAL1111) with BamHI, NdeI and HindIII enzymes, alongside reference 
molecular weight markers and the total number of bands predicted for each digest. 
Samples could also be compared to the equivalent digest of an unaltered HCMV BAC as a 
control. These patterns were used to analyse the BACs and to assess whether the 
recombineering protocol had caused any major off-target affects such as large deletions of 
the genome or major rearrangements. These changes would cause major differences in the 
BAC digest patterns to those predicted (Figure 2.1).  
 
2.1.13 Sanger sequencing 
To verify the addition of the V5 tag and to check that no other alterations had been made 
to the tagged gene, the tagged region of the BACs were sequenced. The region of interest 
(the gene and V5 tag section) was amplified by PCR from miniprep DNA using specific 
forward (For) and reverse (Rev) sequencing primers (Appendix Table 7.1). This DNA was 
run by gel electrophoresis and purified from the agarose gel. The DNA concentration was 
measured and diluted to 5 ng/μl with dH20. 15 μl of this mixture was added to a Eurofins 
sequencing tube (Mix2Seq Kits, Eurofins) with 2μl of each appropriate sequencing primer 
(100 pM), either the forward, reverse or internal primers of the appropriate gene 
(Appendix Table 7.1). This was then sent to Eurofins for sequencing (Eurofins Genomics 
sequencing department, Germany). Sequencing was analysed using CLC workbench 
software (CLC bio, Qiagen) through alignment to the reference sequence of the HCMV 
Merlin genome (NCBI NC_006273.2). Internal reverse sequencing primers proved to give 
the cleanest result for the area of interest but both a forward and reverse read were taken 
to verify that the tag had been inserted correctly. Verified clones were then maxiprepped 
and transfected into fibroblasts. 
 
2.1.14 Purification of virus DNA 
Viral DNA from virus stocks was purified using a QIAamp MinElute virus kit (Qiagen, 57704), 
with all reagents supplied unless otherwise stated, and manufacturers’ instructions 
followed. Briefly, 25 µl protease (reconstituted in buffer AVE) was added to a 1.5 ml micro-
centrifuge tube, followed by the addition of 200 µl of aliquoted virus stock within a tissue 
culture class II cabinet. 200 µl Buffer AL was added and the tube pulse-vortexed for 15 sec 
before incubation at 56°C for 15 min in a heating block. Samples were briefly centrifuged 
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Table 2.8: A list of the restriction endonuclease enzymes with their corresponding buffers 
Enzyme Buffer Company 
BamHI Buffer 3.1 (or 2.1) New England Biolabs (NEB) 
HindIII Buffer 2.1 NEB  
NdeI Buffer 2.1 (or 3.1) NEB 
BamHI Buffer E Promega 
HindIII Buffer E Promega 
NdeI Buffer D Promega 
 
 
 
Figure 2.1: Restriction endonuclease digest patterns of HCMV BAC (pAL1111). 
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(Biofuge fresco, Heraeus) to ensure all liquid was returned to the bottom of the tube and 
250 µl of ethanol (96-100%) was then added, and the tube pulse-vortexed for 15 sec. The 
lysate was incubated with the ethanol for 5 min at room temperature. Samples were briefly 
centrifuged and the lysate from step 7 carefully applied onto the QIAamp MinElute column 
without wetting the rim, and centrifuged at 8000 rpm for 1 min. The QIAamp MinElute 
column was placed in a clean 2 ml collection tube, and the filtrate discarded. 
Next, 500 µl of Buffer AW1 was added, the sample centrifuged and a new collection tube 
used. Repeat with 500µl of Buffer AW2 and then then 500µl of ethanol (96-100%), 
centrifuging between each buffer addition and using a new collection tube each time, 
discarding the flow through. The samples were then centrifuged at 14,000 rpm for 3 min to 
dry the membrane completely. The column lid can be opened and the tube incubated at 
56°C for 3 min to aid this process. The QIAamp MinElute column can then be placed in a 
clean 1.5 ml microcentrifuge tube and 50 µl of Buffer AVE applied to the centre of the 
membrane. The tube is incubated at room temperature for 1 min with the lid closed, and 
then centrifuged at 14,000 rpm for 1 min to elute.  
 
2.1.15 Illumina full genome sequencing 
Purified viral DNA was sent to our collaborators in Glasgow (Davison group, MRC-University 
of Glasgow Centre for Virus Research) for next generation DNA sequencing of the entire 
viral genome. Their analysis compared the viral genomes to the reference Merlin genome 
(NCBI NC_006273.2) and provided us with a list of changes, if any, other than the V5 tag 
addition, which are detailed in Section 3.3, Table 3.1. 
 
2.2 Tissue culture 
2.2.1 Established cell lines 
HCMV viruses were cultured in human foreskin ﬁbroblasts (HFFs) were provided by Dr G. 
Farrar (Porten Down) that were immortalised with telomerase (HF-TERTs) by Dr B. 
McSharry (as described in McSharry et al. (2001)). For infections with adenovirus, HF-TERTs 
transfected with the Coxsackie-adenovirus receptor (HF-CARS) were used (Stanton et al., 
2008, Leon et al., 1998). All cell lines were negative for mycoplasma, as screened for by S. 
Llewelyn-Lacey using the VenorGeM Mycoplasma PCR detection kit (Biochrom AG, 
Germany). 
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2.2.2 Tissue culture media 
Cells were grown in high glucose Dulbecco modiﬁed Eagle’s medium (DMEM, Sigma, 
D5796) supplemented with 10% fetal bovine serum (FBS, Gibco, Life technologies, 10500) 
and 5% penicillin/streptomycin sulphate (pen/strep, Gibco, Life technologies, 15070-063), 
hereafter referred to as 10% DMEM. Media was pre-warmed before adding to the cells, 
and the cells subsequently grown at 37ᵒC in a 5% CO2 incubator (Thermo Fisher, BB15). 
DMEM with 0% or 5% FBS could also be used during experiments, 0% DMEM for infections 
and 5% for growing viral stocks in cell factories (Section 2.2.4) 
 
2.2.3 Culturing of cell lines 
All cell culture work was undertaken within a class II hood for sterility. Both HF-TERTS and 
HF-CARs were cultured as monolayers in 150 cm2 Corning cell culture flasks (Sigma-Aldrich, 
CLS430825), referred to as T150 flasks. When T150 flasks were confluent, the fibroblasts 
were passaged by removing the medium, washing with ~20 ml PBS (Gibco, 14190-094) and 
adding 5 ml 0.05% trypsin-EDTA (x1, Thermo Fisher, 25300-054) for ~3 min until the cells 
detached. The trypsin was neutralized with 10% DMEM and the suspension was split 1:4 
per flask for the seeding of new flasks, or were used to seed flasks or wells for experiments 
(as per Table 2.9).  
 
2.2.4 Seeding of cells for experiments 
Once the trypsinised cells had been neutralised, the number of cells could be estimated. A 
100 μl sample of the suspension was loaded in to a counting chamber haemocytometer 
(Sigma, Z359629) and a coverslip added. Cells were counted across the 4x4 chamber grid 
and an average number of cells per grid calculated. This number was multiplied by 104 to 
give the average number of cells per ml of suspension. The required amount was then 
transferred to the flasks or wells needed for the experiment and topped up with the 
appropriate amount of medium (Table 2.9) and left overnight to settle.  
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Table 2.9: Flasks and plates utilised for tissue culture experiments, their uses and the 
number of cells required for each.  
Flask/plate Use Cells seeded Total amount of 
DMEM 
T150 (150 cm2, 
Corning, Sigma-
Aldrich, 430825) 
Growing and 
maintaining cells/ 
SILAC infections 
~4x106 (a 
confluent flask 
will hold 18x106) 
25 ml 
T25 (25 cm2, 
Corning, Sigma-
Aldrich, 430639) 
Transfections of BAC 
DNA and 72 hour 
infections for 
immunoblotting 
1x106 7 ml (2 ml for infecting 
cells) 
6 well plate 
(Thermo Fisher) 
HCMV titrations 3x105 4 ml (1 ml for infecting 
cells for titrations) 
12 well plate 
(with coverslips) 
(Thermo Fisher) 
Fluorescence 
microscopy 
1x105 2 ml (1 ml for infecting 
cells) 
Cell factory 
(Thermo Fischer, 
140004TS) 
Growing viral stocks Add all cells from 
5 confluent 
T150s 
500 ml whilst 
growing/infecting, 250 
ml whilst collecting 
viral supernatant 
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2.3 Procedures involving adenovirus 
2.3.1 Preparation of adenovirus stocks 
Replication deficient adenovirus (RAd) stocks of US12 family V5-tagged vectors were from 
the Cardiff University Genebank and had been diluted in DMEM to 108 pfu/ml for ease of 
use and were stored at -70⁰C. 
 
2.3.2 Infections with replication deficient adenovirus 
For all infections, HF-CARs were infected the day after being seeded and were infected with 
virus at an MOI of 10 in 10% DMEM and incubated on a rocker at 37⁰C for 2 hours. The 
virus suspension was then removed and replaced with 10% DMEM and left to incubate for 
the time required for infection, with 72 hpi used as the standard time-point. Cells were 
then harvested (Section 2.4.5) for further analysis. 
 
2.4 Procedures using HCMV 
2.4.1 Transfection of fibroblasts with BAC DNA 
HCMV BACS were transfected into fibroblasts using the Basic Fibroblast Nucleofection kit 
(Lonza, VPI-1002) to allow for replication and growth of the viruses. 1x106 HF-TERTs were 
centrifuged at 600 rpm for 10 min, the supernatant discarded and the cell pellet re-
suspended in 100 μl of Nucleofector solution and transferred to a cuvette (provided). 1-5 
ng/μl of each maxiprepped BAC was added to the HF-TERTs in the cuvette and transfected 
using program T-016 on a Nucleofector (Amaxa II/2b Device, Lonza). Transfected cells were 
added to pre-warmed 10% DMEM media in a T25 flask and allowed to grow overnight and 
replaced with fresh 10% DMEM the following day. Viral plaques became visible within 2-4 
weeks, followed by a completely infected monolayer of fibroblasts within a further 2 
weeks. Viral supernatant was collected from 100% infected monolayers and stored as 
passage 1 (P1) cultures at -70⁰C and used to infect subsequent cell factories. 
 
2.4.2 Preparation of HCMV stocks 
HF-TERTS were grown in a cell factory and once confluent were infected with fresh 
supernatant from the transfected cells from the T25 (passage 1). Once the cell factory 
monolayer was 100% infected (2-4 weeks later), 200-400 ml of supernatant was collected 
every 2 days. This was transferred into centrifuge pots (Nalgene, Sigma-Aldrich, Z353744), 
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and centrifuged (Beckman Coulter, rotor JLA 16.250) for 2 hours at 14,000rpm at 21ᵒC (due 
to the specification of the centrifuge pots). Previously used centrifuge pots (Thermo 
Scientific, discontinued) were centrifuged at 35ᵒC. Supernatants were discarded and care 
was taken not to let the pellets dry out. The pellets were re-suspended in 1 ml of 10% 
DMEM using an inoculation loop and transferred to a 15 ml falcon. The virus pot was 
washed with another 1 ml 10% DMEM which was also added to the falcon. These 
suspensions were passed 5 times through a 19 gauge needle (BD microlance 3) and 2-5 ml 
syringe to break up the cell pellet, and the samples centrifuged (Hereus megafuge 1.0) at 
2000 rpm for 2 min. The supernatants were transferred to a new 15 ml falcon and frozen at 
-70ᵒC. Once all supernatants were collected throughout the course of infection (~5/6 
supernatant collections), the entire stock was thawed and pooled together in a 50 ml 
falcon. These were passed through a 19 gauge needle again and then centrifuged at 2000 
rpm for 2 min to remove cell debris. The supernatant was then aliquoted into 0.5-1 ml 
aliquots in screw cap tubes with seals (VWR, 16466-054) and frozen at -70ᵒC. 
 
2.4.3 Titration of HCMV stocks by plaque assay 
6 well plates (1 per virus) were set up with 3x105 HF-TERTS per well and left to adhere 
overnight. 1 aliquot of the virus was thawed and serial dilutions of 10-6, 10-7 and 10-8 made 
in 10% DMEM (10-5, 10-6, 10-7 could be used for low titre viruses). 1 ml of each dilution was 
added to each well in duplicate and left for 2 hours in a rocking incubator at 37⁰C. The virus 
suspension was washed off, and overlay medium (1:1 of 2% Avicel and 2x medium) was 
added to prevent cell-free spread. These plates were incubated at 37⁰C and left 
undisturbed for 14 days. Cells were washed 3 times with PBS (~6 ml per well), then fixed 
with Crystal Violet fix stain. Plaques were counted using a standard white light microscope 
(Nikon TMS) and titres calculated using the average number of plaques counted per 
dilution i.e. average of 4 plaques at a 10-7 dilution gives a titre of 4x107 pfu/ml.  
2% Avicel: 20g of Avicel powder in 1 l of dH20. 
2x medium: 250 ml dH20, 100 ml 10x MEM, 100 ml of FBS, 30 ml of 7.5% sodium 
bicarbonate, 20ml of Penicillin/Streptomycin, 10 ml L-glutamine. All reagents are from 
Gibco, Thermo Fisher. 
Crystal violet fix stain: 0.4g NaH2PO4 (sodium phosphate monobasic), 0.65g Na2HPO4 
(sodium phosphate dibasic), 0.1g crystal violet, 10 ml of 37-40% formalin and 90 ml water. 
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2.4.4 Infections with HCMV 
The day prior to infection, HF-TERTs were seeded into T25 flasks in 0% DMEM. The 
following day, virus was added at MOI 10 in 0% DMEM and incubated on a rocker at 37⁰C 
for 2 hours. The viral supernatant was removed and replaced with 0% DMEM and left to 
incubate for the time required for infection (72 hours as standard). If required, the 
lysosomal inhibitor Leupeptin (Leupeptin hemisulphate microbial, Calbiochem, 108975-
10mg) was added to 200μM final concentration, 18 hours before the time of harvesting (at 
54 hpi for a 72 hpi infection) to prevent lysosomal degradation. Cells were then harvested 
(Section 2.4.5) for further analysis. 
 
2.4.5 Harvesting infected cells 
Cells were harvested from T25 flasks at the appropriate time post infection (72hpi as 
standard). The supernatant was removed and the cells washed with 7ml PBS (Gibco, 
Thermo Fisher), then 4 ml of PBS was added and the T25 laid on ice. The cells were then 
scraped into the PBS using a cell scraper (Greiner Bio-one) and transferred to a chilled 15 
ml falcon tube. These tubes were then centrifuged (Hereus megafuge 1.0) at 1500 rpm for 
3 min at 0⁰C and the supernatant removed. These protein pellets could be frozen at -20⁰C 
and re-suspended with different buffers depending on protein analysis (Section 2.5). 
 
2.5 Protein analysis 
2.5.1 Digestion of samples with endoglycosidases 
Reagents and enzymes for glycosylation analysis were from New England Biolabs unless 
otherwise stated. Protein samples to be analysed for glycosylation, had their harvested 
protein pellets re-suspended in 100 μl of 1X glycoprotein denaturing buffer (by diluting 10X 
glycoprotein denaturing buffer in dH2O). The sample was then transferred to a non-stick 
tube (Axygen, Corning, MCT-060-L-C) and heated to 50ᵒC for 10 min to denature the 
protein sample. The sample was mixed and split into 3 non-stick tubes and incubated either 
untreated, or with endoglycosidase H (EndoH) or peptide-N-glycosidase F (PNGase F) with 
the corresponding G5 or G7 buffers (now discontinued) (Table 2.10) at 37ᵒC overnight. 
PNGase F also required the addition of NP-40 Samples were made to a total volume of 
39μl.  
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Table 2.10: Enzymes and buffers required for studying the N-glycosylation of proteins 
Sample type Sample 
amount 
Buffer Enzyme 
Untreated 30μl 4μl G5 buffer, 5μl dH20 - 
EndoH  30μl 4μl G5 buffer, 4μl dH20 1μl EndoH  
PNGase F  30μl 4μl G7 buffer, 4μl NP-40 1μl PNGase F  
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2.5.2 Preparation of whole cell lysates 
Before further processing, all WCL protein samples required the addition of NuPage sample 
buffer (4X NuPage LDS sample buffer, ThermoFischer Scientific, NP0007) and 1,4-
dithiothreitol (10X DTT, Acros Organics, 426380500) both added to 1X concentration. For 
standard protein pellets of ~100 μl, 20 μl of 4X NuPage and 13 μl of DTT were added. For 
samples that had undergone overnight de-glycosylation (Section 2.5.1), 15 μl Nupage and 6 
μl DTT were added to give a 60 μl final volume.  
Re-suspended pellets then underwent sonication for 25 x 1 sec pulses at 20% power (Vibra-
Cell, VCX130, Sonics and Materials) to shear the DNA, and samples were transferred to 
non-stick 0.5 ml tubes (Axygen). Samples were heated for 10 min to 50ᵒC in the PCR 
machine (T3000 Thermocycler, Biometra) for denaturation as they would smear if they 
were boiled at the standard 95ᵒC due to their transmembrane domains.  
 
2.5.3 Protein electrophoresis 
Protein samples were separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) using 12 or 20 well NuPage 10% bis-tris precast polyacrylamide 
protein gels (ThermoFischer Scientific, NP0302BOX or WG1202BOX). Gels were rinsed and 
loaded into a gel tank and covered in running buffer. 20 µl of the prepared whole cell lysate 
sample was loaded as standard into each well of a gel, alongside 10 µl of a pre-stained 
protein marker (Invitrogen, LC5800). Loading amounts could be lowered if required for 
more highly expressed proteins. The samples were separated by SDS-PAGE at 180 V until 
the dye front reached the bottom of the gel (~70 min).  
Running buffer: 50ml 20X NuPage MOPS SDS running buffer (Invitrogen, 1936381) per 1l 
water 
 
2.5.4 Transfer of polyacrylamide gels to nitrocellulose membranes  
Gels were removed from their casings ready for the transfer to nitrocellulose. The 
nitrocellulose membrane and blotting papers were pre-soaked with 2x transfer buffer and 
positioned in a semi-dry transblotter (Invitrogen, previously Biorad). These were ordered as 
such from the bottom up: thick blotting paper, nitrocellulose membrane, SDS-PAGE gel, 
thin blotting paper, thick blotting paper. The gel was laid flat on the nitrocellulose 
membrane and after stacking, air bubbles could be rolled out to ensure proper transfer. 
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The lid of the transblotter was secured and the transfer run for 2 hours at 10 V (ZOOM dual 
power supply, Invitrogen), although 1 hour at 20 V was also appropriate. 
2x transfer buffer: 50ml NuPage transfer buffer (20X, Novel, life technologies, NP0006-1), 
50ml methanol and 400ml dH20 
 
2.5.5 Immunoblotting 
Nitrocellulose membranes were removed from the transblotter, rinsed in distilled water, 
then incubated in ~15 ml antibody extender (Thermo Scientific, 32110) for 10 min, and 
then rinsed 7 times with ~20 ml dH20. Membranes were then washed with Tris-buffered 
saline with tween20 (TBST) for 1 min and then in blocking buffer (5% milk in TBST) for 1 
hour. All antibodies (Table 2.11) were diluted into blocking buffer to minimise background 
staining on the blots and blots were kept on a rocker at room temperature, except for 
overnight when the blots were kept on a rocker at 4⁰C. Each primary antibody was left on 
the membrane overnight in ~20 ml, then washed 4-5 times with ~25 ml TBST and the 
secondary HRP antibody added for 1 hour in ~20 ml blocking buffer. Following 4-5 washes, 
SuperSignal West Pico (Thermo Fisher scientific, 10481755) was added and the antibody 
detected using either the ECL–Western blotting detection system (RPN 2132; Amersham) 
and X-ray film and developed by Xograph Imaging systems, or by using the GelDoc system 
(Syngene) with images taken at multiple exposure times. Using the X-ray film system, 
exposures were first taken at 2 min, and this was increased or decreased depending on the 
expression level seen. Using the GelDoc system, images were taken at 30 sec intervals up to 
15 min as standard to ensure a range of exposures covered. For both systems, exposure 
times were decreased for high expression proteins (such as US20-V5 which often only 
required 5/10 secs) and increased for low expression proteins such as MICA (which often 
required 30-60 min). After imaging, the membrane was stripped with ~20 ml Restore 
stripping buffer (Thermo Fisher). The membrane was then rinsed, re-blocked and re-probed 
with another antibody. Anti-V5 was generally undertaken first except in the case of 
negative controls or MICA which could be very weak. 
TBST: 29g NaCl (Fischer scientific), 20ml Tris-Cl (Fisher scientific), 5ml 10% Tween20 
(Merck, 9005-64-5), 5ml 10% TritonX (Fisher BioReagents BP151-500), made up to 1l in 
dH20 
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Table 2.11: Antibodies used in immunoblotting and their concentrations  
Antibody Details Concentration Typical 
exposure 
time 
Primary antibodies: 
V5 tag (mouse) Stock donated by Rick 
Randall 
1:10,000 15 min 
Actin (rabbit) Sigma Aldrich, A2066 1:2000 2 min 
UL141 antibodies 
M550.2 and M550.3 
(mouse) 
In house stock (Tomasec et 
al., 2005) 
1:10,000 each 2 min 
MICA/B (mouse) Bam01, Bamomab 1:2000 30 min 
UL99/pp28 (mouse) Clone 5C3, SC-56975, 
Santa cruz 
1:200 2 min 
UL44/ICP36 (mouse) Clone 10d8, Virusys 1:12,800 2 min 
IE1 (mouse) Clone 8B1.2, MAB810R, 
Millipore 
1:200 2 min 
gB (mouse) Clone 2F12, CA005, Virusys 1:2000 1 min 
Secondary antibodies: 
Anti-mouse HRP 
(goat) 
GE Healthcare 1:500 - 
Anti-rabbit HRP (goat) GE Healthcare 1:500 - 
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Tris CL: 4.44g/l Tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl, Fisher scientific, 
BP153-500) and 2.65g/l amount Tris(hydroxymethyl)aminomethane (Tris-base, Fisher 
scientific BPE152-1) in dH20, adjusted to pH8  
Blocking buffer: TBST with 5% milk powder (co-operative dry milk powder) 
Stripping buffer: Restore stripping buffer (Thermo, 21063) 
Supersignal West Pico: 1:1 mix of the luminol/enhancer and the stable peroxide buffer 
reagents supplied within the kit. Reagents must be mixed immediately before being added 
to the membrane. 
 
2.6 Immunofluorescence 
2.6.1 Preparation of coverslips 
Coverslips were added to the base of 12 well plates and sterilised with 70% Ethanol for 10 
min, before washing in PBS 3 times. 1x105 HF-TERTS were seeded onto the sterilised 
coverslips in 0% DMEM, and left overnight. The next day the cells were infected with virus 
at MO1 10 for 2 hours in a rocking incubator and replaced with fresh DMEM before being 
incubated at 37⁰C for 72 hours. 
 
2.6.2 Immunostaining of coverslips  
At 72 hpi cells were washed with PBS and fixed for 10 min with 2% paraformaldehyde 
(PFA). Cells were washed in intracellular (IC) buffer and then IC+ buffer (IC buffer with FBS 
and AB serum) was then added to the cells for 10-20 min to permeabilise the cells and 
block Fc receptors. The primary antibodies (Table 2.12) were diluted in IC+ buffer and 
added to the cells for 30-60 min at 37⁰C in the rocking incubator. The cells were then 
washed 3 times in IC+ buffer and the secondary antibodies and DAPI nuclear stain diluted in 
IC+ buffer added for 30-60 min at 37⁰C in the rocking incubator. Cells were washed in IC 
buffer twice and then fixed with 2% PFA for 10 min. Coverslips were removed from the 12-
well plate using tweezers and mounted cell-side-down onto glass slides using a drop of 
ProLong Gold anti-fade mountant (Invitrogen). Once dried, coverslips were sealed to the 
glass slide using clear nail varnish, and the slide box was covered in foil and kept in the 
fridge when not in use. 
2% paraformaldehyde (PFA): Dissolve 20g of PFA powder to 400ml PBS, adjust pH to 7-7.4 
and top up to 500ml total. Filter sterilize once cooled 
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Table 2.12: Antibodies and dyes used in fluorescence microscopy and their 
concentrations 
Antibodies Company Concentration  
Primary antibodies: 
Anti-V5 (mouse) Stock donated by Rick 
Randall 
1:10,000 
Anti-V5 (rabbit) Abcam (ab15828) 1:2000 
Anti-Pp28 (mouse) Clone 5C3, Santa cruz (SC-
56975) 
1:200 
Anti-Calnexin (mouse) Clone C8.B6, Millipore 
(Mab3126) 
1:400 
Anti-MPZL1 (rabbit) Clone H99, Santa Cruz (SC- 
366775) 
1:50 
Anti-TGN46 (rabbit) Abcam (ab50595) 1:200 
Secondary antibodies: 
Alexa Fluor-594 (AF594) 
anti-mouse (goat) 
Invitrogen (A11020) 1:500 
AF594 anti-rabbit (goat) Invitrogen (A-11072) 1:500 
AF488 anti-mouse (goat) Invitrogen (A-11017) 1:500 
AF488 anti-rabbit (goat) Invitrogen (A-11070) 1:500 
Dyes and stains: 
DAPI nuclear stain (4',6-
diamidino-2-phenylindole) 
Sigma-Aldrich 1:30,000 
Lysotracker dye Red DND-99, Thermo 
Fisher (L7528) 
1:2500 
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Intracellular (IC) buffer: 0.2% saponin (Sigma, S4521), 1% Bovine serum albumin (BSA, 
Sigma-Aldrich, A7906) and 0.05% sodium azide (Fisher scientific, CAS-26626) into PBS. 
IC+ buffer: 40ml IC buffer, 5ml FBS and human AB serum (ABS)  
AB serum: Serum was provided by the Welsh Blood Transfusion service and was prepared 
by Mihil Patel. Briefly, he span the serum for 1 hour at 4⁰C at 53,300 g, then filtered it 
through a 0.45 μm filter, and then a 0.22 μm filter. The serum was then heat inactivated for 
30 min at 56⁰C, and stored in aliquots in the freezer at -20⁰C. 
 
2.6.3 Analysis of HCMV infected cells by fluorescence microscopy  
The Zeiss microscope (Axio Observer Z1) was used to capture all fluorescence microscopy 
images. The Zeiss microscope’s ApoTome was engaged to provide optional sectioning of 
the cells, providing a clearer image of 1 focal plane without scattered light.  A magnification 
of x40 with oil (Immersol 518F, Zeiss) was used as standard. The 3 colour channels used 
were red using AF594 (wavelength 594nm), green using AF488 (488nm wavelength) and 
blue using DAPI nuclear dye (461nm wavelength). The Zen2 Pro (Zeiss) software program 
used for analysis provided a histogram of the levels of each colour detected. The histogram 
was used to adjust the exposure until background levels of fluorescence were minimal, as 
compared to the control samples, and at a similar level amongst samples. Images were 
taken separately as well as merged between the 3 channels using the Zen software, and 
exported as tiffs.  
 
2.7 Virion purification 
140 ml of viral supernatant was collected from cell factories that were fully infected with 
each of the V5-tagged US12 family members. Firstly the supernatant was concentrated 
down to ~15 ml using Vivaflow 50 PES cassettes (Sartorius, VF05P6, 1MDa MWCO). 
Samples were then further concentrated using Vivaspin 20 columns (Sartorius, VS2061, 
1MDa MWCO), centrifuging the columns at 2500 g for 10 min at a time until the sample 
was reduced to 6/7 ml.  
‘Heavy’ and ‘light’ solutions (below) were made the previous day to allow the solutions to 
be fully dissolved. Sodium tartrate gradients were formed using the SG50 gradient maker 
(Hoeffer), with 5 ml of the ‘heavy’ solution in the back chamber and the 4 ml of the ‘light’ 
solution in the front chamber. This allowed the solutions to mix gradually in the outlet 
tube, forming a gradient of solution as they were carefully poured into thin-walled Ultra-
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clear centrifuge tubes (Beckman Coulter, 344057), via the use of a peristaltic pump (Pump 
P1, Pharmacia Fine Chemicals), by continuous top-down pouring. Resulting gradients 
formed with ‘heavy’ solution at the lowest gradient areas, and the ‘light’ solution forming 
the upper areas of the gradient (Section 5.5, Fig. 5.8). The purified virion solution was 
added above this gradient, requiring 2 gradients per virus. For each ultra-centrifugation 
step, opposite tubes were balanced exactly by topping them up with PBS, and all spins 
were performed at 90465.7 x g at 20°C, using an Optima XPN-80 Ultra-centrifuge (Beckman 
Coulter) and the SW41 rotor. The first spin was performed for 45 min to separate the 
components of the viral supernatant by density over the glycerol-tartrate gradient. The 
virions banded in a distinct pattern (Section 5.5, Fig. 5.8) and were recovered using a 
syringe and a 19 guage needle. To remove the gradient-derived salts and other 
contaminants from the purified virus particles, recovered bands were added to a new 
centrifuge tube and washed by gradual dilution in NaPh buffer. The virions were then 
pelleted from the solution by ultra-centrifugation for 1 hour. The final purified virion pellet 
was re-suspended in NaPh buffer and NuPage LDS sample buffer to 1x (4X, ThermoFischer 
Scientific) and 1x DTT. Samples can now be processed by protein electrophoresis and 
immunoblotting as previously described (Section 2.53-2.55). 
Na-phosphate (NaPh) buffer: Mix 19 ml of solution A and 81ml of solution B (pH 7.4). 
Solution A: 0.04M (w/w) sodium-dihydrogenphosphate (sodium dihydrate) in dH20.  
Solution B: 0.04M (w/w) disodium-hydrogenphosphate (anhydrous) in dH20. 
 ‘Heavy’ solution 35% Na-tartrate: 35g Na-tartate and 65g NaPh buffer  
‘Light’ solution 15% Na-tartrate with 30% glycerol: 15g Na-tartrate, 30g glycerol and 55g 
NaPh buffer 
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3. Construction 
of HCMV Merlin 
V5-tagged US12 
family members 
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The US12 gene family consists of a sequential tandem array of 10 genes, designated US12 
to US21, that are not essential for replication in vitro yet highly conserved in clinical 
isolates, thus implying the family plays an important role in vivo (Section 1.8.15). The US12 
family members have been implicated in tropism and immune evasion of the virus. The 
most comprehensive analysis demonstrated that the US12 family act in concert to regulate 
the cell surface expression of a wide array of immune ligands (Section 1.8.15.3) (Fielding et 
al., 2017). Whilst this study brought an impressive insight into the functional role of the 
family during productive infection, the fundamental expression properties of individual 
US12 family members remained largely uncharacterised.  
Although the laboratory in Cardiff has extensive experience in using adenovirus vectors as a 
rapid and efficient way to study the expression of individual HCMV genes, the previous 
study of adenovirus-expressed US12 family members (Dr Ceri Fielding) demonstrated that 
they did not tend to function well in isolation. This was validated by adenovirus (Ad) US18 
and Ad US20 which didn’t appear to downregulate B7-H6 or MICA on the cell surface by 
flow cytometry, despite having these effects in the context of infection (Fielding et al., 
2014, Fielding et al., 2017). It therefore remains important to study these HCMV genes in 
the context of infection. Infection with HCMV also causes large cellular transcriptional and 
causes morphological changes in the infected cell. These morphological changes are caused 
by the remodeling of the host organelles, including the Golgi complex and trans-Golgi 
network (Das et al., 2007), resulting in the formation of the virion assembly compartment 
(vAC). Certain US12 family members have been demonstrated to associate with the vAC 
(Das and Pellett, 2007), and thus they may not interact with other cellular and viral proteins 
or function normally without HCMV infection. As US12 family members appear to 
functionally co-operate, they may therefore not work in the same way when expressed 
alone (Fielding et al., 2014, Fielding et al., 2017). Proteins can also undergo different post-
translational modifications or folding within different expression systems. HCMV gpUL18 
for example exhibited a different apparent molecular mass and different glycosylation 
patterns by SDS-PAGE when expressed by an adenovirus vector, a vaccinia virus vector or 
during a natural HCMV infection (Griffin et al., 2005). As antibodies were not available 
against individual US12 family members, in order to allow for the detection of US12 family 
proteins within the context of HCMV, US12 family members were tagged within an HCMV 
bacterial artificial chromosome (BAC). The HCMV Merlin strain was selected as the 
background virus strain as it is the most representative strain of an original clinical virus for 
which an infectious BAC clone was available. This BAC had been constructed by cloning in 
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the genome of HCMV strain Merlin at passage 5 from its original isolation and was 
designated BAC1111 (Stanton et al., 2010). This Merlin BAC1111 variant had the clinical 
wildtype sequence, except for a frameshift in RL13 and mutation in UL128, which enabled 
efficient replication of progeny virus in vitro, and generated virus progeny that were 
genetically stable during propagation and limited passage (Stanton et al., 2010) (Section 
1.3.1). The low copy number BAC technology was compatible with efficient genome 
editing, and this BAC1111 construct therefore permitted the construction and propagation 
of genetically stable HCMV, and provided a reproducible, characterised and sequenced 
source of clonal virus. BAC1111 was therefore used as the main parental BAC for studies in 
which genetic manipulation of the HCMV genome was required, and US12 family members 
were tagged within this construct. Each of the individual US12 family members was 
modified with a C-terminal tag to minimize any unwanted effects on protein folding or 
function. A V5 epitope tag was chosen due to its small size (14 amino acids), and the fact 
that high-affinity anti-V5 tag antibodies were available from different species commercially. 
It also gave superior detection when tested in parallel with the commonly used Strep tag 
(Dr R. Stanton, personal communication).  
 
3.1 Epitope tagging of HCMV US12 family members within the HCMV 
Merlin BAC  
Epitope tagging of US12 family members in the low copy Merlin BAC1111 variant was 
achieved using recombination-mediated genetic engineering (termed ‘recombineering’) 
(Section 2.1.4), allowing for seamless modification of the BAC genome. BAC1111 was 
transfected into Escherichia coli SW102 by electroporation, and these E. coli also contained 
temperature sensitive lambda (λ) red genes integrated into the genome by a defective λ 
prophage. These λ red recombination genes encode for 3 important enzymes exo, bet and 
gam, which work together to allow recombination to occur. Exo encodes a 5’-3’ 
exonuclease that produces 3′ overhangs from double-stranded DNA, mediating its 
annealing and recombination with homologous DNA in the BAC. Bet (or beta) is a single-
stranded DNA binding protein that promotes annealing of homologous DNA by protecting 
the remaining 3’ single strand tail and preparing the BAC DNA for homologous 
recombination. Together they insert the electroporated DNA into the desired target area, 
creating genetic recombinants. Gam encodes an inhibitor of the E. coli RecBCD exonuclease 
in order to protect the electroporated linear DNA from degradation. These genes are under 
the control of a temperature-sensitive λ repressor, and drive homologous recombination 
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but only when induced at 42°C for 15 mins (Section 2.1.4). This allows the prophage-
containing bacteria to be incubated at 32°C at all other times to ensure that the 
recombinase function was efficiently suppressed to avoid unwanted recombination. 
Homologous recombination was therefore only enabled at set points in the recombineering 
protocol, first to insert the ‘selection cassette’ after the target gene and then to exchange 
this cassette for the V5 tag.  
The selection system for the majority of recombineering experiments used the Rpsl 
(KanR/SmS/LacZ/Rpsl) and the SacB (AmpR/LacZ/SacB) cassettes (Fig. 3.1), both previously 
optimised within the laboratory and chosen because of their efficacy and ease of use 
(Stanton et al., 2010). The two systems require different selection media (Section 2.1.4, 
Table 2.2); the Rpsl cassette encodes for kanamycin resistance (for positive selection) and 
streptomycin sensitivity (for negative selection), whereas the SacB cassette encodes for 
ampicillin resistance (for positive selection), and sucrose sensitivity (for negative selection) 
(Figure 3.2A). Once the selectable marker is inserted into the Merlin BAC, the bacteria 
acquire resistance to the respective antibiotics. The Rpsl and SacB cassettes also contain 
the lacZ gene which encodes for β-galactosidase and acts a visual selectable marker. 
Additon of isopropyl β-D-1-thiogalactopyranoside (IPTG) to the selection plates stimulates 
lacZ transcription, inducing the expresssion of β-galactosidase. β-galactosidase can then 
cleave its colourless substrate X-gal into 5-bromo-4-chloro-indoxyl, which spontaneously 
dimerizes and oxidizes to form a bright blue insoluble pigment (5,5'-dibromo-4,4'-dichloro-
indigo), turning the bacterial colonies blue. This chromogenic assay was utilised to select 
for colonies that had been successful in each of the positive and negative selection steps 
(Fig. 3.3), with blue colonies containing the cassette, and white colonies lacking it. 
Chloramphenicol resistance was also required at each selection step, as the Merlin BAC 
contains a chloramphenicol resistance marker and this ensures that all E. coli colonies 
contain a copy of the BAC, avoiding false positives.  
In order to achieve the insertion of the selection cassette by homologous recombination, 
arms of homology first had to be added to either end of the cassettes. This was achieved 
whilst amplifying the cassette up by polymerase chain reaction (PCR) by using primers that 
contained both homology to ends of the cassette, and homology to either the C-terminus 
of the US12 family member, or the C-terminal intergenic region (Fig. 3.2C). The same 
primers were used to PCR amplify either the Rpsl or SacB cassette as they contained a 
region of identical homology, and therefore only a different PCR template DNA was 
required. This gave the advantage of dual use of the primers, and allowed for easy  
104 
 
 
 Figure 3.1: Selection cassettes used in the protocol of recombineering. Selection 
cassettes contain selectable markers that allow them to be selected for and against 
(positive and negative selection) during recombineering (Fig. 3.2). Selection cassettes are 
inserted into the region of interest (such as the C-termini of US12 family members) to 
allow for positive selection, and then exchanged for the intended modification (V5 tag) to 
allow for negative selection upon cassette removal. Rpsl and SacB are the 2 main cassettes 
used during the standard method of recombineering (Fig. 3.2A). Rpsl confers for 
kanamycin resistance and streptomycin sensitivity, whereas SacB confers for ampicillin 
resistance and sucrose sensitivity. Both also contain LacZ, a β -galactosidase which allows 
easy identification of colonies by blue/white screening as shown in Fig. 3.3. GalK is 
additional selection cassette that is used in the alternative method of recombineering (Fig. 
3.2B). Positive and negative selection rounds use a different galactose carbon source, with 
clones containing the galK cassette able to grow in the presence of galactose, but unable 
to grow in the presence of its analog 2-deoxy-galactose (DOG). 
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Figure 3.2: Recombineering strategy protocols for epitope tagging US12 family members and 
the strategy used to add arms of homology using PCR and primer design. Two 
recombineering approaches were used to V5 tag the C-terminus of US12 family members. A) 
The standard recombineering protocol utilised the Rpsl and SacB cassettes where the cassettes 
were inserted at the C-terminus of the US12 family member gene, and subsequently 
exchanged for the V5 tag. B) The alternative recombineering method utilised the insertion of 
the GalK cassette. As the clones used had selectable marker within the target gene rather than 
at 3’ end, the cassette was exchanged for a PCR product of the complete V5-tagged gene 
instead. The basis of positive and negative selection by blue/white screening is explained in 
Fig. 3.3. Homologous recombination was undertaken at both stages of both protocols (rounds 
1 and 2) by the addition of arms of homology to the sequences to be inserted. C) A more 
detailed representation of Rpsl and SacB recombination protocol, demonstrating how the 
arms of homology were added during PCR amplification. In round 1, the templates of the 
selection cassettes were amplified up using primers that bound to either end of the cassette 
and encoded for the US12 family gene C-terminus or the intergenic region, giving arms of 
homology at either end of the PCR product. For round 2, arms of homology were added to the 
V5 tag through primer/oligo design where 2 overlapping primers joined together, with arms of 
homology at either end. D) A more detailed representation of round 2 of the GalK 
recombination protocol, demonstrating how both the V5 tag sequence and arms of homology 
were added to the US12 family member gene during PCR amplification. Templates of the 
genes were amplified up using primers that bound to either end of the gene and encoded for 
the US16/US17 gene C-terminus and the V5 tag, or the intergenic region. For the addition of 
homology arms on the V5 terminus, the product was put into a Topo vector, and amplified up 
using primers that encoded for both intergenic regions of the US16/US17 gene and the V5 tag, 
providing arms of homology at either end of the PCR product. This entire V5-tagged gene 
could then undergo homologous recombination with the BACs in which the GalK was 
contained within the US16/US17 gene. The orange, yellow, purple and green blocks represent 
the sequencing pattern (A, T, G and C, in no particular order or pattern) to demonstrate the 
areas of homology. The pale green represents the sequence of the V5 tag, blue represents the 
US12 family member and pink represents the selection cassettes. Dashed lines indicate the 
areas of homology that lead to the homologous recombination. 
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Figure 3.3: Blue/white screening on recombineering selection plates. This chromogenic 
assay of blue/white screening was used to identify which clones contained (or had 
removed) the Rpsl (KanR/SmS/LacZ/Rpsl) or SacB (AmpR/LacZ/SacB) selection cassettes. 
BAC containing colonies were grown on LB plates containing antibiotics, X-gal and 
isopropyl β-D-1-thiogalactopyranoside (IPTG). The antibiotics were used to select for 
colonies with and without the particular cassette, and the clones could be further 
identified by the presence or absence of lacZ within the cassettes which acted as a visual 
selectable marker. The lacZ gene encodes for β-galactosidase and is stimulated by (IPTG) 
present in the plates. This allows the X-gal in the plates to be converted into its 5-bromo-
4-chloro-indoxyl product, which dimerizes to produce an insoluble blue pigment. 
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switching between Rpsl and SacB methods for increased efficiency of success.  
Once the chosen cassette was amplified up by PCR to contain the arms of homology, the 
competent E. coli containing the HCMV BAC1111 were induced at 42⁰C for 15 mins. The 
PCR product was then electroporated into the bacteria, allowing homologous 
recombination to occur at the C-terminus of the US12 family gene. Bacteria were allowed 
to recover for 1 hour and were plated out onto selection media to select for colonies in 
which the homologous recombination had occurred and the selection cassette inserted. 
This ‘positive selection’ round utilised the addition of antibiotics for which the inserted 
cassettes contained resistance markers for (kanamycin for Rpsl and ampicillin for SacB). 
Blue colonies were selected for further recombineering if they grew on the positive 
selection plates (kanamycin/ ampicillin) but also failed to grow on the negative selection 
plates (streptomycin/sucrose) to avoid false positives during the second stage of 
recombineering.  
In the second round of recombineering, the same process was followed, except the insert 
was the V5 tag that also contained arms of homology to the C-terminal region of the US12 
family gene of interest. As the V5 tag is much smaller than the selection cassettes, instead 
of undergoing a PCR using primers to add the homology arms of interest to the tag, this 
was done solely through the addition of 2 overlapping oligonucleotides (oligos) containing 
both the V5 tag sequence and the homology arms (Fig. 3.2D). The competent E. coli were 
again induced at 42⁰C for 15 mins, and the oligos electroporated into the bacteria, allowing 
for homologous recombination to occur. The bacteria were again allowed to recover for 1 
hour (or 4 hours for SacB) and were then plated onto selection media to select for colonies 
in which the homologous recombination had occurred and the selection cassette 
exchanged for the V5 tag. To avoid the growth of any colonies that still contained the 
selection cassettes, this ‘negative selection’ round utilised the addition of streptomycin for 
which the Rpsl cassette contained a sensitivity marker for, or sucrose which is toxic to E. 
coli still containing the SacB cassette. The loss of the selection cassette in exchange for the 
sequences encoding the V5 tag also included the loss of lacZ, hence white colonies were 
selected for (Fig. 3.3) and validated as below (Section 3.3).  
To achieve the tagging of members US12, US13, US14 and US15, the Rpsl or the SacB 
cassette were firstly added into pAL1111 after the target gene, with the cassettes 
subsequently swapped for the V5 tag. BACs with V5-tagged US18 and US20 had previously 
been constructed and viruses generated (Fielding et al., 2014). Intermediate constructs of 
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US19 (US19-Rpsl) and US21 (US21-Rpsl) were produced prior to my involvement in the 
project (by Dr Ceri Fielding), and I completed the 2nd round of recombineering that 
exchanged the inserted cassettes for the V5 tag. Despite repeated attempts, the V5 tag 
could not be inserted at the C-termini of either US16 or US17 by recombineering using the 
standard Rpsl and SacB cassettes.  
 
3.2 Epitope tagging of HCMV US16 and US17  
It is unclear as to why recombineering with Rpsl and SacB for US16 and US17 was not 
successful. It is unlikely that the GC content of these 2 genes accounted for the 
incompatibility of the original cloning attempts, as the GC content of US16 and US17 was 
not dissimilar to the other members of the family (Appendix Table 7.2). Perhaps the DNA 
sequence of these 2 genes had a secondary structure (e.g. a hairpin loop) that affected or 
blocked the C-terminus in some way (Nelms and Labosky, 2011). Although US17 does have 
a predicted helix closer to its C-terminus than the other members of the family, in general 
the predicted secondary structures of US16 and US17 are not dissimilar to the rest of the 
family (data not shown). An alternative approach was adopted to epitope tag US16 and 
US17 that utilised a galactokinase (GalK) selection cassette (Fig. 3.1) (Warming et al., 2005).  
E. coli SW102 harbour a functional gal operon, except for the deletion of galK. The inclusion 
of galK on the selection cassette thereby allowed bacteria with a GalK-containing BAC to 
grow on minimal media with galatose as the only carbon source, allowing for positive 
selection (Warming et al., 2005). Galactose was replaced with its analog 2-deoxy-galactose 
(DOG) in the second round of recombineering. If the GalK cassette remained, DOG would 
be phosphorylated and lead to a toxic build-up of 2-deoxy-galactose-1-phosphate, 
removing any colonies that still contained the GalK cassette. Dr Eva Ruckova had previously 
constructed Merlin BAC clones with the Galk cassette inserted into the middle of the US16 
and US17 target genes, albeit for a different purpose (the generation of deletion mutants). 
These clones were therefore used in the second round of recombineering. As the selectable 
marker was within the target gene rather than at the 3’ end, a complete V5-tagged gene 
was used in recombineering rather than just the V5 tag (Fig. 3.2B). The PCR amplification of 
US16-V5 and US17-V5 used DNA primers that incorprated the V5 tag and homology arms to 
the US16 and US17 gene regions when amplifying them from the Merlin BAC1111 (Fig. 
3.2E). These PCR products were purified and transformed into E. coli containing the 42⁰C 
induced Merlin BAC (US16-GalK or US17-GalK). The resulting 2nd round colonies were 
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grown onto the negative selection plates containing 2-deoxy-galactose (DOG) to select for 
those in which homologous recombination had occurred, and the GalK cassette removed. 
This alternative method resulted in the addition of the V5 tag to the C-terminus of both 
US16 and US17, resulting in all 10 members of the US12 family thus being V5-tagged. 
 
3.3 Sequencing validation of the V5 tagged genes 
After the completion of both recombineering stages, the DNA purified from each V5-tagged 
BAC clones were PCR amplified ready for sequencing, using forward and reverse 
sequencing primers to amplify the region of the US12 family gene and V5 tag (Fig. 3.4). The 
size of the PCR product indicates whether is it likely that the tag had been inserted without 
causing unwanted deletions or additions in the gene of interest. As demonstrated by the 
PCR products of US16-V5 using forward and reverse sequencing primers (Fig. 3.5A), clone 
13 gave a band bigger than the expected 1375 bp size, and clone 19 did not produced any 
strong bands of the correct size. Clones 14, 15, 16, 17, 18 and 20 however demonstrated a 
satisfactory quantity of PCR amplification for the region of the correct size, and were 
purified for sequencing.  
Another step to ensure that the clones were likely not to have other unwanted changes in 
the viral genome, was to digest the DNA purified from each BAC clone with a restriction 
endonuclease such as BamHI (Fig. 3.5B). This digest process is unlikely to detect small 
changes such as the addition of the tag, but instead detects major alterations in the BAC 
genome including unwanted recombinations that may have taken place, or large parts of 
the genome that may have been deleted. Therefore if the restriction endonuclease digest 
pattern was similar to that of the parental Merlin BAC, then the clones appeared not to 
have any major BAC alterations and the entire genome is likely to have remained intact. 
Figure 3.5B demonstrates acceptable restriction digest patterns from US16-V5 second 
round clones 14, 15, 16, 17, 18 and 20 that appeared suitable for sequencing. The PCR 
products from these clones were therefore sent for Sanger DNA sequence analysis to 
validate the addition of the tag. To achieve this, they were sent using forward, reverse 
and/or internal primers that were designed to capture the sequence of the area 
surrounding the addition of the tag and the entire US12 family member gene (Fig. 3.4). In 
addition to the detection of the epitope tag in the correct location, the sequence was also 
checked for mutations that could have been introduced by PCR or recombineering into the 
US12 family gene region, by comparison to the known HCMV strain Merlin US12 family  
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Figure 3.4: Sequencing procedure for V5-tagged US12 family members. After 
recombineering has taken place, V5-tagged US12 family member BACs must be verified by 
sequencing. Firstly, forward and reverse primers (yellow arrows) are used to amplify up the 
V5-tagged gene of interest from the BAC by PCR in order to send that region for 
sequencing. Forward, Reverse and/or Internal primers (red arrows, FP, RP, IP) were then 
used for the sequencing analysis of the final clones to check that the V5 tag was inserted 
correctly. The PCR template for each V5-tagged member was sent with each primer 
individually to Eurofins (Germany). The Internal primer was often used if the sequencing 
trace from the Forward primer wasn’t clear enough to determine if the tag region had any 
sequencing issues. Using 2 or more primers meant that the whole region of interest could 
be covered by a strong sequence readout. These could be aligned and compared to the 
NCBI reference sequence for each US12 family member in HCMV strain Merlin. 
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Figure 3.5: PCR and restriction endonuclease digest patterns of US16-V5 
tagged clones. A) Polymerase chain reaction (PCR) of US16-V5 using both the 
forward and reverse US16 sequencing primers to amplify the US16 and V5 tag 
region for sequencing analysis. Expected band size is 1375bp. All US16-V5 clones 
gave the correct size band except for clones 13 and 19. B) Restriction 
endonuclease (BamHI) digest patterns of purified US16-V5 BACs, alongside 
corresponding ladder pattern from BAC pAL1111 parental strain (formulated by 
CLC Main Workbench 7 software). All clones had a similar digest banding 
pattern to the parental strain suggesting that no major BAC alterations had 
occurred during recombineering. Multiple clones were sequenced and #16 was 
subsequently verified and taken forward into the next stages. 
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Figure 3.6: Sanger sequencing alignment example of a HCMV BAC 
containing US16-V5. V5-tagged BACs were sent for Sanger sequencing 
analysis (Eurofins, Germany) individually with both forward and 
reverse sequencing primers and/or the internal reverse primer of the 
V5-tagged US12 family member, as detailed in Appendix Table 7.1. 
Both sequences and nucleotide trace patterns for provided for each 
‘read’ of the sequence sent. The 2 sequencing reads (with trace) from 
the forward and reverse sequencing primers were aligned with the 
reference Merlin sequence (with added V5 tag sequence) in the CLC 
Main Workbench version 7.6 (Qiagen, Denmark, www.clcbio.com). The 
reference sequence used was the HCMV Merlin NCBI ReqSeq 
NC_006273.2, with the sequence of the V5 tag added at the C-
terminus of each US12 family member in place of the stop codon. The 
example here shows the sequencing reads for US16-V5, so US16 
forward and reverse primers were used. The consensus sequence 
alignment (shown in pink) is the overall agreeing consensus of the 2 
sequencing reads in comparison with the reference sequence. Conflicts 
are highlighted, but are only relevant if the trace is well defined at that 
area (accurate), and are disregarded if the trace is missing, low or 
overlapping (inaccurate) or if the peaks of the trace from the opposite 
read are clearer and therefore more accurate.  
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member DNA sequences (NCBI). An example of this comparison output can be seen for 
US16-V5 in Figure 3.6. The regional DNA sequencing analysis confirmed that each US12 
family member gene had the addition of the V5 tag sequence at the C-terminus of the 
gene, and that no other amino acid changed had occured within the genes (Table 3.1). 
The E. coli bacterial cultures containing the validated V5-tagged US12 family member BACs 
were then cultured on a large scale and underwent BAC maxiprep (Section 2.1.11) to purify 
the Merlin BAC DNA. This purified BAC DNA was then transfected into fibroblasts (HF-
TERTs) using Lonza's nucleofector technology, leading to the generation of plaques of 
HCMV-infected cells within 2-3 weeks that were then expanded to produce a virus stock 
within 4-5 weeks (Section 2.4.1). HCMV viral DNA was extracted from stocks of each V5-
tagged virus, and sent to collaborators (Davison group, MRC University of Glasgow Centre 
for Virus Research) for whole genome sequencing to confirm that no unwanted changes 
had taken place in the rest of the genome. All viral genome sequences came back with the 
anticipated C-terminal tags and were otherwise identical to the parental HCMV Merlin 
genome, or at worst contained single nucleotide deletions within non-coding regions of the 
genome (Table 3.1). Such mutations should not affect the overall function of the virus or 
the genes of interest. Once validated, the V5-tagged HCMV Merlin BAC was given a virus 
identifier number (e.g. RCMV2314) for easy documentation within the laboratory and the 
clone number recorded (e.g. clone 3C) (Appendix table 7.3). Multiple stocks of each V5-
tagged virus were grown as required, either by transfecting viral BACs as above, or by 
infection with a passage 1 virus to avoid the risk of mutation.  
 
3.4 Validation of V5-tagged US12 family protein expression by 
immunoblotting  
To assess whether each V5-tagged US12 family member gene produced its respective V5-
tagged protein in vitro, whole cell lysates were collected from infected fibroblasts at 72 hpi 
and were subjected to SDS-PAGE and analysed by immunoblotting with a V5 specific 
antibody. Each of the V5-tagged US12 family member proteins (US12 to US21) were 
detected by the V5 antibody by immunoblot (Fig. 3.7), further validating the V5 tagging of 
these proteins. Prior to SDS-PAGE, it was necessary to denature the proteins at a lower 
temperature than normal (50⁰C instead of the standard 95⁰C), to avoid the formation of 
high molecular complexes and other issues related to their 7TM nature. 
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Table 3.1: The US12 family member sequencing results from the Sanger sequencing of the 
tagged gene region by Eurofins and the Illumina genome sequencing of the viral DNA 
stock by our collaborators (MRC- University of Glasgow Centre for Virus Research) 
Gene Region sequencing (Eurofins, Germany) Viral genome sequencing 
(Illumina) 
US12-V5 V5 tag addition confirmed, and no 
mutations within the sequenced region 
1 nt deletion in US34A-TRS1 
intergenic region (G tract) 
US13-V5 V5 tag addition confirmed, and no 
mutations within the sequenced region 
No unexpected changes 
US14-V5 V5 tag addition confirmed, and no 
mutations within the sequenced region 
1 nt deletion in RNA4.9, 1 nt 
insertion in US13-US14 
intergenic region 
US15-V5 V5 tag addition confirmed, and no 
mutations within the sequenced region 
No unexpected changes 
US16-V5 Gene and V5 tag addition confirmed, and 
no mutations within the sequenced region 
No unexpected changes 
US17-V5 Gene and V5 tag addition confirmed, and 
no mutations within the sequenced region 
No unexpected changes 
US18-V5 Tagged previously (Dr Ceri Fielding), V5 
tag addition confirmed, and no mutations 
within the sequenced region 
Sequenced previously (Dr 
Ceri Fielding), no unexpected 
changes 
US19-V5 V5 tag addition confirmed, and no 
mutations within the sequenced region 
No unexpected changes 
US20-V5 Tagged previously (Dr Ceri Fielding), V5 
tag addition confirmed, and no mutations 
within the sequenced region 
Sequenced previously (Dr 
Ceri Fielding), no unexpected 
changes 
US21-V5 V5 tag addition confirmed, and no 
mutations within the sequenced region 
No unexpected changes 
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Figure 3.7: Validation of V5-tagged US12 family protein expression by immunoblotting 
Fibroblasts were infected with HCMV Merlin encoding V5 tagged US12 genes at an MOI of 
10. Samples were left untreated and were harvested at 72h.p.i. Whole cell lysates were 
extracted and proteins detected using an anti-V5 antibody (mouse) and a rabbit anti-
mouse HRP secondary antibody. Samples were re-probed with an anti-actin antibody as a 
loading control & UL141 as a positive control for viral infection. Exposures captured using 
the GelDoc (Syngene) system. Mock and HCMV 1111 were run on a separate gel below. A) 
All V5-tagged US12 family members. All samples were from the same experiment, except 
for US18-V5 which had inefficient infection of fibroblasts in the initial experiment so was 
repeated separately. B) Lower exposure image of US20-V5 from A for clearer observation 
of doublet band. All samples are representative of at least 3 independent repeats. 
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Members pUS12-V5, pUS14-V5, pUS15-V5, pUS16-V5 and pUS19-V5 were detected as 
singlets (a single dominant protein species), and pUS17-V5, pUS18-V5, pUS20-V5 and 
pUS21-V5 (Fig 3.7) were detected as doublets (two dominant protein species), whereas 
pUS13 exhibited a smeared ladder effect. With pUS20-V5 in this and subsequent 
immunoblots, a shorter exposure time was required in order to reveal the doublet band 
(Fig 3.7B).  
The main protein forms of each family member all fell within the 17-38 kDa range. pUS12-
V5 was detected here at ~24 kDa, and pUS13-V5 exhibited a band at 21 kDa with a smeared 
ladder effect above reaching to ~80 kDa. pUS14-V5 was detected at ~37 kDa, pUS15-V5 at 
20 kDa, and pUS16-V5 at 28/29 kDa. pUS17-V5 was detected with a main band at ~26 kDa 
and a fainter band at 22 kDa, with pUS18-V5 detected as a doublet of ~22 and 25 kDa, and 
pUS19-V5 detected at ~19 kDa. pUS20-V5 was detected as a doublet of ~19 and 24 kDa, 
and pUS21-V5 was detected as a doublet of ~16 and 19 kDa (Fig. 3.7). The molecular 
weights of US12 family members across this and subsequent experiments are detailed in 
Chapter 4, Table 4.5.  
Despite US12 family members typically having 1 or 2 dominant protein species, other lower 
abundance protein species could also be detected. Figure 3.7 demonstrated this to a small 
extent, however the presence of these additional protein forms were more clearly 
visualised at longer exposure times as demonstrated in Figure 3.8. pUS12-V5, pUS18-V5 
and pUS19-V5 were the only members that did not appear to have any additional protein 
forms. Certain members, such as pUS13-V5, still showed complex migration patterns 
despite denaturing at 50⁰C. This most likely relates to the hydrophobic nature of the US12 
family, but could also be caused by post translational processing (such as glycosylation, 
ubiquitination) or proteolysis. The relative migration of the US12 family proteins and their 
post-translational modifications will be investigated and addressed in more detail (Section 
4.4) and the implications discussed further in Section 6.1. 
At 72 hpi, the expression levels of US12 family members were clearly variable, as estimated 
by the strength of signal from the V5 tag. pUS20-V5 appeared to exhibit relatively high 
levels of expression and pUS21-V5 had relatively low expression levels compared to other 
family members (Fig. 3.7). For example, when actin levels were taken into account, the 
detected protein level of pUS20-V5 was estimated to be 33 times higher than that of 
pUS21-V5, 5-8 times higher than pUS15-V5 and pUS19-V5, and 3-4 times higher than 
pUS12-V5 or pUS16-V5 by densitometry (Table 3.2). These differences in expression levels  
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Figure 3.8: Detection of V5-tagged US12 family member proteins, at longer exposure 
times to visualise the extra bands and smears/ladders. At longer exposure lengths, extra 
bands can be detected through immunoblotting of multiple US12 family members. These 
are additional protein forms to the main dominant protein species typically detected, 
and are not consistently seen as they appear to have much lower relative expression to 
the main protein species. These high exposure images have been taken from across 
multiple experiments to find the highest available exposure for each individual protein. 
All samples are high exposures of untreated WCL samples at 72 hpi that have been 
probed by immunoblot with an anti-V5 antibody. Further protein forms were additionally 
detected under different treatment of the samples, including under leupeptin treatment 
(see Chapter 5, Fig. 5.1). 
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Table 3.2: Densitometry calculations to estimate the differences in protein expression 
levels between US12 family members 
Protein Area1* Area2*  Comparative 
area % ◊ 
Comments 
Figure 
3.7 
US12-V5 5950.640 16234.2 29.47232 3.39 times lower 
than pUS20  
US13-V5 35273.337 60749.24 110.287 10% higher than 
pUS20 
US14-V5 20277.534 36583.66 66.41565 2/3 of pUS20 
US15-V5 6631.660 10510.77 19.08173 5.24 times lower 
than pUS20 
US16-V5 14830.409 15196.2 27.58788 3.625 times lower 
than pUS20  
US17-V5 4009.569 4043.033 7.339908 13.64 x lower than 
pUS20 
US18-V5 † † † † 
US19-V5 6157.669 6802.255 12.34913 8.097 times lower 
than pUS20 
US20-V5 41741.546 55082.88 100  
US21-V5 1681.568 1681.568 3.052796 33 times less than 
pUS20 
Figure 
3.8 
US18-V5 4415.225 4623.272 4.93387 20.3 times less than 
pUS20 
US19-V5 13673.832 16067.96 17.14742808 5.83 times less than 
pUS20 & 3.48 times 
more than pUS18 
US20-V5 93704.768 93704.77 100  
* Densitometry plots were made for each lane of protein, and the area under the peak 
calculated using ImageJ (NIH, https://imagej.nih.gov/ij/). Area1 is the raw area for each 
protein, and area2 is the area for each once the different actin protein expresssion levels 
were taken into account 
† US18 was not present in this immunoblot so couldn’t be directly compared 
◊ Area % in comparison with pUS20-V5  
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Figure 3.9: The consistent varying levels of protein expression between US12 family 
members as demonstrated by US18, US19 and US20. Fibroblasts were mock infected or 
infected with HCMV Merlin, or HCMVs encoding V5 tagged US12 genes at an MOI of 10. 
Samples were left untreated and harvested at 72 h.p.i. Proteins were extracted and 
detected using an anti-V5 antibody and an HRP secondary antibody. All samples were 
run with anti-actin used as a loading control. These immunoblots are just 2 examples (A 
and B) of the consistent difference in expression between US18, US19 and US20. 
Samples are representative of at least 4 independent repeats. 
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across the family remained consistent and could also be seen in subsequent blots (Chapter 
4); further exemplified for pUS18, pUS19 and pUS20 in Figure 3.9. In this experiment, 
densitometry calculations indicated that pUS19-V5 was detected at ~3.5 times the amount 
of pUS18-V5, and that pUS20-V5 was detected at 20 times the amount of pUS18-V5, when 
taking actin levels into account (Table 3.2).  
The detection of different US12 family members therefore often required different 
exposure times. Although the use of the same epitope tag for each US12 family member 
permits a comparison, the V5 tag may not be equally accessible to the antibody depending 
on the tertriary structure of the re-folded protein. It should also be borne in mind that 
post-translational processing, such as C-terminal trimming, could result in the tag being 
released while the protein remains functional. Nevertheless, it is reassuring to be able to 
detect, track and characterise expression of US12 family members during experimentation. 
The detected levels of each tagged protein will be influenced by the efficiency of 
transcription, translation and degradation and, in most cases, is likely to be an accurate 
reflection of expression by HCMV. 
All 10 members of the US12 family were readily detected by western blot using the V5 tag, 
suggesting that they are likely to be functional in human fibroblasts, and demonstrates that 
they are all expressed in the context of productive HCMV infection. This is important as 
pUS13, pUS16, pUS19 and pUS21 were not detected in a comprehensive proteomic 
analyses of HCMV gene expression (Weekes et al., 2014). This indicates that 
immunoblotting using V5 tag constructs can be more sensitive than mass spectrometry. In 
addition to demonstrating enhanced sensitivity, the result is also helpful in interpreting the 
systematic proteomic analysis of individual US12 family mutants in which US13, US16 and 
US19 were all shown to be required to suppress expression of cell surface immune ligands 
(Fielding et al., 2017). Having assigned functions to these genes, it is reassuring to now 
demonstrate that they are expressed and can be detected. 
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family members 
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Having inserted a V5 tag at the C-terminus of each individual US12 gene family member, 
my intention now was to use this resource to characterise US12 family expression in human 
fibroblasts. Limited characterisation of individual US12 family members had been 
previously elucidated from focussed studies on US14, US17, US18, US19 and US20 (Guo, 
1993, Das and Pellett, 2007, Das et al., 2006). A more comprehensive view was also 
ascertained from a high definition proteomics study that studied the expression of all 
quantifiable HCMV genes, including some US12 family members, and clustered them based 
on the similarity of their temporal profiles (Tp1 to Tp5) (Weekes et al., 2014)(Section 
1.4.1.4). In addition to informing directly on the expression of US12 gene family members, 
it was intended that the study would also provide an independent assessment on the value 
of the proteomics analysis for this gene set. Utilising immunoblotting to study this gene 
family aimed to validate and extend the findings on US12 family expression by Weekes et 
al. (2014), and to characterise de novo expression (including kinetics) of the HCMV strain 
Merlin US12 family members not detected by proteomics.  
Proteins can also be subject to a variety of post-translational modifications including 
ubiquitination, SUMOylation, glycosylation, phosphorylation and methylation that can 
impact on their properties. For example, glycosylation is known to affect folding, stability, 
activity, distribution, function or impair immune detection by cloaking antigenic domains 
(Wagner et al., 2008, Rudd et al., 2001, Helenius, 1994). Glycans can be attached either to a 
nitrogen residue in asparagine (N-linked) or a hydroxyl group of serine, threonine or 
hydroxylysine (O-linked)(Rudd et al., 2001); with N-linked (N-) glycosylation being the most 
prevalent. N-glycosylation sites often interact with chaperones to stabilise intermediates 
and enable proper folding and assembly in the endoplasmic reticulum (ER) prior to the 
protein’s transfer to the Golgi apparatus (Rudd et al., 2001, Trombetta and Helenius, 1998, 
Helenius, 1994). During a further maturation process through the Golgi apparatus, 
involving the removal of the α1-3 and α1-6 mannose units, the N-glycosylated protein 
becomes resistant to endoglycosidase H (EndoH) cleavage (Freeze and Kranz, 2010). EndoH 
can therefore normally only remove N-glycosylation from proteins retained within the ER, 
whereas Peptide-N-Glycosidase F (PNGase F) removes virtually all N-glycans from a protein. 
Many HCMV proteins are known or predicted to be N-glycosylated, including gpUL18, 
gpUL141, gB and the majority of the RL11 family (Gabaev et al., 2011, Stanton et al., 2010, 
Griffin et al., 2005, Cochrane, 2009). Although there is no evidence that HCMV encodes its 
own glycosyltransferases, the virus does up-regulate the transcription of host 
glycosyltransferases (Cebulla et al., 2000). 
130 
 
Our current understanding of proteins expressed by US12 family members is limited to a 
small number of pioneering studies based on the high passage strains AD169 and Towne. I 
therefore sought to gain a more complete appreciation of the expression kinetics, size and 
post-translational modifications of the entire US12 family, as well as doing so in the more 
clinically relevant Merlin strain. 
 
4.1 Analysis of US12 family members through the use of prediction 
software 
Firstly the US12 family were analysed using prediction software to identify their potential 
traits. This included searching for N-glycosylation sites, organelle localisation motifs, and 
predicting their transmembrane domains and membrane topology. Most prediction 
software were created to identify motifs solely in eukaryotic or prokaryotic proteins, rather 
than viral ones. However, HCMV has evolved to replicate in human cells, so it would be 
natural for HCMV proteins to contain human motifs. Multiple software resources were 
used to provide an overview on the potential traits present in the US12 family.  
4.1.1 N-glycosylation motifs of US12 family members 
The prediction resource sites NetNGlyc (Gupta et al., 2004), Prosite (de Castro et al., 2006) 
and Eukaryotic Linear Motifs (ELM) (Dinkel et al., 2016) were used to analyse the US12 
family members for the presence of N-glycosylation motifs. All 3 sites investigated the US12 
family sequences for the N-glycosylation motif Asn-Xaa-Ser/Thr (Asparagine-Xaa-
Serine/Threonine) or Asn-Xaa-Ser/Thr-Xaa where Xaa is any amino acid except for proline. 
ELM also searched for an additional atypical motif Asn-X-Cys (Cysteine). 
It was universally predicted that US14, US16, US17 and US20 contained potential N-
glycosylation sites (Table 4.1). US18 contained N-glycosylation motifs that were predicted 
not to be functional or not utilised for N-glycosylation within the cell due to either 
structural or conformational constraints. For example, the first site within US18 contained a 
proline just after the asparagine residue, which would cause conformational constraints, 
and its second site occurred within the transmembrane domain of the protein so would 
also not be glycosylated during infection (Dinkel et al., 2016). As one of US14’s motif sites 
was scored below the threshold levels of the NetNGlyc software, it was also unlikely that 
this motif was N-glycosylated within the cell. US13 was predicted to have an atypical N- 
glycosylation motif that was predicted by ELM alone, and less is known about the  
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Table 4.1 N-glycosylation motifs predicted within the US12 family 
Gene† NetNGlyc* Prosite* ELM* 
US12 - - - 
US13 - - 1 atypical motif: NIC (62-
64aa).  
US14 2 motifs: NGTL (291-
294aa) and NSTT (299-
302aa)꙳ 
2 motifs: NGTL (291 - 
294) and NSTT (299 - 
302)  
2 generic motifs: DNGTLS 
(290-295aa) and LNSTTA 
(298-303aa) 
US15 - - - 
US16 1 motif: NCTL (178-
181aa) ꙳ 
1 motif: NCTL (178-
181aa) 
1 generic motif: DNCTLS 
(177-181aa). 
US17 1 motif: NLTR (287 – 
290aa) 
1 motif: NLTR: (287 – 
290aa)  
1 generic motif: RNLTRT 
(286-291aa) 
US18 2 motifs: NPTR (159-
162aa)꙳, and NMSV 
(242-245aa) ꙳ 
1 motif: NMSV (242-
245aa)  
- 
US19 - - - 
US20 3 motifs: NYSF (61 – 
64aa), NATV (88 – 
91aa) and NGTL  (242 
– 245aa)  
3 motifs: NYSF (61-
64), NATV (88-91), 
NGTL (242-245) 
3 generic motifs: ENYSFF 
(60-65), SNATVL (87-92) 
and DNGTLT (241-246aa) 
and 2 atypical motifs: NFC, 
(56-58) and NQC (202-
204aa) 
US21 - - - 
 
*NetNGlyc 1.0 Server (http://www.cbs.dtu.dk/services/NetNGlyc/), PROSITE (ExPASy) 
resource portal (de Castro et al., 2006) and Eukaryotic Linear Motif (ELM) resource (Dinkel 
et al., 2016). ELM hits are those remaining after internal filtering by the software to remove 
motifs that are unlikely to be utilised in practice 
† Protein sequences were translated from the DNA sequences of US12 family members 
from HCMV Merlin reference strain (NCBI RefSeq NC_006273.2).  
꙳ Unlikely to be utilised for N-glycosylation within the cell due to structural or 
conformational constraints 
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constraints and restrictions of this motif and the likelihood of this residue being 
glycosylated during infection. US12, US15, US19 and US21 were consistently predicted not 
to contain any N-glycosylation motifs.  
4.1.2 Localisation motifs of US12 family members 
Multiple prediction software, including Phobius (Kall et al., 2004), ELM (Dinkel et al., 2016) 
and Protter (Omasits et al., 2014) failed to detect any cleavable N-terminal signal peptides 
within US12 family members. However, the ELM resource did predict other motifs within 
the family that link to localisation, including non-cleavable ER retention motifs and 
lysosomal sorting signals. Although no US12 family were predicted to have the most 
common ER retention motif KDEL; US12, US13, US14, US15, US16, US17, US19 and US20 
were all predicted to contain the ER retention motif TRG_ER_diArg_1 (Table 4.2). This motif 
was defined by two consecutive arginine (Arg/R) residues (RR) with or without a single 
residue insertion (RXR), and with an adjacent arginine or hydrophobic residue which may 
be on either side of the Arg pair. The functional motif needs to be exposed within a 
cytosolic region of the membrane protein and requires a distinct proximity to the 
transmembrane region, otherwise the motif is unused. Due to this, the ELM software 
filtered the results using globular domain filtering, structural filtering and context filtering 
to remove motifs that were unlikely to be used (Dinkel et al., 2016) and subsequently 
excluded US18 from the list of members likely to contain a functional ER retention motif. 
US21 was not predicted to contain any ER retention motifs by ELM, however an alternative 
motif was found within US21 using a different prediction site, Psort II (Nakai and Horton, 
1999), which predicted an N terminus XXRR-like motif. Psort II also predicted US15 to 
contain an N-terminus CCRR-like motif and C terminus KKXX-like motif, US16 to have an N 
terminus XXRR-like motif, and US20 to contain a C terminus KKXX-like motif (Table 4.2). The 
XXRR-like motif is an N-terminal di-arginine motif, usually of type II proteins, and the KKXX-
like motif is a C-terminal di-lysine motif, usually of type Ia proteins. Their existence is not 
sufficient for the localization of proteins to the ER membrane however, and the likelihood 
of these functioning as such is unknown.  
Members US12, US13, US14, US18 and US20 were also predicted to contain the lysosomal 
targeting motif ‘TRG_LysEnd_APsAcLL_1’ with the consensus motif [Asp/Glu/Arg/Gln]-X-X-
X-Leu-[Leu/Val/Ile], where X is any amino acid (Table 4.2). This is a sorting and 
internalisation signal directing transmembrane proteins (generally type I) from the cell 
surface or TGN to the lysosomal-endosomal compartment. The motif interacts with the 
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Table 4.2: Lysosomal targeting, ER retention and endocytic trafficking motifs predicted 
within the US12 family. 
 Gene† ELM* hits  Psort II* hits 
US12 4 x ER retention motif TRG_ER_diArg_1 
and 1x lysosomal targeting motif 
TRG_LysEnd_APsAcLL_1 
 
US13 2x  ER retention motif TRG_ER_diArg_1 
and 2x lysosomal targeting motif 
TRG_LysEnd_APsAcLL_1 
 
US14 1x  ER retention motif TRG_ER_diArg_1 
and 1x lysosomal targeting motif 
TRG_LysEnd_APsAcLL_1 
  
US15 2x ER retention motif TRG_ER_diArg_1 1x XXRR-like ER retention motif and 
1x KKXX-like ER retention motif  
US16 5x ER retention motif TRG_ER_diArg_1  1x XXRR-like ER retention motif  
US17 3x ER retention motif TRG_ER_diArg_1 
 
US18 2x lysosomal targeting motif  
TRG_LysEnd_APsAcLL_1 
 
US19 1x ER retention motif TRG_ER_diArg_1 
 
US20 2x ER retention motif TRG_ER_diArg_1 
and 2x lysosomal targeting motif 
TRG_LysEnd_APsAcLL_1 
KKXX-like ER retention motif 
US21 None XXRR-like ER retention motif  
                                                                                                                                                                               
*Eukaryotic Linear Motif (ELM) resource (Dinkel et al., 2016) and Psort II programs (Nakai 
and Horton, 1999). ELM hits are those remaining after internal filtering by the software to 
remove motifs that are unlikely to be utilised in practice. 
† Protein sequences were translated from the DNA sequences of US12 family members 
from HCMV Merlin reference strain (NCBI RefSeq NC_006273.2). 
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adaptor proteins AP1, AP2, AP3 and probably AP4, although it is unclear how the specificity 
for binding to APs is achieved. US16, US19 and US21 also contained the sequence for this 
motif, but were removed from the prediction after ELM filtering as previously described 
(Dinkel et al., 2016).   
Some members also contained the sequence for the TRG_ENDOCYTIC_2 motif which is a 
tyrosine (Y)- based sorting signal that can direct trafficking within the endosomal and the 
secretory pathways, however none of these remained as motifs that were predicted to be 
utilised after ELM filtering had taken place (Dinkel et al., 2016), except for US20 (Table 4.2). 
4.1.3 Transmembrane domain and topology predictions of US12 family members 
The US12 family are predicted to each encode a polypeptide that passes through a lipid 
membrane multiple times. Multiple prediction websites predicted between 6 and 8 
transmembrane (TM) domains for the US12 family members (Table 4.3). Often it was the 
presence of a less hydrophobic region, the possibility of a re-entrant loop instead of a TM 
domain or conflicting membrane orientations that caused the differences in the predictions 
between resources. Nevertheless, the consensus across prediction sites was that each 
member had 7 TM domains (Table 4.3). In line with these predictions, the protein topology 
prediction software Protter (Omasits, Ahrens, Müller, & Wollscheid, 2014) also predicted 
7TM domains for each family member, and provided a unique non-linear perspective on 
how the US12 family members might cross the membrane (Figure 4.1). The mid-section of 
each of the proteins (between TM domains 1 and 7) was observed to contain mostly intra-
membrane regions with only small looped external sections between each TM domain. 
Generally, the longest regions of each protein that were not within the membrane 
appeared to be at the N and C-termini, except for US19 which had a very short exposed C-
terminus (Figure 4.1). Predicted N-glycosylation sites were also indicated. The Protter N-
termini orientation of each US12 family member was manually selected based on the 
consensus across all prediction sites (Table 4.3). These included Psort (Nakai and Horton, 
1999), TMPred (Hofmann and Stoffel, 1993) and the Constrained Consensus Topology 
prediction server (CCTOP) (Dobson et al., 2015) which compared 10 methods of membrane 
topology prediction in order to reach a consensus. It was revealed that the prevalent 
prediction was that the N-terminus of the US12 family members would be cytoplasmic, and 
that the C-terminus would be non-cytoplasmic (Table 4.3). N- and C- termini orientations 
are generally predicted using either the ‘positive-inside’ rule where cytoslic loops near the 
lipid bilayer are known to contain more positively charged amino acids or by the by the net 
charge difference of the 15 residues flanking the most N-terminal transmembrane  
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Table 4.3: US12 family predictions of transmembrane domains and membrane topology  
 
CCTOP* (consensus from 
10 sites) 
TMpred* Psort* 
US12 7TMDs with N-terminus 
cytoplasmic and C-
terminus non-cytoplasmic 
7TMDs, with the N-terminus 
inside (cytoplasmic) and C-
terminus outside 
6 TMDs, with N-
terminus outside 
(non- cytoplasmic)  
US13 7TMDs with N-terminus 
cytoplasmic and C-
terminus non-cytoplasmic 
7TMDs, with the N-terminus 
inside (cytoplasmic) and C-
terminus outside 
7TMDs, with N-
terminus inside 
(cytoplasmic)  
US14 7TMDs with N-terminus 
cytoplasmic and C-
terminus non-cytoplasmic 
7TMDs, with the N-terminus 
inside (cytoplasmic) and C-
terminus outside  
6TMDs, with N-
terminus inside 
(cytoplasmic)  
US15 7TMDs with N-terminus 
cytoplasmic and C-
terminus non-cytoplasmic 
6TMDs , with the N-terminus 
inside (cytoplasmic) and C-
terminus inside  
7TMDs, with N-
terminus inside 
(cytoplasmic)  
US16 7TMDs with N-terminus 
cytoplasmic and C-
terminus non-cytoplasmic 
7TMDs, with the N-terminus 
inside (cytoplasmic) and C-
terminus outside 
8TMDs, with N-
terminus outside 
(non-cytoplasmic)  
US17 7TMDs with N-terminus 
cytoplasmic and C-
terminus non-cytoplasmic 
7TMDs, with the N-terminus 
inside (cytoplasmic)  and C-
terminus inside 
7TMDs, with N-
terminus inside 
(cytoplasmic)  
US18 7TMDs with N-terminus 
cytoplasmic and C-
terminus non-cytoplasmic 
7TMDs, with the N-terminus 
outside  (non-cytoplasmic) and 
C-terminus inside 
7TMDs, with N-
terminus inside 
(cytoplasmic)  
US19 7TMDs with N-terminus 
cytoplasmic and C-
terminus non-cytoplasmic 
7TMDs, with the  N-terminus 
outside (non-cytoplasmic)  and 
C-terminus inside 
6TMDs, with N-
terminus inside 
(cytoplasmic)   
US20 7TMDs with N-terminus 
cytoplasmic and C-
terminus non-cytoplasmic 
7TMDs , with the N-terminus 
inside  (cytoplasmic) and C-
terminus outside 
7TMDs, with N-
terminus inside 
(cytoplasmic)  
US21 7TMDs with N-terminus 
cytoplasmic and C-
terminus non-cytoplasmic 
8TMDs, with the N-terminus 
outside (non-cytoplasmic)  and 
C-terminus outside 
7TMDs, with N-
terminus inside 
(cytoplasmic)  
 * The Constrained Consensus Topology CCTOP prediction server (Dobson et al., 2015) 
compared 10 methods of membrane topology prediction in order to reach a consensus. 
The TMpred server (Hofmann and Stoffel, 1993) classified ‘inside’ as normally meaning the 
cytoplasmic face, and ‘outside’ as the lumenal face of the membrane, depending on the 
organelle. Psort (Nakai and Horton, 1999) predicted that the more positive portion of the 
protein faces the cytosol.  
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Figure 4.1: Predicted topology structures of the US12 family members. US12 family 
protein topologies were determined from the amino acid sequence of each member when 
inputted into Protter software (Omasits, Ahrens, Müller, & Wollscheid, 2014) which 
allowed the predicted topology and featured annotations to be visualised. For each 
member, the software allows you to visualise the predicted 7-transmembrane domains 
(numbered 1-7 in purple), along with any N-glycosylation sites predicted (in green, with 
arrows) in a non-linear manner. N-termini were manually orientated to correspond with 
the consensus that the N-terminus of each member was most likely to be cytoplasmic 
(Section 5.1.3) 
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segment. Psort predicted that the more positive portion of the protein would face the 
cytosol, and the TMpred server classified the ‘inside’ orientation as normally meaning the 
cytoplasmic face, and ‘outside’ as the lumenal face of the membrane, depending on the 
organelle. ‘Outside’ or ‘non-cytoplasmic’ may also refer to the termini being extracellular 
facing if the protein was found to localise at the plasma membrane. 
 
4.2 Kinetics of HCMV US12 family member expression  
Having established that all V5-tagged US12 family members could be detected by 
immunoblot (Chapter 3, Fig. 3.6), their expression kinetics were studied at 4 time-points 
over the course of a productive HCMV infection (Fig. 4.2). The immunoblot expression 
kinetics of US12 family members were also compared to the average temporal class 
patterns from Weekes et al. (2014), as demonstrated by Figure 1.5 (Section 1.4.1.4). 
Where data was available, a comparison was also made with the ‘quantitative temporal 
viromics’ (QTV) evaluation of the US12 family members’ temporal class and presented 
graphs were generated by interrogating the QTV data from supplemental Table S2 (Weekes 
et al., 2014). Densitometry calculations were also made from the immunoblot data and 
these output data were plotted as line graphs of relative expression over time (Fig. 4.3), in 
order to make these comparisons easier. 
Immunoblotting detected all ten US12 family members compared to a combined total of 
only six US12 proteins by QTV across both whole cell lysate (WCL) and plasma membrane 
(PM) samples (Fig. 4.2). The ability of the QTV study to detect pUS15, pUS17 and pUS18 
varied across experiments, with these ‘partially detected’ proteins lacking detection in 
either the WCL or the PM QTV samples. 
pUS13-V5, pUS18-V5 and pUS19-V5 were designated as being Tp3 proteins on the basis of 
the immunoblot data, with all three proteins readily detected at 48 hpi and their 
expression increasing over time and only levelling out at 96 hpi (Fig. 4.2), thus following the 
average pattern of Tp3 proteins. pUS21-V5 was assigned to Tp5 as it was barely detectable 
at 48 hpi by immunoblot with its expression subsequently increasing over time right up 
until 96 hpi (Fig. 4.2). To further categorise pUS21-V5, its expression pattern could be 
observed with the addition of the viral replication inhibitor phosphonoformate (PFA), as 
late proteins, including Tp5 proteins, should be majorly reduced in its presence. 
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Figure 4.2: Immunoblot time-course of US12 family protein expression compared to the 
US12 family data from the quantitative temporal viromics (QTV) study. Fibroblasts were 
mock infected or infected with HCMV Merlin, or HCMVs encoding V5 tagged US12 genes at 
an MOI of 10. Samples were left untreated and harvested at 24, 48, 72 and 96 hpi. Whole 
cell lysates were extracted and proteins detected by immunoblotting using an anti-V5 
antibody and an HRP secondary antibody. All samples were also tested with anti-actin used 
as a loading control, IE1 as a Tp1 protein control, and UL44 and UL99 as Tp5 protein 
controls. Immunoblots have a side-by-side comparison with supplementary QTV 
proteomics data collected on the US12 family found in Table S2 (Weekes et al., 2014). 
Fibroblasts were mock infected or infected with HCMV Merlin at a MOI of 10. For each 
member, whole cell lysate (WCL, encoded in orange) and plasma membrane (PM, coded in 
blue) samples were collected as described in (Weekes et al., 2014). Line graphs were 
represented as relative expression (0-1) over time. For one experiment, phosphonoformate 
(PFA) was added at 300ug/ml from the time of infection onward (encoded in purple). 
Proteins were identified by mass spectrometry.  
146 
 
 
147 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Densitometry time-course of US12 family protein expression 
from immunoblot data in Figure 4.2. In order to graphically represent the 
US12 family total protein expression over time, the GeneTools program 
(www.syngene.com/software/genetools-automatic-image-analysis/) was 
used to calculate the densitometry of each US12 family member at each 
time-point (24, 48, 72 and 96 hpi) from the whole cell lysate (WCL) 
immunoblot time-course data (Figure 4.2). The densitometry output data 
for each US12 family member were then plotted as relative expression 
over time. This allowed for an easier comparison between the data in this 
thesis and the expression of each US12 family member from the 
proteomics quantitative temporal viromics (QTV) study (Table S2 in 
Weekes et al. (2014) as depicted in Figure 4.3). US12 family members 
were assigned a temporal kinetics class (Tp1-5) through the comparison of 
their expression over time and the average temporal profiles for proteins 
in each temporal class (Figure 1.5). 
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pUS16-V5 and pUS20-V5 (Fig. 4.2) both had high levels of protein expression from early 
time-points (24 hpi) and generally stayed at high levels across the immunoblot time-course, 
following the average pattern of Tp2 proteins. This designation supported the 
categorisation of pUS20 as a Tp2 protein by QTV. Some late proteins can be detected at 
early time-points due to their presence in input virions, as frequently demonstrated by the 
early (24 hpi) detection of the Tp5 structural protein pp28/ppUL99 (Fig. 4.2). However, the 
pp28 levels for pUS20-V5, and especially for pUS16-V5, are relatively low at 24 hpi so their 
presence was likely to be at least partially due to de novo protein expression. 
pUS12 was also previously designated by QTV to be a Tp2 protein, and its immunoblot 
expression pattern did show some similarities to the average Tp2 protein profile. However, 
it demonstrated more similarities to the distinct Tp4 pattern, with maximal expression at 
48 hpi and low expression at other time-points so has been classified as a Tp4 protein by 
immunoblot (Fig. 4.2). Observing pUS12 expression with and without PFA would further 
substantiate this as viral DNA inhibition should have little effect on early proteins, but will 
partially inhibit the majority of late proteins.  
pUS17-V5 was expressed especially late in infection, with very low expression levels at 48 
hpi which subsequently increased over time, peaking at 96 hpi (Fig. 4.2). This was 
comparable to the average pattern of Tp5 proteins so pUS17 was categorised as such. 
pUS17 was also categorised as a late protein by QTV but was instead designated as a Tp4 
protein as its peak expression by QTV was earlier at 48 hpi. 
Immunoblotting detected pUS14-V5 at low levels from 24 hpi, increasing steadily over 
time, so it was accordingly categorised as a Tp3 protein (Fig. 4.2). This correlated with its 
designation as a Tp3 protein by QTV. pUS15-V5 was also suggested to be a Tp3 protein 
through immunoblot analysis, as its protein expression was detected from 48 hpi and seen 
to increase over time, peaking at 72 hpi. However pUS15 was instead designated as a Tp2 
protein by QTV as it had demonstrated an extra peak in expression prior to 24 hpi. 
Collecting and immunoblotting earlier time-points would further determine whether 
pUS15-V5 was in fact a Tp2 or Tp3 protein. 
The immunoblot data presented here generally agreed with the QTV data, with both 
datasets providing the same classifications for pUS14 and pUS20, and similar patterns of 
expression seen over time for pUS12, pUS15 and pUS17 (Table 4.4). The other family 
members had not previously been assigned a temporal class so these classifications were 
novel. The inclusion of additional time-points to provide more coverage earlier in infection 
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Table 4.4: Summary of the comparison between the US12 family data from the 
immunoblot time-course and the QTV proteomics study, alongside previously published 
results. 
Gene Time-course 
expression pattern* 
QTV expression 
pattern* 
Previously published immunoblot 
results 
US12 Tp4 pattern Tp2 protein N/A† 
US13 Tp3 pattern Not detected N/A† 
US14 Tp3 pattern Tp3 protein  N/A† 
US15 Tp3 pattern Tp2 protein N/A† 
US16 Tp2 pattern Not detected Detected at 48, 72 and 96 hpi 
(Luganini et al., 2017, Bronzini et 
al., 2012).                            
US17 Tp5 pattern Tp4 protein  
 
US18 Tp3 pattern Not assigned a 
temporal class 
Detected from 34 hpi (Guo, 1993).  
US19 Tp3 pattern Not detected Detected at a low level at 18 hpi 
and detected until 72 hpi (Guo, 
1993). 
US20 Tp2 pattern Tp2 protein.  Detected from 18 hpi and until 72 
hpi (Guo, 1993), and detected 
equally from 24 to 96 hpi 
(Cavaletto et al., 2015). 
US21 Tp5 pattern Not detected N/A† 
 
    * In relation to Figure 4.2. QTV data can also be found in Table S2 by Weekes et al. 
(2014). 
    † N/A, not applicable as no previously published results 
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and the utilisation of an inhibitor of virus replication (e.g. PFA) would further substantiate 
the expression kinetics of US12 family members. 
All US12 family member proteins could be detected by 48 hpi, while by 72 hpi most were 
near peak levels of expression. By 72 hpi, strain Merlin has also established a full 
productive infection in fibroblasts, with viral DNA replication activated, late genes being 
expressed and viral immune evasion functions being deployed. For these reasons, the 72h 
time-point was favoured in later experiments.  
Although a similar pattern of HCMV IE1, UL44 and UL99 gene expression appears relatively 
similar across all V5-tagged viruses and the HCMV 1111 control virus, it cannot be formally 
ruled out that the V5 tag is not having an effect on the growth of the viruses without first 
undertaking growth curve experiments. 
 
4.3 N-glycosylation states of the US12 family members when 
expressed in isolation 
To simplify the analysis, I sought to investigate whether any of the US12 family proteins 
were subject to N-glycosylation using a set of replication-deficient adenovirus (Ad) 
recombinants encoding the ten US12 family members, all with a C-terminal V5 tag 
(produced by Dr S. Seirafian). The fibroblasts used in this study were engineered to 
overexpress the Coxsackie-adenovirus receptor (HF-CARs) to facilitate Ad vector delivery. 
Cell extracts were then treated with EndoH or PNGase F to remove N-glycans before being 
analysed by SDS-PAGE and immunoblot to detect any alteration in mobility of the protein 
resulting from glycosidase treatment.  
The majority of US12 family members expressed from Ad vectors had predominant protein 
species, yet multiple extra protein forms and/or smear-type patterns were also seen (Fig. 
4.4). The only infection for which multiple protein bands or smears could not be detected 
was with Ad US21-V5, which solely presented with its 2 main protein species of 17 and 17.5 
kDa. The apparent molecular weights of the US12 family are presented later in Table 4.5 
(Section 4.5). Ad pUS15-V5 and pUS18-V5 were not detected in the untreated or EndoH 
treated samples, so it was impossible to compare their molecular weights between 
treatment types to determine whether they were N-glycosylated. All other US12 family 
members expressed from Ad vectors showed no reduction in molecular weight of their 
main protein form(s) and were therefore non-N-glycosylated proteins (Fig. 4.4). The only 
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Figure 4.4: The N-glycosylation patterns of V5-tagged US12 family members 
as expressed from an adenovirus expression system. Fibroblasts (HF-CARS) 
were mock infected or infected with replication-deficient adenovirus (Rad) 
1253, or RAds encoding V5 tagged US12 genes an MOI of 10. Samples were 
harvested at 72h.p.i. Proteins were extracted using the whole cell lysate 
method. Samples were either left untreated, or treated with EndoH or 
PNGase F treatment overnight. Samples were immunoblotted and detected 
using an anti-V5 antibody and an HRP secondary antibody. All samples were 
run with anti-actin as a loading control. All samples are representative of 2 
independent experiments. *US14-V5 and US17-V5 RAds had been codon 
optimized and therefore had much higher expression levels 
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differences in molecular weight seen between the treatments was observed in the minor 
protein species of Ad pUS14-V5 and pUS17-V5 at 72 hpi, which do not represent the 
protein as a whole. pUS14-V5 appeared to have 2 minor species which displayed N- 
glycosylation, with a ~37 kDa EndoH sensitive glycoform and a ~17 kDa EndoH resistant 
form (Fig. 4.4). This implied that the 17 kDa protein glycoform had been processed through 
the Golgi, and that the ~37 kDa glycoform had yet to pass through the ER. pUS17-V5 
similarly appeared to have an N-glycosylated low abundance protein species of 24 kDa that 
was sensitive to both EndoH and PNGase F (Fig. 4.4). Both US14-V5 and US17-V5 had 
previously been codon optimised within the Ad vector, which may have affected their 
expression and modifications within this system. This also caused them to have much 
higher expression levels than the other US12 family members so these N-glycosylated 
protein species may have not been detected or present under non-optimised conditions.  
There also remains the possibility that Ad pUS12-V5 could be partially N-glycosylated, as its 
lower ~22 kDa protein form could be scarcely detected in untreated or EndoH conditions, 
but appears to be highly abundant after PNGase F treatment. However, as US12 is not 
predicted to contain any N-glycosylation motifs (Table 4.1), this is improbable. Instead, this 
difference is more likely caused by differential detection due to differential loading or a 
difference in treatment conditions. A similar effect was also seen with Ads pUS13-V5, 
pUS15-V5, pUS18-V5 and pUS20-V5 (Fig. 4.4). Alongside US12, US15, US19 and US21 also 
did not contain any N-glycosylation motifs (Table 4.1). 
Overall, there is minimal evidence for N-glycosylation of these proteins in isolation which 
was unexpected as there are predicted N-glycosylation sites within some US12 family 
members. US13, US16, US18 and US20 were all predicted to contain N-glycosylation motifs, 
yet none of these proteins showed signs of N-glycosylation (Table 4.1, Fig. 4.4). US14 and 
US17 were also predicted to contain N-glycosylation motifs so it was surprising that only 
minor subsets appeared to be N-glycosylated. 
It may be that these N-glycosylation sites are not used, or it may be that expressing the 
proteins in isolation does not lead to the correct processing of these US12 family members. 
Using the adenovirus as an expression system is advantageous due to the ease of 
recombineering and of growing the viruses, but it doesn’t seem to provide reliable results 
for these transmembrane proteins without the context of infection, which is highlighted by 
the differences seen in comparison to the HCMV time-course (Fig. 4.2). 
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4.4 N-glycosylation states of the US12 family members in the context 
of HCMV infection 
To follow up the N-glycosylation results of the US12 family proteins in isolation, I wanted to 
assess whether the US12 family member proteins were N-glycosylated in the context of 
HCMV infection. HCMV Merlin viruses containing the V5-tagged US12 members were used 
to infect fibroblasts (HF-TERTs), with WCLs harvested at 72 hpi. These were either left 
untreated or were treated with EndoH or PNGase F, then detected with an anti-V5 
antibody. HCMV UL141 was known to be N-glycosylated and was ER-localised and 
therefore sensitive to both enzymes so was used as a positive control (Tomasec et al., 
2005). 
Seven out of 10 of the US12 family members appeared not to be N-glycosylated in the 
context of HCMV infection, with only pUS14-V5, pUS17-V5 and pUS20-V5 demonstrating N-
glycosylation (Fig. 4.5). HCMV pUS14-V5 was fully N-glycosylated, with both EndoH and 
PNGase F able to remove the N-glycosylation, causing a reduction in size from ~37 kDa to 
~33 kDa. HCMV pUS17-V5 however was only partially glycosylated, with only the 
predominant protein species of pUS17-V5 having N-glycosylation which could also be 
removed by both EndoH and PNGase F. This reduced the predominant higher molecular 
weight protein species (~26 kDa) to the size of the lower molecular weight species (23 kDa) 
(Fig. 4.5). Similarly, HCMV pUS20-V5 was partially N-glycosylated, although in this case it 
was the minor subset of the protein that was N-glycosylated and this could again be 
removed by both EndoH and PNGase F. This reduced the higher molecular weight protein 
(~23 kDa) of pUS20-V5 to ~19 kDa. All 3 of these proteins were predicted to contain 
functional N-glycosylation sites (Table 4.1). It was also predicted by structural models that 
these sites would be exposed to the lumen of the ER where they would be exposed to the 
glycosylation ‘machinery’ (Fig. 4.1). The data presented here therefore demonstrated that 
3 members of the US12 family were N-glycosylated at 72 hpi when expressed in the context 
of HCMV infection. The fact that the glycosylation was EndoH-sensitive inferred that these 
proteins had immature glycosylation, thus had not transited through the Golgi apparatus.     
All other US12 family members displayed no change in molecular weight (Fig. 4.5), and 
these proteins therefore appeared un-glycosylated. Some of these members did appear to 
have potential N-glycosylation sites however (Table 4.1) although not all of these sites 
were predicted to be utilised or functional, and US13 contained an atypical N-glycosylation 
site only (Section 4.1.1). Therefore, US16 remained the only member that was predicted to  
156 
 
 
Figure 4.5 
157 
 
 
 
 
 
Figure 4.5: The N-glycosylation states of the US12 family proteins. Fibroblasts (HF-
TERTs) were mock infected or infected with HCMV Merlin or HCMVs encoding V5-
tagged US12 gene viruses at an MOI of 10 and collected at 72 hpi. Samples were 
processed using the Whole Cell Lysate (WCL) method and underwent overnight de-
glycosylation with enzymes EndoH and PNGase F. Samples were detected using an 
anti-V5 antibody and an HRP secondary antibody, with anti-actin as a loading control 
and anti-UL141 as a positive control that is known to be N-glycosylated and EndoH 
sensitive. Removal of N-glycosylation can be seen by the reduction in the apparent 
molecular weight of the protein.  
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contain a useable N-glycosylation site that did not show signs of N-glycosylation by 
immunoblot. If the C-termini of US16 is non-cytoplasmic as predicted (Table 4.3), then 
according to the topology, the N-glycosylation site therefore would not be luminal (Figure 
4.1) and therefore could not be glycosylated. For the same reason, only 2 of the 3 
asparagine residues of US20 would be luminal and available for N-glycosylation in this 
orientation. Although no other reductions in molecular weight could be seen in other 
members, there were some slight differences seen between the treatment types, as 
discussed further in Section 4.5. With pUS12-V5, a considerable reduction in protein 
amount could be detected in the PNGase F treated sample, despite relatively consistent 
loading and the protein appearing to remain the same molecular weight as the untreated 
and EndoH treated samples (Fig. 4.5). Similar minor differences were also seen in the 
PNGase F treated sample of pUS13-V5 and pUS21-V5. With pUS13-V5 it was hard to 
distinguish whether there were any changes in band size, as although there seems to be a 
slight difference with the PNGase F treatment sample, there was no reduction in band size 
detectable to suggest N-glycosylation. Slight differences were also detected in the PNGase 
treated samples of pUS17-V5 and pUS18-V5 (fainter) and pUS15-V5 (higher detection) but 
these were likely to be due solely to loading differences. The apparent molecular weights of 
the US12 family are presented later in Table 4.5 (Section 4.5). 
 
4.5 A comparison of US12 family members when expressed in 
isolation and in HCMV expression systems 
All US12 family members could be detected by immunoblotting when expressed from 
HCMV, however not all could be detected when expressed in isolation using the adenovirus 
vector expression system (Section 4.3 and 4.4). This was especially obvious in the 
untreated and EndoH treated samples adenovirus samples of pUS15-V5 and pUS18-V5, 
with Ad pUS20-V5 also demonstrating much weaker detection unless treated with PNGase 
F (Fig. 4.4). The differences seen were likely due to the harshness of the PNGase F 
treatment conditions which may have affected denaturation, or may potentially have 
caused easier access of the antibody to the tag. This also implies that the severe treatment 
conditions associated with PNGase F may be required just to get some of them into 
solution (as they are not detected without this treatment), and this may be due to their 
transmembrane structure. As this happened to a lesser extent in the HCMV samples, this 
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further solidified the importance of examining these proteins within the context of 
infection. 
In both expression systems, US12 family members appear to have 1 or 2 predominant 
protein forms, the molecular weights of which were comparable across expression systems, 
with the greatest size difference seen for the main protein form of pUS12-V5, presenting as 
43 kDa in isolation and 25 kDa in the context of HCMV infection (Table 4.5). Extra bands 
and/or extra ‘smears’ were seen for the majority of US12 family members, especially at 
higher exposure levels (Fig. 3.8, Chapter 3), but expressing them in isolation resulted in 
further protein forms and more prominent smearing patterns by immunoblot (Fig. 4.4, 4.4, 
Table 4.5). These multiple extra protein species were particularly prominent for Ad pUS14-
V5, pUS15-V5 pUS16, pUS17-V5, pUS18 and pUS19 compared to their HCMV counterparts. 
Differences were also noted in the N-glycosylation patterns between the 2 systems, with 
the adenovirus expression system persistently demonstrating less N-glycosylation. 
Primarily, pUS20-V5 was shown to be N-glycosylated exclusively in the context of HCMV 
infection (Fig. 4.5). Although both systems demonstrated that pUS14 and pUS17 were 
partially N-glycosylated, differences were seen in their glycoforms, with more substantial 
protein subsets N-glycosylated in HCMV infection (Fig. 4.4 and 4.4). Differences in N-
glycosylation of HCMV proteins between HCMV and Ad is a common occurrence (Griffin et 
al., 2005). 
The US12 family molecular weights and banding patterns were much more consistent 
across HCMV experiments, however they did vary slightly between immunoblots so 
consensus or average sizes were calculated from across all immunoblot experiments (Table 
4.6). The molecular weights of their main protein forms ranged from 17 to 38 kDa, and 
these were all within 10 kDa of their predicted sizes (Table 4.5). The slight variations seen 
were likely due to the slight differences in the way that the gels ran during immunoblotting, 
as well as the distance between the protein of interest and the size markers which may 
affect measurement accuracy.  
 
4.6 Conclusions 
The differences between the US12 family proteins expressed in isolation and expressed in 
the context of HCMV infection, could be caused by differential post-translational 
modifications such as ubiquitination, or from aberrant migration due to the proteins not 
being fully denatured. One possibility for the additional multiple higher bands observed in  
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Table 4.5: Summary of US12 family member protein sizes in comparison to their 
predicted sizes, their sizes in an adenovirus expression system, and their previous 
published sizes 
Gene Predicted 
size † 
Average protein size 
in HCMV infection* 
Protein size in 
adenovirus 
expression system  
Protein sizes in 
published data 
US12 32.48 kDa 25 kDa ~43 kDa None 
US13 29.46 kDa 21 kDa with smear 
>80 kDa 
Ladder/smear  None 
US14 34.3 kDa 37 kDa Doublet of ~22 and 
32kDa 
None 
US15 29.1 kDa ~23 kDa ~24 and ~40 kDa 
under PNGase 
treatment◊ 
None 
US16 34.69 kDa ~28 kDa ~30 kDa 33 kDa (Bronzini et al., 
2012) 
US17 31.91 kDa ~26 kDa and faint 
band 23 kDa 
~20 kDa, with fainter 
bands seen at ~24, 
39 and 52 kDa 
10 and 80 kDa (Das et 
al., 2006) 
  
US18 30.2 kDa ~22 and 24 kDa Doublet of ~18 and 
~19 kDa under 
PNGase treatment◊ 
36 kDa (Guo) 
US19 26.42 kDa ~19 kDa ~19 kDa, with 
possible higher bands 
32 kDa (Guo) 
US20 28.53 kDa ~19 and 23 kDa ~19, ~22 and 33 kDa 43 and 36 kDa (Guo); 
25 and 30kDa 
(Cavaletto et al., 2015) 
US21 26.93 kDa ~17 and 19 kDa ~17 and 17.5 kDa None 
† Predicted using Protein Molecular Weight prediction software at 
http://www.bioinformatics.org/sms/prot_mw.html 
* A consensus taken from all immunoblots of the US12 family (Table 4.6), and rounded to 
the nearest kDa 
◊ Could not be detected in untreated conditions 
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Table 4.6: Summary of HCMV US12 family member protein sizes across multiple 
immunoblots to determine an average or consensus molecular weight  
Protein Protein sizes◊ 
Figure 3.7 Figure 4.2 Figure 4.5 Figure 5.1† Figure 5.9        
(in virion) 
US12 ~24 kDa ~22 kDa ~27 kDa 28/29 kDa  25/26 kDa in 
virion 
US13 21 kDa and 
smear to 
>80 kDa 
Smear from 
~22 to >160 
kDa 
Smear from 
20 to >160 
kDa 
Smear from 
21/22 to >60 
kDa 
~22 kDa in 
virion (and 
possible smear) 
US14 ~37 kda  ~34 kDa 37/38 kDa 
(32/33 kDa 
de-
glycosylated) 
37/38 kDa ND* 
US15 20 kDa ~26/27 kDa ~22 kDa ~24 kDa  ND* 
US16 28/29 kDa ~31 kDa ~27/28 25/26 kDa 27/28 kDa in 
virion 
US17 ~26 kDa 
and faint 
band a 22 
kDa 
~24/25 kDa 
and faint 
band at 
22/23 kDa 
28/29 kDa 
and ~25kDa 
(~25 kDa de-
glycosylated) 
~24 kDa and 
faint band at 
21/22 kDa 
ND* 
US18 ~22 and 25 
kDa 
~24/25 and 
26/27 kDa 
~20 and 22 
kDa 
~21 and 
23/24 kDa 
19, 20/21 and 
a faint band at 
17 kDa in virion 
US19 ~19 kDa ~18 kDa ~20 kDa 19/20 kDa ~18 kDa in 
virion 
US20 19 and ~24 
kDa 
18/19 and 
22/23 kDa 
18/19 and 
21 kDa 
~20 and 
24/25 kDa 
18/19 and ~22 
kDa, and extra 
higher weight 
bands in the 
virion  
US21 ~16 and 19 
kDa 
~17 and 19 
kDa 
16/17 and 
20 kDa 
16 and 18/19 
kDa 
17/18 and 14 
kDa in virion 
 
◊ Protein sizes were calculated from the middle of the protein band. The extra bands 
detected at higher exposures have not been included as these were not detected or well-
defined under “normal” conditions and were not consistently seen. 
† Extra bands and extra smears/ladders were especially detected with the addition of 
leupeptin (a lysosomal inhibitor), especially for US12, US15 and US20 
* ND= Not detected in the virion. 
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the adenovirus samples could be due to dimerisation or multimerisation of the protein 
which could possibly be present due to inefficient denaturing or due to the strong 
hydrophobic interactions within these proteins. This could be especially possible for Ad 
pUS12-V5 and pUS17-V5 which were detected at regular intervals that could represent 
monomers, dimers and multimers. Ad pUS12-V5 for example, could be seen around 20,40, 
60 and 80 kDa (22, 43, 59 and 78 kDa) under PNGase treatment and Ad pUS17-V5 could be 
seen at around both 20 and 40 (~39) kDa (Fig. 4.4). The dissimilarities observed suggested 
that studying the US12 family within HCMV was much more beneficial and representative 
of infection and it appears that the family are not processed properly when expressed in 
isolation. It is therefore likely that they need other HCMV proteins to be processed 
correctly and possibly also to function, and they may require other US12 family members if 
they form complexes as hypothesised. This could explain why previous studies found little 
function when the proteins were expressed individually. It would be interesting to see 
whether expressing the whole family from an adenovirus vector would alleviate some of 
these problems.  
Of the three US12 family members N-glycosylated in the context of HCMV infection, pUS20 
was the only member previously demonstrated to be partially glycosylated in the HCMV 
strain TR (Cavaletto et al., 2015), with N-glycosylation a novel characteristic for pUS14 and 
pUS17. The removal of N-glycosylation from these 3 proteins by both EndoH and PNGase F 
suggests that all 3 of these proteins had not been processed through the Golgi. The 
significance of this N-glycosylation is discussed further in Section 6.1. For pUS17 and pUS20 
which were only partially N-glycosylated, a proportion of these protein subsets therefore 
remained un-N-glycosylated during infection. One possibility is that their 2 protein species 
are in different sub-compartments, with UL141 previously demonstrated to be 
differentially glycosylated in the virion than it is within the cell (Dan Cochrane, thesis). 
N-glycosylation was the sole cause of the pUS14-V5 increased molecular weight observed 
by immunoblot compared to its predicted size (Table 4.5) and pUS14-V5 was the only US12 
family member whose main protein form appeared at a greater molecular weight than was 
predicted. All other members are likely to have alternative PTMs to account for their 
differences in size. Many of the other US12 family members were instead smaller than 
predicted (Table 4.5) which is generally more unusual. This can be more common for 
membrane proteins however as their hydrophobic residues within transmembrane 
domains can affect detergent binding and folding, which can lead to differential gel 
migration for the same size protein (Rath et al., 2009). The process of running 
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transmembrane proteins by SDS-PAGE could also be the cause of the ‘smears’ seen by 
immunoblot. Smaller-than-predicted molecular weights could also be caused by alternate 
splicing or cleavage for example. 
As N-glycosylation was not the cause of the doublet bands of pUS18-V5 and pUS21-V5, 
alternative post-translational modifications such as phosphorylation, prenylation or 
methylation may be the explanation, else they may have undergone processing such as 
alternative splicing or cleavage. For Merlin US18, a shorter transcript isoform had also been 
identified in which transcription was initiated within the US18 coding sequence and 
translation was predicted to produce an N-terminally truncated version of pUS18 (Stern-
Ginossar et al., 2012). However, this RNA transcript was first detected until 72 hpi, whereas 
our doublet band could be observed from 48 hpi. This truncated 350 bp RNA transcript was 
also predicted to encode a 12.95 kDa product, smaller than the faster migrating species 
detected in this thesis (~20 kDa). Due to the differences in timing and size, it seems less 
likely that this transcript is the cause of the second protein form in pUS18-V5 and more 
likely to be caused by post-translational modifications. 
US12 family member protein sizes were also relatively similar (although again, often 
smaller) to previously published data on US12 family members (Table 4.5). Differences 
seen could be due to the use of different HCMV strains and different cell types along with 
the different methods of detection used. The V5 tag is only predicted to add ~1.4 kDa onto 
the protein’s molecular weight, but other tags used will alter a protein’s molecular weight 
by differing amounts, so the use of alternative epitope tags may also have played a role in 
the differences seen. Despite most US12 family members appearing to be of a similar size 
across different strains, pUS17 was shown to have the biggest difference in size, with 
AD169 pUS17 detected at 10 and 80 kDa (Table 4.5). On the other hand, Merlin pUS17-V5 
in this thesis was detected at ~23 and 26 kDa, which was much closer to the predicted 31.9 
kDa size. Strain differences or post-translational modifications could be the cause of this 
variance and this would need to be investigated further. AD169 pUS17 was previously 
demonstrated to be segmented through the separate detection of its C- and N-termini (Das 
and Pellett, 2007, Das et al., 2006), and an N-terminal tag or antibody would be required to 
establish whether Merlin pUS17 was also segmented or not. N-terminal tags and/or specific 
US12 family member antibodies may be beneficial to help study the US12 family in the 
future, and in confirming the apparent detected size of each US12 family member protein. 
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Each member has been predicted to have 7TM domains, and in order for the N-
glycosylation motif sites to be accessed, the asparagine residues of pUS14, pUS17 and 
pUS20 would need to be in the lumen of the ER. This would require each of their C-termini 
to be lumenal (non-cytoplasmic), in order for the majority of N-glycosylation sites to 
likewise being lumenal, and correspondingly, each US12 family member is generally 
predicted to have non-cytoplasmic C-terminals and cytoplasmic N-terminals (Fig. 4.1, Table 
4.3). The implications of this topology are discussed further in Section 6.1 and 6.3.1. 
Knowing their expression patterns may also aid in determining likely functions of the US12 
family members. Immunoblotting appeared more sensitive and superior for detecting this 
gene family, detecting all 10 family members compared to only 6 by proteomics (Weekes et 
al., 2014). It is not known why the immunoblotting would be more sensitive than 
proteomic mass spectrometry in the case of the US12 family protein detection, but it may 
be due to the hydrophobic nature of the proteins due to the number of transmembrane 
domains, differences in sample processing or the low quantity of US12 family proteins 
expressed in the cell. Of the six US12 family members detected by proteomics, each was 
only detected by 1-3 peptides, and even the more sensitive detection system using the new 
Orbitrap Fusion in the proteomics WCL3 experiment only detected a maximum of 2 
peptides per US12 family protein. This together with the fact that US12 was also the only 
US12 family member detected in all PM and WCL proteomics samples (Weekes et al., 
2014), supports that low abundance could definitely be a contributing factor to the lack of 
detection by proteomics (Weekes et al., 2014). Other factors may include the use of mass 
spectrometry and software databases used to identify the proteins, as deducing chemical 
structures and subsequently protein sequences from mass-to-charge ratios can be a 
challenging computational task (Bruce et al., 2013). There is also the possibility that the V5 
tag could be affecting the stability or turnover rates of the US12 family proteins, and this 
could explain why V5-tagged US12 family proteins were better detected in the 
immunoblots rather than in the proteomics in which un-tagged US12 family proteins were 
detected by mass spectrometry. A differing rate of protein degradation was previously 
demonstrated between tagged and untagged versions of human protein DJ-1, where the N-
terminal Flag-tagged DJ-1 had a reduced rate of degradation compared to the C-terminal 
V5 tagged version or the untagged version, resulting in higher cellular levels (Alvarez-
Castelao et al., 2012). Therefore there is a small chance that the degradation rates of V5-
tagged US12 family members may differ slightly to those in vivo, however the use of tagged 
proteins is unavoidable at present due to the lack of specific US12 family antibodies. 
165 
 
The immunoblot time-course revealed that US12 family members ranged from early Tp2 
proteins (such as pUS20) to late Tp5 proteins (such as pUS17), with all members detected 
by 48 hpi, and the majority of US12 family protein expression peaking around 72 hpi. As 
well as being broadly in agreement with the QTV data, these immunoblot expression 
patterns were also demonstrated to be in accordance with other limited published data 
available on US12 family kinetics (Bronzini et al., 2012, Guo, 1993, Luganini et al., 2017) 
(Table 4.4). pUS20 for example, was designated by immunoblot and QTV to be a Tp2 
protein and this was also consistent with previous findings in which pUS20 was detected 
from 18 hpi until 72 hpi (Guo, 1993) or detected equally from 24 hpi to 96 hpi (Cavaletto et 
al., 2015).  
These immunoblot data have advanced upon previous findings by having an improved 
detection of US12 family members that were previously either not detected, only partially 
detected, or those only detected in unquantified immunofluorescence studies. They have 
also enhanced preceding studies through the use of a more clinically relevant strain. The 
novel insight that the majority of the US12 family members are expressed as Tp3 proteins 
may help to determine at what point during infection they are exerting their function and 
may hint at their potential functions (Discussion 6.1). 
Taking everything into account, the US12 family proteins were demonstrated to have 
incorrect processing outside of the context of HCMV infection, and all further experiments 
were consequently undertaken solely in HCMV. In conclusion, the US12 family findings 
corroborate with the limited data currently known, and novel characteristics have been 
revealed, increasing the knowledge on the basic fundamentals of the US12 family in 
regards to their expression kinetics, protein sizes and N-glycosylation states. 
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An appreciation of a HCMV protein’s localisation within a cell can inform on its role or 
function, with IE1’s transient association with punctate nuclear domains previously helping 
to inform on its role in disrupting nuclear bodies (Wilkinson et al., 1998, Kelly et al., 1995). 
Nuclear localisation can often indicate regulatory or structural roles, with the regulatory 
protein IE2 and the structural major capsid protein (pUL86) also found within the nucleus 
(Sanchez et al., 1998). Tightly associated tegument proteins are most likely added to the 
capsid in the nucleus, whereas outer tegument proteins are often added later in the virion 
assembly compartment (vAC) (Sanchez et al., 2000b). The tegument protein pp65 (UL83) 
accumulates along the nuclear periphery, and was found to have a direct interaction with 
nuclear lamins, linking its location to its function (Sanchez et al., 1998). Therefore, tracking 
the location of specific US12 family members within HCMV infected cells was undertaken 
for the primary goal of characterising their expression, but with the further aspiration that 
it might provide further insights into their roles, mechanisms-of-action and interactions 
within the cell. Functional studies had revealed that the US12 family regulated the cell 
surface expression of a broad range of plasma membrane proteins involved in different 
aspects of the immune response, including the regulation of cell adhesion molecules, NK 
cell ligands, cytokines and cytokine receptors (Fielding et al., 2017). Moreover, it was 
established that many of these immune ligands were targeted by multiple members of the 
US12 family. This was most notable for US18 and US20 which acted in co-operation to 
target the NKG2D ligand MICA and the NKp30 ligand B7-H6, and both further targeted an 
additional set of proteins (Fielding et al., 2014, Fielding et al., 2017). This lead to the 
hypothesis that multiple US12 family members were forming and acting as complexes. In 
that context, a major objective was to determine whether multiple US12 family members 
trafficked to the same locations.  
The localisations of US12 family members were investigated within the context of HCMV 
infection, as US12 family members had demonstrated not to be processed correctly in 
isolation (Chapter 4), and due to the virus re-organising the host organelles during infection 
(Section 1.4.1.6).  
5.1 Rescue of US12 family member expression by the inhibitor 
leupeptin 
Proteomic studies showed that many of the cellular targets of the US12 family could be 
rescued by the addition of leupeptin (Fielding et al., 2017), an inhibitor of serine and thiol 
proteases that suppresses lysosomal degradation by 80-85% (Grinde and Seglen, 1980). 
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This observation led us to believe that the US12 family may use lysosomal degradation as a 
mechanism to degrade their target proteins. I sought to investigate whether the US12 
family were similarly degraded themselves and whether they could likewise be rescued by 
the inhibitor leupeptin. To this end, fibroblasts were infected with the HCMV library of V5-
tagged US12 family members, with the leupeptin added before harvesting the cells. MICA 
was used as a positive control protein as it had previously been shown to be targeted for 
lysosomal degradation and rescued by leupeptin addition (Fielding et al., 2014, Fielding et 
al., 2017). 
The changes in expression of US12 family member proteins upon the addition of leupeptin 
could be classified into 3 distinct groups. Firstly, a subset of US12 family members (pUS16-
V5, pUS19-V5 and pUS21-V5) appeared to be unaffected, with their expression remaining 
consistent with or without leupeptin addition and thus appeared not to be degraded in 
lysosomes (Fig. 5.1). Secondly, there were US12 family members that showed a substantial 
increase in abundance, including an increase in their dominant protein form(s); as 
demonstrated by pUS12-V5, pUS13-V5, pUS15-V5, pUS18-V5 and gpUS20-V5 (Fig. 5.1). This 
increase was most pronounced with pUS12-V5 (~15-fold) or could be more subtle, such as 
with pUS18-V5 (~2-fold), as calculated by densitometry. Generally an increase in the 
abundance of the main form of the protein was observed alongside increases in higher 
molecular weight bands, with pUS18-V5 being the exception. For example, leupeptin 
treatment not only resulted in an increase in abundance of the main protein species of 
pUS15-V5 (~24 kDa), but also revealed a ladder/smear of multiple higher molecular weight 
species ranging up to nearly 60 kDa. The final subset of proteins did not appear to have an 
increase in expression levels of the main protein species, however an increase was 
observed in some of the higher molecular weight forms only. This was observed with 
gpUS14-V5 and gpUS17-V5 (Fig. 5.1), although this was more evident at higher exposure 
levels (Fig. 5.2). For gpUS14-V5, the main form of the protein was detected at 37/38 kDa 
and remained unchanged but an increase occurred in the bands/smear that ranged 
between 40 and 80 kDa (Fig. 5.1 & 5.2). Similarly, the main doublet of gpUS17-V5 remained 
unaffected by leupeptin, but an increase occurred in the smear at 28-35 kDa (Fig. 5.1 & 
5.2). For both of these US12 family members, multiple additional protein forms were also 
revealed at these longer exposure times, however these also remained at equal levels of 
expression with and without leupeptin treatment (Fig. 5.2). 
The three US12 family members whose expression were not modified by leupeptin (pUS16-
V5, pUS19-V5 and pUS21-V5), were correspondingly not predicted to contain the  
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Figure 5.1: US12 family members are degraded and are rescued by the addition of 
the lysosomal inhibitor leupeptin. Fibroblasts were mock infected or infected with 
HCMV Merlin, or HCMVs encoding V5 tagged US12 genes at an MOI of 10. Samples 
were left untreated or had leupeptin (a lysosomal inhibitor) added 18 hours prior to 
harvesting at 72 hpi. Proteins were extracted and US12 family members detected 
using an anti-V5 antibody and an HRP secondary antibody. All samples were run 
with anti-actin used as a loading control & MICA as a positive control.  
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Figure 5.2: Increase in protein expression of higher weight molecular bands at higher 
exposure levels of pUS14-V5 and pUS17-V5. Fibroblasts were mock infected or 
infected with HCMV Merlin, or HCMVs encoding V5 tagged US12 genes at an MOI of 
10. Samples were left untreated or had leupeptin (a lysosomal inhibitor) added 18 
hours prior to harvesting at 72h.p.i. Proteins were extracted and detected using an 
anti-V5 antibody and an HRP secondary antibody. All samples were run with anti-actin 
used as a loading control. Areas of protein bands of increased expression highlighted 
by red arrows, and the ‘main’ bands seen at normal exposure levels indicate by blue 
arrows. 
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TRG_LysEnd_APsAcLL_1 lysosomal targeting sequences by Eukaryotic Linear motif (ELM) 
software as previously described (Section 4.1.2, Table 4.2). Of the 5 family members shown 
to have their dominant protein forms regulated by leupeptin, US12, US13, US18 and US20 
were all predicted to contain 1 or 2 lysosomal targeting sites from their sequence which 
showed a good correlation between the predicted and experimental results (Section 4.1.2). 
The only member for which an increase in protein abundance was detected without the 
identification of the TRG_LysEnd_APsAcLL_1 motif was pUS15, along with the higher 
molecular weight forms of gpUS17 (Section 4.1.2). 
These results demonstrated that leupeptin inhibited the degradation of the main protein 
form(s) of 5 family members and rescued higher molecular weight forms of 6 members. 
This result is consistent with the observation that the US12 family is involved in targeting 
proteins for proteolysis and indicates that these viral proteins may be co-degraded 
alongside their targets, potentially in lysosomes.  
 
5.2 Immunofluorescence co-localisation of US12 family members with 
lysosomes 
Since the expression of six US12 family members could be rescued by leupeptin, it was a 
natural next step to investigate whether they co-localised with lysosomes. Fibroblasts 
infected with V5-tagged US12 family members were incubated with or without leupeptin 
for 18 h prior to cells being stained with LysoTracker, a red fluorescent dye which labels 
lysosomes. Cells were then fixed, permeabilised and stained with anti-V5 antibodies to 
detect the individual US12 family members.  
The lysosomes were first investigated for their localisation within the cell in comparison to 
the virion assembly compartment (vAC), which is found adjacent to the nucleus and 
defined by pp28 staining (Section 1.4.1.6). In HCMV infected cells the lysosomes were 
organised in a ring/zone around the vAC with their association demonstrated in Figure 5.3. 
In uninfected cells, the lysosomes instead appeared to be distributed throughout the 
cytoplasm of the cells (Fig. 5.4). 
No member of the US12 family co-localises specifically with the lysosomes even in the 
presence of leupeptin, as assessed by overlap with the LysoTracker dye (Fig. 5.4). Although 
the US12 family proteins did not generally exhibit evidence of specific co-localisation with 
the lysosomes, they were often found in the same region of the cell as the lysosomes,  
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Figure 5.3: The association of the vAC marker pp28 with lysosomes. In 
relation to Figure 5.4, fibroblasts (HF-TERTs) were infected with HCMV Merlin at 
MOI of 10. Samples were left untreated and lysosomes were stained with 
LysoTracker (red) at 72 h.p.i. and then fixed. Cells were then co-stained with the 
anti-pp28 antibody (mouse) and anti-mouse Alexa-Fluor AF488 (green), with the 
nucleus identified with the nuclear stain DAPI. Images were taken using a Zeiss 
microscope (Axio Observer Z1 with ApoTome) using optional sectioning. 
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Figure 5.4: The US12 family member proteins are not generally associated with 
lysosomes. Fibroblasts (HF-TERTs) were mock infected or infected with HCMV Merlin or 
HCMVs encoding V5-tagged US12 gene viruses at MOI of 10. Samples were either left 
untreated or had leupeptin (a lysosomal inhibitor) added 18 hours prior to harvesting. 
Lysosomes were stained with LysoTracker (red) at 72 h.p.i. and then fixed. Cells were then 
co-stained with the anti-V5 antibody (mouse) and anti-mouse Alexa-Fluor AF488 (green), 
with the nucleus identified with the nuclear stain DAPI. Images were taken using a Zeiss 
microscope (Axio Observer Z1 with ApoTome) using optional sectioning. Images 
representative of 2 independent experiments. 
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which occurred with pUS12-V5, pUS13-V5, gpUS14-V5, pUS16-V5, gpUS17-V5, pUS18-V5 
and pUS21-V5 (Fig. 5.4). Limited evidence of selective co-localisation with lysosomes 
(yellow fluorescence staining) was discernible for some family members including pUS13-
V5, pUS15-V5 and gpUS20-V5 upon the addition of leupeptin as demonstrated in Figure 
5.5. This co-localisation correlated to these 3 members being rescued by the addition of 
leupeptin by immunoblot (Fig. 5.1). Overall, these data suggested that the US12 family do 
not commonly co-localise with lysosomes in vitro. The addition of leupeptin does not 
appear to significantly change the US12 family’s localisations within the cell, in which they 
are detected in juxta-nuclear cytoplasmic inclusions and/or sub-cellular punctate structure 
locations that required further investigation.  
 
5.3 Immunofluorescence co-localisation of US12 family members with 
the endoplasmic reticulum 
While US12 family members did not appear to typically traffic to lysosomes, a number were 
detected in defined sub-cellular punctate structures within the cell. To investigate whether 
these structures were the endoplasmic reticulum (ER), the US12 family members were co-
stained with the ER marker calnexin at 72 hpi in fibroblasts. Although calnexin is an ER 
protein, it should be noted that HCMV re-models host cell organelles during productive 
infection to promote virus replication and maturation, best illustrated by the formation of 
the vAC which includes the rearrangement of organelles such as the Golgi, TGN and early 
endosomes (Section 1.4.1.6). The ER is thus not the same in infected cells as it is prior to 
infection as “ER-derived” membranous structures are being hijacked by the virus. 
The sub-cellular punctate structures (SPS) described above was identified as the ER for 
pUS12-V5, pUS13-V5, gpUS14-V5, pUS15-V5, pUS16-V5, gpUS17-V5, gpUS20-V5 and 
pUS21-V5 (Fig 5.2) (Fig. 5.6). pUS18-V5 appeared mostly cytoplasmic with only a very faint 
concentration with the ER marker calnexin. Correspondingly, all of these US12 family 
members were identified as having the predicted ER retention motif ‘TRG_ER_diArg_1’, 
except for US18 and US21 as predicted by the Eukaryotic Linear Motif (ELM) software as 
described in Section 4.1.2 (Table 4.2). US21 however was predicted to possess an XXRR-like 
ER retention motif by Psort II software (Section 4.1.2). Therefore pUS18-V5 was the only 
member that appeared to faintly co-localise with the ER despite not containing an ER motif, 
and pUS19-V5 was the only member predicted to contain an ER retention motif that was 
not localised to the ER. 
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Figure 5.5 Rare examples in which US12 family member proteins show some association 
with lysosomes. Extra images in relation to Figure 5.2, showing some partial co-localization 
with lysosomes in the presence of the lysosomal inhibitor leupeptin for US13-V5, US15-V5 
and US20-V5. Fibroblasts (HF-TERTs) were mock infected or infected with HCMV Merlin or 
HCMVs encoding V5-tagged US12 gene viruses at MOI of 10. Lysosomes were stained with 
LysoTracker (red) at 72 h.p.i. and then fixed. Cells were then co-stained with the anti-V5 
antibody (mouse) and anti-mouse Alexa-Fluor AF488 (green), with the nucleus identified 
with the nuclear stain DAPI. Images were taken using a Zeiss microscope (Axio Observer Z1 
with ApoTome) using optional sectioning. 
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Figure 5.6: Co-localisation of V5-tagged US12 family members with the ER marker 
Calnexin. Fibroblasts were mock infected or infected with HCMV Merlin or HCMVs 
encoding V5-tagged US12 gene viruses at an MOI of 10. Cells were fixed at 72 h.p.i with 4% 
paraformaldehyde. Samples were stained using anti-V5 (rabbit) and anti-Calnexin (mouse) 
antibodies, with the secondary antibodies anti-mouse AlexaFlour (AF)488 (green) and anti-
rabbit AF594 (red), and the nuclear stain DAPI (blue). 
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The majority of the US12 family members that had ER co-localisation, were also associated 
with a juxta-nuclear cytoplasmic inclusion (Fig. 5.6). This ‘dual localisation’ was 
demonstrated for pUS12-V5, pUS13-V5, gpUS14-V5, pUS15-V5, pUS16-V5, gpUS20-V5 and 
pUS21-V5. In general, the ER co-localisation of these proteins appeared more 
concentrated, especially for pUS21-V5 in which faint cytoplasmic inclusion localisation 
could be observed only in some cells (Fig. 5.6). gpUS17-V5 on the other hand, co-localised 
with the ER only, and pUS19-V5 was unique in that it did not localise to the ER but instead 
exclusively formed around the periphery of the cytoplasmic inclusion.   
 
5.4 Immunofluorescence co-localisation of US12 family members with 
the virion assembly compartment (vAC) 
The juxta-nuclear cytoplasmic inclusion location of multiple US12 family members that was 
observed alongside their ER co-localisations, was believed to correlate to the virion 
assembly compartment (vAC). The vAC forms adjacent to the nucleus, causing the kidney 
shaped nucleus that is characteristic of late HCMV infection, with the vAC forming next to 
its concave surface (Section 1.4.1.6) (Alwine, 2012, Das et al., 2007). In order to determine 
whether US12 family members associated with the vAC, fibroblasts were infected with the 
panel of V5-tagged US12 family member HCMV recombinants for 72 hours and the cells 
stained with an anti-V5 antibody, and an anti-pp28 (ppUL99) antibody as a marker for the 
vAC (Sanchez et al., 2000b).  
The majority of US12 family members were indeed found in association with the vAC (Fig. 
5.7) although often adjacent to, rather than overlapping, the pp28 marker. This could be 
partly due to a lower level of protein detection seen for most US12 family members in this 
location, or their co-localisation with an alternative vAC protein. US16-V5 most commonly 
showed distinct co-localisation with pp28 and was associated with the outer portion of the 
vAC, and pUS19-V5 was unique in that it ringed around the periphery of the vAC only (Fig. 
5.7). gpUS17-V5 was the only member that showed no association with the vAC, and 
pUS21-V5 only showed occasional faint association, and these members were otherwise 
observed at the sub-cellular punctate structure (SPS) location that was previously revealed 
to be the ER (Section 5.3). Again, some US12 family members demonstrated ‘dual 
localisation’ with both the vAC and SPS defined as the ER. pUS12-V5, gpUS14-V5 and 
gpUS20-V5 characteristically had dual localisation in the majority of cells examined, 
whereas pUS13-V5, pUS15-V5 and pUS21-V5 demonstrated occasional dual localisation in a  
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Figure 5.7: Some US12 family member proteins are associated with the virion assembly 
compartment (vAC). Fibroblasts (HF-TERTs) were mock infected or infected with HCMV 
Merlin or HCMVs encoding V5-tagged US12 gene viruses at MOI of 10. Cells were fixed at 
72 h.p.i. and stained for the V5-tagged proteins (anti-V5 rabbit antibodies) and the vAC 
(anti-pp28 mouse); with Alexa-Fluor AF488 (green) and AF594 (red) as secondary 
antibodies. The nucleus was identified with the nuclear stain DAPI. Images were taken 
using a Zeiss microscope (Axio Observer Z1 with ApoTome) using optional sectioning. 
Images representative of at least 2 or 3 independent experiments. 
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subset of cells only. These members generally had less defined vAC associations, and 
appeared more concentrated at the SPS/ER (Fig. 5.7). pUS18-V5 appeared to be 
disseminated throughout the cytoplasm, and was slightly more concentrated in the vAC of 
some cells, and occasionally faintly detected at the SPS location. 
Although not readily quantifiable by immunofluorescence, US12 family members appeared 
to be expressed at varying levels of abundance, which corresponded with the findings by 
immunoblot. Similarly, pUS18-V5 was consistently the hardest member to detect, even 
when rescued with leupeptin, implying that it perhaps had lower expression levels than the 
other US12 family members. pUS19-V5 on the other hand was consistently detectable with 
high efficiency, possibly due to its concentrated localisation around the periphery of the 
vAC. HCMV control (1111) was used as a control for non-specific staining or potential 
interactions with HCMV Fc receptors. 
In total, 5 members (pUS12, gpUS14, pUS16, pUS19 and gpUS20) showed strong co-
localisation with the vAC, 3 members showed weak or occasional vAC co-localisation 
(pUS13, pUS15, pUS18 and pUS21-V5), and gpUS17 showed no association with the vAC 
(Fig. 5.7).   
 
5.5 Presence of US12 family members in the HCMV virion  
Proteins must traffic to the vAC in order to be packaged into virions (Section 1.4.1.6). 
pUS12, pUS13, gpUS14, pUS18, gpUS20 had previously been detected in Merlin virions by 
proteomics (Murrell, 2014) and these members also exhibited at least partial association 
with the vAC at 72 hpi (Section 5.4). pUS15-V5, pUS16-V5, pUS19-V5 and pUS21-V5 also 
showed weak or occasional association with the vAC so we wanted to see whether this was 
consistent with these members also being packaged into virions. In order to test this 
theory, fibroblasts were infected with the panel of V5-tagged US12 family HCMV viruses 
and virions were collected by removing the supernatant after the monolayer became 100% 
infected. In order to reduce sample volume, the viral supernatants were first pumped 
through vivaflow cassettes to concentrate each sample down to 10-15 ml, and 
subsequently loaded onto vivaspin columns and centrifuged to reduce the volume further 
(Section 2.7). Both the cassettes and the columns functioned by utilising membranes that 
allowed water and small molecules to exit, retaining larger macromolecular structures such 
as HCMV virion particles. Once the sample volume had been reduced to 5-7 ml, they were 
loaded onto sodium (Na)-tartrate gradients (Fig. 5.8 A), 2 tubes per viral sample.  
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Figure 5.8: Purifying virions using a sodium-tartrate gradient. Virions were purified from 
viral supernatant collected from fibroblasts (HF-TERTs) infected with HCMV Merlin or 
HCMVs encoding V5-tagged gene viruses. Supernatants were concentrated using vivaflow 
cassettes and vivaspin columns down to a volume of 5-7ml. A) Sodium tartrate gradients 
were made by the mixing of ‘heavy’ (green) and ‘light’ (blue) gradient buffers, and poured 
from the top with the use of a gradient maker and a peristaltic pump. Concentrated viral 
supernatant was loaded onto the gradient, 2 per virus, and centrifuged to separate out the 
viral components. B) An example of the separation seen when using a V5-tagged US12 
family member virus on the sodium-tartrate gradient. The virion band forms below the 
viral supernatant but above the aggregated cellular debris. This band was often faint but 
could be more easily visualised using laser light. A syringe and needle were used to extract 
the entire virion layer and after further washing and pelleting steps, the virions could be 
immunoblotted. 
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Ultracentrifugation was then undertaken, resulting in the separation of viral and cellular 
particles over the gradient, with larger molecular weight particles travelling further through 
the gradient. This separated out the virion particles and cellular debris from the viral 
supernatant, with the virions forming a distinct band in the gradient (Fig. 5.8 B). The virion 
layer was extracted using a needle and syringe, and the gradient washed off by adding 
NaPh buffer, and the sample ultracentrifuged to pellet the virions (Section 2.7). This pellet 
was re-suspended in NuPage buffer (diluted in NaPh buffer), and run by SDS-PAGE and 
immunoblotted. The V5 tagged US12 family members were detected using the V5 tag 
antibody and were re-probed to measure the level of cross contamination with proteins 
from the infected cells and supernatant. Calnexin is an abundant cellular protein and along 
with the virus encoded protein IE1 should not be packaged into the virions, with gB acting 
as a positive control. Virions were also purified in parallel from characterised HCMV strain 
Merlin recombinants in which UL148 and UL4 each had C-terminal V5 epitope tags. 
gpUL148 is a virion glycoprotein that has recently been shown to encode an immunevasin 
(Murrell, 2014, Wang et al., 2018), and although gpUL4 was historically designated as a 
virion protein (Chang et al., 1989), more recent studies from our laboratory have revealed 
that gpUL4 is secreted from infected cells and is not a virion component (Varnum et al., 
2004, Murrell, 2014, Seirafian, 2012). As a high abundance secreted glycoprotein, gpUL4 
was considered to be the most sensitive control to test for virion contamination, with any 
proteins of lower or equal expression indicated as unlikely to be in the virion. 
US12 family members that were detected in HCMV purified virions included pUS12-V5, 
pUS13-V5, pUS16-V5, pUS18-V5, pUS19-V5, gpUS20-V5, and pUS21-V5 (Fig 5.9). These 
were split into 2 subsets depending on the level of detection. pUS13-V5 and pUS21-V5 
were detected at a relatively low abundance in the virion, with pUS16-V5 only just 
detectable and was detected barely above the expression levels of the pUL4-V5 negative 
control. Therefore it could not be confirmed whether pUS16-V5 was a true virion protein or 
was present due to cellular contamination. Taking into account the lower loading of pUS21-
V5 as indicated by gB levels, pUS21-V5 may actually be in the virion in a higher abundance 
than initially perceived (Fig. 5.9 A and B). 
The remaining subset of proteins (pUS12-V5, pUS18-V5, pUS19-V5 and gpUS20-V5) were 
detected as higher abundance virion proteins, with pUS18-V5, pUS19-V5 and gpUS20-V5 
consistently detected in relatively large quantities (Fig. 5.9). The comparative expression 
levels of pUS18-V5, pUS19-V5 and gpUS20-V5 correlated with previous immunoblots,  
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Figure 5.9: The presence of the US12 family members in the virion. HF-TERTs in a cell 
factory were infected with each of the V5-tagged HCMV viruses and 140ml of supernatant 
was collected ~48hrs after the monolayer was 100% infected. In batches, these were then 
concentrated using vivaflow cassettes and vivaspin columns and run onto sodium-tartrate 
gradients and the virion layer extracted (Fig. 5.4), washed and pelleted before 
immunoblotting. The V5 tagged US12 family members were detected using the V5 tag 
antibody (mouse) and anti-mouse HRP antibody. gB was used as a loading control, IE1 as a 
negative control and Calnexin as a cellular contamination control. UL4-V5 was used as a 
‘negative’ control due to being a protein suggested not to be in the virion, and UL148-V5 is 
a known virion protein used as a positive control. A) All 10 V5-tagged US12 family member 
viruses alongside UL4-V5 and 1111 virions, with UL148-V5 virions run on a separate gel. B) 
Samples from A re-run on a new gel to more clearly identify protein bands of pUS18-V5 
and pUS21-V5. C) Lower exposure image of US20-V5 from A. All samples (except for US16-
V5) are representative of 1 independent experiment run on 3 separate blots. 
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where gpUS20-V5 was the highest expressed and pUS18-V5 was the lowest expressed of 
the 3 proteins (Section 3.4). pUS12-V5 virion expression levels appear to be higher than 
those of pUS13-V5, although a repeat experiment indicated that they were expressed at 
more equal levels (data not shown).  
Most US12 family members on the virion displayed the same number and same molecular 
weight of protein bands seen in previous immunoblots (Chapters 3 and 4) however the 
smear/ladder pattern of pUS13-V5 was less obvious in the virion preparation, although a 
faint detection of a smear could still be seen at ~35-55 kDa. This meant that the reduced 
detection of the smear was likely due to the lower levels of pUS13-V5 expression seen 
instead of being due to differential post-translational modifications in the virion. Virion 
pUS18-V5 was more defined and more readily detected than pUS18-V5 in previous whole 
cell lysate immunoblots, and an additional faint protein species could be seen at ~18 kDa, 
situated below the standard doublet band usually detected (visualised here at ~19 and 20 
kDa) (Fig. 5.9 A and B). This protein species may have been present in previous 
immunoblots but not detected due to the lower level of expression of this third protein 
species compared to the doublet, especially considering that WCL pUS18-V5 generally had 
relatively low expression levels. On the other hand, it is also possible that the virion pUS18-
V5 is differentially modified to the cellular pUS18-V5, as previously demonstrated by 
gpUL141, which presented with an additional protein band in the virion (Cochrane, 2009).  
It also appeared that virion pUS21-V5 contained a different number of protein forms to 
previous WCL immunoblots, with only 1 band appearing to be detected instead of the 
characteristic doublet. However, upon re-running the sample (Fig. 5.9 B), both protein 
forms were clearly visible and there was therefore no difference between the WCL and 
virion pUS21-V5. Thus, all US12 family members detected (except potentially pUS18-V5) 
appeared to be the same size and have the same number of protein species whether found 
on the virion or in the cell. 
The detection of pUS12, pUS13, pUS18-V5 and gpUS20 as virion proteins (Fig. 5.9) supports 
the previous detection of all of these members in the virion by virion proteomics (Murrell, 
2014)(Table 5.1). The proteomic and immunoblot methods designated pUS13 as a ‘low-
confidence’ or ‘low abundance’ virion protein, and designated pUS12 and gpUS20 as ‘high-
confidence’ or ‘high abundance’ virion proteins respectively. Neither method detected 
pUS15 or gpUS17, with gpUS17 also not detected in the AD169 virion (Gurczynski et al., 
2014); and gpUS17 is thus thought not to be present in HCMV virions. pUS19-V5 and  
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Table 5.1: Detection of US12 family members in the vAC and their presence in virions  
Protein vAC 
localisation 
(Fig 5.7) 
In the virion by 
immunoblot? (Fig 
5.9) 
Merlin Virion 
proteomics * 
Published virion 
data 
pUS12 Yes Yes High confidence 
(7/8 samples) 
 
pUS13 Yes, 
occasional 
Yes, low 
abundance 
Low confidence 
(3/8 samples) 
 
gpUS14 Yes Not detected High confidence 
(8/8 samples) 
 
pUS15 Yes, 
occasional 
Not detected Not detected 
 
pUS16 Yes, 
peripheral 
Yes, low 
abundance, 
possible 
contamination 
Not detected pUS16 not 
detected in TR 
virions (Bronzini et 
al., 2012).  
gpUS17 No Not detected Not detected pUS17 not 
detected in AD169 
virions (Gurczynski, 
Das, & Pellett, 
2014).  
pUS18 Yes, 
occasional 
but faint 
Yes, high 
abundance 
Low confidence 
(1/8 samples) 
 
pUS19 Yes, rings 
around the 
vAC 
Yes, high 
abundance 
Not detected 
 
gpUS20 Yes Yes high 
abundance 
High confidence 
(6/8 samples) 
 
pUS21 Yes, 
occasional 
Yes, low 
abundance 
Not detected 
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pUS21-V5 were only detected in the virion by immunoblotting and this further supports the 
observation that immunoblotting is more sensitive than proteomics in detecting US12 
family members (Chapter 3). gpUS14-V5 was the only member that was detected by 
proteomics that was not verified by immunoblot as being present on the virion. It is 
possible that modifications to this protein may have obscured the V5 tag from detection. 
 
5.6 Comparison of US12 family localisations across multiple 
experiments 
The intracellular distribution of US12 family members were generally very consistent within 
and between experiments (Table 5.2). However, there was an observed variation of the 
distribution of some US12 family members across some cells and experiments. For 
example, pUS13-V5 and pUS15-V5 co-localised with both the ER and vAC markers in both in 
the lysosome and ER tracking experiments (Fig. 5.4 and 5.6), but in the vAC tracking 
experiments, they localised mainly to the ER/SPS location, with their vAC localisations less 
readily observable (Fig. 5.7). A similar observation had previously been observed with 
AD169 pUS14 which was described as being distributed in a uniform granular manner 
throughout the cytoplasm, concentrating in the AC in some cells only (Das & Pellett, 2007). 
It seems likely that this 72 hpi time-point is capturing a translocation of these US12 family 
members between the vAC and ER, causing the slight variations in their observed 
distributions. Multiple time-points would help to further validate this theory and identify 
which direction the proteins are travelling in. 
The intracellular distribution of US12 family members described above correlates well with 
the members identified in the Merlin virion, and with previous descriptions in the 
literature, particularly with studies using the low passage HCMV strain TR (Cavaletto et al., 
2015) (Table 5.1). Initial studies have suggested that pUS19-V5 may partially co-localise 
with TGN46, an organelle marker for the trans-Golgi network, although further studies are 
required (Figure 5.10). It was anticipated that US12 family members may co-localise with 
some of their target proteins, and experiments were set up to attempt to visualise the 
localisations of target proteins including MICA (1:400 anti-MICA/B BAM01 mouse antibody, 
Bamomab), B7-H6 (1:200 non-commercial anti-B7-H6 CH31 monoclonal antibody) and 
PTPRM (1:50 anti-PTPRM 2C10 mouse antibody, Santa Cruz). However, these proteins 
could not be detected at observable levels within these initial studies, or the proteins 
appeared not to have a specifically defined location within the cell (data not shown).  
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Table 5.2: Summary of US12 family localisations from co-localisation studies with 
lysosomes, the virion assembly compartment (vAC) and the endoplasmic reticulum (ER) 
Protein Lysosome co-
localisation? (Fig 
5.4) 
ER co-
localisation? (Fig 
5.6) 
VAC co-
localisation? (Fig 
5.7) 
Summary 
pUS12 No, seen at JCI† 
and SPS* 
Yes, ER plus JCI† Yes, vAC plus faint 
SPS* 
ER and vAC 
localisation 
pUS13 No, seen at JCI† 
and SPS* 
Yes, ER plus JCI† Yes, faint vAC plus 
SPS* 
ER and vAC 
localisation 
gpUS14 No, seen at JCI† 
and SPS* 
Yes, ER plus JCI† Yes, vAC plus SPS* ER and VAC 
localisation 
pUS15 No, seen at JCI† 
and SPS* 
Yes, ER plus JCI† Occasional vAC, 
plus SPS* 
ER and occasional 
vAC localisation 
pUS16 No, but partial 
crossover due to 
JCI† location 
Yes ER plus JCI† Yes, outer portion 
of vAC 
Outer portion of 
vAC and 
occasional ER 
localisation 
gpUS17 No, seen at SPS* 
and faint at JCI† 
Yes, ER No, seen at SPS* ER localisation 
pUS18 No, seen 
cytoplasmic 
(faint) 
Possible faint ER 
plus JCI†, mainly 
cytoplasmic 
Yes, faint vAC but 
mainly 
cytoplasmic 
Cytoplasmic 
dispersive 
localisation, 
occasional 
concentration in 
vAC and ER 
pUS19 No, seen at a JCI†  No, seen to ring 
around the JCI† 
Yes, rings around 
the vAC 
Rings around the 
vAC periphery 
gpUS20 No, seen at JCI† 
(faint) and SPS* 
Yes, ER plus JCI† Yes, faint vAC plus 
SPS* 
ER and faint vAC 
localisation 
pUS21 No, seen at SPS* 
and occasional 
faint JCI† 
Yes, ER plus faint 
JCI† 
Occasional vAC, 
plus SPS* 
ER and faint 
occasional vAC 
localisation 
 
* SPS= Sub-cellular punctate structure location (separately determined to be the 
ER) 
† JCI= Juxta-nuclear cytoplasmic inclusion location (separately determined to be 
the vAC) 
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Figure 5.10: The association of US19-V5 with trans-Golgi network marker 
TGN46. Fibroblasts (HF-TERTs) were infected with HCMV Merlin at MOI of 10. 
Samples were left untreated, fixed at 72 hpi and stained with an anti-V5 antibody 
(mouse) and anti-mouse Alexa-Fluor AF594 (red) and co-stained with an anti-
TGN46 antibody (rabbit) and anti-rabbit AF488 (green), with the nucleus identified 
with the nuclear stain DAPI. Images were taken using a Zeiss microscope (Axio 
Observer Z1 with ApoTome) using optional sectioning. Image is representative of 
one independent experiment. 
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Figure 5.11: The localisation of US12 family target protein MPZL1. Fibroblasts 
(HF-TERTs) were infected with HCMV Merlin at MOI of 10. Samples were left 
untreated and lysosomes were stained with LysoTracker (red) at 72 hpi and 
then fixed. Cells were then co-stained with the anti-MPZL1 antibody (rabbit) 
and anti-mouse Alexa-Fluor AF488 (green), with the nucleus identified with the 
nuclear stain DAPI. Images were taken using a Zeiss microscope (Axio Observer 
Z1 with ApoTome) using optional sectioning. 
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MPZL1 however was detectable (1:50 anti-MPZL1 H99 rabbit antibody, Santa Cruz) and 
appeared to concentrate in the vicinity of the vAC, inside the ring of lysosomes, where it 
had a granular appearance (Figure 5.11). Future studies could therefore assess for co-
localisation with US12 family members that have been implicated as having MPZL1 as a 
target protein (Fielding et al., 2017). 
5.7 Conclusions 
The majority of the US12 family co-localise to some extent in both the ER and the vAC at 72 
hpi, with the exception of pUS19-V5 which solely co-localises to the periphery of the vAC, 
and gpUS17-V5 with solely co-localises to the ER (Table 5.2). These findings broadly 
correlate to the prediction of ER retention motifs in most US12 family members (Section 
4.1.2, Table 4.2) although other methods of trafficking to the ER are also possible (Section 
6.3.1). This study provides the first description of the intracellular localisation of pUS12-V5, 
pUS13-V5, pUS15-V5, pUS19-V5 and pUS21-V5 within HCMV infected cells. Moreover, the 
association of pUS16-V5 and gpUS20-V5 with the ER and vAC respectively had not 
previously been demonstrated. These studies also provide evidence that many US12 family 
members traffic to similar locations within the cell, which would be required if US12 family 
members act together in complexes (Section 6.4).  
Seven members of the US12 family were found to be on the HCMV Merlin virion by 
immunoblot, and this correlated with their vAC localisations by immunofluorescence. Only 
one member with vAC localisation (gpUS14-V5) was not verified as being incorporated into 
the virion, although one cannot discount the possibility that its V5 tag could have been 
cleaved or rendered inaccessible. Access to a gpUS14-specific antibody would help to 
determine whether this protein was indeed on the virion. pUS21-V5 was the only member 
detected on the virion that was not regularly co-localised to the vAC. However, an 
occasional weak association of pUS21-V5 with the vAC in some cells has been revealed, and 
it would be interesting to investigate whether this association increases at later time 
points. Virion proteins pUS18 and gpUS20 had previously been shown to have roles in 
tropism, virion production and content (Hai et al., 2006, Cavaletto et al., 2015) (Section 
1.8.15), so their incorporation into the virion is likely to link to these roles (Section 6.3.2). 
pUS16 however could not be confirmed as a virion protein and was also not detected 
previously in TR virions (Bronzini et al., 2012) (Table 5.1). The presence of pUS16 in the 
virion could therefore be cellular contamination or could be “accidentally” packaged due to 
its close association with the vAC and its role in tropism. 
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Immunoblotting combined with an extremely high affinity antibody to the V5 tag has 
provided a more sensitive method for detecting US12 family members both in the infected 
cell and purified virions than proteomics (Chapter 4, and Weekes et al. (2014)). It is 
possible that the 7TM domains and extreme hydrophobicity of the US12 family may have 
presented distinct problems for the proteomic analysis. In the virion proteomics study 
(Murrell, 2014), even the high abundance US12 family members were not detected in all 
samples, with pUS20 found in 6 out of 8 samples for example. This may imply that the virus 
either doesn’t always incorporate US12 family members into the virion, or that they may 
be incorporated in varying amounts. Further immunoblot studies would need to be done in 
order to validate the frequency of each protein’s incorporation into the virion. The 
demonstration that a subset of US12 family members encode virion proteins agrees and 
extends published findings and virion proteomics data from our research group (Table 5.2) 
and has provided important new evidence that pUS19 and pUS21 are also virion proteins. 
Immunoblotting also supports previous proteomics experiments in relation to the 
lysosomal degradation of the US12 family members, with both methods detecting the 
prevention of degradation of pUS12, gpUS14, pUS15, gpUS17, pUS18 and gpUS20 protein 
expression by leupeptin, a lysosomal inhibitor (this thesis and Fielding et al. (2017)). 
Immunoblotting additionally indicated that pUS13 was also targeted for degradation and 
that the degradation of gpUS14-V5 and gpUS17-V5 was detected in their higher molecular 
weight forms only. This rescue of higher molecular weight forms was also identified in 
pUS12-V5, gpUS14-V5, pUS15-V5, pUS16-V5 and gpUS20-V5, alongside the rescue of their 
dominant protein species. These degraded higher molecular weight protein species are 
likely to be misfolded or incorrectly modified protein forms that were targeted for 
degradation through the normal cellular degradation process for incorrect proteins. For 
US12 family members in which the main protein species is rescued from degradation by 
leupeptin, it is more likely that these proteins are specifically targeted for degradation. As 
pUS15-V5 is targeted for degradation without containing the TRG_LysEnd_APsAcLL_1 
motif, there may be alternative ways of targeting this family for degradation, including 
through several non-consensus sorting motifs that have previously identified or clathrin-
independent routes (Staudt et al., 2017). These increases in protein expression were seen 
over an 18 h period (54-72 hpi) and further increases would likely be observed over the 
entire course of infection and could provide better detection and rescue validation of those 
members which only had minimal rescue in protein expression.  
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In total, nine US12 family member proteins demonstrated vAC associations and nine US12 
demonstrated ER co-localisation within fibroblasts. Despite the rescue of these proteins by 
the addition of leupeptin, none of the US12 family members appeared to have frequent co-
localisation with lysosomes, and the implications of this are discussed further in Section 
6.2.  
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6 Discussion  
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HCMV has the largest genome of any human virus and contains a remarkable array of 15 
gene families whose members are generally not essential for virus replication in vitro 
(Section 1.8). These gene families together constitute a substantial proportion of the HCMV 
gene content and many are not shared by other human herpesviruses. Some gene families 
contain members with similar functions, e.g. both members of the US2 gene family 
suppress cell surface expression of MHC-1. Therefore, there is a hope that the identification 
of the function of one member of a family will provide insight into additional members. 
Many gene families appear to have arisen through a classical ‘accordion’ gene expansion 
(Elde et al., 2012), and this can arise after the capture of a host gene, followed by 
subsequent expansion and divergence. The US12 family is a remarkable tandem array of 10 
related genes that appear to have arisen by expansion, possibly from the capture of host G 
protein-coupled receptor (GPCR) gene (Lesniewski et al., 2006). All US12 family members 
contain multiple GPCR signature motifs, however none contain the whole set of GPCR 
motifs and US12 family members have no known GPCR functions (Lesniewski et al., 2006) 
(Section 1.8.15). Phylogenetically, the US12 family represent a distinct branch of the 7TM 
superfamily, but the closest branches contain transmembrane Bax inhibitor-1 containing 
motif (TMBIM) family members, with Golgi anti-apoptotic protein (GAAP, CGI-119, 
TMBIM4) being the nearest human ortholog to any US12 family member (Lesniewski et al., 
2006). US21 has the most similarity to TMBIM4 as well as PP1201 (TMBIM1) and LFG 
(Lifeguard/TMBIM2) (Lesniewski et al., 2006, Holzerlandt et al., 2002) and it was therefore 
suggested that proto-US21 was the original ancestral gene from which the rest of the 
family duplicated and diverged (Lesniewski et al., 2006) (Section 1.8.15). 
 
The US12 family members are highly conserved, despite being dispensable for replication in 
vitro and despite HCMV displaying the highest level of genetic diversity of all human 
herpesviruses (Dunn et al., 2003b, Sijmons et al., 2015)(Section 1.8.15), indicating that 
their functions are important for HCMV persistence in vivo. US18 and US20 were the first 
US12 family members to be identified as having NK evasion functions (Fielding et al., 2014), 
which they achieve by controlling the cell surface levels of MICA (Section 1.8.15.4). It was 
hypothesised that the whole family could be affecting the cell surface proteome, so a 
proteomics approach was undertaken. The US12 family were demonstrated to regulate the 
cell surface proteome, and their cellular targets were identified (Fielding et al., 2017). 
This thesis aimed to complement this study, by further characterising the US12 family gene 
products for their expression, degradation and localisation patterns. A fundamental 
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appreciation of US12 family gene expression was important in order to understand the 
proteomic data. 
 
HCMV proteins are often not processed correctly or function in the same way outside of 
the context of infection, and previously, experimental data had indicated that the US12 
family members also demonstrated a lack of full function when expressed individually from 
adenovirus vectors (Dr C. Fielding, as detailed in Section 3), and this thesis has further 
determined that the US12 family had altered expression levels and different N-
glycosylation patterns when studied in isolation, and some members had limited protein 
detection by immunoblot when the sample was untreated (Figure 4.4). The difficulties of 
studying US12 family members in isolation is likely to be due to the lack of other HCMV 
proteins required for the US12 family to be expressed, processed or to function correctly. 
Without the context of infection, there is also a lack of rearrangement of the host cellular 
machinery to form the viral assembly compartment (vAC), which may distort the US12 
family protein’s localisation and may affect interactions with cellular and viral binding 
partners. Consequently, this thesis studied the US12 family by inserting a V5 tag at the C-
terminus of each US12 family member within the HCMV Merlin BAC genome. 
 
6.1 Characterisation of HCMV US12 family expression and post-
translational modifications.  
Three US12 family members were identified as containing N-glycosylation within the 
context of infection: gpUS14-V5, gpUS17-V5 and gpUS20-V5 (Section 4.4). gpUS17-V5 and 
gpUS20-V5 were detected as a doublet by immunoblot, with only the higher molecular 
weight species sensitive to digestion with endoglycosidase H (EndoH). N-glycosylation can 
be important for protein folding, stability and function, with many glycosylated proteins 
found in the HCMV virion envelope, however only gpUS20-V5 was identified in the Merlin 
virion by immunoblot (Section 5.5), although gpUS14-V5 had been detected in the virion 
previously by proteomics (Murrell, 2014). 
This finding also corresponds with the prediction that the C-termini of these three US12 
family members would be non-cytoplasmic, allowing all or the majority of their N-
glycosylation sites to be facing the lumen of the ER and accessible to the glycosylation 
machinery (Section 4.1.3). This also indicates that the US12 family members are likely to 
have opposing membrane topology to 7TM GPCRs, which generally have non-cytoplasmic 
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N-termini (Lesniewski et al., 2006), however TMBIMs generally have cytoplasmic N-termini 
(Figure 6.1). For some TMBIMs, such as GAAP/TMBIM4, it has recently been discovered 
that their last transmembrane domains (‘TM7’) were not true transmembrane domains, 
but instead formed probable re-entrant loops, resulting in both the C- and N-termini 
belonging to the cytosolic side of the membrane (Carrara et al., 2012) (Figure 6.1). 
Although some US12 family members were predicted to contain re-entrant loops 
themselves by certain prediction software programs (Section 4.1.3), no re-entrant loops 
were predicted for any of the US12 family’s TM7 domains. This is likely because the US12 
family have more hydrophobic TM7 domains than those of TMBIM4 and TMBIM6, as 
determined for gpUS20 (Cavaletto et al., 2015). Some US12 family members were also 
predicted to contain only 6 transmembrane domains, however the overall consensus 
remains that each US12 family member most likely has 7 TMDs, and gpUS20 was 
experimentally demonstrated to have a cytosolic N-termini and its C-termini in the ER 
lumen (Cavaletto et al., 2015). The structure of GPCRs and TMBIMs appears to be 
important for their function so the US12 family topology being the reverse of GPCRs 
suggests that they may have a non-GPCR related function. As they do appear however to 
have their N-termini on the same side of the membrane as TMBIM members, of which they 
are more closely related (Figure 6.1), it does not rule out TMBIM-related functions being 
possible for US12 family members.  
Aside from N-glycosylation, there appears to be other post-translational modifications 
(PTMs) of US12 family members, with many members demonstrating protein forms of 
different molecular weights or ladder/smear patterns by immunoblot (Section 3.4, 4 and 
5.1). A smeared pattern can be caused by the nature of running hydrophobic 
transmembrane proteins by SDS-PAGE, as they can often appear to aggregate at high 
temperatures or may not fully denature, and this had previously been noted for pUS18 and 
pUS20 (Fielding et al., 2014). However, ubiquitination and SUMOylation of proteins can 
also result in a laddering or smear pattern (Choo and Zhang, 2009, Seyfried et al., 2008, 
Wang et al., 2017). pUS13-V5 demonstrates the most extensive ladder pattern across 
immunoblots, with pUS12-V5, gpUS14-V5, pUS15-V5, pUS16-V5, gpUS17-V5, gpUS20-V5 
and pUS21-V5 demonstrating lesser degrees of smears or ladders, often only detected at 
longer exposure times or upon the addition of leupeptin (Chapter 3.4, 4.2, 4.4 and 5.1). If 
the ladder and smear patterns of US12 family members is due to ubiquitination, this could 
mean that this subset of US12 family proteins could be targeted for ubiquitin-mediated 
degradation in the proteasome. Ubiquitin can also affect cellular  
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Figure 6.1: Membrane topology predictions for the US12 family, GPCRs and 
TMBIMs. Predicted or proven membrane topologies A) GPCR and US12 family 
topologies across the plasma membrane. B) GPCR and US12 family topologies across 
an organelle membrane. C) TMBIM and US12 family topologies across an organelle 
membrane, based on the findings of TMBIM4 and TMBIM6 (Section 6.1). 
221 
 
localisations, activity and can promote or prevent protein interactions (Schnell and Hicke, 
2003). This possibility could be established by immunoprecipitating each V5-tagged protein 
and immunoblotting the sample with an anti-ubiquitin antibody. SUMOylation is analogous 
to ubiquitination and can change the localisation of proteins, their stability or enzymatic 
activity, and their interactions with cellular components or binding partners (Boggio and 
Chiocca, 2006). Viral proteins can also influence SUMOylation, and some viral proteins 
need to be SUMOylated in order to function correctly (Boggio and Chiocca, 2006). 
SUMOylation of US12 family members could be tested through the use of a cell line that 
expresses His-tagged SUMO available at Cardiff (Prof. G. Wilkinson, personal 
communication). There currently seems to be no correlation between those US12 family 
members with ladder or smear patterns and those without in terms of localisation, and no 
link can be made to protein function, with these US12 family members having a range of 
functions, and the most extensively laddered protein pUS13-V5 having no known function. 
 
Expression of all members of the US12 family was tracked using a high affinity antibody to 
the V5 epitope tag. If the V5 tags were always recognised with equal efficiency, then the 
different US12 family members are demonstrated to be expressed at different levels to 
each other. These differences could be quite extreme, with gpUS20-V5 detected at 33 
times higher levels than pUS21-V5 by densitometry (Section 3.4). Three distinct 3’ co-
terminal transcripts have been reported for the US12 family, that encode for US21 alone, 
US20-US18 and US17-US12 (Guo, 1993, Towler, 2007, Gatherer et al., 2011). gpUS20-V5 
was expressed more efficiently than pUS19 and pUS18 in the context of HCMV infection 
(Section 3.4), consistent with it being with the first ORF on the polycistronic transcript 
(Guo, 1993). pUS18 was detected at 20 times lower levels than gpUS20-V5 by densitometry 
and consistently had the lowest expression of the 3 proteins (Section 3.4), potentially 
because ribosomes can be expected to translate downstream ORFS with reduced efficiency 
due to falling off prematurely. Although an attractive model, the US17-US12 transcript set 
did not appear to follow such a pattern of expression (Section 3.4). Therefore, lower 
expression of US12 family members may also have been the result of quicker protein 
turnover or an obstruction to the detection of the V5 tag due to protein folding or similar. 
It has also been suggested that there are additional transcripts within the US12-US17 
region of Han and AD169 HCMV strains that may subsequently affect the protein levels of 
each US12-US17 member (Fig. 6.2) (Lu et al., 2016). US21 is individually situated on its own 
transcript (Guo, 1993) so may have its own transcriptional and translational control, and in  
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 Figure 6.2: Transcriptional map of US12-US17 from HCMV Han (Lu et al., 2016). The 
predicted ORFs (indicated by hollow arrows) of HCMV Han in the US12-US17 region, as taken 
from Lu et al. (2016), figure 7. TATA elements (indicated by hollow triangles) and polyA signals 
(indicated by black triangles) are indicated at the bottom of the figure. Transcripts detected 
have their 5′ and 3′ ends of the transcripts labelled, with their approximate lengths given in 
brackets, as estimated by Northern Blot and RACE. 
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general, has lower expression levels than most other US12 family members (Section 3.4). It 
cannot be ruled out that the addition of the V5 tags could have affected the transcriptional 
levels of the US12 family in some way, which may have in turn affect the protein levels. 
Although the V5 tags of the US12 family do not appear to overlap with any known TATA 
elements or polyA signals, it would be beneficial to study the transcript levels with and 
without V5 tagging to provide evidence for or against this possibility. It is also possible that 
the V5 tag may have affected the stability or degradation of US12 family members (Section 
4.6). 
At least five of the US12 family members have their main protein form targeted for 
degradation within the context of HCMV infection which would also affect the amount of 
protein available for detection, with pUS12-V5 demonstrating up to a 15 fold increase upon 
the addition of Leupeptin by densitometry (Section 5.1). The detection of pUS13-V5 as a 
smear/ladder may also partly explain why this protein was harder to detect than if the total 
protein amount was found in a single molecular weight band. This is supported by 
densitometry that demonstrated that in some experiments the pUS13-V5 sample 
contained as much protein as the gpUS20-V5 sample but appeared much weaker due to 
the ladder effect (Section 3.4). Outside of the context of infection, these expression 
patterns weren’t followed, suggesting that these differences in expression were related to 
HCMV infection, however Ad-US14-V5 and Ad-US17-V5 had previously been codon 
optimised which had increased their protein levels (Section 4.4). 
 
The nature of the protein expressed by each US12 family member remained constant over 
the course of a productive HCMV infection and where relevant, was generally similar to the 
protein packaged in to the virion with respect to its molecular weight and banding pattern 
by immunoblot (Section 4.2 and 5.5). pUS18-V5 was the only family member in which an 
additional protein band could be detected in the virion, and this may be due to alternative 
processing or modifications to the virion form of the protein. It is possible that this 
additional pUS18-V5 form is N-glycosylated, as other HCMV proteins such as gpUL141 have 
shown to be differently glycosylated in the virion than in the WCL (Cochrane, 2009). An 
attempt to verify this was made, but not enough protein was present for detection of 
pUS18-V5 after de-glycosylation treatment. Glycosylation generally increases the molecular 
weight of a protein however, whereas this additional protein form of pUS18-V5 had a lower 
molecular weight (18 kDa) than the standard doublet detected (Section 5.5). The simplest 
explanation was that this band could not be detected in previous immunoblots due to its 
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lower abundance, as it was detected at a lower expression level than the original doublet, 
and because pUS18-V5 consistently had low expression levels in the WCL. There is also the 
possibility that this lower band could relate to the truncated US18 transcript that was 
detected in Merlin from 72 hpi (Stern-Ginossar et al., 2012) (Section 4.6) which could 
correlate with the incorporation of this 18 kDa pUS18-V5 protein into the virion. 
 
Immune evasion proteins are often required early in infection to prevent the host 
mounting an immune response to HCMV. For example, US3 is expressed as a Tp1 
(immediate early) protein and functions early to prevent antigen processing and 
presentation at early stages of infection in order to limit immune recognition (Colberg-
Poley, 1996, Noriega et al., 2012b). Therefore it was expected that the US12 family would 
have relatively early expression patterns if involved in immune evasion, as US18 and US20 
had demonstrated to be (Fielding et al., 2014) and as indicated by the US12 family’s ability 
to regulate cell surface immune ligands (Fielding et al., 2017). Instead, the US12 family 
mostly belonged to the Tp3 temporal expression kinetic class (as described in Section 
1.4.1.4) but ranged from Tp2 early proteins (pUS16-V5 and gpUS20-V5) to Tp5 late proteins 
(gpUS17-V5), with the majority of members having their highest expression levels at 72 hpi. 
Although immediate early time-points were not collected, all family members could be 
detected by either 24 hpi (pUS12-V5, gpUS14-V5, pUS16-V5, pUS18-V5 and pUS20-V5) or 
48 hpi (pUS13-V5, pUS15-V5, gpUS17-V5, pUS19-V5 and pUS21-V5) (Section 4.2) and 
members may be expressed from earlier time-points, even if they are not abundant at 
those times. Their broad expression patterns might correlate with their modulation of 
cellular immune ligands including MICA and MICB which accumulate in the cell at high 
levels at multiple time-points without the presence of the US12 family members (Fielding 
et al., 2017). The requirement of different US12 family members at different times may 
also indicate towards different functions. pUS16-V5 and gpUS20-V5 had high expression 
levels across all time-points so could have a role that either requires their expression 
throughout the duration of infection or could have both early and late roles. pUS16-V5 and 
gpUS20-V5 were also the only Tp2 expressed proteins, and along with pUS12-V5 were the 
only US12 family members to have their highest relative expressions at 48 hpi. pUS12 and 
gpUS20 have been demonstrated to play a role in NK evasion, along with gpUS14 and 
pUS18 which are Tp3 proteins (Fielding et al., 2014, Fielding et al., 2017) and this role 
would likely be required from early time points, with all 4 of these members detected by 24 
hpi (Section 4.2). Their NK evasion roles also link with the known targets of these US12 
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family members, with US20 able to target the NK ligands MICA, MICB, ULBP2 and B7-H6 
(Fielding et al., 2017, Fielding et al., 2014). US18 was also able to target MICA and B7-H6 in 
concert with US20, and US12 was able to target ULBP2 (Fielding et al., 2014, Fielding et al., 
2017). There are currently no known NK ligand targets for pUS14 however. One of the 
target proteins of the US12 family is pUL16, an NK evasion protein that functions by 
sequestering NK ligands such as MICB, ULBP1, 2, 4 and 6 in the ER (Rolle et al., 2003). 
Deletion of US12, US13 or US20 lead to increased cell surface and intracellular expression 
of UL16, and the deletion of US16, US17 or US18 appeared to lead to an increase of UL16 in 
the plasma membrane only (Fielding et al., 2017). This may show functional redundancy of 
NK ligand targeting between UL16 and the US12 family, or it may be that UL16 becomes 
degraded indirectly through its interaction with MICB and ULBP2 which are targeted for 
degradation by the US12 family.  
Being categorised as Tp3 does not diminish their capacity to be involved in immune 
evasion, with other proteins classified as Tp3 (Weekes et al., 2014) demonstrated to be 
involved in immune evasion, nuclear egress and protein translocation, including UL40 
(Prod’homme et al., 2012), UL50 (Sharma, Kamil, Coughlin, Reim, & Coen, 2014), IRS1 
(Child, Hakki, De Niro, & Geballe, 2004; Ziehr, Vincent, & Moorman, 2016) and US6 (Lehner, 
Karttunen, Wilkinson, & Cresswell, 1997). Even the Tp5 late protein gpUL141 targets NK 
ligands (CD112 & CD155) (Prod'homme et al., 2010, Tomasec et al., 2005, Weekes et al., 
2014), so the possibility that pUS21 (a Tp5 protein) also contributes to NK evasion (Fielding 
et al., 2017) is still plausible.  
 
Non-immune evasion functions may require expression of the US12 family at later time-
points, with both pUS16 and gpUS20 having published roles in tropism which would be 
required later in infection (Bronzini et al., 2012, Cavaletto et al., 2015, Luganini et al., 
2017). pUS16 alters tropism by reducing the content of the pentamer on the virion, which 
prevents entry into endothelial and epithelial cells (Bronzini et al., 2012, Luganini et al., 
2017). Altering the virion content or its maturation can not only have tropism effects, but 
can also cause early effects on the next newly infected cell. For example, the deletion of 
US17 causes a larger amount of non-infectious viral particles, which results in a 2.6-fold 
increase in the level of intracellular pp65 delivered to each cell, which is the likely cause of 
the markedly blunted the host cell antiviral response in the newly infected cell (Gurczynski 
et al., 2014). US17 can both differentially regulating transcripts at 96 hpi compared to the 
AD169 parental virus, as well as differentially regulate transcripts at 12 hpi in the recently 
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infected cell, effectively having both early and late functional effects, despite being a late 
protein. Proteins that are incorporated into the virion themselves would also be expected 
to be expressed later in infection. pUS21-V5 for example is a Tp5 protein and has been 
shown to be present in HCMV Merlin virions (Section 4.2 and 5.5) although US21 currently 
has no known target proteins or functions to explain its late expression pattern, or why its 
presence in the virion may be required. 
 
6.2 Regulation and degradation of US12 family members and their 
targets 
The US12 family target cellular proteins and direct a subset of them for degradation 
(Fielding et al., 2014, Fielding et al., 2017) (discussed in Section 1.8.15.3), and their ER 
localisations may allow them access to these proteins to achieve this. The cell surface 
immune ligands that are targeted by the US12 family would have to pass through the ER 
and Golgi to arrive at the plasma membrane. The US12 family members that localise to the 
ER would thus would be in a position to interact with their target proteins and could direct 
these proteins for degradation before they were translocated to the cell surface. It was 
hypothesised that US12 family members may directly transport their target proteins for 
degradation and that the degradation of US12 family members (Section 5.1) may be an 
indirect consequence of this. In support of this theory, many of the US12 family (and their 
targets) could be rescued by leupeptin, generally recognised to be a lysosomal inhibitor.  
US12 and US13 had also previously been identified as being at least partially belonging to 
the lysosomal fraction of HCMV AD169 organelles, with US12 identified at 24 and 48 hpi 
and US13 at 120 hpi (Jean Beltran et al., 2016).  
The lysosomal targeting of cellular proteins is also a property of the TMBIM family, with 
TMBIM1 and 3 targeting TLR4 and Gb3 synthase for lysosomal degradation respectively 
(Yamaji et al., 2010, Zhao et al., 2017). It is also possible that instead of directing their 
target ligands for degradation from the ER, they could be targeting them from the plasma 
membrane (PM) instead. Many US12 family members were detected in the PM by 
proteomics (Weekes et al., 2014, Fielding et al., 2017), and although they have not been 
identified on the PM by immunofluorescence, this could be because their abundance on 
the PM was too low or too transient to detect. If the US12 family do translocate to the PM, 
they would likely be retrieved by the endosomal transport system, in a similar way to how 
virion glycoproteins are retrieved (Section 1.4.1.7, Figure 6.3). These endosomal vesicles  
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Figure 6.3 
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Figure 6.3: Model for the hypothesis of US12 family members processing and 
transport through the cell. The US12 family members are likely translated at the 
ER, where some members are N-glycosylated. Then all or a subset of US12 family 
proteins are likely processed through the Golgi and TGN before being exported 
to the PM. The US12 family members may then be retrieved via the endocytic 
system, potentially along with their target proteins similarly to how virion 
glycoproteins are thought to be transported to the vAC. It is then likely that 
these endocytic vesicles (which accumulate in the centre of the vAC) can 
envelope the tegumented capsids and these enveloped virions are then egressed 
from the cell. It is possible that at some point during the transport cycle the 
endocytic vesicles can fuse with lysosomes in order to degrade their enclosed 
proteins which may account for the degradation of some US12 family members 
and their targets. In this diagram the US12 family are represented by US20 
(purple 7TM protein) as US20 is known to localise to the ER and the vAC, has 
been identified on the PM by proteomics, and has been detected on HCMV 
virions. This however is likely not the case for all US12 family members, as not all 
US12 family members are found in the vAC or on the virion. The US12 family may 
also affect their target proteins at the ER. 
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are subsequently found in the centre of the vAC, however these endosomes can also fuse 
with lysosomes, which may be the mechanism through which the US12 family target 
proteins are degraded and would explain why US12 family members are often degraded 
themselves also (Section 5.1).  
 
Evidence against this theory as well as the original hypothesis that the US12 family may 
transport their targets to lysosomes directly, includes the observation that US12 family 
members did not co-localise specifically with lysosomes, even in the presence of leupeptin.  
There could be a number of technical reason for this lack of co-localisation, as upon 
entering the lysosome the V5 tag may become shielded from antibodies as a consequence 
of modifications to the US12 family proteins, such as differential protein folding, 
obstructing interactions or the C terminus being trimmed. Although HCMV proteins have  
previously been shown to co-localise with lysosomes (Tirabassi and Ploegh, 2002), a 
positive control using a protein known to be targeted and degraded in the lysosome would 
have been beneficial in verifying whether immunofluorescence was accurate enough to 
conclusively detect specific co-localisation between proteins and lysosomes in this setting. 
However, as some co-localisation could occasionally be detected with some US12 family 
members (Figure 5.5), this suggests that the co-localisation would have been detectable. 
Therefore, the simplest explanation is that the US12 family of proteins are not being 
targeted to lysosomes, but act elsewhere. One possibility is that the US12 family could be 
directing their target proteins for lysosomal degradation without going there themselves 
and another possibility is that neither the US12 family or their targets are degraded 
lysosomally. Leupeptin is recognised to be a relatively specific lysosomal inhibitor due to its 
inhibition of serine and thiol proteases found in the lysosome, but more than 20% of its 
activity of serine and thiol proteases takes place outside of lysosomes (Seglen et al., 1979). 
Consequently, the leupeptin-sensitive proteolysis of US12 family members and/or their 
cellular targets could be non-lysosomal, and this would explain the lack of co-localisation of 
the US12 family with lysosomes. The expression of two US12 family target proteins MICA 
and B7-H6 however, could be rescued not only with leupeptin, but also by folimycin 
(concanamycin) which inhibits acidification of organelles, such as lysosomes (Fielding et al., 
2014, Charpak-Amikam et al., 2017), increasing the likelihood of the degradation of at least 
some target proteins occurring in lysosomes. However, this would need further 
investigation and the use of additional specific protease inhibitors would need to be 
obtained to further specify the mechanism of action of the US12 family. 
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It would also be useful to investigate any effects of leupeptin on HCMV replication as 
although there is no published data pertaining to negative side effects of leupeptin on 
HCMV, other degradation inhibitors can have adverse effects. MG132 (a proteasome 
inhibitor) for example, is known to block viral DNA replication and assembly of HCMV 
(Kaspari et al., 2008). Therefore, an effect on HCMV replication or similar by Leupeptin 
cannot be ruled out, and experiments with Leupeptin should be analysed with caution. 
Observing the differences of HCMV vAC formation (using a vAC marker such as pp28) upon 
the addition of Leupeptin may provide an indication as to whether HCMV infection is 
affected by Leupeptin.  
Other degradation pathways that cannot be rescued by leupeptin may also be utilised and 
the library of V5-tagged US12 family member HCMV’s now permits for this to be 
investigated. As ubiquitin is one possible cause of the protein ladders seen on some US12 
family members (Section 6.1), they may undergo ubiquitin-related degradation. 
Ubiquitination has previously been shown to target GPCRs for lysosomal or proteasomal 
degradation (Bonifacino and Traub, 2003), so could similarly be used to target the US12 
family. 
 
The degradation of US12 family protein targets was identified by proteomic analysis which 
revealed that many cellular proteins were downregulated on the PM and in the WCL, and 
many were demonstrated to be rescued by leupeptin (Fielding et al., 2017). A small subset 
however were downregulated on the PM, but not in the WCL, indicating that they may be 
retained, and possibly sequestered by the US12 family, rather than degraded. For instance, 
US13 downregulated MICA on the PM but not in the WCL and IL6ST was similarly regulated 
by US18. It would be interesting to investigate this retained subset of US12 family hits 
further by validating their cell surface downregulation by flow cytometry and using 
immunofluorescence to identify whether their cellular localisation matched that of the 
US12 family member responsible. If these proteins are sequestered, it could work on the 
same principle as HCMV gpUL141 which binds to CD155 (human PVR) in the endoplasmic 
reticulum and prevents its maturation and transport to the cell surface. It may also indicate 
that US12 family members work together to retain and then subsequently degrade their 
target proteins. For example, if one or more US12 family members targeted MICA for 
retention, and US13 was responsible for the degradation of US13, it would explain why 
MICA is downregulated from the PM but not the WCL in the HCMV US13 deletion mutant. 
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Many of the proteins that the US12 family have demonstrated to target are linked to the 
proposed or validated functions of those family members. For example, US12, US14, US18, 
US20 (and potentially US21) were demonstrated to have NK evasion functions, and US18 
and US20 target many immune ligands and have been validated as targeting the NK ligands 
MICA and B7-H6 (Fielding et al., 2017, Fielding et al., 2014). The regulation of other NK 
ligands by the remaining family members has yet to be validated, however it appears that 
US12 regulates ULBP2 in the PM and WCL, and MICB in the WCL; and that US21 appears to 
regulate B7-H6 in the WCL (Fielding et al., 2017), however the potential NK evasion 
function of US21 may also be due to unforeseen effects on US20 by the deletion mutant. 
US14 has no known NK ligand targets (Fielding et al., 2017), so may be functioning in a 
different way to the other US12 family members that have NK evasion functions, and may 
possibly regulate a currently unknown or untested NK ligand. HCMV genes have 
predominantly undergone negative selection and are under strong evolutionary 
constraints, however US14 and US18 are subjected to higher levels of positive selection 
than would be expected from their diversity (Sijmons et al., 2015) (Section 1.8.15), 
suggesting that they were highly advantageous to the virus. This supports their proposed or 
proven roles in NK evasion, with many HCMV genes of high positive selection, 
predominantly functioning to modulate host immune and antiviral pathways (Sijmons et 
al., 2015). Although the whole family are dispensable for replication in vitro, the deletion of 
US13 from HCMV Towne does cause a moderate growth defect in fibroblasts (10-1-10-
2)(Dunn et al., 2003b). As there appears to be no unique immune ligands that US13 targets 
compared to the rest of the US12 family (Fielding et al., 2017), the growth defect may 
indicate an additional alternative function. The only noticeable difference within the target 
proteins of pUS13 is that MICB is more highly upregulated in the PM in the US13 deletion 
mutant than with the other US12 family member deletion mutants. Immunoblotting of 
immunoprecipitations (IP) of the V5-tagged family members would further identify which 
cellular proteins are binding to them, and could detect other potential target proteins. Not 
all target proteins may bind directly however so cellular targets that are indirectly 
regulated may remain unknown. 
Targeting cellular proteins for degradation may help to reduce protein misfolding, leading 
to regulation of the ER stress response within the cell, and US17 can regulate 
the ER stress pathway through its regulation of ER stress response genes and chaperones, 
including BiP/GRP78, DDIT3/CHOP and CHAC1 levels (Gurczynski et al., 2014). BiP has many 
roles within the cell and is an ER chaperone that is involved in the folding and assembly of 
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proteins and can prevent the aggregation of unfolded proteins, modulating the regulation 
of the UPR response (Hegde et al., 2006). BiP can also bind calcium and is involved in 
maintaining calcium homeostasis in the ER (Buchkovich et al., 2008). TMBIMs can regulate 
the UPR response and apoptosis through the modulation of ER calcium homeostasis (Rojas-
Rivera et al., 2012) so US17’s regulation of BiP may also be linked with the modulation of 
calcium levels. BiP is upregulated 1.6 fold by HCMV AD169 ΔUS17, and each US12 family 
member deletion mutant in Merlin also appears to downregulate BiP (HSPA5) in 
proteomics (Fielding et al., 2017). Therefore, other members of the US12 family may also 
be able to modulate the ER stress response, and the finding that the majority of US12 
family members are localised to the ER (Section 5.3) means that this interaction would be 
possible as BiP is also known to localise to the ER (Buchkovich et al., 2009). Additionally, BiP 
is later diverted to the vAC so the possibility of BiP chaperoning some of the US12 family 
members to the vAC should be investigated, although US12 family members may first need 
to translocate to the PM, especially those found on the virion. BiP is also required for virion 
assembly (Buchkovich et al., 2008) so its association with US17 may aid US17 in its role of 
modulating virion content (Gurczynski et al., 2014).  
 
6.3 Localisation of the US12 family members within the cell 
Immunofluorescence studies do have their limitations with some small differences seen 
across different experiments as indicated in Table 5.2 (Section 5.6). These small differences 
however are likely due to slight differences in the time of infection of each cell, with the 0 
hpi time-point occurring after a 2 hour infection incubation period. The images presented 
in this thesis however are representative of at least 2 independent experiments and 
represent the most common localisations seen within each sample. Using percentages as a 
way of quantifying the different types of localisation concentrations within cells would have 
been useful to assess the representation in a quantifiable way. Table 5.2 however indicates 
that the proteins have relatively consistent localisations between different experiments 
and the US12 family members usually only differ in their concentrations between their ER 
and vAC localisations within the same cell. If this was due to an impact of the timing of 
infection, it could potentially be partially alleviated in the future by synchronising the 
infection so that all cells are in the same growth phase when infected. Infecting the cells 
over a shorter time period than 2 hours (Section 2.3.2) may also aid in co-ordinating the 
time of infection, however the 72 hpi time-point may just be capturing the translocation of 
the US12 family (Section 6.3.3). 
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The localisation data on the US12 family presented here agrees with information available 
on members from the low passage strain TR and the highly passaged strain AD169. For 
both Merlin and TR, pUS16 localised to the outer portion of vAC (this thesis and Bronzini et 
al. (2012)) and gpUS20 associated with the ER (this thesis and Cavaletto et al. (2015)). In 
addition, Merlin pUS16-V5 and gpUS20-V5 could also occasionally be found in the ER and 
the vAC respectively. The trafficking of Merlin gpUS14-V5 to the ER and the vAC paralleled 
observations that AD169 gpUS14 was distributed in a uniform granular manner throughout 
the cytoplasm, concentrating in the vAC in some cells (Das and Pellett, 2007). HCMV Merlin 
pUS18-V5 could be detected in the cytoplasm at 72 hpi and was observed to marginally 
concentrate in the vAC and ER of some cells. Likewise, AD169 pUS18 exhibited a 
cytoplasmic localisation that became more concentrated in the vAC at later time-points up 
to 144 hpi (Das and Pellett, 2007). However, HCMV Merlin gpUS17-V5 exhibited an ER 
localisation which did not align with published data for AD169, in which gpUS17 was 
cleaved into 2 distinct domains with the N-terminus localised to the vAC and the C-
terminus to the nuclei, the vAC and the cytoplasm (Das and Pellett, 2007, Das et al., 2006). 
The fact that the C-terminally tagged Merlin gpUS17-V5 was not detected in the nucleus 
suggests that Merlin gpUS17-V5 is unlikely to be processed or cleaved in the same way as 
AD169 gpUS17, and this is supported by the lack of nuclear localisation of Towne gpUS17-
V5 also (Das and Pellett, 2007). The AD169 study also used BiP as the ER marker which has 
varying localisation with different BiP antibodies, and can be occasionally detected in the 
vAC (Buchkovich et al., 2009). HCMV infection may have also altered the distribution of the 
ER markers, with calnexin and BiP possibly not remaining in the same positions during 
HCMV infection. To formally address any differences, it would be useful to generate an 
antibody directed against the N-terminus of Merlin gpUS17, or attach an N-terminal tag 
and run a comparison by immunoblot, however it is not expected that the AD169 gpUS17 
will represent the gpUS17 of clinical strains due to its highly passaged nature. 
 
6.3.1 Endoplasmic reticulum localisation of US12 family members 
ER localisation of US12 family members was demonstrated through their co-localisation 
with calnexin, a resident ER protein. The host cell machinery becomes rearranged during 
HCMV infection (Section 1.4.1.6), with the ‘ER’ becoming more condensed in HCMV 
infection than in uninfected cells, visualised as cytoplasmic structures towards the 
periphery of the cell (Cavaletto et al., 2015, Buchkovich et al., 2009, Alwine, 2012). The 
US12 family members’ localisation to the ‘ER’ or ER-derived membrane would therefore 
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need verifying through the co-localisation of additional ER markers. Aside from calnexin 
(this thesis), gpUS20 has also been shown to co-localise with an additional ER marker, 
calreticulin (Cavaletto et al., 2015) which helps supports the location of gpUS20 as the ER.   
All US12 family members, except for gpUS19-V5, showed at least partial co-localisation 
with the ER, and correspondingly were predicted to be translated at the ER, with 
transmembrane domains (TMDs) previously shown to act as localisation signals in the 
absence of signal motifs. Different TMD lengths have demonstrated to be the cause of the 
different localisations of syntaxins (Watson and Pessin, 2001), and altering the 
transmembrane domain of UL16 had previously shown to control its intracellular trafficking 
(Valés-Gómez and Reyburn, 2006). The ideal TMD for insertion into the ER is one of ~20 
residues (Shao and Hegde, 2011) and the first TMD domains of the US12 family members 
are 22 residues long (except for US20 which is 21 residues long) so are all an appropriate 
length for localisation to the ER membrane. This hydrophobic TMD gets recognized by the 
signal recognition particle on the ribosome, at which point translation is halted until the 
ribosome moves to the ER (Shao and Hegde, 2011). This is known as co-translation and the 
vast majority of integral membrane proteins are assembled at the ER and inserted into the 
ER membrane as they are synthesized (Shao and Hegde, 2011). Being translated at the ER 
may also give them an advantage as it may reduce the competition of cellular mRNA 
translation. Each US12 family member (except for US18) also contained a consensus ER 
retention motif TRG_ER_diArg_1 or an N terminus XXRR-like ER motif; thus predicting their 
retention at the ER (Section 4.1.2). This may also explain why US18’s co-localisation to the 
ER appears less frequent or more transient. Although the majority of US12 family members 
have at least a portion of their total protein ‘retained’ at the ER as predicted, another 
portion tends to associate with the vAC, although their mechanism of transfer to the vAC is 
unknown. They could achieve this translocation through the binding of other proteins 
bound for the vAC or may be chaperoned there. Proteomics suggests that some US12 
family members are found on the plasma membrane also (Weekes et al., 2014, Fielding et 
al., 2017), so US12 family proteins may travel from the PM to the vAC via the endosomal 
transport system (Figure 6.3). 
In accordance with their partial ER localisations, US12, US14, US15 and US16 were all 
identified in the ER/Golgi fraction of HCMV AD169 sub-organelle proteomics in at least 1 
time-point across the course of infection (Jean Beltran et al., 2016). pUS12 was associated 
with the ER/Golgi fraction at 72 hpi, gpUS14 at 96 hpi, pUS15 at 96 and 120 hpi, and US16 
at 120 hpi (Jean Beltran et al., 2016). 
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N-glycosylation findings also support the ER localisation demonstrated for gpUS14-V5, 
gpUS17-V5 and gpUS20-V5, with these protein species containing EndoH sensitive N-
glycosylation, suggesting that they have yet to have passed through the ER to the Golgi. 
gpUS14-V5 was the only protein shown to be fully N-glycosylated and it had partial 
localisation to the ER. gpUS17-V5 was shown to be solely localised to the ER and showed 
only partial N-glycosylation, with a portion of gpUS17 protein remaining non-N-
glycosylated. gpUS20-V5 also showed partial N-glycosylation but had dual localisations 
within the cell (the ER and vAC). This may mean that there is a chance that the N-
glycosylated and un-glycosylated subsets may go to different locations within the cell, or 
that they have differing functions. Although N-glycosylation has only been demonstrated at 
72 hpi, the band patterns of all 3 proteins remains the same over the course of infection, 
suggesting that this complete (gpUS14) or partial (gpUS17 and gpUS20) N-glycosylation is 
likely to occur across all time-points. gpUS20-V5 was the only member that was both N-
glycosylated and also present in the virion, however it was unable to be determined 
whether the virion form of pUS20-V5 was similarly N-glycosylated. gpUS14 had previously 
been detected in the virion but this could not be verified in this thesis.  
The sole ER localisation of gpUS17-V5 appears to preclude it from being packaged into 
virions as all members present in the virion have at least a partial or transient association 
with the vAC (Section 5.3, 5.4 and 5.5). gpUS17-V5 has been identified to function in virion 
maturation however, and other US12 family members involved in altering virion content or 
tropism also localise to the ER, and this may give them access to some of the virion 
components which are assembled there, or to manipulate virion proteins as they 
translocate through the ER. pUS16 for example is known to function by reducing the virion 
content of the pentamer on the virion (Luganini et al., 2017). 
As mentioned there is some US12 family member homology to the TMBIM family (Section 
1.8.1.5), and TMBIM proteins localize to membranes of various cellular organelles, 
including the ER (Lisak et al., 2015). At the ER, TMBIMs can modulate apoptotic and ER 
stress signalling by influencing cellular calcium levels (Lisak et al., 2015, Rojas-Rivera et al., 
2012). US17 also appears to do this and therefore other members of the US12 family may 
function in a similar way and be involved in the regulation of ER stress pathways (as 
discussed in Section 6.2). pUS19 is the only member shown to have no co-localisation with 
the ER, and it is also the least similar to TMBIMs so is the least likely to be involved in these 
potential functions. 
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Confirming the topology and termini orientations of the US12 family experimentally would 
be helpful to fully determine their similarities and differences to TMBIMs (Section 4.1.3, 
Figure 6.1) and their structure would affect how they function. The predicted membrane 
topology for the US12 family (Section 4.1.3) is supportive of their N-glycosylation findings, 
as this orientation would allow for all N-glycosylation motifs of gpUS14 and gpUS17, and 2 
of the 3 N-glycosylation motifs of gpUS20 to be present in the lumen of the ER and 
available for N-glycosylation. This orientation could be verified by performing selective 
permeabilization of the membranes during immunofluorescence to determine which side 
of the membrane the V5-tagged C-termini are on. The N-terminus could also be studied, 
however it would either need to be tagged separately or specific N-terminus antibodies 
would need to be used for each family member. Knowing the termini orientations would 
indicate at the orientation of all subsequent TMDs, although in order to specifically identify 
the orientation of the loop containing the N-glycosylation motif, you would need to use 
specific antibodies to that specific motif-containing segment would be required.  
6.3.2 Localisation of US12 family members with the virion assembly compartment  
All US12 family members, except for gpUS17-V5, show some association with the vAC, 
although they often do not show specific co-localisation to the UL99/pp28 vAC marker 
used. The vAC is made up of many host organelles, so further studies would need to be 
done to identify the specific vAC structure or membrane that each vAC-associated US12 
family member is localised to, including co-staining with markers for the Golgi, trans-Golgi 
network (TGN) and early endosomes. If the US12 family co-localised with endosomes, this 
would further support the model that they may be trafficked from the PM to the vAC via 
the endosomal transport system (Figure 6.3). Having an association with the vAC means 
that these US12 family members could be in prime position to regulate the virion content, 
with pUS16-V5 known to regulate the amount of pentamer in the virion (Luganini et al., 
2017). Other US12 family members that localise to the vAC may also have a function 
involved with the assembly and exit of virions, or may be present because they are added 
to the virion themselves. There does appear to be a clear trend between the vAC 
localisation of proteins and their presence in the virion, as demonstrated by the virion 
presence of HCMV vAC proteins such as pp28 (Sanchez et al., 2000b, Landini et al., 1987) 
and now with 7/9 of the vAC-localised members of the US12 family.  
 
US12 family members that had only occasional or weaker localisation to the vAC at 72 hpi 
(pUS12, pUS13, pUS18 and pUS21), may instead become more concentrated at the vAC 
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later in infection, or their localisation in the vAC may be brief due to the rapid egress of the 
virions from the cell. This correlates to previous studies that indicated that AD169 pUS18 
did not readily accumulate in the vAC until later time-points including 144 hpi (Das and 
Pellett, 2007). pUS16 was the only member detected in the virion preparations which was 
not abundant enough to be definitively designated as a virion protein, with its low level 
detection likely to reflect a background level of cellular contamination in virion 
preparations or passive low level incorporation into the virion due to its close association 
with the vAC, and its role in altering the virion content (Luganini et al., 2017). Other US12 
family members found in the virion are present in relatively high abundance, which makes 
it much more likely that they have a function that requires being specifically packaged into 
the virion. For example, pUS18 and gpUS20 are both incorporated into the virion and both 
play a role in tropism (Cavaletto et al., 2015; Hai et al., 2006), and although their 
mechanism of action is currently unknown, is may require their presence in the virion. 
Equally, pUS18 and gpUS20 also have NK evasion functions and their presence in the virion 
may instead link to this role, and there is a chance that they could target their cellular NK 
ligands upon entry to the next newly infected cell. pUS12, gpUS14 and gpUS20 could be 
detected by QTV proteomics at 0 hpi (Figure 4.2) (Weekes et al., 2014) indicating that the 
presence of these US12 family members in the virion (this thesis and Murrell (2014)) was 
enough to lead to a detectable level of protein within the newly infected cell, which 
supports this theory. pUS12 and gpUS20 also appeared to be detected in the PM in cells 
infected with irradiated virus (Weekes et al., 2014), suggesting that their early delivery and 
localisation to the PM may be important for an early functional role. pUS12, gpUS14 and 
possibly pUS21 also have NK evasion functions and are also found on the virion, alongside 
other immune evasion proteins such as gpUL141 (this thesis and Murrell (2014)). It would 
be interesting to determine whether the levels in the virion would be high enough to utilise 
their immune evasion functions in the newly infected cell, and it would be interesting to 
see whether US18 or US20 for example could affect MICA levels solely from their presence 
on irradiated virus. The other members in the virion (pUS12-V5, pUS13-V5, pUS19-V5 and 
pUS21-V5) have unknown functions as of yet. They may also be involved in immune 
evasion, as they regulate an array of cellular immune ligands between them (Fielding et al., 
2017), or their functions may be unrelated to immune evasion, and could be related to 
roles in tropism or similar. This is more likely for pUS13 and pUS19 which had the least 
number of cellular targets within the proteomics study, so are likely to be incorporated into 
238 
 
the virion for a role other than immune evasion. Some members may even be incorporated 
into the virion through their binding association with another virion protein. 
 
As the US12 family are membrane proteins, it is expected that those present in virions will 
be found in the virion envelope. This hypothesis could be tested using electron microscopy 
(EM) with gold labelling of the V5-tagged viral proteins, as previously achieved for gpRL13-
V5 (Stanton et al., 2010). Detergent fractionation of the virion could also be carried out by 
splitting the envelope into soluble (envelope) and insoluble (tegument and capsid) fractions 
to detect which fraction the US12 family proteins are present in, as previously achieved for 
US22 family members (Adair et al., 2002).  
Both US18 and US20 are in the virion and both have two functions, NK evasion and tropism 
(Fielding et al., 2014, Cavaletto et al., 2015, Hai et al., 2006). Therefore other US12 family 
members may also have dual or multiple functions. US22 family members are tegument 
proteins found in the virion and they too are also implicated to function early in infection 
as well as having possible additional functions at later time points (Adair et al., 2002). 
 
6.3.3 Translocalisation of US12 family members over time 
Previous studies have shown differing US12 family localisations over time (Das and Pellett, 
2007, Das et al., 2006), and this thesis identified US12 proteins in different concentrations 
or multiple locations at the same time-point. This suggested that either the 72 hpi time-
point was capturing a translocation period between the vAC and ER, or that dual 
localisation may be seen across the time-course of infection. Therefore, it would be 
beneficial for future studies to observe the proteins at multiple time points throughout the 
course of infection and determine if and how their localisations change. If the 72 hpi time-
point is capturing a change in localisation over time, it would be beneficial to know which 
direction they are translocating and whether family members remain in the same 
localisations as each other across all time-points. The localisation of US12 family members 
(Section 5.3 and 5.4) are likely to link to their functions (Section 1.8.15) and their 
translocation likely also reflects this. If multiple localisations are common across all time-
points of infection, this may indicate that US12 family members could have multiple 
functions, or may need to go to multiple locations to perform a single function. This would 
correlate with the broad range of target proteins that members have, especially US20 
which targets 54 cellular proteins (Fielding et al., 2017), and links to the fact that multiple 
members have already been shown to have more than 1 function, including US17, US18 
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and US20 (Gurczynski et al., 2014, Cavaletto et al., 2015, Hai et al., 2006, Fielding et al., 
2014, Fielding et al., 2017). As the ER stress pathway (and BiP) have also been shown to 
have a role in virion maturation, assembly complex formation and function (Buchkovich et 
al., 2008) this potentially links both the ER and vAC localisations of the US12 family, and 
their roles could potentially modulate pathways related to protein folding or trafficking 
between the ER and the vAC. Some US12 family proteins may solely travel to the vAC to be 
packaged into virions (Section 5.5).  
The majority of US12 family members are found in the ER and/or the vAC, with multiple 
members targeting the same cellular proteins, with some US12 family members having 
more dispersive vAC associations and others having more distinctive vAC patterns. There 
are no obvious links between the specific localisations of each US12 family protein and the 
proteins that they target, with US18 and US20 targeting many of the same proteins, 
without appearing to be in large concentrations at the same localisations as each other. 
This could potentially mean that they have slightly different ways of directing the same 
protein for degradation, or are able to direct their targets for degradation in the same way 
from their respective locations. It does however appear that they would overlap in small 
quantities in the ER and the vAC, and may co-localise more specifically at different time-
points of infection. Although pUS19-V5 showed association with the vAC, it was unique in 
that it ringed around the vAC periphery in a distinctive pattern. It is also the member that 
targets the least number of proteins in common with other family members, and is one of 
the few members not affected by the addition of leupeptin. Combined with US19 having 
the least homology to GPCRs and the rest of the US12 family (Lesniewski et al., 2006), it is 
likely that US19 has a different function to the other family members. 
It may be possible that only the location(s) in which the US12 family proteins are most 
abundant can be clearly visualised by immunofluorescence. This may explain why some 
members are found at a single site within one cell, and have multiple localisations in a 
neighbouring cell. This may also account for why US12 family members cannot be 
visualised at the plasma membrane, despite being detected in the PM by proteomics 
(Weekes et al., 2014, Fielding et al., 2017), else their association with the PM may be too 
transient, with the proteins being rapidly translocated to the vAC. Interestingly, the fact 
that the C-termini are predicted to be non-cytoplasmic, means that if the US12 family 
members are on the surface, their C-termini would be extracellular (Figure 6.1) and the 
opportunity then exists to use the V5-tag in flow cytometry to directly measure whether 
any US12 family member can be detected on the cell surface. Their presence on the plasma 
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membrane would be logical for members found on the virion as virion envelope proteins go 
to the cell surface to form the virion envelope before going back to the vAC to envelope the 
nucleocapsids (Section 1.4.1.7).  
In considering the impressive role that the US12 family plays in modulating surface 
expression of immune ligands/receptors, it seemed reasonable to expect that US12 family 
members would be found associated with their target proteins, as has been observed for 
other HCMV immune evasion functions such as gpUL141 (Prod'homme et al., 2010, Smith 
et al., 2013b, Tomasec et al., 2005). For many of the US12 family targets such as MICA, B7-
H6 and ALCAM, it proved difficult to source antibodies that are fully compatible with the 
immunofluorescence technique (Section 5.6). The fact that many of these targets are also 
targeted by proteolysis by the actions of the US12 family does not help such analyses, 
although the addition of inhibitors such as leupeptin could be used to rescue the targets. 
An antibody to MPZL1 did however give a defined localisation, and appeared within the 
vicinity of the vAC (Section 5.6) and it could be subsequently tested for its co-localisation 
with gpUS14, pUS18, and gpUS20 which have all been implicated in targeting MPZL1 
(Fielding et al., 2017). If these US12 family members do not chaperone their target proteins 
for degradation however, then their association with them may be transient and may still 
be hard to detect through immunofluorescence. Nevertheless, it is now possible to address 
this and other interesting degradation and co-localisation questions using the constructed 
HCMV library of V5-tagged US12 family gene members.  
 
6.4 The possibility of the US12 family working in complexes 
pUS18 and gpUS20 have already been demonstrated to work in concert, with US18 and 
US20 targeting MICA for degradation at a much higher rate than either member 
individually, with US18 only marginally affecting MICA levels alone (Fielding et al., 2014). 
They were similarly shown to act in concert to suppress B7-H6 to reduce NK activation, and 
both target multiple other cellular proteins including ULBP2, IL6ST, KIT, KITLG, JAM3, 
ACVR1, ACVRL1, IFNGR1, MPZL1, CXADR, ALCAM, SDC4, CD99 and SDC1. A subset of these 
cellular targets were additionally regulated by US14 and/or US16 (Fielding et al., 2017). In 
fact, across all plasma membrane proteins targeted by the US12 family, 29% were 
regulated >3 fold by 2 or more family members, and 6% targeted by 3 or more family 
members (Fielding et al., 2017). US12 family members may therefore work together in a 
complex. The deletion of certain family members also affects the expression levels of other 
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members, with US14 expression increased during infection with HCMV ΔUS15, and US15 
expression increased during infection with HCMV ΔUS20 (Fielding et al., 2017). This 
suggested that US12 family members may compensate for each other, further implicating a 
cross-over of functions. 
Multiple US12 family members are also found in the same general localisations as each 
other, with 9/10 members co-localising with the ER marker calnexin (Section 5.3), implying 
that all of these members may be in close enough proximity to form a complex. 9/10 of the 
US12 family are also associated with the vAC, with the majority of members generally 
showing dispersive vAC association (Section 5.4, Figure 6.4). This was true for pUS12-V5, 
pUS13-V5, gpUS14-V5, pUS15-V5, gpUS20-V5 and pUS21-V5, with pUS18-V5 showing 
occasional concentration in the vAC also, so in theory these members would be physically 
close enough in the vAC to be able to complex. Although occasionally dispersive in the vAC, 
pUS16-V5 generally localised to the outer portion of the vAC only, and pUS19-V5 was 
observed in a distinctive pattern around the periphery of the vAC (Section 5.4, Figure 6.4). 
Due to this unique localisation of pUS19-V5, this member was the least likely to form a 
complex with any other US12 family members. It would be beneficial to further specify the 
exact vAC localisations of each US12 family member with other vAC organelle markers. 
A large subset of members were additionally regulated by leupeptin, so appear to be 
targeted for degradation in the same way. Although this does not prove that they are 
working together, it does suggest that they are functioning in a similar way. To more 
rigorously test this US12 family complex hypothesis, multiple members could be tested for 
co-localisation with each other. We have recently acquired antibodies specific to pUS18 
and gpUS20 so after optimisation, these antibodies could be used to test the co-localisation 
of all V5-tagged US12 family members with pUS18 and gpUS20. Multiple US12 family 
members could also be tagged with different tags (e.g. the V5 tag, Strep tag and 6xHis tag) 
within the same virus to observe co-localisations. Confocal or super resolution microscopy 
could also be exploited to enhance the resolution which may further inform on potential 
co-operation between family members. 
Stable isotope labelling with amino acids in cell culture (SILAC) immunoprecipitations (IPs) 
could also be undertaken to identify each V5-tagged family member’s binding partners by 
mass spectrometry. During SILAC IP, samples are differentially labelled with heavy, medium 
or light isotopes which allows the V5-tagged sample to be directly compared to the non-
tagged Merlin control in order to identify any differences in protein enrichment.  
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Figure 6.4 
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Figure 6.4: Depiction of the localisations of the US12 family within the cell at 72 
hpi. Observed localisations of US12 family members within the cell in relation to the 
ER, the vAC (as crudely depicted by concentric circles of the Golgi (dark grey) and 
TGN (light grey), as portrayed in more detail in Figure 1.7), and the lysosomes that 
were demonstrated to ring around the vAC in HCMV infected cells. Localisations of 
each US12 family member were identified across multiple immunofluorescence 
experiments at 72 hpi (Table 5.2) and show the multiple localisations for some US12 
family members, however their concentration and frequency of localisation to each 
location has not been depicted. US12 family members are depicted as 7 
transmembrane protein patterns (Figure 4.1) to represent the crossing of each 
protein through a membrane, however specific membranes within the vAC have not 
been identified and therefore could not be depicted. pUS12-V5, pUS13-V5, gpUS14-
V5, pUS15-V5, pUS18-V5, gpUS20-V5 and pUS21-V5 have dispersive vAC 
localisations, whereas pUS16-V5 tends to localise more to the outer portion of the 
vAC, and pUS19-V5 has a unique pattern around the periphery of the vAC. All 
members except pUS19-V5 co-localise to the ER however many not necessarily be 
present within the same membrane as depicted. Some US12 family members may 
also complex together (Section 6.4). All US12 family members are 7TM proteins so 
they will be present through a membrane, although these are currently unidentified 
(except for the ER). 
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Preliminary SILAC IP studies on pUS18-V5 and gpUS20-V5 indicated that multiple US12 
family members are ‘pulled down’ in the IP, through their direct or indirect binding with 
pUS18-V5 or gpUS20-V5. This study identified that gpUS14, pUS15, pUS16, pUS18 and 
gpUS20 were typically detected in both pUS18-V5 and gpUS20-V5 IPs (Dr C. Fielding). This 
suggests that these members are likely to co-operate and possibly complex together, and 
undertaking SILAC IPs on all remaining V5-tagged US12 family members will help to further 
solidify this theory. It may also reveal new binding partners within the US12 family. SILAC IP 
data suggests that gpUS14, pUS15, pUS16, pUS18 and gpUS20 may form a complex 
together or can bind to each other, and this is largely supported by immunofluorescence 
data. All of these members have at least partial association with the ER and the vAC, and 
pUS16-V5 is the only member that appears to have an altered localisation within the vAC, 
although it is possible that it is also dispersive across the vAC in a lower abundance that 
was not easily detected by immunofluorescence. It is interesting to speculate that the 
proposed complex may form in one or both of these localisations and it may be possible 
that the members of the complex could change depending on the conditions within the 
cell, or have different associated members at different locations within the cell. Other 
complexes have also been known to alter their constituents, including the entry complexes, 
which can vary between gH/gL/gO and gH/gL/pUL128-131 (Li et al., 2015, Luganini et al., 
2017, Zhou et al., 2013). 
These potential complex members all belong to expression class Tp2, Tp3 or Tp4, all with 
relatively high expression levels at 48 and 72 hpi, which would aid their ability and 
likelihood of being able to complex together. It is unlikely that pUS19 forms part of this 
complex, due to its different localisation, and its lack of crossover with the rest of the US12 
family’s cellular targets (this thesis and Fielding et al. (2017). pUS19-V5 was also not 
rescued by the addition of leupeptin (Section 5.1) and has the least similarity to TMBIM 
family members (Lesniewski et al., 2006). Although co-operation between HCMV proteins is 
not novel, with HCMV US2 and UL141 known to work together (Hsu et al., 2015), multiple 
members of a family or a whole HCMV gene family working together in a complex has not 
been previously described or inferred. Working in complexes would further explain why the 
US12 family members are so difficult to study in isolation. It also gives limitations to the 
results recovered from single deletion mutant assays as the deletion of one member may 
not detect all of its target proteins if there is redundancy in function. This was first 
recognised with US18 which had limited effects on MICA when deleted individually 
(Fielding et al., 2014). The block deletion mutant therefore gives extra insights into proteins 
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that may be targeted by multiple members at once by showing a larger increase of a target 
protein than what can be explained by single genes together (Fielding et al., 2014, Fielding 
et al., 2017). However, without double and triple knockout mutants of multiple family 
members, the full extent of the families targeting of cellular proteins and which members 
of the family operate together may not be fully realised.  
 
6.5 Conclusions 
All US12 family members were successfully tagged within the context of HCMV and all were 
detected by immunoblot which was an advantage over previous methods for detecting the 
US12 family. A total of nine US12 family members were shown to co-localise to the ER (or 
ER-derived membranes) and nine family members showed association with the vAC, which 
corresponded to 7 of those family members being detected in the virion. This data 
corresponds to the known functions of the family including their involvement with tropism 
and virion content modulation, along with their NK evasion functions. This thesis has also 
shed light onto the fact that the US12 family members are degraded similarly to their 
targets, and that this degradation is unlikely to be solely lysosomal. The importance of 
studying HCMV proteins within the context of infection, especially 7TM proteins, has also 
been re-affirmed. 
It has previously been suggested that the US12 family should be split into sub-families 
(Lesniewski et al., 2006; Rigoutsos et al., 2003) with US17, US18, US19 and US21 suggested 
to be separated from the family definition altogether. However, this data provides 
evidence to the contrary, given that the family all have the same localisations, and that 
multiple members target the same cellular proteins, especially US18 and US20, so it is 
highly unlikely that they are not related. It is also possible that some US12 family members 
may work together in complexes and this thesis has provided further supporting evidence 
of this hypothesis. 
Gene families as a whole are generally not studied together, so it has been beneficial to 
observe all members at once in terms of their expression and localisations within the same 
system to get a better idea of how they work. Studying the US12 family members in parallel 
has therefore furthered previous studies that were done across a range of strains and cell 
types on just a few family members. Some members such as US12, US13, US15, US19 and 
US21 had no previous experimental data published on them in terms of their expression 
and/or localisations. This study has revealed both similarities and differences between 
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US12 family members and resulted in further characterisation of this gene family. As a 
whole this study has identified many novel traits of the US12 family, including 2 novel N-
glycosylated proteins, novel ER and vAC localisations within the cell, previously unknown 
expression patterns over time, and the novel characteristic that over half of the family are 
targeted for degradation. 
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Appendix Table 7.1: List of primers and oligos used during the recombineering, PCR and 
sequencing stages of cloning  
 
Gene Primer 
type 
Sequence 
US12 SacB/Rpsl 
cassette 
insertion 
For: CGTCGGGAGAACACGGTGTTTTAGGGTGCGGGGGACAAAGGACAGTA 
CGACAGATTAGGTGATAGAAACGTTTTTTTTTACCTGTGACGGAAGATCACTT 
Rev: TAGTACCCCTGACGGCCCCCATCTGGTATCCAAACTACGCCGGGGCCCT 
AGGCCGCACGGCACACTGGCTTTTTCATAAACTGAGGTTCTTATGGCTCTTG 
Sequencing 
primers 
For: CCCTGTCTAGACTCAAAAG 
Rev: ATCGTCCCCCTTTCTCTATA 
Int Rev: GCTAAGTTTCATGCTTCC 
V5 tag 
oligos 
For: 
GCGGGGGACAAAGGACAGTACGACAGATTAGGTGATAGAAACGTTTTTTT 
ttacgtagaatcaagacctaggagcgggttagggattggcttaccagcgct 
Rev: 
CAAACTACGCCGGGGCCCTAGGCCGCACGGCACACTGGCTTTTTCATAAA 
Agcgctggtaagccaatccctaacccgctcctaggtcttgattctacgtaa 
US13 SacB/Rpsl 
cassette 
insertion 
For: 
CGGGTGCTCGACGAACAGTCGTCGGGGCTTCAGGTACCCGGCAAGTTTTA 
TAGAGAAAGGGGGACGATGGGTGGTGGCTACCTGTGACGGAAGATCACTT 
Rev: GTCCCAACCTCTGGCGCCTGCCCTGGACGACCGTCTTTGCCGCCTTCAG 
ATCCTCGTATTGCGAAGGTGGCGGTGGCTCGCTGAGGTTCTTATGGCTCTTG 
Sequencing 
primers 
For: GCCGAGTGGCTCGCC 
Rev: CTGGGCACCTATCATCATTA 
Int Rev: ATGGTTGGGGACAGTTTT 
V5 tag 
oligos 
For: 
TTCAGGTACCCGGCAAGTTTTATAGAGAAAGGGGGACGATGGGTGGTGG 
ttacgtagaatcaagacctaggagcgggttagggattggcttaccagcgct 
Rev: 
CGTCTTTGCCGCCTTCAGATCCTCGTATTGCGAAGGTGGCGGTGGCTCG 
agcgctggtaagccAatccctaacccgctcctaggtcttgattctacgtaa 
US14 SacB/Rpsl 
cassette 
insertion 
For: GGGTCCATGAGGCGGGTGATGCGCCCGAGTGAACGGGTGAGCGTCTC 
GGTGGAGTCTTCTTATAAACCAGCGGGTCTCACCTGTGACGGAAGATCACTT 
Rev: ATCATCATTACCGGGTTGACAACGGCACGCTCAGCGTCATCCTCAACAG 
CACCACCGCGACGTTCCAGAGCAGGGTTGCTCTGAGGTTCTTATGGCTCTTG 
Sequencing 
primers 
For: GGAGGGAAGCCCATTGC 
Rev: TCATTACCTGTCTAGCCG 
Int Rev: ACCTGGTTGCATAAGACT 
V5 tag 
oligos 
For: 
AGTGAACGGGTGAGCGTCTCGGTGGAGTCTTCTTATAAACCAGCGGGTC 
ttacgtagaatcaagacctaggagcgggttagggattggcttaccag 
Rev: 
CAGCGTCATCCTCAACAGCACCACCGCGACGTTCCAGAGCAGGGTTGCT 
Agcgctggtaagccaatccctaacccgctcctaggtcttgattctacg 
US15 SacB/Rpsl 
cassette 
insertion 
For: CGCGGTTTCCCGCTGCGTGGAAACTGTCTCCATGTCGGGACCGCAGCG 
CCCGGCGGCGTATCCGCAAGGTCTCGAAGCTACCTGTGACGGAAGATCACTT 
Rev: 
TGGTTTTCACTCTGCTGATGGTGCTGAGAATCATGACCCTGCGCACCTTT 
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TTGCAAACCTACTTTTCCTCTGACAAGCTGCTGAGGTTCTTATGGCTCTTG 
Sequencing 
primers 
For: CGGACGCGGCTTCC 
Rev: GTCGCTACAGCTCTTTATTA 
Int Rev: CACCTTACTGGCCTTTCT 
V5 tag 
oligos 
For: 
TCCATGTCGGGACCGCAGCGCCCGGCGGCGTATCCGCAAGGTCTCGAAG 
ttacgtagaatcaagacctaggagcgggttagggattggcttaccagcgct 
Rev: CATGACCCTGCGCACCTTTTTGCAAACCTACTTTTCCTCTGACAAGCTG 
Agcgctggtaagccaatccctaacccgctcctaggtcttgattctacgtaa 
US16 SacB/Rpsl 
cassette 
insertion 
For: CCCTTTTTCTCTTCTCATGGTGCGCTGCGTTCTCTGGAAACGGCTGCTCT 
GTCCGAAAACCAGTTCCGAACGAAAATCTACCTGTGACGGAAGATCACTT 
Rev: 
GGGCGAGAGGGTGGACAACGGCGTTGACGACGAAGCATGGGACAGGT 
CGTTCGGCGTTAACGTCATCGCGTCGGACGACGCTGAGGTTCTTATGGCTCT
TG 
Sequencing 
primers 
For: GGGGCACGTAGATGACCG 
Rev: CTCATTAGACAAACTCATCG 
Int Rev: TCGTGGTCTTTCTGGCTA 
V5 tag 
oligos 
For: GTTCTCTGGAAACGGCTGCTCTGTCCGAAAACCAGTTCCGAACGAAAAT 
ttacgtagaatcaagacctaggagcgggttagggattggcttaccagcgct 
Rev: CGACCTGTCCCATGCTTCGTCGTCAACGCCGTTGTCCACCCTCTCGCCC 
agcgctggtaagccaatccctaacccgctcctaggtcttgattctacgtaa 
US17 SacB/Rpsl 
cassette 
insertion 
For: 
GGCGGCCCGCGGTTCTAACAGGCTTGATTGGTGGAGACGGCCGGCGCGG 
CGGGTGGGGGAAACGACGAGTTTTTCCGTTACCTGTGACGGAAGATCACTT 
Rev: 
CGCCATGGTTCGCGTGAGGTTTCTCTGTACCTCCCGCAAAAGGTCACAGC 
CCGAAATGGAGGCCGCGTTGGTGGCCCCGGCTGAGGTTCTTATGGCTCTTG 
Sequencing 
primers 
For: GTCTAAGACGCGAGATCCG 
Rev: CCCAGTAGACAGACAGAACA 
Int Rev: GGGCCTGCTCACCATTTA 
V5 tag 
oligos 
For: 
TGGTGGAGACGGCCGGCGCGGCGGGTGGGGGAAACGACGAGTTTTTCCG 
ttacgtagaatcaagacctaggagcgggttagggattggcttaccagcgct 
Rev: 
CTGTGACCTTTTGCGGGAGGTACAGAGAAACCTCACGCGAACCATGGCG 
Agcgctggtaagccaatccctaacccgctcctaggtcttgattctacgtaa 
US18* 
(Fielding 
et al., 
2014) 
SacB/Rpsl 
cassette 
insertion 
For: 
GGGAGGTTCATCGTCTGTCTCTAGAGGGAAGGTGGGGAACGTCTAAGCG 
AGCGGGAGCGTGTCATCTCCCCCATCTTTCCTGTGACGGAAGATCACTTCG 
Rev: 
CGGCCACGTCTGGGTGCAGCAGTACGCCGAGAAACACGGCGGACGCATC 
GACGGCGTGAGTCTCCTCAGCTTGTTGTAACTGAGGTTCTTATGGCTCTTG 
Sequencing 
primers 
For: AGAGTGTAATATAATCACCG 
Rev: CTCTATGTCGAAAATGTGGC 
V5 tag 
oligos 
For: 
AGGTGGGGAACGTCTAAGCGAGCGGGAGCGTGTCATCTCCCCCATCTTT 
ttacgtagaatcaagacctaggagcgggttagggattggcttaccagcgct 
Rev: 
CGAGAAACACGGCGGACGCATCGACGGCGTGAGTCTCCTCAGCTTGTTG 
Agcgctggtaagccaatccctaacccgctcctaggtcttgattctacgtaa 
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US19*  
 
SacB/Rpsl 
cassette 
insertion 
For: 
CAGCACCCGGTTACCGCGGATTTGATTGACGTCACGAGTGTGGTCAAACCG 
TGGCGGCACCCTGTATCCGACCCGTCGCCTGTGACGGAAGATCACTTCG 
Rev: 
GCTACGCCTCTATGTCGAAAATGTGGCTTTATTCATCGGCATGTACCATCTT 
CTGAGGCTCTGGTTGTGGAGCCCATGACTGAGGTTCTTATGGCTCTTG 
Sequencing 
primers 
For: GGAGCGGCACGATGGTGACC 
Rev: TCTGCCCACCTAACCAATGC 
V5 tag 
oligos 
For: 
CGTCACGAGTGTGGTCAAACCGTGGCGGCACCCTGTATCCGACCCGTCG 
ttacgtagaatcaagacctaggagcgggttagggattggcttaccagcgct 
Rev: TTTATTCATCGGCATGTACCATCTTCTGAGGCTCTGGTTGTGGAGCCCA 
Agcgctggtaagccaatccctaacccgctcctaggtcttgattctacgtaa 
US20* 
(Fielding 
et al., 
2014)  
SacB/Rpsl 
cassette 
insertion 
For: 
ACGGTCCATTCTAGCGGGACGACATGAAGCATGGCGACAAGCGCGGCTG 
CTGTGAAAACGGGCGCGGTTTTATAGGCACCTGTGACGGAAGATCACTTCG 
Rev: CCGTTGGATTAGTCTTTCGGACGGCGCGCCTTTGGACAACGGGACTTT 
GACAGCCGCCAGTACGACGGGGAAGTCCTAACTGAGGTTCTTATGGCTCTTG 
Sequencing 
primers 
For: TAGCTCGGCCACCGGTGGCG 
Rev: TCCGTGCTCTACTTCATGCC 
V5 tag 
oligos 
For: 
CATGGCGACAAGCGCGGCTGCTGTGAAAACGGGCGCGGTTTTATAGGCA 
ttacgtagaatcaagacctaggagcgggttagggattggcttaccagcgct 
Rev: 
GCCTTTGGACAACGGGACTTTGACAGCCGCCAGTACGACGGGGAAGTCC 
Agcgctggtaagccaatccctaacccgctcctaggtcttgattctacgtaa 
US21* SacB/Rpsl 
cassette 
insertion 
For: 
TGCGGCGCACCTACCCTTCTCTTATACACAAGCGAGCGAGTGGGGCACG 
GTGACGTGGTCACGCCGCGGACACGTCGACCTGTGACGGAAGATCACTTCG 
Rev: 
CAGCGCCCACACTGCTCAGACGACGGTCGCTGCGACGGTCGCTGCCACA 
GCAGCGGCGTCGCCCCAGTTCGTCTCCTAACTGAGGTTCTTATGGCTCTTG 
Sequencing 
primers 
For: GCTGAAAGATGAAGATGGCG 
Rev: ACCCGACCAGATGGGAGACG 
Int Rev: GTCAGGCTTCCACTTTAG 
V5 tag 
oligos 
For: 
AAGCGAGCGAGTGGGGCACGGTGACGTGGTCACGCCGCGGACACGTCGA 
ttacgtagaatcaagacctaggagcgggttagggattggcttaccagcgct 
Rev: 
CGCTGCGACGGTCGCTGCCACAGCAGCGGCGTCGCCCCAGTTCGTCTCC 
Agcgctggtaagccaatccctaacccgctcctaggtcttgattctacgtaa 
 
For= Forward primer. Rev= Reverse primer. Int Rev= Internal reverse primer. Lowercase 
letters denote the V5 tag portion of the primer and underlined letters denote the SacB/Rpsl 
cassette homology  
*US18-V5 and US20-V5 had been completed, and mid-stage clones of US19-Rpsl and US21-
Rpsl had been prepared (Dr Ceri Fielding).  
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Appendix Table 7.2: The guanine-cytosine (GC) content of US12 family members 
Gene NCBI† Gene ID  NCBI† Aliases GC content (%)* 
US12 3077562 HHV5wtgp143 55.79 
US13 3077576 HHV5wtgp144 57.38 
US14 3077456 HHV5wtgp145 59.49 
US15 3077565 HHV5wtgp146 57.67 
US16 3077558 HHV5wtgp147 59.78 
US17 3077567 HHV5wtgp14 58.39 
US18 3077472 HHV5wtgp14      57.94 
US19 3077522 HHV5wtgp150 62.79 
US20 3077561 HHV5wtgp151 54.64 
US21 3077437 HHV5wtgp152 55.87 
 
 
† The National Center for Biotechnology Information (NCBI) 
* GC content redicted by a DNA/RNA GC content calculator website 
(http://www.endmemo.com/bio/gc.php) using DNA sequences taken from HCMV Merlin 
(Human herpesvirus 5 -NC_006273.2) on NCBI. Percentages rounded to the nearesr 0.01% 
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Appendix Table 7.3: Clone numbers, designated virus codes for each once fully sequenced  
Gene tagged Clone identifier Virus number 
US12-V5 Clone 1-2 RCMV2314 
US13-V5 Clone 4C RCMV2172 
US14-V5 Clone 4C RCMV2174 
US15-V5 Clone 2F RCMV2190 
US16-V5 Clone 16 RCMV2329 
US17-V5 Clone 7 RCMV2330 
US18-V5 Clone 2 RCMV1692 
US19-V5 Clone neo1-1 RCMV2158 
US20-V5 Clone 3 RCMV1691 
US21-V5 Clone 6A  RCMV2192 
None Parental virus RCMV1111 
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